Therapeutic,Format,CH1 Isotype,VD LC,Highest_Clin_Trial (Feb '25),Est. Status,HeavySequence,LightSequence,HeavySequence(ifbispec),LightSequence(ifbispec),100% SI Structure,99% SI Structure,95-98% SI Structure,Year Proposed,Year Recommended,Target,Companies,Conditions Approved,Conditions Active,Conditions Discontinued,Development Tech,Notes,Genetics (Bispecifics delimited with semicolon),Alternative Therapeutic Names
Abagovomab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS,DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK,na,na,None,None,None,2006,2007,MUC16/CA125,Menarini,na,na,Ovarian cancer;Pancreatic cancer ,,,Murine,ACA 125;ACA125;ACA-125
Abazistobart,Whole mAb,G4,Kappa,TBC,TBC,EVKLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKRLEWVATISGGGRYTYYPDTVKGRFTISRDNAKNSHYLQMNSLRAEDTAVYFCASPYGGYFDVWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISNFLHWYQQKPGQAPRLLIKYASQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYFCQQSNSWPHTFGQGTKVEIK,na,na,7vux:HL,None,None,2025,na,PDCD1/CD279/PD1,Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd,na,Cancer,na,,,Chimeric and Humanised,609A
Abciximab,Fab,G1,Kappa,Approved,NFD,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA,EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK,na,na,6v4p:CD,None,None,1993,1994,ITGA2B/CD41,Janssen Biologics BV;Eli Lilly,Coronary artery restenosis;Unstable angina pectoris,na,Arterial occlusive disorders;Myocardial infarction;Stroke,,Sequence sourced through DrugBank. Biosimilars available from ISU Abxis and Harvest Moon Pharmaceuticals,Chimeric,c7E3;CentoRx;Centrex;ReoPro
Abelacimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL,na,na,6r8x:CB,None,None,2018,2019,F11,Novartis;Anthos Therapeutics;Labcorp Drug Development;TIMI Study Group,na,Venous Thromboembolism; Stroke;Thrombosis,na,,Feb '22: Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3.,Genetically human,MAA-868
Abiprubart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQRLEWIGYINPSNDYTKYNQKFKDRATLTADKSANTAYMELSSLRSEDTAVYYCARQGFPYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRRWIYDTSKLASGVPARFSGSGSGTDYTLTISSLEPEDFAVYYCHQLSSDPFTFGGGTKVEIK,na,na,None,None,None,2023,2024,TNFRSF5/CD40,Primatope Therapeutics;Kiniksa Pharmaceuticals,na,Rheumatoid arthritis;Autoimmune disorders,na,,,Humanised,KPL404;KPL-404;KPL 404
Abituzumab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK,na,na,None,None,None,2013,2014,ITGAV/CD51,Merck,na,Colorectal cancer;Systemic scleroderma ,Ovarian cancer;Prostate cancer;Solid tumours ,,4o02 claims to be abituzumab (17E6); but is not,Humanised,DI 17E6;EMD525797
Abrezekimab,Fab,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,IL13,UCB,na,na,Asthma,,Jun '22: Added missing FWH3 and CDRL3 residues,Humanised,UCB 4144;UCB4144;UCB-4144;VR-942
Abrilumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2014,2015,ITGA4B7,Amgen;AstraZeneca,na,na,Crohn's disease;Ulcerative colitis ,,,Genetically human,Abrilimumab;AMG-181;MEDI-7183
Acapatamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I/II,Discontinued,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,FOLH1/GCPII/PSMA;CD3E,Amgen,na,na,Cancers;Prostrate cancer;Metastatic cancer,BiTE Technology. ,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG 160;AMG160;AMG-160
Acasunlimab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-III,Active,EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK,None;None,None;None,None;None,2020,2021,PDL1/CD274;TNFRSF9/CD137/4-1BB,Genmab;BioNTech,na,Non-small cell lung cancer;Endometrial cancer;Solid tumours,na,,,Humanised;Humanised,BNT-311;BNT311;GEN-1046;GEN1046
Acimtamig,Bispecific (VH-VK-VH'-VL Homodimer),na;na,Lambda;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGESLKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGSAYYYDFADYWGQGTLVTVSS,SYVLTQPSSVSVAPGQTATISCGGHNIGSKNVHWYQQRPGQSPVLVIYQDNKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQVWDNYSVLFGGGTKLTVL,QVQLQQSGAELARPGASVKMSCKASGYTFTTYTIHWVRQRPGHDLEWIGYINPSSGYSKYNQNFKGKTTLTADKSSNTAYMQLNSLTSEDSAVYYCARRADYGNYEYTWFAYWGQGTTVTVSS,DIVMTQSPKFMSTSVGDRVTVTCKASQNVGTNVAWFQQKPGQSPKVLIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYHTYPLTFGGGTKLEIN,None;None,None;None,7seg:AB:HL;None,2023,2023,FCGR3A/CD16/CD16A;TNFRSF8/CD30,Affimed Therapeutics,na,Hodgkin's disease;Peripheral T/NK cell lymphoma,na,,Genetics of both Fvs: musmus/homosap,Chimeric and/or humanised;Chimeric and/or humanised,AFM13;AFM-13
Acrixolimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFLRYAMHWVRQAPGKGLEWVAVISYDGRYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTTTFDSWGQGTLVTVSS,DIVMTQTPLSLPVTPGEAASISCRSSQSLLDSEDGNTYLDWYLQKPGQSPQLLIYTLSHRASGVPDRFSGSGSGTDFTLEISRVEAEDVGVYYCMQRRDFPFTFGQGTKVDIK,na,na,None,None,None,2022,2022,PDCD1/CD279/PD1,Y-Biologics,na,Solid tumours,na,,,Genetically human,YBL-006
Actoxumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,Clostridium difficile Toxin A,Bristol-Myers Squibb;Merck;University of Massachussets Medical School,na,na,Clostridium difficile,Medarex HuMAb Mouse,,Genetically human,CDA 1;CDA-1;MBL-CDA1;MDX-066;MK-3415A (combination of actoxumab and bezlotoxumab)
Adakitug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFSHYGMYWVRQAPGKGLEWVAVIWYDGSYEYNADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRVGLFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGPSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSLTFGPGTKVDIK,na,na,None,None,None,2024,2024,CXCL8,Bristol-Myers Squibb,na,Colon sarcoma;Myelodysplastic syndromes;Gastric adenocarcinoma,na,,,Genetically human,BMS-986253;BMS986253;HuMax-IL8;HuMax-Inflam;MDX018;MDX-018
Adalimumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,na,na,6cr1:HL/4nyl:AB:CD:EF:HL,3wd5:HL/8xj0:BA:DC:FE:HG,None,1999,2000,TNF/TNFA,Abbvie;MedImmune;180 Life Sciences,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma,Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis,Interstitial cystitis ,CAT Phage Display,Many biosimilars and related drugs.,Genetically human,D2E7;HUMIRA
Adebrelimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,PDL1/CD274,Jiangsu Hengrui Medicine;Atridia,Small cell lung cancer,Non-small cell lung cancer;Oesophageal cancer;Cancer;Solid tumours,Haematological malignancies,,Genetics: musmus/homosap,Chimeric and/or humanised,HTI-1088;HTI1088;HTI-1316;HTI1316;SHR 1316;SHR1316;SHR-1316
Adecatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQGTTVTVSS,ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,EPCAM/CD326,Micromet Inc;Merck Sorono;Amgen,na,na,Breast cancer;Colorectal cancer;Prostate cancer,,Sequence sourced through https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2123299,Genetically human,MT 201;MT201;MT-201
Adezkibart,Whole mAb,G1,Lambda,TBC,TBC,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYALSWVRQAPGQGLEWMGTRPPTSRTASYAQKFQGRVTITVDESTSTGYMELSSLRSEDTAVYYCASNDFVYGSYRFWGQGTTVTVSS,NFMLTQPHSVSESPGKTVTISCTRTSGNIAGYFVQWYQQRPGSSPTTVIYEDYQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDDYRRAAFGGGTKLTVL,na,na,None,None,None,2025,na,FLT3LG,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Adimanebart,Whole mAb,G1,Lambda,TBC,TBC,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYGMSWVRQAPGKGLEWVSAIPWSGGSTYYKESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRSGRIAFGALDAWGQGTLVTVSS,QTVVTQEPSFSVSPGGTVTLTCGLSSGSVTSSNYPDWYQQTPGQAPRTLIYSTDSRHSGVPDRFSGSILGNKAALTITGAQADDESDYYCGLYSYSGSKNYVFGGGTKLTVL,na,na,None,None,None,2025,na,MUSK,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Adintrevimab,Whole mAb,G1,Lambda,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAWAGTGFEYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL,na,na,None,7u2d:HL,7u2e:HL,2021,2022,SARS-CoV-2 Spike,Adagio Therapeutics,na,COVID-19,na,,,Genetically human,ADG-20;ADG20
Aducanumab,Whole mAb,G1,Kappa,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,6cnr:HL/6co3:HL,None,None,2013,2014,APP,Biogen;Neurimmune,Alzheimer's disease ,na,na,,,Genetically human,ADUHELM;BIIB 037;BIIB-037;NI-10;NI10
Afasevikumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK,na,na,6ppg:HL:BA,None,None,2015,2016,IL17A,NovImmune;Genentech,na,na,Autoimmune disorders;Inflammation,,,Genetically human,MCAF-5352A;MCAF5352A;NI-1401;NI1401;RG-7624;RG7624;RO5553110 
Afimkibart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYDFTYYGISWVRQAPGQGLEWMGWISTYNGNTHYARMLQGRVTMTTDTSTRTAYMELRSLRSDDTAVYYCARENYYGSGAYRGGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPWTFGQGTKVEIK,na,na,None,None,None,2024,na,TNFSF15/TL1A/VEGI,Pfizer;Roche,na,Ulcerative colitis;Crohn's disease;Inflammatory bowel diseases,na,,,Genetically human, PF 6480605;PF-06480605;PF06480605;RG-6631;RG 6631;RG6631;RO-7790121;RO 7790121;RO7790121;RVT-3101;RVT 3101;RVT3101
Alacizumab,di-Fab,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK,na,na,None,None,None,2007,2008,KDR/CD309/VEGFR2,UCB,na,na,Non-small cell lung cancer ,,,Humanised,CDP-791;CDP791
Alcestobart,Whole mAb,G4,Lambda,Phase-II,Active,QVQLQESGGGVVRPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWSGGSTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCATGGYWGQGTLVTVSS,DIRLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQGGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYSTPYTFGQGTKLTVL,na,na,None,None,None,2024,na,LAG3/CD223,BeiGene;Leads Biolabs,na,Non-small cell lung cancer;Oesophageal cancer;Squamous cell cancer;Colorectal cancer;Solid tumours,Lymphoma;Malignant melanoma,,,Genetically human,LBL-007; LBL007;LBL 007
Aldastotug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGESLRISCKGSGYSFTTYWISWVRQMPGKGLEWMGLIDPSDSYTNYSPSFKGHVTISTDKSISTAYLQWSSLKASDTAMYYCARGGYYGSEEDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSRLAWFQQKSGQAPRLLIFDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEFK,na,na,None,None,None,2024,2024,SIGLEC15/CD33L3,Pyxis Oncology,na,Oncology,na,Transgenic Mouse,,Genetically human,BSI 060T;BSI-060T;BSI060T;PYX 106;PYX-106;PYX106
Alemtuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK,na,na,1bey:HL/1ce1:HL,None,None,2000,2001,CD52,Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge,Chronic lymphocytic leukaemia;Multiple sclerosis ,Lymphoma;T-cell prolymphocytic leukaemia ,Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma ,,,Humanised,Campath;Campath-1H;LDP-03;LDP03;Lemtrada;Remniq
Aletekitug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGEISTGYYFHWVRQAPGKGLEWMGRIDPEDDSTKYAERFKDRVTMTEDTSTDTAYMELSSLRSEDTAVYYCTTWRIYRDSSGRPFYVMDAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCLASEDIYTYLTWYQQKPGKAPKLLIYGANKLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQGSKFPLTFGQGTKLEIK,na,na,None,None,None,2024,na,IL18,GSK,na,Atopic dermatitis,Crohn's disease;Delayed graft function;Inflammatory bowel diseases;Type 2 diabetes mellitus,,,Humanised,GSK-1070806;GSK 1070806;GSK1070806
Alextatug,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVESGGALVKPGGSLRLSCAASGFTFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL,na,na,None,None,None,2023,2024,RNP complex containing PABPC1,Atreca,na,na,Solid tumours,,,Genetically human,ATRC-101;ATRC101;ATRC 101
Alirocumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital,Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias,Coronary artery disease,na,VelocImmune Mouse,,Genetically human,Praluent;REGN-727;REGN727;SAR-236553
Alomfilimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK,na,na,7joo:HL,None,None,2020,2021,ICOS/CD278,Kymab,na,na,Gastic cancers;Non-small cell lung cancer;Melanoma;Hepatocellular carcinoma;Esophageal cancer;Head and neck squamous cell carcinoma,,,Genetically human,KY-1044;KY1044;SAR-445256
Alnuctamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Celgene Corporation,na,Multiple myeloma,na,,Genetics of both Fvs: musmus/homosap,Chimeric and/or humanised;Chimeric and/or humanised,BMS-986349;BMS986349;CC-93269;CC93269;EM-901;EM901
Alpitatug,Whole mAb,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSDTLSLTCAVSGNSITSDYAWNWIRQPPGKGLEWIGYISYSGSTTYNPSLKSRVTMSRDTSKNQFSLKLSSVTAVDTAVYYCATGYYYGSGFWGQGTLVTVSS,DIVLTQSPDSLAVSLGERATINCKASESVEYFGTSLMHWYQQKPGQPPKLLIYAASNRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQTRKVPYTFGQGTKLEIK,na,na,None,None,None,2024,na,KLK2/KLK2A2/hGK-1/hK2,TBC,TBC,TBC,TBC,TBC,ADC with Satetraxetan (and 225Ac),Humanised,TBC
Alsevalimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK,na,na,None,None,None,2019,2020,VTCN1/B7H4,Five Prime Therapeutics,na,na,Solid tumours,,,Genetically human,FPA-150;FPA150
Amatuximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS,DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK,na,na,7ued:HL,4f33:BA:DC:FE:HG/4f3f:BA/8cxc:HL,None,2010,2011,MSLN,Eisai Co Ltd;Morphotek;National Cancer Institute (USA),na,na,Pancreatic cancer;Solid tumours;Mesothelioma,,,Chimeric,MORAb-009; MORAB-009-006;MORAb009
Amdokitug,Whole mAb,G1,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFDMSWGRQAPGKRLEWVAFMSSGGSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGERYGSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGKAPKLLISGATSLETGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYWSTPFTFGSGTKLEIK,na,na,None,None,None,2025,na,IL17A,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Amtabafusp,Whole mAb Fusion,G1,Lambda,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKSRFTISRDDSKNSLYLEMNSLRTEDTAVYYCVRHGNFGHSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTGHYANWVQQKPGQAPRGLIGGTSNRAPGVPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNRWVFGGGTKLTVL,na,na,None,None,None,2024,na,CD3E,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Amivantamab,Bispecific mAb,G1;G1,Kappa;Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,None;6wvz:HL,None;None,None;None,2019,2020,EGFR/ERBB1/HER1;MET/HGFR,Genmab;Janssen Research & Development,Non-small cell lung cancer,Gastic cancer;Oesophageal cancer;Solid tumours,na,,,Genetically human;Genetically human,CNTO4424;JNJ 372;JNJ372;JNJ-372;JNJ-61186372;JNJ61176372;JNJ-6372;JNJ6372;RYBREVANT
Amlenetug,Whole mAb,G1,Kappa,Phase-III,Active,EVQLLESGGGLVQTGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSAIRSQGDRTDYADSVKGRFTISRDNSQNTLYLQMNSLRAEDTAVYYCAKNWAPFDSWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,8b9v:HL,None,None,2024,2024,SNCA/PARK1/PARK4,Lundbeck,na,Multiple system atrophy,na,,,Genetically human,LU AF82422
Amlitelimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK,na,na,None,None,None,2020,2021,TNFSF4/CD134/CD252/OX40L,Kymab,na,Atopic dermatitis,na,,,Genetically human,KY-1005;KY1005;SAR-445229
Amostomig,Bispecific mAb,G1;G1,Lambda;Lambda,Phase-I/Phase-II,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMYWVRQAPGKGLEWVSSIEDSSINTGGGTETTYYTDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCAKGDYYCTTYECQHYYGMDYWGQGTTVTVSS,QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS,QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL,None;None,None;None,None;None,2024,2024,IAP/CD47/MER6/OA3;PDL1/CD274,Biocad CJSC,na,Solid tumours,na,,Fv2 same sequence as Manelimab,Humanised;Humanised,TBC
Amrecibart,Whole mAb,G4,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLDWVSFIRSGGDTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVHPYTWDYGDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,na,na,None,None,None,2025,na,F11,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Amubarvimab,Whole mAb,G1,Kappa,Phase-II/III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK,na,na,7cdi:HL/7xnf:HL/8gx9:HF:IL/7x2k:HL,7e8m:HL,7swo:HL,2021,2022,SARS-CoV-2 Spike RBD,Brii Biosciences,na,na,COVID-19,,,Genetically human,BRII-196;BRII196
Amulirafusp,Whole mAb Fusion,G1,Kappa,Phase-I/II,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKHELK,na,na,None,4kaq:HL/2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM/8vgn:AB:HL,None,2024,2024,MS4A1/CD20,ImmuneOnco Biopharmaceuticals,na,Oncology,na,,,Chimeric,IMM-0306;IMM 0306;IMM0306
Anbenitamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,2021,ERBB2/CD340/HER2 (Domain II);ERBB2/CD340/HER2 (Domain IV),Alphamab,na,Breast cancer;Gastric cancer,na,,4llu is 94.7% identical to ERBB2 (domain II) Fv. ADC with repodatecan reported in PL132,Humanised;Humanised,KN-026;KN026
Andecaliximab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK,na,na,5th9:HL:IM:JN,None,None,2016,2017,MMP9/GELB,Gilead Sciences,na,na,Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma,,,Chimeric,GS-5745;GS5745
Anetumab,Whole mAb ADC,G1,Lambda,Phase-II,Discontinued,QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL,na,na,8cz8:AA:CC,None,None,2013,2014,MSLN,Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA) ,na,na,Fallopian tube cancer;Peritoneal cancer;Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma,MorphoSys HuCAL Phage Display,ADC with ravtansine,Genetically human,BAY 94-9343;BAY-94-9343;BAY-94-9343-SPDB-DM4 
Anifrolumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK,na,na,4qxg:HL,None,None,2013,2014,IFNAR1,Medarex;Medical University of Vienna;MedImmune,Systemic lupus erythematosus,Lupus nephritis,Rheumatoid arthritis;Scleroderma,Medarex UltiMAb Mouse,,Genetically human,MDX-1333;MDX1333;MEDI-546;MEDI546;Saphnelo
Anivovetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA,DIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK,na,na,None,None,3iy6:BA/3jcx:HL,2022,2022,Minor Capsid VP2 (Canine),Kindred Biosciences,na,Canine parvovirus,na,,Chimeric: Rat/Dog,Chimeric,KIND030;KIND 030;KIND-030
Anrukinzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK,na,na,None,None,None,2007,2008,IL13,Pfizer;Wyeth,na,na,Asthma;Ulcerative colitis,,,Humanised,IMA-638;IMA638;PF-05230917;PF0523917
Anselamimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK,na,na,None,None,None,2021,2022,Light Chain Amyloid Fibrils,Caelum Biosciences,na,AA amyloidosis,na,,Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7. Chimeric: Mouse/Human,Chimeric,11-1F4;CAEL-101;CAEL101
Ansipastobart,Whole mAb,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGSSFSSYAYSWVRQAPGKGLEWISAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYSRADEWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSISNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL,na,na,None,None,None,2024,2024,NT5E/CALJA/CD73,BioRay Pharm,na,Advanced Solid Tumors,na,,,Genetically human,BR101;BR-101;BR 101
Ansuvimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS,DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK,na,na,None,5fha:HL/5fhc:HL,None,2020,2021,Zaire Ebolavirus Glycoprotein,Ridgeback Biotherapeutics,Zaire ebolavirus infection,na,na,,,Genetically human,EVB114;EVB-114
Anumigilimab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYWMGWVRQAPGKGLEWVSSISSSGGVTPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLGELGWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLIYYASNLQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2021,2022,CSF3R/CD114,CSL Behring,na,na,Inflammatory diseases;Hidradenitis suppurativa;Localised pustular psoriasis,,,Genetically human,CSL-324;CSL324
Anvatabart,Whole mAb ADC,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2022,2023,ERBB2/CD340/HER2,Fudan University,na,Solid cancers;Breast cancer,na,,Anvatabart has an identical V domain to Coprelotamab; Cinrebafusp; Timigutuzumab; and Trastuzumab. ADC with opadotin and pactil,Humanised,ARX788;ARX-788;ARX 788
Anzurstobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK,na,na,7st5:HL:hl,None,None,2022,2023,SIRPA,Celgene Corporation,na,Acute myeloid leukaemia;Myelodysplastic syndromes,Non-Hodgkin's lymphoma;Solid tumours,,,Genetically human,BMS-986351;BMS986351;CC-95251;CC95251
Apamistamab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Active,EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS,DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,PTPRC/CD45,Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Hodgkin's disease;Non-Hodgkin's lymphoma,,,Murine,Iomab-ACT;Iomab-B
Apitegromab,Whole mAb,G4,Lambda,Preregistration,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL,na,na,None,None,6umx:HL:hl,2020,2021,pro-MSTN/GDF8/GDF-8/pro-GDF8,Scholar Rock,na,Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries,na,,,Genetically human,SRK-015;SRK015
Aplitabart,Whole IgM+J Chain (Cyclic Pentamer),M3,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,na,na,None,None,None,2024,2024,TNFRSF10B/CD262/DR5/TRAILR2,IgM Biosciences,na,Colorectal cancer;Non-Hodgkin's lymphoma;Solid tumours,Acute myeloid leukaemia,,IgM Version of Tigatuzumab (same Fv sequence),Humanised,IGM-8444;IGM8444
Aprutumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL,na,na,None,None,None,2016,2017,FGFR2/CD332,Bayer,na,na,Solid tumours,,ADC with ixadotin,Genetically human,BAY-1179470;BAY1179470
Arcitumomab,Whole mAb,G1,Kappa,Approved (w),NFD,EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSS,QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIK,na,na,1clo:HL,None,None,1995,1996,CEA/CEACAM,Immunomedics;Giliad Sciences,Colorectal cancer,na,na,,,Murine,
Armocibart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYGISWVKQAPGQGLEWIGEIYPRSTNTYYNEKFMGKATLTADKSSSTAYMELSSLRSEDTAVYYCARESFYGDYGAMDFWGQGTLVTVSS,DIVLTQSPLSLPVTPGEPASIFCKSSQSLLESDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQGTHFPRTFGQGTKVEIK,na,na,None,None,None,2024,na,TFPI,Suzhou Alphamab Co. Ltd.,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Arumakimig,Bispecific mAb,G1;G1,Lambda;Kappa,TBC,TBC,EVQLVQSGAEVKKPGSSVKVSCKASGGTFKSYAISWVRQAPGQGLEWMGNIIPMTGQTYYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAAYHPLVFDNWGQGTLVTVSS,DIVLTQPPSVSGAPGQRVTISCSGSSSNIGNHYVNWYQQLPGTAPKLLIYRNNHRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSWDYSGFSTVFGGGTKLTVL,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,None;None,None;5bvj:HG:FE:DC:BA/4g6j:HL/4g5z:HL/5bvp:HL,None;None,2025,na,IL18;IL1B,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Genetically human,TBC
Ascrinvacumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK,na,na,None,None,None,2015,2016,ACVRL1/SKR3,Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals,na,na,Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer;Age-related macular degeneration;Cancer;Liver Cancer,,,Genetically human,PF-03446962;PF03446962
Aselizumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVASISTGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDYDGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGQGTKVEIK,na,na,None,None,None,2003,2003,L-Selectin,PDL Biopharma,na,na,Adult respiratory distress syndrome;Crohn's disease;Psoriasis;Reperfusion injury;Shock,,,Humanised,HuDreg-55;HuDreg55
Astegolimab,Whole mAb,G2,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL1RL1/ST2,Amgen;Genentech;University of Leicester,na,Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease,Asthma;Rhinosinusitis,,,Genetically human,AMG-282;AMG282;RG 6149;RG6149;RG-6149;RO 7187807;RO7187807;RO-7187807
Atenastobart,Whole mAb,G1,Lambda,Phase-I,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSTFTMNWVRQAPGKGLEWVSSISSKGSYIEYAESFKVRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARYGIKNELNWVFDYWGQGTLVTVSS,QSALTQPPSASGSPGQTVTISCTGTSTDVGYYEYVSWYQQHPGKAPKLMIYETSKRLSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYRYEHQVSFGGGTKLTVL,na,na,None,None,None,2024,na,TNFRSF9/CD137/4-1BB,Chugai Pharmaceutical,na,Solid tumours,na,,,Genetically human,STA-551;STA 551;STA551
Atezolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,na,na,5x8l:FK:HM:GL:JO:SN,5xxy:HL,None,2014,2015,PDL1/CD274,Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University,Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer,Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma,Hodgkin's disease;Myelodysplastic syndromes,Human Phage Display,,Humanised,MPDL-3280A;MPDL3280A;RG-7446;RG7446;RG7446-42;RO-5541267;RO5541267;TECENTRIQ
Atibuclimab,Whole mAb,G4,Kappa,Phase-II,Active,DVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2020,2021,CD14,ICOS Corporation;Implicit Bioscience,na,Acute lung injury;COVID-19,Adult respiratory distress syndrome;Motor neuron disease;Septic shock,,,Chimeric,IC-14;IC14
Atidortoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,Staphylococcus aureus Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,,,Genetically human,ASN-1;ASN1;ASN200 (combination of atidortoxumab and berlimatoxumab);ASN-200
Atigotatug,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGSVQPGESLRLSCVASGFTFSRYKMNWVRQAPGKGLEWVSYISRSGRDIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAGTVTTYYYDFGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK,na,na,None,None,None,2024,2024,Fucosyl-GM1,Bristol Myers Squibb,na,Relapsed/refractory small cell lung cancer,na,,,Genetically human,BMS-986012;BMS986012;BMS 986012
Atinumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK,na,na,None,None,None,2010,2011,RTN4/Nogo,Novartis,na,na,Spinal cord injuries,,,Genetically human,ATI355;ATI-355
Atisnolerbart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYNIFWVRQATGQGLDWMGWMNPFRNNAGYAQKFQGRVTVTWDTSISTAYMELSSLSSEDTAIYYCAREHGSSWGFFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,7mxl:JK/7n0v:HL,None,None,2022,2023,Bet v 1,Regeneron,na,Allergic rhinitis;Birch pollen allergy,na,,Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5715. Identical V region sequence to Bremzalerbart.,Genetically human,REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart)
Atoltivimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK,na,na,7tn9:GH:IJ,None,None,2018,2019,Zaire Ebolavirus Glycoprotein,Regeneron Pharmaceuticals,na,na,Ebola virus infections,,,Genetically human,REGN 3470;REGN3470;REGN-3470;INMAZEB (combination with Maftivimab and Odesivimab)
Avdoralimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,C5AR1/CD88,Novo Nordisk;Innate Pharma,na,na,Rheumatoid arthritis;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours;Bullous pemphigoid,,,Genetically human,IPH-5401;IPH5401;NN-8210;NN8210
Avelumab,Whole mAb,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,PDL1/CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma,Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma;Bone metastases;Anal cancer;Cervical cancer;Vulvovaginal cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains,Genetically human,BAVENCIO;MSB-0010718C;MSB0010718;CPF-06834635;CPF06834635
Avitotamig,Whole mAb,G1,Kappa,TBC,Active,QVQLQQSGAEVVKPGASVKVSCKASGYSFTDYNMYWVRQAPGQGLEWMGYIDPYKGGTIYNQKFQGRATLTRDTSISTAYMELSRLRSDDTAVYYCAREMITAYYFDYWGQGSSVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDINKYIAWYQHKPGKAPKLLIYYASNLQPGVPSRFSGSGSGRDFTFTISSLQPEDIATYYCLQYDNLLTFGAGTKLELK,na,na,None,None,None,2024,2024,SIGLEC3/CD33/p67,Y-mAbs Therapeutics,na,Acute myeloid leukemia,na,TBC,,Humanised,YMS-5A;YMS5A;YMS 5A
Avizakimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,IL21,MedImmune;Boston Pharmaceuticals,na,Systemic lupus erythematosus,Autoimmune disorders,,,Humanised,BOS-161721;BOS161721
Axatilimab,Whole mAb,G4,Kappa,Preregistration,Active,EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK,na,na,None,None,None,2019,2020,CSF1R/CD115/M-CSFR,Syndax Pharmaceuticals;AstraZeneca;UCB,na,Cholangiocarcinoma;Graft-versus-host disease;COVID-19,Solid tumours,,,Humanised,INCA-34176;INCA34176;SNDX-6352;SNDX6352;UCB 6352;UCB6352;UCB-6352
Azerutamig,Bispecific Mixed mAb and scFv-CH2-CH3,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGAPMGAAAGWFDPWGQGTVLTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSFPRTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKCLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGCGTKVEIK,None;None,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL/5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL,2024,na,KLRK1/NKG2D/CD314;ERBB2/CD340/HER2,Dragonfly Therapeutics;Gilead Sciences,na,Solid tumours;Breast cancer;Non-small cell lung cancer,na,,,Genetically human,DF-1001;DF 1001;DF1001
Azintuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS,DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK,na,na,None,None,None,2016,2017,SLAMF7/CD319,AbbVie,na,na,Multiple myeloma,,ADC with vedotin,Chimeric and humanised,ABBV-838;ABBV838
Azirkitug,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLKLSCAASGFIFSNAVMYWVRQASGKGLEWVARIKTKFNNYATYYADAVKGRFTISRDDSKNMVYLQMNSLKTEDTAVYYCTAGDRNKPFAYWGQGTLVTVSS,ETVVTQSPATLSLSPGERATLSCRASTSVITLLHWFQQKPGQAPRLLIHGASNLESRVPARFSGSGSGTDFTLTISSLEPEDFATYFCQQSWNDPYTFGQGTKLEIK,na,na,None,None,None,2024,2024,CCR8/CKR-L1/CDw198,AbbVie,na,na,Non-small cell lung cancer;Squamous cell cancer,TBC,,Humanised,ABBV 514;ABBV-514;ABBV514
Bafisontamab,Bispecific Mixed mAb and Fab,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK,5sx4:HL:JI/5sx5:HL:JK;None,None;None,None;None,2021,2022,EGFR/ERBB1/HER1;MET/HGFR,EpimAb Biotherapeutics,na,Non-small cell lung cancer;Solid tumours,na,,Fv1 is Panitumumab,Genetically human;Humanised,EMB-01;EMB01
Balertatug,Whole mAb,G1,Kappa,TBC,TBC,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK,na,na,None,None,None,2025,na,CD70,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Balonkibart,Whole mAb,G4,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFSFVSYVMGWVRQAPGKGLEWVSSISGSLTNTYYADPVKGRFTISRDNSKNTLYLQMNSLRAEDTAAYYCVTYDILTGHLFDYWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRSSQGIRNDFGWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTINNLQPEDFATYYCLQDYTYPFTFGPGTKVDIK,na,na,None,None,None,2025,na,NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Balstilimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,Agenus;Ludwig Institute for Cancer Research,na,Cervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma,na,,,Genetically human,AGEN-2034;AGEN2034;RebmAb-700;RebmAb700
Bamlanivimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK,na,na,7l3n:DE/7kmg:AB:DE,None,None,2020,2021,SARS-CoV-2 Spike,Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases,COVID-19,na,na,,,Genetically human,LY 3819253;LY3819253;LY-3819253;LY CoV 555;LY-CoV-555
Bapineuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK,na,na,None,None,4ojf:HL/4hix:HL,2005,2006,APP,JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation,na,na,Alzheimer's disease,,"Jain paper: ""Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL""",Humanised,AAB-001;AAB001
Bapotulimab,Whole mAb,G2,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR,na,na,None,None,None,2020,2021,ILDR2,Bayer,na,Solid tumours;Squamous cell cancer,na,,,Genetically human,BAY-1905254;BAY1905254
Barecetamab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL,na,na,7d85:BC:EF,None,None,2020,2021,ERBB3/HER3,ISU Abxis,na,na,Solid tumours;Head and neck cancer,Antibody Phage Display,,Genetically human,ISU-104; ISU104
Barzolvolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIK,na,na,None,None,None,2021,2022,KIT/CD117,Celldex Therapeutics,na,Chronic idiopathic urticaria,na,,Genetics: musmus/homosap,Chimeric and/or humanised,CDX-0159;CDX0159
Basiliximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS,QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK,na,na,1mim:HL/3iu3:AB:CD:HL,None,None,1996,1997,IL2RA/CD25,Cerimon Pharmaceuticals;Novartis,Renal transplant rejection;Transplant rejection,na,Ulcerative colitis;Uveitis,,,Chimeric,CHI 621;CHI621;CHI-621;Simulect
Batoclimab,Whole mAb,G1,Lambda,Preregistration,Active,QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS,SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,FCGRT/FcRn,Immunovant Sciences,na,Graves' Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura,na,,,Genetically human,HBM-9161;HBM9161;HL-161;HL161;HL-61;HL61;IMVT 1401;IMVT-1401;IMVT1401;RVT 1401;RVT-1401;RVT1401
Bavituximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS,DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK,na,na,None,None,None,2006,2007,Phosphatidylserine,Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center,na,Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours,Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer,,,Chimeric,3G4;Tarvacin
Bavunalimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS,DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2020,2021,LAG3/CD223;CTLA4/CD152,Xencor,na,na,Solid tumours,,Bavunalimab is the new name for Pavunalimab (PL125). (Jun '22) Corrected IMGT H25 S->A. Genetics of both Fvs: musmus/homosap,Chimeric and/or humanised;Chimeric and/or humanised,XmAb-22841;XmAb22841;XmAb-841;XmAb841
Bebtelovimab,Whole mAb,G1,Lambda,Approved,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL,na,na,7mmo:AB:DE,None,None,2022,2022,SARS-CoV-2 Spike RBD,Eli Lilly;AbCellera,COVID-19,na,na,,,Genetically human,LY-3853113;LY3853113;LY-CoV1404;LY CoV1404
Becotatug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK,na,na,None,None,None,2022,2023,EGFR/ERBB1/HER1,CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology,na,Cancers;Non-small cell lung cancer;Metastatic cancers,na,,ADC with vedotin,Humanised,JMT101;JMT-101
Bedinvetmab,Canine Whole mAb,G2,Lambda,Approved,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS,QSVLTQPTSVSGSLGQRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL,na,na,None,None,None,2018,2019,NGFB (Canine),na,na,Canine lupus familiaris,na,,June '22: Corrected FWL1 sequence,Genetically canine,ZTS-00508841;ZTS00508841;LIBRELA
Befovacimab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL,na,na,None,None,None,2019,2020,TFPI,na,na,Haemophilia,na,,,Genetically human,BAY-109;BAY109;BAY-1093884;BAY1093884
Begelomab,Whole mAb,G2b,Kappa,Phase-II/III,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS,QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK,na,na,None,None,None,2014,2015,DPP4/ADCP2/CD26,ADIENNE,na,Graft-versus-host disease,na,,,Murine,SAND-26;SAND26
Belantamab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK,na,na,None,None,None,2017,2018,TNFRSF17/CD269/BCMA/TNFRSF13A,GlaxoSmithKline,Multiple myeloma,na,na,,,Humanised,GSK-2857914;GSK2857914
Belimumab,Whole mAb,G1,Lambda,Approved,Active,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL,na,na,5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE,None,6erx:HI:DE:QR:MN:FG:OP,2003,2004,TNFSF13B/CD257/BAFF,Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology,Systemic lupus erythematosus;Lupus nephritis,Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease,Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome,CAT Phage Display,,Genetically human,GSK1550188;GSK-1550188;HGS-1006;HGS1006
Belrestotug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGVIGPSGASTSYAQKFQGRVTLTRDTSTSTVYMELSSLRSEDTAVYYCARDHSDYWSGIMEVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYFSPPWTFGGGTKVEIK,na,na,None,None,None,2022,2023,TIGIT/WUCAM/VSTM3,GlaxoSmithKline;iTeos Therapeutics,na,Multiple myeloma;Haematological malignancies;Solid tumours;Non-small cell lung cancer,na,,,Genetically human,EOS 884448;EOS-884448;EOS884448;EOS-448;EOS448;GSK-4428859;GSK4428859
Beludavimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,na,na,None,7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB/7tm0:JK:LM:NO/7tn0:BA:CD/7xck:AB/7x1m:AB/7xsw:AB:HL/7yad:AB:CD/7yr0:CB/7yqy:HF:IG:JE/7yqx:HF:IG/7yxz:IG:JH/8df5:AB:CD/8dw2:DC/8dw3:DC/8fxb:HL/8fxc:HL/8hws:IJ/8s9g:HL/8vye:AB:IJ:RS/8vjg:AB/8wyj:ST:EG:IK/8wpw:AB/8wpy:AB/8y6a:CD/9au1:MN,None,2021,2022,SARS-CoV-2 Spike RBD,GlaxoSmithKline,na,na,COVID-19,,Beludavimab and Sotrovimab have identical Fvs,Genetically human,GSK-4182137;GSK4182137;VIR-7832;VIR7832
Bemarituzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK,na,na,None,None,7sob:GI:HJ:NO/7soc:HL,2017,2018,FGFR2/CD332,Five Prime Therapeutics;ZAI Lab,na,Gastric cancer,Oesophageal cancer;Solid tumours,POTELLIGENT Technology,,Humanised,AMG-552;AMG552;FPA-144;FPA144
Bempikibart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHAMHWVRQAPGKGLEWVSGISWNSRGIGYADSVKGRFTIFRDNAKNSLYLQMNSLRAEDTALYYCAKDEYSRGYYVLDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLWITFGQGTRLEIK,na,na,None,None,None,2022,2023,IL7R/CD127,Q32 Bio Inc.,na,Atopic dermatitis,na,,,Genetically human,ADX-914;ADX914
Benmelstobart,Whole mAb,G1,Kappa,Approved,Active,QITLKESGPTLVKPTQTLTLTCTVSGFSLSTYGVHWIRQPPGKALEWLGVIWRGVTTDYNAAFMSRLTITKDNSKNQVVLTMNNMDPVDTATYYCARLGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKAPKLLIYYAANRYTGVPDRFSGSGYGTDFTFTISSLQPEDIATYFCQQDYTSPYTFGQGTKLEIK,na,na,None,None,None,2023,2023,PDL1/CD274,Crown Bioscience;Apollomics;Chia Tai Tianqing Pharmaceutical Group;Chinese Academy of Medical Sciences;Fudan University;Shandong Cancer Hospital and Institute;Shanghai Tenth Peoples Hospital;The First Affiliated Hospital of Zhengzhou University;Zhengda Tianqing Pharmaceutical Group Co. Ltd.,Small cell lung cancer,Biliary cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Renal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gynaecological cancer;Hepatitis B;Hodgkin's disease;Liver cancer;Nasopharyngeal cancer;Squamous cell cancer;Acral lentiginous melanoma;Cholangiocarcinoma;Solid tumours,Triple negative breast cancer,,,Humanised,APL 502;APL502;APL-502;CBT-502;CBT502;CBT 502;TQ-B2450;TQ B2450
Benralizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK,na,na,None,None,None,2009,2010,IL5RA/CD125,AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa,Asthma,Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis,Skin disorders,POTELLIGENT Technology,,Humanised,BIW-8405;BIW8405;Fasenra;KHK 4563;KHK-4563;KHK4563;MEDI-563;MEDI563
Bentracimab,Whole mAb,G1,Lambda,Phase-III,Active,QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS,QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL,na,na,5alb:HL,None,5alc:HL,2020,2021,AR-C124910XX,MedImmune;AstraZeneca;PhaseBio,na,Haemorrhage (reversal of effects of ticagrelor),na,,,Genetically human,MEDI-2452;MEDI2452;PB-2452;PB2452
Benufutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK,na,na,6t3j:AB:FG,None,None,2019,2020,TNFRSF10B/CD262/DR5/TRAILR2,Genmab;VU University Medical Center;iDD Biotech,na,Solid tumours;Multiple myeloma,na,,Chimeric: Mouse/Human,Chimeric,GEN1029;GEN-1029;Hx-DR5-01;Hx-DR5-05;iDD 004;iDD-004;iDD004
Bepranemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,MAPT,UCB BioPharma,na,Progressive supranuclear palsy (PSP);Alzheimer's Disease,na,,June '22: Removed duplicate residue from FWL3,Humanised,RG-6416;RG6416;UCB-0107;UCB0107
Berlimatoxumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK,na,na,5k59:HL:EF,None,None,2017,2018,Staphylococcus aureus Toxin A,Adimab;Arsanis;X4 Pharmaceuticals,na,na,Staphylococcal infections,,,Genetically human,ASN-2;ASN2;ASN200 (combination of atidortoxumab and berlimatoxumab);ASN-200
Bermekimab,Whole mAb,G1,Kappa,Preregistration (w),Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,na,na,None,None,None,2018,2019,IL1A,XBiotech Inc.,na,Systemic scleroderma,Haematological malignancies;Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer,,,Genetically human,CA-18C3;CA18C3;CV-18C3;CV18C3;Hutruo;JNJ-77474462;JNJ77474462;RA-18C3;RA18C3;T2-18C3;T218C3;Xilonix
Bersanlimab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL,na,na,None,None,None,2017,2018,ICAM1/CD54,BioInvent International,na,na,Multiple myeloma,n-CoDeR,,Genetically human,BI-505;BI505
Besufetamig,Bispecific mAb,G1;G1,Kappa;Kappa,TBC,TBC,QVQLVQSGSELKQPGASVKVSCKASGYTFTHYALHWLRQAPGQGLEWMGWLNTNTENPTFAQGFTGRFVFSLDTSVTTAYLQISSLKAEDTAVYYCARGDMVVPTTIWNYYHFMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAQIWYNARKQEYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2025,na,PDCD1/CD279/PD1;CD3E,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Genetically human,TBC
Betinukibart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGSELKKPGASVKVSCKASEYIFTNYGMNWVKQAPGQGFEWMGWIDTNTGEPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTATYYCANYGWGYFDYWGQGTTVTVSS,DVVMTQTPPSLPVNPGEPASISCRSSQSLVHSNGYTYLHWYLQKPGQSPQLLIYKVSNHLSGVPDRFSGSGSGTDFTLKISWVEAEDVGVYFCSQSTHVPYTFGGGTKLEIK,na,na,7wkx:AC:BD,None,None,2024,na,IL17A,Shanghai Huaota Biopharmaceutical;Shenzhen Bay Laboratory,na,Plaque psoriasis;Ankylosing spondylitis;Psoriatic arthritis,na,,,Humanised,Hb0017;Hb-0017
Betifisolimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKLSCKASGYIFTTYWMHWVKQRPGQGLEWIGMIQPNSGGTKYNEKFKKKATLTVDKSISTAYMELSRLTSDDTAVYYCARGAGTVDYFDYWGQGSTLTVSS,DIVLTQSPASLAVSVGQRATITCRASESVDIYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEAQDTATYYCQQSTEDPYTFGGGTKLEIK,na,na,None,None,None,2022,2022,PDL1/CD274,MabSpace Biosciences;Transcenta Holding,na,Solid tumours,Haematological malignancies,,Genetics: musmus/homosap,Chimeric and/or humanised,MSB-2311;MSB2311
Bevacizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1bj1:HL:KJ/7v5n:BA:FE,None,6bft:AB:HL/1cz8:HL:YX,2000,2001,VEGFA,All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital,Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer,Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma,Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer,,Biosimilars available,Humanised,12-IgG1;rhuMAb-VEGF;AVASTIN
Bexatamig,Bispecific (H-gamma1-VH-G1CH1h_L-kappa)_L-kappa-G1hCH2CH3,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSSGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCESSQSLLSSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYVINWVRQAPGQGLEWMGEIYPGSGTNYYNEKFKAKATITADKSTSTAYMELSSLRSEDTAVYYCARRGRYGLYAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQGNTRPWTFGGGTKVEIK,4jzj:HL:AB;6ias:HL/6iap:HL,None;None,None;None,2024,2024,IL3RA/CD123;NCR1/NKP46/NKp46/LY94/CD335,Innate Pharma,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma ,na,,,Humanised;Humanised,NKp46-1;IPH-6101;IPH 6101;IPH6101;SAR-443579;SAR 443579;SAR443579;SAR’579
Bexmarilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK,na,na,None,None,None,2019,2020,STAB1,Faron Pharmaceuticals,na,Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis,na,,,Humanised,FP 1305;FP-1305;FP1305
Bezetabart,Whole mAb ADC,G1,Kappa,Phase-I/II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFNFSDYGMHWVRQAPGKGLEWVAVIWYDGSISYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGTVEHGAVYGTDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIGSWLAWYQQKPGKAPKLLIYAADRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHTYPLTFGGGTKVEIK,na,na,None,None,None,2023,2024,CD74/HLA class II histocompatibility antigen gamma chain,Sutro Biopharma;BioNova Pharmaceuticals;Sutro Biopharma,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Haematological malignancies;Multiple myeloma;Leukaemia,Modified at two specific positions with reactive 4-(azidomethyl)-L-phenylalanine residues,,Genetically human,BN 301;BN-301;BN301;SP7675;SP-7675;SP 7675;STRO-001;STRO001;STRO 001
Bezlotoxumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK,na,na,4np4:HL:IM,None,None,2012,2013,Clostridium difficile Toxin A,Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme,Clostridium difficile,na,na,Medarex HuMAb Mouse,,Genetically human,CDB1;CDB-1;MBL-CDB1;MBLCDB1;MDX 1388;MDX1388;MDX-1388;MK 6072;MK6072;MK-6072;Zinplava
Bifikafusp,Whole mAb Fusion,E,Kappa,Preregistration,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,7ah1:AA,None,None,2010,2011,FN extracellular domain B,Philogen,na,Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours,Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer,,Radretumab+Bifikafusp+Onfekafusp have identical V domains,na,L19-IL2/L19-TNF;L19IL2/L19TNF;L19(scFv)-IL2/L19(scFv)2-TNF
Bimagrumab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL,na,na,5nhr:HL:AB,5nhw:HL/5nh3:HL:IM/5ngv:HL,None,2012,2013,ACVR2B,MorphoSys;Novartis,na,Cachexia;Muscular atrophy;Type 2 diabetes mellitus,Inclusion body myositis,MorphoSys HuCAL Phage Display,,Genetically human,BYM-338;BYM338
Bimekizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK,na,na,8ruu:HL:BC,None,None,2013,2014,IL17A,UCB,Plaque psoriasis,Ankylosing spondylitis;Psoriatic arthritis;Hidradenitis suppurativa;Ulcerative colitis;Axial spondylarthritis,Psoriasis;Rheumatoid arthritis,,Fv sequence identical to Galvokimig,Humanised,Bimzelx;CDP-4940;CDP4940;UCB-4940;UCB4940
Bintrafusp,Whole mAb Fusion,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,4nki:HL/5grj:HL,None,None,2015,2016,PDL1/CD274,AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine,Merkel cell carcinoma;Urogenital cancer,Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma,na,Human Phage Display,Avelumab and Bintrafusp have identical V domains,na,GSK-4045154;GSK4045154;M-7824;M7824;MSB-0011359C;MSB0011359C
Birinkibart,Whole mAb,G4,Kappa,TBC,Active,QMQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTGDTSTDTAYLELSSLRSEDTALYYCATGRYTSLATTYGFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDNWPYTFGQGTKLEIK,na,na,None,None,None,2024,na,CSF2RB/CD131/IL3RB/IL5RB,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Birtamimab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,SAA1,Neotope Biosciences;Onclave Therapeutics;Prothena,na,na,Amyloid light-chain amyloidosis,,Genetics: musmus/homosap,Chimeric and/or humanised,NEOD-001; NEOD001
Bleselumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK,na,na,8yx1:HL:AB,None,None,2015,2016,TNFRSF5/CD40,Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin,na,na,Transplant rejection;Plaque psoriasis;Focal segmental glomerulosclerosis;Renal transplant rejection,,,Genetically human,ASKP 1240;ASKP1240;ASKP-1240
Blinatumomab,Bispecific T-Cell Engager,na;na,Kappa;Kappa,Approved,Active,QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS,DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK,DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,None;None,None;None,None;None,2008,2009,CD19;CD3E,Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis,Precursor B-cell lymphoblastic leukaemia-lymphoma,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma,Chronic lymphocytic leukaemia,BiTE Technology,,Murine;Murine,AMG-103;AMG103;Blincyto;MEDI-538;MEDI538;MT-103;MT103
Blontuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS,DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL,na,na,None,None,9cq4:HL:CD,2015,2016,MS4A1/CD20,Aratana Pharmaceuticals,na,Canine B-cell lymphoma,na,,Chimeric:  Mouse/Dog,Chimeric,AT-004;AT004;VT-007;VT007
Blosozumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,Eli Lilly,na,Postmenopausal osteoporosis,na,,,Humanised,LY-2541546;LY2541546;TST-002;TST002
Bococizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,3sqo:HL,None,None,2013,2014,PCSK9,Halozyme Therapeutics;Pfizer,na,na,Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia,,,Humanised,PF-04950615;PF04950615;PF-4950615;PF4950615;RN-316;RN316
Bocunebart,Whole mAb,G1,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGIDLNSYYMTWVRQAPGKGLEWIGFIDAGGDAYYASWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYFCARDLDLWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCQSSESVYGNYLAWFQQKPGKAPKFLIYEASKLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCAGGDISEGVAFGGGTKVEIK,na,na,None,None,None,2025,na,ADCYAP1/PACAP,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Bosakitug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGVIDPSDSDTTYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCTRSLDGYYDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRPTENIYSYLAWYQQKPGKAPKLLIYFARTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPWTFGGGTKVEIK,na,na,None,None,None,2024,na,TSLP,Biosion;CTTQ,na,Asthma;Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease;Hypersensitivity,na,,,Humanised,BSI-045B;BSI-04502;BSI045B;BSI04502;TQC2731;TQC-2731
Boserolimab,Whole mAb,G1,Kappa,Phase-II,Active,EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSLRSEDTAVYYCAREGDAMDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPKRWIYDTSKLASGVPARFSGSGSGTDYSLTISSLEPEDFAVYYCQQWNSYPFTFGQGTKLEIK,na,na,8ds5:CB,None,None,2022,2023,TNFRSF7/CD27,Bionovion;Merck Sharp & Dohme,na,Non-small cell lung cancer;Small cell lung cancer,Solid tumours,,,na,MK-5890;MK5890
Botensilimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYAESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLFGPFDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,CTLA4/CD152,Agenus,na,Solid tumours,na,,,Genetically human,AGEN-1181;AGEN1181
Brazikumab,Whole mAb,G2,Lambda,Phase-III,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL,na,na,None,None,None,2016,2017,IL23A,Allergan;Amgen;AstraZeneca,na,na,Psoriasis;Crohn's disease;Ulcerative colitis,,,Genetically human,AMG-139;AMG139;MEDI-2070;MEDI2070
Bremzalerbart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCSVSGGSITNYFWTWIRQSPGKGLEWIGYIYYSGGTNYNPSLKSRVTISIDTSKNQFSLNMNSVTAADTAVYYCAGSYYYGVDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIKSFLAWYRQKPGQAPRLLIYDASNRPTGIPARFSGSGSGTDFTLTINSLESEDFAVYFCQQRNNWPFTFGPGTKVDIK,na,na,7mxl:AB/7n0u:HL,None,None,2022,2023,Bet v 1,Regeneron Pharmaceutical,na,Allergic rhinitis;Birch pollen allergy,na,,Identical V region sequence to Atisnolerbart,Genetically human,REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart)
Brenetafusp,Fusion Protein (scFv fused to TCR Fab),na,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,na,na,None,None,None,2023,2023,CD3,Immunocore,,Malignant melanoma;Solid tumours;Endometrial cancer;Non-small cell lung cancer;Ovarian cancer,,,6kr0:DD has an identical heavy chain. Identical sequence to Tebentafusp.,na,IMC-F106C;IMC F106C
Brentuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA,DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2010,2011,TNFRSF8/CD30,Bristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine,Anaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma,Adult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma,Graft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus,,ADC with vedotin,Chimeric,Adcetris;cAC10-vcMMAE;SGN-35;SNG35
Briakinumab,Whole mAb,G1,Lambda,Preregistration (w),Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL,na,na,5n2k:LK:BA:PO:DC:NM:FE/5njd:RQ:TS:XW:VU:PO:NM,None,None,2009,2010,IL12B/CLMFp40,Cambridge Antibody Technology;Abbott GmbH & Co. KG,na,na,Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis,,,Genetically human,A-796874.0;ABT-874;ABT874;BSF 415977;BSF-415977;BSF415977;J 695;J695;J-695;LU 415977;LU-415977;LU415977;Ozespa;WAY-165772;WAY165772
Briquilimab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIK,na,na,None,None,None,2022,2022,KIT/CD117,Jasper Therapeutics;Amgen;National Heart;Lung and Blood Institute;Stanford University,na,na,Inflammation;Acute myeloid leukemia;Severe combined immunodeficiency,,Genetics: musmus/homosap,Chimeric and/or humanised,AMG-191;AMG191;JSP-191;JSP191
Brivekimig1,Trispecific Single Domains (VH-VH-VH'-VH''-VH'); Bispecific entry,na,na;na,Phase-II,Active,DVQLVESGGGVVQPGGSLRLSCAASGRTFSSIYAKGWFRQAPGKEREFVAAISRSGRSTSYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAVGGATTVTASEWDYWGQGTLVTVSS,na,EVQLVESGGGVVQPGGSLRLSCAASGRTFSSIYAKGWFRQAPGKEREFVAAISRSGRSTSYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAVGGATTVTASEWDYWGQGTLVTVSS,na,None;None,None;None,None;None,2024,2024,TNFSF4/CD134/CD252/OX40L;TNF/TNFA,Sanofi,na,Focal segmental glomerulosclerosis;Hidradenitis suppurativa,na,,Humanised: Alpaca/Human;Humanised: Alpaca/Human,Humanised;Humanised,SAR 442970;SAR-442970;SAR442970
Brivekimig2,Trispecific Single Domains (VH-VH-VH'-VH''-VH'); Monospecific entry,na,na,Phase-II,Active,EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,na,na,None,None,None,2024,2024,ALB,Sanofi,na,Focal segmental glomerulosclerosis;Hidradenitis suppurativa,na,,Humanised: Alpaca/Human. Same VH sequence as Lunsekimig2.,Humanised,SAR 442970;SAR-442970;SAR442970
Brivestobart,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLQQWGAGLLKPSETLSLTCGVYGGSFSGYYWSWIRQPPGMGLEWIGEINHRGNTNYNPSLKSRVTISEDTSKNQFSLRLSSVTAADTAVYFCTRGEDYSDYDYYGDFWGQGTLVTVSS,EIVLTQSPATLSLSQGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYAASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAIYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2024,na,LAG3/CD223,Guangzhou Gloria Biosciences,na,Solid tumours,na,,,Humanised,GLS-012;GLS 012;GLS012
Brodalumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL17RA/CD217,Amgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis,Axial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis,Asthma;Crohn's disease;Rheumatoid arthritis,Abgenix XenoMouse,,Genetically human,AMG-827;AMG827;KHK-4827KHK4827;Kyntheum;LP 0160;LP-0160;LP0160;LUMICEF;Siliq
Brolucizumab,scFv,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS,EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL,na,na,None,None,None,2014,2015,VEGFA,ESBATech;Alcon,Wet age-related macular degeneration,Diabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy,na,,,Humanised,Beobyu;Beovu;ESBA-1008;ESBA1008;RTH-258;RTH258
Brontictuzumab,Whole mAb,G2,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKVSGYTLRGYWIEWVRQAPGKGLEWIGQILPGTGRTNYNEKFKGRVTMTADTSTDTAYMELSSLRSEDTAVYYCARFDGNYGYYAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWFQQKPGQAPRTLIGGTNNRAPGVPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNHWVFGGGTKLTVL,na,na,None,None,None,2014,2015,NOTCH1,OncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center,na,na,Adenoid cystic carcinoma;Solid tumours;Haematological malignancies;Colorectal cancer,,,Humanised,OMP-52M51;OMP52M51
Budigalimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EIQLVQSGAEVKKPGSSVKVSCKASGYTFTHYGMNWVRQAPGQGLEWVGWVNTYTGEPTYADDFKGRLTFTLDTSTSTAYMELSSLRSEDTAVYYCTREGEGLGFGDWGQGTTVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSHGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,AbbVie,na,Colorectal cancer;Ovarian cancer;Small cell lung cancer;Solid tumours;Endometrial cancer;Fallopian tube cancer;HIV-1 infections;Peritoneal cancer;Squamous cell cancer,na,,Genetics: musmus/homosap,Chimeric and/or humanised,ABBV-181;ABBV181
Budoprutug,Whole mAb,G1,Kappa,Phase-I,Active,QVQLEQPGAEVVKPGASVKVSCKTSGYTFTSNWMHWVKQTPGKGLEWIGEIDPSDSYTNYNQKFDGKAKLTVDKSSSTAYMEVSDLTAEDSATYYCARGSNPYYYAMDYWGQGTSVTVSS,QIVLTQSPATLSASPGEKATMTCSASSGVNYMHWYQQKPGTSPKRWIYDTDKTASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRGSYTFGGGTKLEIK,na,na,None,None,None,2023,2024,CD19,ValenzaBio;ACELYRIN,na,Focal segmental glomerulosclerosis,na,,B lymphocyte surface antigen B4; Leu-12. Genetics: musmus/homosap,Chimeric and/or humanised,VB119;VB-119;TNT-119;TNT119;TNT 119
Bulumtatug,Whole mAb,G1,Kappa,TBC,Active,EVQLQESGPGLVKPSETLSLTCTVSGFSLIDYGVSWIRQPPGKGLEWIGVIWGGGKIYYNSVLKSRVTISKDNSKSQVSLKLSSVTAADTAVYYCAKQGGLLFYAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNTYSQKNYLAWYQQKPGQPPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYNTPFTFGGGTKVEIK,na,na,None,None,None,2024,na,LAG3/CD223,Jiangsu Maiweikang New Drug R & D Co. Ltd.,TBC,TBC,TBC,TBC,ADC with Fuvedotin,Chimeric and/or humanised,TBC
Burfiralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGKGLEWMGNIDPYYGSDTYAQKFQGRVTMTVDKSISTAYMELSRLRSDDTAVYYCARETGTRAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKPGKAPKLLIYVADNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHFYGSPRTFGGGTKVEIK,na,na,None,None,None,2022,2022,VIM,ImmuneMed,na,COVID-19 Pneumonia;Pneumonia;Hepatitis B;Alcholic hepatitis;Non-alcoholic steatohepatitis;Psoriasis;Scleroderma,na,,,Humanised,hzVSF; hzVSF-v13
Burosumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIK,na,na,7ven:BA,None,None,2016,2017,FGF23,Kyowa Hakko Kirin;Ultragenyx Pharmaceutical ,X-linked dominant hypophosphataemic rickets;Osteomalacia,Nevus,na,,,Genetically human,Crysvita;KRN 23;KRN23;KRN-23;UX 023;UX023;UX-023
Cabiralizumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDNYMIWVRQAPGQGLEWMGDINPYNGGTTFNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARESPYFSNLYVMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASQSVDYDGDNYMNWYQQKPGQAPRLLIYAASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHLSNEDLSTFGGGTKVEIK,na,na,None,None,None,2015,2016,CSF1R/CD115/M-CSFR,Apexigen;Bristol-Myers Squibb;Five Prime Therapeutics;University of Chicago;Yale University,na,Pancreatic cancer;Pigmented villonodular synovitis;Cancer;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Solid tumours ,Rheumatoid arthritis,,,Humanised,BMS-986227;BMS986227;FPA-008;FPA008;ONO-4687;ONO4687
Cabotamig,Bispecific (VH-G1CH1h-G4CH2CH3-scFv),G1/G4;na,Kappa;Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQTPGKGLEWVAVIDSNGGSTYYPDTVKDRFTISRDNSKNTLYLQMNSLRAEDTAVYYCSSYTNLGAYWGQGTLVTVSA,DIQMTQSPSSLSASVGDRVTITCRASQDISGYLNWLQQKPGGAIKRLIYTTSTLDSGVPKRFSGSGSGTDFTLTISSLQSEDFATYYCLQYASSPFTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,None;None,None;None,None;None,2023,2024,CDH17;CD3E,Arbele,na,Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Gastrointestinal cancer;Liver cancer;Pancreatic cancer;Biliary cancer,na,,6kr0:DD has an identical heavy chain to Fv2.,Humanised;Humanised,ARB202;ARB-202
Cadonilimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Approved,Active,QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,QVVLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVL,None;None,None;None,None;None,2020,2021,PDCD1/CD279/PD1;CTLA4/CD152,Akeso Biopharma,Cervical cancer,Non-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma,na,,June '22: Corrected FWH1 and FWL2 sequences. Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AK-104;AK104
Cafelkibart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGLEWVARIRSKANNYATYYADSVKDRFTISRDDSKNTLYLQMNNLKTEDTAVYYCVRDRSRGEDYAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNANTYLYWFLQKPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLKISRVEAEDVGVYYCMQHLEYPFTFGQGTKLEIK,na,na,None,None,None,2024,2024,CCR8/CKR-L1/CDw198,LaNova Medicines Limited;Shanghai Pulmonary Hospital,,Non-small cell lung cancer; Triple negative breast cancer;Solid tumours,,,Humanised: musmus/homosap,Humanised,LM108;LM-108;LM 108
Calpurbatug,Whole mAb,G1,Kappa,Phase-I,Active,QSQVQLVESGPGLVKPSETLSLTCRVSGDSNRPSYWSWIRQAPGKAMEWIGYVYDSGVTIYNPSLKGRVTISLDTSKTRFSLKLTSVIAADTAVYYCARERFDRTSYKSWWGQGTQVTVSS,DIVLTQAPGTLSLSPGDRATLSCRASQRLGGTSLAWYQHRSGQAPRLILYGTSNRATDTPDRFSGSGSGTDFVLTISSLEPEDFAVYYCQQYGSPPYTFGQGTTLDIK,na,na,None,None,None,2022,2023,Bacteria Proteins HU and IHF,Trellis Bioscience,na,Methicillin-resistant Staphylococcus aureus infections;Bacterial infections,na,,Conserved epitopes on HU (histone-like protein) and IHF (integrin host factor),Genetically human,TRL1068;TRL-1068
Calotatug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHGYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYHHSPLTFGGGTKVEIK,na,na,None,None,None,2024,2024,ERBB2/CD340/HER2,Mersana Therapeutics,na,Solid tumours,na,,,Genetically human,XMT-2056;XMT2056;XMT 2056
Camidanlumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVENYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL2RA/CD25,ADC Therapeutics;Genmab,na,Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours,Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma,,ADC with tesirine,Genetically human,ADCT-301;ADCT301
Camoteskimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISADGYYWSWIRQPPGKGLEWIGSLYYSGSTYYNPSLKGRVTISGDTSKNQFSLKLSSVTAADTAVYYCARTPAYFGQDRTDFFDVWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSHHPPWTFGQGTKLEIK,na,na,None,None,None,2022,2022,IL18,Avalo Therapeutics;MedImmune,na,Adult-onset Still's disease;Juvenile rheumatoid arthritis,Chronic obstructive pulmonary disease;Multiple myeloma,,,Genetically human,AEVI-007;AEVI007;AVTX-007;AVTX007;CERC-007;CERC007;MEDI 2338;MEDI-2338;MEDI2338
Camrelizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYMMSWVRQAPGKGLEWVATISGGGANTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLYYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCLASQTIGTWLTWYQQKPGKAPKLLIYTATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVYSIPWTFGGGTKVEIK,na,na,7cu5:BB,None,None,2016,2017,PDCD1/CD279/PD1,Chinese PLA General Hospital;Hangzhou Cancer Hospital;Incyte Corporation;Jiangsu Hengrui Medicine Co.;Nanjing Medical University;Peking University People's Hospital;Sun Yat-Sen University,Hodgkin's disease,Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Biliary cancer;Cervical cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gastric cancer;Osteosarcoma;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Urogenital cancer;Diffuse large B cell lymphoma;Breast cancer;Malignant melanoma,na,,,Humanised,AiRuiKa;Carbarizumab;Carrizumab;HR-301210;HR301210;INCSHR-1210;INCSHR1210;SHR 1210;HSR1210;HSR-1210
Canakinumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK,na,na,None,4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL,None,2007,2008,IL1B,Charite - Universitatsmedizin Berlin;Novartis;Triemli hospital;University Hospital Tubingen;University Hospital Zurich,Adult-onset Still's disease;Cryopyrin-associated periodic syndromes;Familial autosomal dominant periodic fever;Familial Mediterranean fever;Gouty arthritis;Juvenile rheumatoid arthritis;Peroxisomal disorders,Cardiovascular disorders;Behcet's syndrome;Non-small cell lung cancer;Abdominal aortic aneurysm;Atherosclerosis;Malignant melanoma;Osteoarthritis;Peripheral arterial occlusive disorders;Pulmonary sarcoidosis;Schnitzler syndrome;Sickle cell anaemia;Breast cancer;Pancreatic cancer;Renal cell carcinoma,Chronic obstructive pulmonary disease;Asthma;Diabetic retinopathy;Polymyalgia rheumatica;Rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus,Medarex UltiMAb Mouse,,Genetically human,ACZ-885;ACZ885;Ilaris
Canrivitug,Whole mAb,G1,Lambda,TBC,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGGSISSHYWSWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARHYDILTGFDWFDPWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGTHYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSFDNSLTAPYVFGTGTKVTVL,na,na,None,None,None,2023,2023,SARS-CoV-2 RBD,TBC,,,SARS-CoV-2 Infection,,,Genetically human,TBC
Cantuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGETVKISCKASDYTFTYYGMNWVKQAPGQGLKWMGWIDTTTGEPTYAQKFQGRIAFSLETSASTAYLQIKSLKSEDTATYFCARRGPYNWYFDVWGQGTTVTVSS,DIVMTQSPLSVPVTPGEPVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLVSGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCLQHLEYPFTFGPGTKLELK,na,na,None,None,None,2003,2004,MUC1/PEM/EMA,ImmunoGen;GlaxoSmithKline,na,na,Gastric cancer;Solid tumours,,ADC with mertansine and ravtansine,Humanised,C-242 DM4;huC242-DM4;IMGN-242;IMGN242
Caplacizumab,Nanobody,na,na,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSS,na,na,na,7a6o:B/7eow:B,None,None,2011,2012,VWF,Ablynx,Thrombotic thrombocytopenic purpura,na,Thrombosis,Nanobody Technology,,Humanised,ALX-0081;ALX0081;ALX-0681;ALX0681
Carlumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK,na,na,None,4dn3:HL/4dn4:HL,None,2010,2011,CCL2/MCP1,MorphoSys;Janssen Biotech,na,na,Idiopathic pulmonary fibrosis;Ovarian cancer;Prostate cancer;Solid tumours,Human Phage Display,,Genetically human,CNTO-888;CNTO888
Carotuximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVKLEESGGGLVQPGGSMKLSCAASGFTFSDAWMDWVRQSPEKGLEWVAEIRSKASNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTGIYYCTRWRRFFDSWGQGTTLTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2015,2016,ENG/CD105,National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute,na,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration,,,Chimeric,DE-122;DE122;TRC-105;TCR105
Casdozokitug,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRSYGMNWVRQAPGKGLEWVSGISSSGSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGGRTSYTATAHNWFDPWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLFSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHASAPPTFGGGTKVEIK,na,na,7zxk:HL:JI,None,None,2022,2023,IL27,Surface Oncology,na,Solid tumours;Hepatocellular carcinoma,na,Artificial human yeast display library,,Genetically human,SRF 388;SRF-388;SRF388
Caxmotabart,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2024,na,ERBB2/CD340/HER2,LegoChem Biosciences;Iksuda Therapeutics;LigaChem Biosciences;Shanghai Fosun Pharmaceutical ,Breast cancer;HER2 positive breast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours,na,,,ADC with Entudotin. Identical Fv sequence to Trastuzumab etc.,Humanised,FS-1502;FS 1502;FS1502;IKS-014;IKS 014;IKS014;LCB-14;LCB 14;LCB14;LCB14-0110
Cemavafusp,Fusion Protein (Toxin fused to an scFv),na,Kappa,Phase-I,Active,EVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQRHGKSLEWIGGINPNNGGTWYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYFCARPYYYGSREDYFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPRSSPKPWIYLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGGGTKLELK,na,na,None,None,None,2023,2023,PDL1/CD274,TBC,na,Head and neck cancer;Non-small cell lung cancer;Solid tumours,na,,,na,MT-6402;MT 6402;MT6402
Cemiplimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR,na,na,7wvm:AB:CD/8gy5:HL:AB,None,None,2018,2019,PDCD1/CD279/PD1,Inovio Pharmaceuticals;ISA Pharmaceuticals;Regeneron Pharmaceuticals;Sanofi;Sidney Kimmel Cancer Center;SillaJen Biotherapeutics;University of Texas M. D. Anderson Cancer Center,Squamous cell cancer;Basal cell cancer;Non-small cell lung cancer,Cervical cancer;Oropharyngeal cancer;Prostate cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Ovarian cancer;Peritoneal cancer;Solid tumours;Head and neck cancer;Malignant melanoma;Renal cell carcinoma,B-cell lymphoma,,,Genetically human,Libtayo;REGN-2810;REGN2810;SAR-439684;SAR439684
Cendakimab,Whole mAb,G1,Kappa,Phase-III,Active,EVTLRESGPGLVKPTQTLTLTCTLYGFSLSTSDMGVDWIRQPPGKGLEWLAHIWWDDVKRYNPALKSRLTISKDTSKNQVVLKLTSVDPVDTATYYCARTVSSGYIYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASQDIRNYLNWYQQKPGKAPKLLIFYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDIATYYCQQGNTLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL13,Abbott Laboratories;AbbVie;Receptos,na,Eosinophilic oesophagitis,Allergic asthma,,,Humanised,ABT-308;ABT308;CC 93538;CC93538;CC-93538;RPC 4046;RPC4046;RPC-4046
Cenvacibart,Whole mAb,G4,Kappa,TBC,TBC,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYSMNWIRQAPGKGLEWISYISFSGNSIYYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTAIYYCTSRDWGYAFDIWGQGTMVTVSS,DIQMTQSPSFLSASLGDRVTITCQASQDISNYLNWYQVKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQQYDNLPYIFGQGTKLEIK,na,na,None,None,None,2025,na,F11,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Cenzestotug,Whole mAb,G1,Kappa,TBC,TBC,QVQLVESGGGVVQPGRSLRISCAVSGFSLTSYGVLWVRQAPGKGLEWLGVIWSGGSTDYNAAFISRLTISRDNSKSTVYFQMNSLRAEDTAVYYCAREEFGYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGGAVKLLIYYTSRLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQTNTLPWTFGGGTKLEVK,na,na,None,None,None,2025,na,TNFRSF4/CD134/OX40,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Cepeprubart,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSASSTIYYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSYGYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSRSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQTTHVPLTFGQGTRLEIK,na,na,None,None,None,2023,2024,SELPLG/CD162/PSGL1,Selexys,na,Venous Thromboembolism;Asthma;Pulmonary Disease;Chronic Obstructive,na,,,Genetically human,SelK-2;SelK2
Cergutuzumab,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,na,na,None,None,None,2015,2016,CEACAM5/CD66e,Roche,na,na,Solid tumours,,,Humanised,CEA-IL-2v;RG-7813;RG7813;RO-6895882;RO6895882
Certolizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK,na,na,5wuv:HL/5wux:HL:AB:CD,None,None,2004,2004,TNF/TNFA,UCB,Ankylosing spondylitis;Crohn's disease;Plaque psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Spondylitis;Non-radiographic axial spondyloarthritis,Interstitial cystitis;Juvenile rheumatoid arthritis,Cognition disorders,,,Humanised,CDP-870;CDP870;Cimzia;PHA-738144;PHA738144;Simziya
Cetrelimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFDTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARPGLAAAYDTGSLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRNYWPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1/CD279/PD1,Janssen Research & Development ,na,Multiple myeloma;Prostate cancer;Solid tumours;Urogenital cancer;Bladder cancer,na,,,Genetically human,JNJ 63723283;JNJ63723283;JNJ-3283;JNJ3283
Cetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC,5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,1999,2000,EGFR/ERBB1/HER1,Array BioPharma;Bristol-Myers Squibb;Celldex Therapeutics Inc;Centre Jean Perrin;Eli Lilly;Merck KGaA;New York University School of Medicine;Novartis;Pierre Fabre;Roche;University Hospital Ghent;University of California;University of Heidelberg;University of Michigan Comprehensive Cancer Center,Colorectal cancer;Head and neck cancer,Non-small cell lung cancer;Bladder cancer;Breast cancer;Gastric cancer;Mesothelioma;Rectal cancer;Squamous cell cancer;Adenoid cystic carcinoma;Oesophageal cancer,Pancreatic cancer;Prostate cancer,,Ficerafusp and Cetuximab have the same Fv sequence.,Chimeric,IMC-C225;IMC C225;LY-2939777;LY2939777
Cevostamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVESGPGLVKPSETLSLTCTVSGFSLTRFGVHWVRQPPGKGLEWLGVIWRGGSTDYNAAFVSRLTISKDNSKNQVSLKLSSVTAADTAVYYCSNHYYGSSDYALDNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVRNLVVWFQQKPGKAPKLLIYSGSYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSPPYTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRQAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWTSTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSFILRTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,FCRL5/CD307;CD3,Genentech,na,Multiple myeloma,na,,Genetics of Fv1: musmus/homosap,Chimeric and/or humanised;Genetically human,BFCR-4350A;BFCR4350A;RG 6160;RG6160;RG-6160;RO-7187797;RO7187797
Cibisatamab,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASAAVGTYVAWYQQKPGKAPKLLIYSASYRKRGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYYTYPLFTFGQGTKLEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEFGMNWVRQAPGQGLEWMGWINTKTGEATYVEEFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARWDFAYYVEAMDYWGQGTTVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,CEACAM5/CD66e and CD3E;CD3E,Roche,na,na,Solid tumours;Non-small cell lung cancer;Colorectal cancer,,,Humanised;Humanised,RG-7802;RG7802;RO-6958688;RO6958688
Ciduvectamig,Bispecific mAb,G4;G4,Kappa;Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYSMSWVRQAPGKGLEWVSVISGSGGFTDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMPLNSPHDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPLTFGGGTKVEIK,QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL,None;None,None;None,None;None,2022,2023,TMEFF2;CD3E,Janssen Research & Development,na,na,Prostate cancer,,,Genetically human;Genetically human,JNJ-70218902;JNJ70218902;JNJ 902; JNJ-902; JNJ902
Cifurtilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,8xy9:HL:BC:EF:GI,None,None,2022,2022,TNFRSF5/CD40,Merck;Seagen,na,Melanoma;Lymphoma,na,,Same Fv sequence as Dacetuzumab,Genetically human,hS2C6nf
Ciletatug,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYAFTNYLIEWVRAQPGWGLEWMGLINPGSGGTNYNEKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGYYGNSFAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCKSSQSLLNSGNQKNYLTWYLQKPGQSPQLLIYWASTRESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQNAYYYPYTFGGGTKVEIK,na,na,None,None,None,2024,na,CLDN18,RemeGen,na,Solid tumours,na,,ADC with Vedotin,Humanised, RC-118;RC118;RC 118;YH005 - ADC
Cilgavimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRDVWMSWVRQAPGKGLEWVGRIKSKIDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTAGSYYYDTVGPGLPEGKFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLMYWASTRESGVPDRFSGSGSGAEFTLTISSLQAEDVAIYYCQQYYSTLTFGGGTKVEIK,na,na,7l7e:CD:EF:MN:OP/8d8q:HL/8suo:IM,None,8ekd:EF,2020,2021,SARS-CoV-2 Spike RBD,AstraZeneca,COVID-19,na,na,,,Genetically human,AZD1061;AZD-1061;COV2-2130;AZD7442 (combination of cilgavimab and tixagevimab);AZD-7442 (combination of cilgavimab and tixagevimab);EVUSHELD (combination of cilgavimab and tixagevimab)
Ciltistotug,Whole mAb,G2,Kappa,TBC,TBC,QVQLVQSGAEVKKPGASVKLSCKASGYTFISYYIYWVKQAPGQGLEWIGGINPRNGGTNFNEKFKSRATLTVDTSISTAYMELSRLRSEDTAVYYCTRHGNGVYWGQGTTLTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSNGNTYLHWYQQRPGQSPNHLIYQVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQTTHVPWTFGGGTKVEIK,na,na,None,None,None,2025,na,TNFRSF5/CD40,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Cinpanemab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVESGGGLVEPGGSLRLSCAVSGFDFEKAWMSWVRQAPGQGLQWVARIKSTADGGTTSYAAPVEGRFIISRDDSRNMLYLQMNSLKTEDTAVYYCTSAHWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGEALPMQFAHWYQQRPGKAPVIVVYKDSERPSGVPERFSGSSSGTTATLTITGVQAEDEADYYCQSPDSTNTYEVFGGGTKLTVL,na,na,6ct7:HL:AB,None,None,2018,2019,SNCA/PARK1/PARK4,Neurimmune Therapeutics;Biogen,na,na,Parkinson's disease,,,Genetically human,BIIB 054;BIIB-054;BIIB054
Cinrebafusp,Fusion Protein,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2/CD340/HER2,Eli Lilly and Company;Pieris Pharmaceuticals;Seagen,na,Gastic cancer;Solid tumours,na,,Identical Fv sequence to Anvatabart; Coprelotamab; Trastuzumab; Timigutuzumab,na,PRS-343;PRS343
Cirevetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGAEVKKPGASVKVSCKTSGYTFISSWMNWVRQAPGAGLDWMGQIYPGDGDTNYNGKFKGRVTLTADTSTSTAYMELSSLRAGDIAVYYCARHYDGSTDYWGQGTLVTVSS,EIVMTQSPASLSLSQGEKVTITCRASENIYSNLAWYQQRPGQAPKLLIYAATNLADGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2022,2022,TGFB1 (Canine),Zoetis,na,Chronic kidney disease,na,,,Caninised,ZTS-00521426;ZTS00521426;ZTS 00521426
Citatuzumab,Fab Fusion,G1,Kappa,Phase-I,Discontinued,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM/CD326,Viventia Biotech;Sesen Bio,na,na,Solid tumours,,,na,VB6-845;VB6845
Cixutumumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL,na,na,None,None,None,2008,2009,IGF1R/CD221,Eli Lilly;ImClone Systems;M. D. Anderson Cancer Center;National Cancer Institute (USA) ,na,na,Breast cancer;Colorectal cancer;Head and neck cancer;Liver cancer;Neuroendocrine tumours;Non-small cell lung cancer;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Rhabdomyosarcoma;Sarcoma;Soft tissue sarcoma;Solid tumours;Thymoma,Dyax Human Phage Display,,Genetically human,IMC-A12;IMCA12;LY301221;LY-201221;NSC 742460;NSC-742460;NSC742460
Cizutamig,Bispecific Mixed Domains (L-kappa-H-gamma1_[VH-G1(CH1-h)]_L-kappa),G1;G1,Kappa;Kappa,Phase-I,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNFWMHWVRQAPGQRLEWMGAFYPGNDDTYYNQKFKGRVTITADTSASTAYMELSSLRSEDMAVYYCARSGYYGSSDAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLATGIPSRFSGSGSGRDFTLTISSLQPEDFATYYCQSVLTTPWTFGQGTKLEIK,EVQLVQSGAEVKKPGASVKVSCKASGFSFTNYYVHWMRQAPGQGLEWIGWISPGSDNTKYNEKFKGRVTLTADTSISTAYMELSRLRSDDTAVYYCARDDYGNYYFDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNARTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYILRTFGGGTKVEIK,None;None,None;None,None;None,2024,na,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,EpimAb Biotherapeutics;Candid Therapeutics,na,Cancer;Myasthenia gravis,na,,,Humanised;Humanised,CN-106;CN106;CN 106;CND-106;CND106;CND 106
Claseprubart,Whole mAb,G4,Kappa,TBC,TBC,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISRSGSTKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDENYALDWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQHYEDYPLTFGGGTKVEIK,na,na,None,None,None,2025,na,C1S,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Clazakizumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK,na,na,None,None,None,2012,2013,IL6,Alder Biopharmaceuticals;Cedars-Sinai Medical Center;Medical University of Vienna;Vitaeris,na,Renal transplant rejection;COVID-19,Anaemia;Cachexia;Fatigue;Stomatitis;Crohn's disease;Graft-versus-host disease;Inflammation;Psoriatic arthritis;Rheumatoid Arthritis,,,Humanised,ALD 518;ALD-518;ALD518;BMS-645429;BMS645429;BMS-945429;BMS945429;CSL-300;CSL300
Clervonafusp,di-Fab Fusion,G1,Kappa,Phase-II,Active,EVQLQESGGGVVQPGGSLRLSCAASGFTFSNYGMHWIRQAPGKGLEWVSYISSGSSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRSEDTAVYYCARRGLLLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTISCRASKSVSTSSYSYMHWYQQKPEKAPKLLIKYASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHSREFPWTFGAGTKLELK,na,na,None,None,None,2018,2019,SLC29A2,Valerion Therapeutics,na,Glycogen storage disease type II,na,,June '22: Corrected FWL2 and CDRL3 sequences,na,VAL-1221;VAL1221
Clesitamig,Bispecific Mixed Domains ((V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_L-kappa)]_(H-gamma1_L-kappa)); Trispecific through dual targetting Fv2,G4;G1,Kappa;Kappa,Phase-I,Active,QVTLTESGPALVKPTQTLTLTCTFSGFSLSSSYDMGWVRQAPGQGLEWMGTIYTGDYSTDYASWAKGRVTISVDRSKNQFSLKLSSVTAADTAVYYCARHTGYGYFGLWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCQSTESVYGSDWLSWYQQKPGQPPKLLIYQASNLEIGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQGYYSGYIYAFGGGTKVEIK,QVQLVESGGGLVQPGRSLRLSCAASGFKFSNVWFHWVRQAPGKGLEWVAQIKDYYNAYAAYYAPSVKGRFTISRDDSKNSIYLQMNSLKTEDTAVYYCHYVHYASASTLLPAEGVDAWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCQPSQEVVHMNRNTYLHWYQQKPGQAPRLLIYKVSNRFPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQGTSHPFTFGQGTKLEIK,None;None,None;None,None;None,2024,na,DLL3;CD3&TNFRSF9/CD137/4-1BB,Roche,na,Neuroendocrine tumours;Small cell lung cancer,na,,,Humanised;Humanised,RO 7616789;RO-7616789;RO7616789
Clesrovimab,Whole mAb,G1,Kappa,Preregistration,Active,EVQLVESGGGLVRPGRSLRLSCTVSGFSFDDSAMSWVRQAPGKGLEWISFIKSKTYGGTKEYAASVKGRFTISRDDSKNIAYLQMNSLKTEDTAVYYCTRGAPYGGNSDYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQDVRGALAWYQQKPGKAPKLLIFDASSLETGVPSRFSGSGSGTVFTLTISSLQPEDFAAYYCQQFLDFPFTFGQGTRLEIK,na,na,6ous:MN:OP:QR:ST:UV:WX/9mml:MN/9mmv:MN,None,None,2022,2022,RSV gpF,Merck Sharp & Dohme,na,Respiratory syncytial virus infections,na,,,Genetically human,MK-1654;MK1654;RB1;RB-1
Cliramitug,Whole mAb,G1,Kappa,TBC,TBC,QLQLQESGPGLVKPSETLSLTCSVSGGSIISRSSYWGWIRQPPGKGLEWIGGIYHSGNTYDNPSLKSRLTMSVDTSKNQFSLNLRSVTAADTAVYYCARIVPGGDAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTIACRASQSVGTYLNWYQQKRGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSPPTFGQGTKVEIK,na,na,None,None,None,2025,na,Misfolded TTR,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Clivatuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,QVQLQQSGAEVKKPGASVKVSCEASGYTFPSYVLHWVKQAPGQGLEWIGYINPYNDGTQYNEKFKGKATLTRDTSINTAYMELSRLRSDDTAVYYCARGFGGSYGFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTMTCSASSSVSSSYLYWYQQKPGKAPKLWIYSTSNLASGVPARFSGSGSGTDFTLTISSLQPEDSASYFCHQWNRYPYTFGGGTRLEIK,na,na,None,None,None,2009,2010,MUC1/PEM/EMA,Immunomedics,na,na,Pancreatic cancer,,ADC with tetraxetan,Humanised,IMMU-107;IMMU107
Cobolimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAAASGFTFSSYDMSWVRQAPGKGLDWVSTISGGGTYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIRRYLNWYHQKPGKAPKLLIYGASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQSHSAPLTFGGGTKVEIK,na,na,8gsi:BA,None,None,2018,2019,HAVCR2/TIM3,AnaptysBio;GlaxoSmithKline;TESARO,na,Non-small cell lung cancer;Liver cancer;Malignant Melanoma,Solid tumours,,,Humanised,GSK-4069889;GSK4069889;TSR 022;TSR-022;TSR022;WBP 296A;WBP-296A;WBP296A
Codrituzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK,na,na,None,None,None,2013,2014,GPC3,Perseus Proteomics;Chugai Pharmaceutical;Roche,na,Liver cancer,na,,,Humanised,GC-33;GC33;RG-7686;RG7686;RO-5137382;RO5137382
Cofetuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGPEVKKPGASVKVSCKASGYTFTDYAVHWVRQAPGKRLEWIGVISTYNDYTYNNQDFKGRVTMTRDTSASTAYMELSRLRSEDTAVYYCARGNSYFYALDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGKSFMHWYQQKPGQAPRLLIYRASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNEDPWTFGGGTKLEIK,na,na,None,None,None,2017,2018,PTK7,Stemcentrx;Indiana University;Pfizer;Stemcentrx,na,na,Breast cancer;Non-small cell lung cancer;Solid tumours,,,Humanised,ABBV-647;ABBV647;PF-06647020;PF06647020;PF-6647020;PF6647020;PF-7020;PF7020
Coltuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTDYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,6ani:HL:IM,None,None,2013,2014,CD19,ImmunoGen,na,Diffuse large B cell lymphoma,Precursor cell lymphoblastic leukaemia-lymphoma,,ADC with ravtansine,Chimeric,SAR3419;SAR-3419
Comekibart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVSYISSGSTTIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARISTVVAKRYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQINALPFTFGQGTKLEIK,na,na,None,None,None,2024,2024,IL4R/CD124,Shanghai Maiji Biotechnology,na,Atopic dermatitis;Asthma,na,,,Humanised,BC005;BC-005;BC 005;MG-010;MG010;MG 010;MG-K10;MG K10
Conatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYFWSWIRQLPGKGLEWIGHIHNSGTTYYNPSLKSRVTISVDTSKKQFSLRLSSVTAADTAVYYCARDRGGDYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQGISRSYLAWYQQKPGQAPSLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGSSPWTFGQGTKVEIK,na,na,4n90:DE:FG:HI,None,None,2008,2009,TNFRSF10B/CD262/DR5/TRAILR2,Amgen;Takeda,na,na,Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma;Solid tumours,Abgenix XenoMouse,,Genetically human,AMG-655;AMG655
Concizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQTPEKRLEWVATISRSGSYSYFPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGGYDEGDAMDSWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLESDGKTYLNWYLQKPGQSPQLLIYLVSILDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQATHFPQTFGGGTKVEIK,na,na,4dtg:HL,None,None,2012,2013,TFPI,Novo Nordisk,Haemophilia B,Haemophilia A;Haemophilia,na,,,Humanised,mAb-2021;mAb2021;NN-7415;NN7415
Coprelotamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2020,2021,ERBB2/CD340/HER2,Genor Biopharma,na,HER2 positive breast cancer,Breast cancer,,Coprelotamab has an identical Variable region to Anvatabart; Cinrebafusp; Trastuzumab;  and Timigutuzumab. Jul '23: Corrected by removing biosimilar label.,Humanised,GB 221;GB221;GB-221
Coramitug,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLELVAEINNSGDTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHYYYGGGYGGWFFDVWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQLLIYRVSNLASGVPSRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPLTFGQGTKLEIK,na,na,None,None,None,2023,2024,Misfolded TTR,Neotope Biosciences;Novo Nordisk,na,Transthyretin-related hereditary amyloidosis;Cardiovascular disorders,na,,Chimeric: Mouse/Human,Chimeric,NNC6019;NNC-6019;PRX004;PRX-004
Cosfroviximab,Whole mAb,G1,Kappa,Phase-II,Active,DVKLLESGGGLVQPGGSLKLSCAASGFSLSTSGVGVGWFRQPSGKGLEWLALIWWDDDKYYNPSLKSQLSISKDFSRNQVFLKISNVDIADTATYYCARRDPFGYDNAMGYWGQGTSVTVSS,DIVMTQSPLSLSTSVGDRVSLTCKASQNVGTAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADYFCQQYSSYPLTFGAGTKLELR,na,na,None,5kel:CD:JN:MO/5kem:DE:IJ/5ken:GH:QP:CD:NO:JI,None,2016,2017,Zaire Ebolavirus Glycoprotein,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,,Chimeric,c13C6-FR1-N
Cosibelimab,Whole mAb,G1,Lambda,Approved,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAISWVRQAPGQGLEWMGVIIPAFGEANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Dana-Farber Cancer Institute;Checkpoint Therapeutics;TG Therapeutics Inc,Squamous cell cancer,Cancer;Non-small cell lung cancer,Lymphoma,,,Genetically human,CK 301;CK301;CK-301;TG 1501;TG1501;TG-1501
Crebankitug,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFDDSVMHWVRQAPGKGLEWVSLVGWDGFFTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQGDYMGNNWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIDSSYVQWYQQRPGSSPTTVIYEDDQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDFHHLVFGGGTKLTVL,na,na,None,None,None,2024,2024,IL7R/CD127,Pfizer;Zura Bio,na,Atopic dermatitis;Ulcerative colitis;Multiple sclerosis;Type 1 diabetes mellitus;Alopecia areata;Immunological disorders,TBC,,,Genetically human,ZB-168;ZB168;ZB 168
Crefmirlimab,scFv Engineered Dimer,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHFVRQAPGKGLEWIGRIDPANDNTLYASKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCGRGYGYYVFDHWGQGTLVTVSS,DVQITQSPSSLSASVGDRVTITCRTSRSISQYLAWYQQKPGKVPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQHNENPLTFGGGTKVEIK,na,na,None,None,None,2022,2022,CD8A,ImaginAb,na,Solid tumours;Cervical cancer;Gastic cancer,Graft-versus-host disease,,Uses G1 and CH3 region in the dimer. Genetics: musmus/homosap,Chimeric and/or humanised,IAB 22 M2C;IAB-22-M2C
Crenezumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,5vzx:HL:EI/5vzy:HL,5kmv:HL:EI,None,2011,2012,APP,AC Immune;Genentech;Universidad de Antioquia,na,na,Alzheimer's disease,,,Humanised,MABT5102A;MABT-5102A;R 5490245;R5490245;R-5490245;RG 7412;RG7412;RG-7412;RO 5490245;RO5490245;RO-5490245
Crexavibart,Whole mAb,G1,Lambda,Phase-II/III,Active,EVQLVESGGGLIQPGGSLRLSCAASGFTVSNNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDKSKNTLYLQMNSLRAEDTAVYYCAREGEVEGYNDFWSGYSRDRYYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL,na,na,None,7k90:HL:MN:OP/8dce:HH,None,2022,2022,SARS-CoV-2 Spike RBD,NIAID,na,COVID-19,na,,,Genetically human,C-144-LS;BMS-986413;BMS986413;BMS 986413
Crizanlizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYDINWVRQAPGKGLEWMGWIYPGDGSIKYNEKFKGRVTMTVDKSTDTAYMELSSLRSEDTAVYYCARRGEYGNYEGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGHSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDENPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,SELP/CD62,Selexys Pharmaceuticals;Novartis,Vaso-occlusive crisis,Priapism;Myelofibrosis;COVID-19,na,,,Humanised,SEG-101;SEG101
Crotedumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYLMNWVRQAPGKGLEWLANIQEDGIEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREPSHYDILTGYDYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFILTVSSLQPEDFATYYCLQYNSNPFTFGPGTKVDIK,na,na,None,None,None,2015,2016,GCGR,Regeneron Pharmaceuticals;Sanofi,na,na,Type 2 diabetes mellitus,,,Genetically human,REGN-1193;REGN1193
Crovalimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGLVQPGRSLRLSCAASGFTVHSSYYMAWVRQAPGKGLEWVGAIFTGSGAEYKAEWAKGRVTISKDTSKNQVVLTMTNMDPVDTATYYCASDAGYDYPTHAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSSLAWYQQKPGKAPKLLIYGASETESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNTKVGSSYGNTFGGGTKVEIK,na,na,5b71:DC:BA,None,None,2018,2019,C5,Chugai Pharmaceutical;Roche,Paroxysmal nocturnal haemoglobinuria ,Atypical Haemolytic Uraemic Syndrome,na,,,Genetically human,CH 7092230;CH7092230;CH-7092230;RG 6107;RG-6107;RG6107;RO 7092230;RO-7112689;RO7112689;SKY 59;SKY-59;SKY59
Crusekitug,Whole mAb,G1,Kappa,TBC,TBC,EVQLQESGPGLVKPSETLSLTCTVSGIDLSLFYMSWIRQPPGKGLEWIGTIHEVASSYYASWAKGRVTISKDTSKNQFSLKLSSVTAADTAVYYCARETYSSRYPYPNIWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCQASQNIGGSLAWYQQKPGKAPKLLIYGASSLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSYNTISTYGLAFGGGTKVEIK,na,na,None,None,None,2025,na,IL17A,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Cudarolimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGRPWYSETGTSAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQSDHYPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,Innovent Biologics,na,na,Solid tumours,,,Genetically human,IBI-101;IBI101
Cugrastomig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSISDYYWNWIRQPPGKGLEWIGEINHRGTTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYDWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQTISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTNLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,None;None,None;None,7um3:HL:IM;None,2024,2024,LAG3/CD223;PDCD1/CD279/PD1,Akeso Biopharma;Kangfang Huike (Shanghai) Biology Co,na,HER2-negative gastric cancer;Neoplasms;Refractory Hodgkin Lymphoma,na,,Ivonescimab Fv2; Penpulimab; and Cugrastomig Fv2 have the same sequences.,Genetically human,AK 129;AK-129;AK129
Cusatuzumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSVYYMNWVRQAPGKGLEWVSDINNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDAGYSNHVPIFDSWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGLKSGSVTSDNFPTWYQQTPGQAPRLLIYNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVEFGGGTQLTVL,na,na,None,None,None,2017,2018,CD70,arGEN-X,na,Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours,Nasopharyngeal cancer;Autoimmune disorders,POTELLIGENT Technology. SIMPLE Antibody Technology.,,Humanised,ARGX-110;ARGX110;JNJ 74494550;JNJ74494550;JNJ-74494550;JNJ-4550;JNJ4550
Dacetuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK,na,na,8yx9:HL:BC:EF:GI,None,None,2007,2008,TNFRSF5/CD40,Seattle Genetics,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma,,,Humanised,huS2C6;PRO 64553;PRO-64553;PRO64553;RG 3636;RG3636;RG-3636;SGN 14;SGN14;SGN-14;SGN-40;SGN40
Daclizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK,na,na,3nfs:HL/3nfp:HL:AB,None,None,1994,1998,IL2RA/CD25,AbbVie;Biogen;Dana-Farber Cancer Institute;National Cancer Institute (USA);PDL BioPharma,Renal transplant rejection,Multiple sclerosis,Asthma;Graft-versus-host disease;Haematological malignancies;Immune-mediated uveitis;Liver transplant rejection;Psoriasis;Tropical spastic paraparesis;Type 1 diabetes mellitus;Ulcerative colitis,GS Gene Expression System,Daclizumab is the new name for Dacliximab (PL78). Biosimilar available,Humanised,BIIB-019;BIIB019;Dacliximab;RO 247375;RO247375;RO-247375;Zenapax;Zinbryta
Dafsolimab,Whole mAb,G2b,Kappa,Phase-III,Active,QVQLQQSGAELARPGASVKMSCKASGYTFTSYTMHWVKQRPGQGLEWIGYINPSSGYTNYIQRFKDKATLTADKSSSTAYMQVSSLTSEDSAVYYCARGSRYDYYGMDYWGQGTSVTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK,na,na,None,None,None,2020,2021,CD3E,Xenikos,na,Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease,na,,ADC with setaritox,Murine,SPV-T3a;SPVT3a
Dalidnetug,Whole mAb,G1,Kappa,TBC,TBC,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGSGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGEPASISCKSSQSLLDYDGKTYLNWLLQKPGQSPQRLIYRVTNRDTGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRSFGQGTKVEIK,na,na,None,None,None,2025,na,APP,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Dalnicastobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2022,2023,TNFRSF5/CD40,MD Anderson Cancer Center;Lyvgen Biopharma,na,Cancer;Gastric cancer;Head and neck cancer;Esophageal;Hepatocellular carcinoma;Metastatic cancer,na,,,Genetically human,LVGN-7409;LVGN7409
Dalotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK,na,na,None,None,None,2009,2010,IGF1R/CD221,Pierre Fabre;Merck & Co,na,na,Multiple myeloma;Neuroendocrine tumours;Non-small cell lung cancer;Solid tumours;Breast cancer;Colorectal cancer;Pancreatic cancer ,,"Jain paper: ""Entries in WHO-INN documents (PL102 and RL64) have errors""",Humanised,F 50 035;F-50-035;h7C10;MK-0646;MK0646;MK-646;MK646
Dalutrafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKASGYAFSSSWINWVRQMPGKGLEWMGRIYPRAGDTNYAGKFKDQVTISADKSISTAYLQWSSLKASDTAMYYCASLLDYSMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPLTFGQGTKVEIK,na,na,None,None,None,2021,2022,TGFBR2,Gilead Sciences,na,na,Solid tumours,,,na,AGEN-1423;AGEN1423;GS-1423;GS1423
Danburstotug,Whole mAb Fusion,G1,Lambda,Phase-III,Active,QMQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAYSWVRQAPGQGLEWMGGIIPSFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGPIVATITPLDYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTATIACGGENIGRKTVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCLVWDSSSDHRIFGGGTKLTVL,na,na,None,None,None,2022,2022,PDL1/CD274,Sorrento Therapeutics;Asan Medical Center;ImmuneOncia Therapeutics,na,Extranodal NK-T-cell lymphoma;Gastric cancer;Liver cancer;Oesophageal cancer;Solid tumours,na,,,Genetically human,IMC-001;IMC001;STI-3031;STI3031;STI-A1015;STIA1015
Danvilostomig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPGKGLEYIGYIGDTTGIAYASWANGRFTISKDNTKNTVDLQMNSLRAEDTAVYYCARGWSYLDIWGQGTLVTVSS,ALVMTQSPSSLSASVGDRVTITCQASQNIYSNLAWYQQKPGKVPKLLIYQASTLASGVPSRFSGSGYGTDFTLTISSLQPEDVATYYCQGGYYSAALNTFGGGTKVEIK,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL;None,None;None,7su0:HL:IM/7su1:HL;None,2022,na,CTLA4/CD152;PDCD1/CD279/PD1,Sichuan Baili Pharmaceutical;SystImmune,na,na,Cervical cancer;Colorectal cancer;Gastric cancer;HER2 negative breast cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Solid tumours;Squamous cell cancer;Urogenital cancer,,Danvilostomig Fv1;Ipilimumab; Sovipostobart; and Tazlestobart all have the same sequence,Genetically human;Humanised,SI-B003;SI B003
Dapirolizumab,Fab,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSSTNYHVHWVRQAPGKGLEWMGVIWGDGDTSYNSVLKSRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARQLTHYYVLAAWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDLYYNLAWYQRKPGKAPKLLIYDTYRLADGVPSRFSGSGSGTDYTLTISSLQPEDFASYYCQQYYKFPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD40LG/CD154,Biogen;Biogen Idec;UCB,na,Systemic lupus erythematosus;Multiple sclerosis,Amyotrophic lateral sclerosis;Rheumatoid Arthritis,,,Humanised,BIIB 133;BIIB133;BIIB-133;CDP-7657;CDP7657
Daratumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK,na,na,7dun:HL/7duo:HL/7dha:CB,None,None,2009,2010,ADPRC1/CD38,Boston Medical Center;Bristol-Myers Squibb;Dana-Farber Cancer Institute;French Innovative Leukemia Organisation;Genentech;Genmab;Janssen Biotech;Janssen Research & Development;M. D. Anderson Cancer Center;Syros Pharmaceuticals,Multiple myeloma,Amyloid light-chain amyloidosis;Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Myelodysplastic syndromes;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor T-cell lymphoblastic leukaemia-lymphoma;Prostate cancer;T-cell lymphoma;Waldenstrom's macroglobulinaemia;Solid tumours,Non-small cell lung cancer,Medarex HuMAb Mouse,,Genetically human,DALINVI;Darasarex;DARZALEX;HuMax-CD38;JNJ-54767414;JNJ54767414
Daretabart,Whole mAb,G1,Kappa,TBC,TBC,EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGTQGSVTVSS,DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,None,2025,na,Ganglioside GD2,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Dargistotug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTSYPMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARVGGYSVDEYAFDVWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLSSYPTFGGGTKVEIK,na,na,None,None,None,2022,2023,TIGIT/WUCAM/VSTM3,Merck;Gilead;Nektar Therapeutics,na,na,Solid tumours;Carcinoma;Bladder cancers;Metastatic cancers;Urothelial cancers,,,Genetically human,M6223;M-6223
Datopotamab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWMGWINTHSGVPKYAEDFKGRVTISADTSTSTAYLQLSSLKSEDTAVYYCARSGFGSSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,TACSTD2/TROP2/EGP1,Daiichi Sankyo,HER-2 negative breast cancer,Non-small cell lung cancer;Triple negative breast cancer;Solid tumours;Gastric cancer;Urogenital cancer,na,,ADC with deruxtecan,Humanised,DS 1062a;DS1062a;DS-1062a;DS-1062;DS1062;S-1062a;S1062a
Davutamig,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGTSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGITWNSYNIDYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDDDYSNYVYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFIVTTNYMTWLRQAPGKGLEWVSLIYSSGHTYYADSVKGRFTISRHNSKNTLYLQMDSLRAEDTAVYYCASAFAADVFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2023,2023,MET/HGFR;MET/HGFR,Regeneron Pharmaceuticals,na,Cancers;Non-small cell lung cancer,na,,Biparatopic,Genetically human;Genetically human,REGN 5093;REGN-5093;REGN5093
Daxdilimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTIDTSTSTAYMELRSLRSDDTAVYYCARNGLWGWDSDAFDIWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTVVFGGGTKVTVL,na,na,None,None,None,2020,2021,LILRA4/CD85g,Viela Bio,na,Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury,na,,,Genetically human,HZN-7734;HZN7734;MEDI-7734;MEDI7734;VIB-7734;VIB7734
Dazukibart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWMHWVRQAPGQGLEWMGHIDPSDSYTYYNQKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWDYGNLLFEYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQDIGNYLNWYQQKPGKAFKLLIYSTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGIILPITFGGGTKVEIK,na,na,None,None,None,2023,2023,IFNB1,Pfizer,na,Dermatomyositis,na,,,Humanised,PF-06823859;PF06823859
Dectrekumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLWFGDLDAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERAILSCRAGQSVSSYLVWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPVYTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL13,Novartis,na,na,Asthma;Idiopathic pulmonary fibrosis;Keloids;Oesophagitis;Rectal fistula;Seasonal allergic rhinitis,,,Genetically human,QAX-576;QAX576
Delpacibart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWIGEINPINGRSNYAEKFQGRVTLTVDTSSSTAYMELSRLRSDDTAVYYCARGTRAMHYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWGTPLTFGGGTKVEIK,na,na,None,None,None,2022,2023,TFRC/CD71,Avidity Biosciences,na,Myotonic dystrophy,na,,ADC with Braxlosiran or Etedesiran or Zotadirsen,Humanised,AOC1001;AOC-1001
Demcizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISSYNGATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Celgene Corporation;OncoMed Pharmaceuticals,na,na,Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours,,,Humanised,OMP-18M21;OMP18M21;OMP-21M18;OMP21M18
Demupitamab,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,None,5sx4:HL:JI/5sx5:HL:JK,None,2019,2020,EGFR/ERBB1/HER1,Sinocelltech,na,Cancers,na,,Likely to be a Panitumumab biosimilar,Genetically human,N63Ab
Denecimig,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFHDYAMHWVRQVPGKGLEWVSGISWRGDIGGYVKSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKSYGSGSFYNAFDSWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKFLIYKASKLERGTPSRFSGSGSGTEFSLTISSLQPDDFATYYCLEYSSYIRTFGQGTKVEIK,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTSWIVWVRQMPGKGLEWMGMIDPSDSFTSYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARLHYYNSEEFDVWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGQSSRTRGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSQLFTFGQGTKLEIK,None;7ahu:BA:HL,7ahv:AB;None,None;None,2022,2023,F9;F10,Genmab;Novo Nordisk,na,Haemophilia A,na,Human antibody phage display library. Transgenic mice.,Aug '23: Corrected name,Genetically human;Genetically human,NN-7769;NN7769;NNC0365-3769;Mim8;Mim-8
Denikitug,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQASGKGLEWVGRIRSKSNNYATYYADSVKDRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRGLLRYRFFDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPFTFGGGTKVEIK,na,na,None,None,None,2024,2024,CCR8/CKR-L1/CDw198,Jounce Therapeutics;Concentra Biosciences;Gilead Sciences,na,na,Solid tumours,,Humanised: musmus/homosap,Humanised,GS-1811;GS1811;GS 1811;JTX-1811;JTX1811;JTX 1811 
Denintuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPGKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQGSVYPFTFGQGTKLEIK,na,na,None,None,None,2014,2015,CD19,Seattle Genetics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,ADC with mafodotin,,Humanised,SGN-19A;SGN19A
Denosumab,Whole mAb,G2,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,None,2005,2006,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,Amgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network,Bone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis,Breast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma,Multiple myeloma ,Abgenix XenoMouse,Biosimilars available,Genetically human,AMG162;AMG-162
Denrakibart,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIDPSDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVGPADVWDAFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLLSFDNINKLAWYQQKPGQPPKLLIYDASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQFYSVPSTFGQGTKVEIK,na,na,None,5wk2:HL/5wk3:QP:SR:UT:WV,None,2024,na,CCL17/ABCD-2/SCYA17/TARC,GSK,na,Pain,na,,,Genetically Human,GSK-3858279;GSK 3858279 ;GSK3858279 
Depatuxizumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDFAWNWIRQPPGKGLEWMGYISYSGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTAGRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR/ERBB1/HER1,Ludwig Institute for Cancer Research;AbbVie,na,na,Solid tumours,,,Chimeric and humanised,ABT-806;ABT806;ch806;ch-806
Depemokimab,Whole mAb,G1,Kappa,Phase-III,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,2020,2021,IL5,GlaxoSmithKline,na,Asthma,na,,,Humanised,AQ82742999;AQ-82742999;GSK 294;GSK-294;GSK294;GSK-3511294;GSK3511294
Derlotuximab,Whole mAb Radiolabelled,G1,Kappa,Approved,Active,QVQLKESGPGLVAPSQSLSITCTVSGFSLTDYGVRWIRQPPGKGLEWLGVIWGGGSTYYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKEKRRGYYYAMDYWGQGTSVTVSS,ENVLTQSPAIMSASPGEKVTMTCRASSSVSSSYLHWYQQKSGASPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSVEAEDAATYYCQQYSGYPLTFGGGTKLEIK,na,na,None,None,None,2015,2016,DNA/H1 Complex,Avid Bioservices;MediPharm Biotech,Lung cancer,Glioblastoma,na,,,Chimeric,TNT-1;TNT1
Devextinetug,Whole mAb,G2,Kappa,Phase-II,Active,EIQLQQSGPELGKPGASVKVSCRASGFSFADYYIYWVKQSHGKSLELIGYIDPFNGGDTYNQIFKGKATLTVDKSSSTAFMYLNSLTSEDSAVYYCAAFRNPSFDFWGQGTTLTVSS,QIVLIQSPPIMSASPGEKVTLTCSASSSVSSRYLYWYQQKPGSSPKLWIYGTSNLASGVPARFSGSGSGTSFSLTISSMEAEDAASYFCHQWSSFPFTFGSGTKLEIK,na,na,None,None,None,2022,2023,Metamphetamine,InterveXion Therapeutics;NIDA,na,Methamphetamine overdose,na,,,Chimeric,IXT-M200;IXT M200;IXTM200
Dezamizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFATYNMHWVRQAPGQGLEWMGYIYPGDGNANYNQQFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGDFDYDGGYYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIHNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGAPLTFGQGTKLEIK,na,na,None,None,None,2016,2017,APCS/SAP,Pentraxin Therapeutics;GlaxoSmithKline,na,na,Amyloidosis,,,Humanised,GSK-2398852;GSK2398852
Dibotatug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLLESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISTSSNFIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLGRYYYYMDVWGKGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKSLIYAASSLQSGVPSKFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK,na,na,None,None,None,2024,2024,KLRD1/CD94,Dren Bio,na,Large granular lymphocytic leukaemia Lymphoma;Autoimmune disorders,na,Transgenic Mouse,,Genetically human,DR-01;DR01;DR 01
Dilpacimab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFPMAWVRQAPGKGLEWVATISSSDGTTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGYYNSPFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDIYSNLAWYQQKPGKAPKLLIYDTNNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPPTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,None;1bj1:HL:KJ/7v5n:BA:FE,None;None,None;6bft:HL:AB/1cz8:HL:YX,2018,2019,DLL4;VEGFA,AbbVie,na,Colorectal cancer;Solid tumours,na,,,Humanised;Humanised,ABT-165;ABT165
Dinutuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS,EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:AB:CD/4tuk:HL,2013,2014,Ganglioside GD2,National Cancer Institute (USA);New Approaches to Neuroblastoma Therapy Consortium;St. John of God Foundation;United Therapeutics Corporation,Neuroblastoma,Small cell lung cancer,Malignant melanoma,,,Chimeric,ch14.18;Ch14.18OP 08;OP08;OP-08
Diridavumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGAEVKKPGSSVKVSCKASGGPFRSYAISWVRQAPGQGPEWMGGIIPIFGTTKYAPKFQGRVTITADDFAGTVYMELSSLRSEDTAMYYCAKHMGYQVRETMDVWGKGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNDYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEANYYCATWDRRPTAYVVFGGGTKLTVL,na,na,3gbn:HL/3gbm:HL:IM/5c0s:HL/6uyn:HL/8dim:HI:BC:EF/8diu:EF:GC:HI/8dis:HL:AC:BG/8f38:DG:EH:FI,None,4evn:AB:CD:IJ:OP:KL:EF:GH:MN,2014,2015,Influenza A HA2,National Institute of Allergy and Infectious Diseases;Crucell,na,Influenza A virus (H1N1) infections,na,,,Genetically human,CR-6261;CR6261;JNJ-54235025;JNJ54235025;mAb CR6261;mAb-CR6261
Disitamab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDYYIHWVQQAPGKGLEWMGRVNPDHGDSYYNQKFKDKATITADKSTDTAYMELSSLRSEDTAVYFCARNYLFDHWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQFATYTFGGGTKVEIK,na,na,None,None,None,2018,2019,ERBB2/CD340/HER2,Yantai Rongchang Biological Engineering,Gastric cancer,Breast cancer;Urogenital cancer;Non-small cell lung cancer;Cholangiocarcinoma;Lung cancer,Solid tumours,,ADC with vedotin,Humanised,Aidixi;RC 48;RC48;RC-48
Divozilimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQPGAEVVKPGASVKVSCKASGYTFTSYNMHWVRQAPGRGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDKSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTLVTVSS,QIVLSQSPAILSASPGERVTLTCRASSSVSYIHWFQQKPGKAPKPLIYATSNLASGVPSRFSGSGSGTDFSLTISRVEPEDFAVYYCQQWTSNPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,MS4A1/CD20,Biocad,na,Relapsing-remitting multiple sclerosis,na,,Genetics: musmus/homosap,Chimeric and/or humanised,BCD-132;BCD132
Docaravimab,Whole mAb (Mouse),G2b,Kappa,Approved,Active,QVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS,DVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK,na,na,None,None,None,2019,2020,Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-III,Candila Healthcare,Rabies,na,na,,Mouse antibody,Murine,MAb 62-71-3;Zydus Cadila (cocktail with Miromavimab);Rabimabs (cocktail with Miromavimab);Twinrab (cocktail with Miromavimab))
Domagrozumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSTISSGGSYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQDYAMNYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKVEIK,na,na,None,5f3h:EF:GH:AB:CD,None,2015,2016,MSTN/GDF8/GDF-8,Kennedy Krieger Institute;Pfizer,na,na,Duchenne muscular dystrophy;Limb girdle muscular dystrophies,,,Humanised,PF 6252616;PF6252616;PF-06252616;PF06252616
Domvanalimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFGMHWVRQAPGKGLEWVAFISSGSSSIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARMRLDYYAMDYWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKSISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPWTFGGGTKVEIK,na,na,None,None,None,2020,2021,TIGIT/WUCAM/VSTM3,Arcus Biosciences,na,Solid tumours;Non-small cell lung cancer,na,,,Humanised,AB 154;AB154;GS-0154;GS0154
Donanemab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYDFTRYYINWVRQAPGQGLEWMGWINPGSGNTKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCAREGITVYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSRGKTYLNWLLQKPGQSPQLLIYAVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGTHYPFTFGQGTKLEIK,na,na,None,None,None,2018,2019,APP,Eli Lilly,na,Alzheimer's disease,na,,,Humanised,LY 3002813;LY3002813;LY-3002813
Donitabart,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGSSFTGKNMNWVRQNIGQGLEWMGAIDPFYGGTSYNQKFKGRVTLTVDKSISTAYMELSRLRSDDTAVYYCVSGMFYWGQGTLVTVSS,DIVMTQTPLSLSVTPGERASLSCRSSQNLVHRNGNTYLHWYLQKPGQSPKLLIHKVNNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPPLTFGQGTKLELK,na,na,None,None,None,2024,2024,Ganglioside GD2,Biocad CJSC,na,na,Neuroblastoma,,Humanised: musmus/homosap,Humanised,BCD 245;BCD-245;BCD245
Donzakimig1,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Bispecific entry,G1;na,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSLSSYAMIWVRQAPGKGLEWIGIIDIEGSTYYASWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARDRFVGVDIFDPWGQGTLVTVSS,AVQLTQSPSSLSASVGDRVTITCQASEDIYTNLAWYQQKPGKAPKLLIYWASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQASVYGNAADSRYTFGGGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKCLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGCGTKVEIK,None;None,None;5fuo:HL/5fuz:HL,None;None,2023,2024,IL22;ALB,UCB Biopharma,na,Atopic dermatitis,na,,VH-CH1-h-scFv_L-kappa segment. Fv2 identical to Galvokimig Fv2.,Humanised;Humanised,UCB-1381;UCB 1381;UCB1381
Donzakimig2,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Monospecific entry,na,Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYYIHWVRQAPGQCLEWMGRIGPGSGDINYNEKFKGRATFTVDKSTSTAYMELSSLRSEDTAVYYCARFHYDGADWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNINENLDWYQQKPGKAPKLLIYYTDILQTGIPSRFSGSGSGTDYTLTISSLQPEDFATYYCYQYYSGYTFGCGTKLEIK,na,na,None,None,None,2023,2024,IL13,UCB Biopharma,na,Atopic dermatitis,na,,Final scFv segment. Fv3 identical to Galvokimig Fv3,Humanised,UCB-1381;UCB 1381;UCB1381
Dostarlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSTISGGGSYTYYQDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASPYYAMDYWGQGTTVTVSS,DIQLTQSPSFLSAYVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTLHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHYSSYPWTFGQGTKLEIK,na,na,7wsl:HL,None,None,2018,2019,PDCD1/CD279/PD1,AnaptysBio;European Network of Gynaecological Oncological Trial Groups;GlaxoSmithKline;TESARO,Endometrial cancer;Solid tumours,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer;Breast cancer;Cervical cancer;Liver cancer;Malignant melanoma;Neuroendocrine tumours;Pancreatic cancer;Rectal cancer;Small cell lung cancer;Squamous cell cancer,na,,,Humanised,ANB 011;ANB011;ANB-011;GSK-4057190;GSK4057190;JEMPERLI;TSR 042;TSR042;TSR-042;WBP 285;WBP285;WBP-285
Dovanvetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVLLVQSGAEVRTPGASVKIFCKASGYSFTSYTIHWLRQAPAQGLEWMGNINPTSGYTENNQRFKDRLTLTADTSTNTAYMELSSLRSADTAMYYCARWGFKYDGEWSFDVWGAGTTVTVSS,EIQMTQSPSSLSASPGDRVTITCRASQGISIWLSWYQQKPGNIPKVLINKASNLHIGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCLQSQTYPLTFGGGTKLEIK,na,na,None,None,None,2019,2020,IL31 (Feline),na,na,na,na,,,Felinised,ZTS-00521505;ZTS00521505
Dresbuxelimab,Whole  mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSS,DIVMTQSPSSLAVSVGERVTISCKSSQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK,na,na,None,None,None,2021,2022,NT5E/CALJA/CD73,Akeso Biopharma,na,COVID-19,na,,,Humanised,AK-119;AK119
Drotokibart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAFISSGSSIIYYADIVKGRSTISRDNAKNTLYLQMNSLRAEDTAVYYCTRGNKRGFFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVPYMYWYQQKPGQAPRLLIYLTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWRAYPPMLTFGGGTKVEIK,na,na,None,None,None,2024,na,IL4R/CD124,Shanghai Hengrui Pharmaceutical,na,Atopic dermatitis;Prurigo nodularis;Sinusitis,Asthma,,,Humanised,SHR 1819;SHR-1819;SHR1819
Drozitumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS,SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL,na,na,4od2:BA,None,None,2010,2011,TNFRSF10B/CD262/DR5/TRAILR2,Genentech,na,na,Chondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer,,,Genetically human,PRO-95780;PRO95780;RG7425;RG-7425
Duligotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK,na,na,None,None,3p0v:HL:IM/3p0y:HL/3p11:HL,2012,2014,ERBB3/HER3,Genentech;Roche,na,na,Solid tumours;Colorectal cancer;Head and neck cancer,,Duligotuzumab is the new name for Duligotumab (PL110),Humanised,MEHD-7945A;MEGD7945A;RG 7597;RG7597;RG-7597;RO-5541078;RO5541078
Dupilumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK,na,na,6wgb:AB:CD/6wgj:AB:CD:EF/6wgk:AB:CD:EF:GH/6wgl:AB/6wg8:AB,None,None,2012,2013,IL4R/CD124,Aimmune Therapeutics;Regeneron Pharmaceuticals;Sanofi,Asthma;Atopic dermatitis;Nasal polyps,Chronic obstructive pulmonary disease;Eosinophilic oesophagitis;Grass pollen hypersensitivity;Peanut hypersensitivity;Urticaria,Allergic asthma,VelocImmune Mouse,,Genetically human,Dupixent;REGN-668;REGN668;SAR-231893;SAR231893
Durvalumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK,na,na,5xj4:HL/5x8m:BC,None,None,2014,2015,PDL1/CD274,Advaxis;AIO Studien gGmbH;AstraZeneca;Big Ten Cancer Research Consortium;Canadian Cancer Trials Group;Case Comprehensive Cancer Center;Celgene International SARL;Centre hospitalier de l'Universite de Montreal;Centre Leon Berard;Charite - Universitatsmedizin Berlin;Childrens Hospital Los Angeles;Dana-Farber Cancer Institute;Eli Lilly;Fondazione IRCCS Istituto Nazionale dei Tumori;GlaxoSmithKline;Gradalis;Grand Hopital de Charleroi;Grupo Espanol de Tumores Neuroendocrinos;Gustave Roussy;Immunocore;Innate Pharma;Institut Claudius Regaud;Juno Therapeutics;Kyoto Breast Cancer Research Network;Ludwig Institute for Cancer Research;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;Mirati Therapeutics;Myriad Genetic Laboratories;National Cancer Institute (USA);National Health and Medical Research Council;Northwestern University;Pharmacyclics;Plexxikon;Radboud University;Samsung Medical Center;Spanish Oncology Genito-Urinary Group;Swiss Group for Clinical Cancer Research;UNC Lineberger Comprehensive Cancer Center;UNICANCER;University College London;University of Colorado at Denver;University of Kansas Medical Center;University of Maryland Greenbaum Cancer Center;University of Southern California;University of Sydney;University of Texas M. D. Anderson Cancer Center;VentiRx Pharmaceuticals;Washington University School of Medicine;Yale University;Yonsei University College of Medicine,Non-small cell lung cancer;Urogenital cancer;Small cell lung cancer,Biliary cancer;Bladder cancer;Cervical cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Ovarian cancer;Peritoneal cancer;Renal cell carcinoma;Solid tumours;Breast cancer;Gynaecological cancer;Pancreatic cancer;Acute myeloid leukaemia;Brain metastases;Cholangiocarcinoma;Colorectal cancer;Diffuse large B cell lymphoma;Endometrial cancer;Gallbladder cancer;Gastric cancer;Germ cell and embryonal neoplasms;Glioblastoma;Mesothelioma;Multiple myeloma;Myelodysplastic syndromes;Neuroendocrine tumours;Oesophageal cancer;Oropharyngeal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Haematological malignancies;Lung cancer;Lymphoma;Malignant melanoma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Renal cancer;Gastrointestinal cancer;Myelofibrosis;Vulvovaginal cancer,CNS cancer;Lymphoproliferative disorders;Thyroid cancer,,,Genetically human,Imfinzi;MEDI-4736;MEDI4736
Dusigitumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARDPYYYYYGMDVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIENNHVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCETWDTSLSAGRVFGGGTKLTVL,na,na,None,None,None,2012,2013,IGF1 and IGF2,MedImmune,na,na,Breast cancer;Liver cancer;Solid tumours,,,Genetically human,MEDI-573;MEDI573
Duvakitug,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWLNPNSGYTGYAQKFQGRVTMTADRSTSTAYMELSSLRSEDTAVYYCAREVPETAAFEYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTSSSSDIGAGLGVHWYQQLPGTAPKLLIEGYYNRPSGVPDRFSGSKSGTSASLTITGLLPEDEGDYYCQSWDGTLSALFGGGTKLTVL,na,na,None,None,None,2023,2023,TNFSF15/TL1A/VEGI,Sanofi;Teva Pharmaceuticals,na,Inflammatory Bowel Disease,na,,,Genetically human,TEV-574/TEV574/TEV 574/SAR447189/SAR-447189/SAR 447189
Duvortuxizumab,Bispecific scFv with Crossover,na;na,Kappa;Lambda,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS,ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2016,2017,CD19;CD3E,Janssen Biotech;MacroGenics,na,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,,Chimeric and humanised;Chimeric and humanised,JNJ-64052781;JNJ64052781;MGD 011;MGD-011;MGD011;MGD 11;MGD-11;MGD11
Ebdarokimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCQSSGYTFTSYWIGWVRQMPGQGLEWIGIMSPVDSDIRYNPMFRGQVTMSVDKSSSTAYLQWSSLKASDTAMYYCARRRPGQGYFDFWGQGTMVTVSS,EIVLTQSPATLSASPGERATISCRASQSVGTWVAWYQQKPGQAPRSLIYAASNLQSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYNIYPYTFGQGTRLEIK,na,na,None,None,None,2020,2021,IL12B/CLMFp40,Akeso Biopharma,Plaque Psoriasis,Ulcerative colitis;Systemic lupus erythematosus,Crohn's disease;Psoriatic arthritis,,,Humanised,AK-101;AK101
Eblasakimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGVIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARMPNWGSLDHWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYASFGQGTKVEIK,na,na,None,None,4hwe:HL/4hwb:HL,2021,2022,IL13RA1/CD213A1,ASLAN Pharmaceuticals,na,Atopic dermatitis,Asthma,,,Genetically human,ASLAN 004;ASLAN-004;ASLAN004;CSL 334;CSL334;CSL-334;MK 6105;MK6105;MK-6105
Ebrasodebart,Whole mAb,G4,Lambda,Phase-I,Active,QIQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARWGRWLAHDYWGQGTLVTVSS,QAVLTQPPSVSVSPGQTASITCSGDKLGNKNAYWYQQKPGQSPVLVMYQSTRRPSGIPERFSASNSGNTATLTISGTQAMDEADYYCQAWDSSSGWEVFGGGTKLTVL,na,na,None,None,None,2024,2024,TMEM219/IGFBP-3R,Enthera,na,Inflammatory bowel diseases;Type 1 diabetes mellitus,na,,,Genetically human,Ent-001;Ent001;Ent 001
Ebribafusp,Fusion Protein,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYINWVRQAPGQGLEWMGVINPYSGGTSYNQKFKGRVTMTVDTSTSTAYMELSSLRSEDTAVYFCSSPYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGGGTKVEIK,na,na,7ue9:HL,None,None,2024,2024,C3d,Q32 Bio,na,IgA nephropathy;Lupus nephritis;Membranoproliferative glomerulonephritis;Skin disorders,na,,,Chimeric and/or humanised,3d8b;ADX-097;ADX 097;ADX097
Ebronucimab,Whole mAb,G1,Lambda,Approved,NFD,EVQLVESGGGLVQPGRSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSGISSSSSYISYADSVQGRFTISRDNGKNSLYLQMNSLRAEDTALYFCAREYDFWSAYYDAFDVWGQGTMVTVSS,QSELTQPRSVSGSPGQSVTISCTGTSRNIGGGNDVHWYQQHPGKAPKLLISGVIERSSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCQSFDGSLSGSVFGTGTDVTVL,na,na,None,None,None,2020,2021,PCSK9,Akeso Biopharma,Hypercholesterolaemia;Hyperlipoproteinaemia type Iia,na,na,,,Genetically human,AK-102;AK102
Eciskafusp,Fusion Protein,G1,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,na,na,None,None,None,2022,2023,PDCD1/CD279/PD1,Roche,na,Solid tumours,na,,Fv identical in sequence to Tobemstomig and Lomvastomig Fv1.,na,RO7284755;RO-7284755;RG6279;RG-6279
Ecleralimab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYWMHWVRQAPGKGLEWVGHIKSKTDAGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCAREIYYYAFDSWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDNIGSKYVHWYQQKPGQAPVLVIYGDNERPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQAADWVDFYVFGGGTKLTVL,na,na,None,None,None,2021,2022,TSLP,Novartis,na,Chronic obstructive pulmonary disease,Asthma,,,Genetically human,CSJ-117;CSJ117;NOV-14;NOV14
Eclutatug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYGMNWVRQAPGKGLEWVSSISPSGSYFYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLPGFNPPFDHWGQGTLVTVSS,DIQMTQSPATLSVSPGERATLSCKASQNVGGNVDWYQWKPGQAPRLLIYGASNRYTGIPARFRGSGSGTEFTLTISSLQSEDFAVYYCLQYKNNPWTFGQGTKVEIK,na,na,None,None,None,2024,na,CLDN1,INSERM;The Mount Sinai Hospital;University of Strasbourg;Alentis Therapeutics,na,Squamous cell cancer;Solid tumours,Cholangiocarcinoma;Liver cancer,,Conformational epitope of EL1 loop,Humanised,ALE.C04;ALE-C04;ALE C04
Ecromeximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVTLVESGGDFVKPGGSLKVSCAASGFAFSHYAMSWVRQTPAKRLEWVAYISSGGSGTYYSDSVKGRFTISRDNAKNTLYLQMRSLRSEDSAMYFCTRVKLGTYYFDSWGQGTTLTVSS,DIQMTQTASSLPASLGDRVTISCSASQDISNYLNWYQQKPDGTVKLLIFYSSNLHSGVPSRFSGGGSGTDYSLTISNLEPEDIATYFCHQYSKLPWTFGGGTKLEIK,na,na,None,None,None,2002,2003,GD3 ganglioside,Kyowa Hakko;Kyowa Kirin;Life Science Pharmaceuticals;Ludwig Institute for Cancer Research,na,na,Malignant melanoma,,,Chimeric,KM-871;KM871;KW-2871;KW2871
Eculizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,5i5k:HL:XY,None,None,2002,2003,C5,Alexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc,Neuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria,Delayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19,Antiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus,GS Gene Expression System,Biosimilars available,Humanised,5G1-1;5G1.1;Soliris
Edrecolomab,Whole mAb,G2a,Kappa,Approved (w),NFD,QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA,NIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK,na,na,None,None,None,1995,1996,EPCAM/CD326,Ajinomoto;Centocor Inc,Colorectal cancer ,na,Adenocarcinoma;Pancreatic cancer,,,Murine,1083 17-1A;1083-17-1A;17-1A;Adjuqual;CO17-1A;CO17 1A;M-17-1A;Panorex
Efalizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK,na,na,3eo9:HL/3eoa:HL:BA/3eob:HL:BA,None,None,2001,2002,ITGAL/CD11A/LFA1A,Genentech;Merck Serono;XOMA,Psoriasis,na,Psoriatic arthritis;Type 1 diabetes mellitus,,,Genetically human,HU 1124;HU1124;HU-1124;Raptiva;Xanelim
Efungumab,scFv,na,Kappa,Phase-III,Discontinued,EVQLVESGAEVKKPGESLRISCKGSGCIISSYWISWVRQMPGKGLEWMGKIDPGDSYINYSPSFQGHVTISADKSINTAYLQWNSLKASDTAMYYCARGGRDFGDSFDYWGQGTLVTVSS,DVVMTQSPSFLSAFVGDRITITCRASSGISRYLAWYQQAPGKAPKLLIYAASTLQTGVPSRFSGSGSGTEFTLTINSLQPEDFATYYCQHLNSYPLTFGGGTKVDIK,na,na,None,None,None,2006,2007,Heat Shock Protein 90 Homolog,NeuTec Pharma,na,na,Breast cancer;Candidiasis,,,Genetically human,Mycograb
Eglatoprutug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSYAQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRASESVDIYGQSFMHWYLQKPGQSPQLLIYLASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQNNEDPYTFGGGTKVEIK,na,na,None,None,None,2022,2023,KIT/CD117,TBC,TBC,TBC,TBC,,,Humanised,TBC
Eldelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK,na,na,None,None,None,2013,2014,CXCL10/IP10,Bristol-Myers Squibb;Medarex,na,na,Crohn's disease;Ulcerative colitis;Multiple sclerosis;Rheumatoid arthritis;Spinal cord injuries,Medarex UltiMAb Mouse,,Genetically human,BMS-936557;BMS936557;MDX-1100;MDX1100
Elegrobart,Whole mAb,G1,Kappa,TBC,TBC,QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSS,DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIK,na,na,None,None,None,2025,na,TBC,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Elezanumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHGISWVRQAPGQGLDWMGWISPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELSSLRSEDTAVYYCARVGSGPYYYMDVWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSSVGDSIYVSWYQQHPGKAPKLMLYDVTKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCYSYAGTDTLFGGGTKVTVL,na,na,None,None,None,2016,2017,RGMA,AbbVie,na,Multiple sclerosis;Spinal cord injuries;Stroke,na,,,Humanised,ABT-555;ABT555
Elgemtumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINSQGKSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGDEGFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSFPTTFGQGTKVEIK,na,na,None,None,4p59:HL,2014,2015,ERBB3/HER3,MorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology,na,na,Breast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours,Medarex HuMAb Mouse,,Genetically human,LJM-716;LIM716;NOV-6;NOV6
Elipovimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QMQLQESGPGLVKPSETLSLTCSVSGASISDSYWSWIRRSPGKGLEWIGYVHKSGDTNYNPSLKSRVHLSLDTSKNQVSLSLTGVTAADSGKYYCARTLHGRRIYGIVAFNEWFTYFYMDVWGTGTQVTVSS,SDISVAPGETARISCGEKSLGSRAVQWYQHRAGQAPSLIIYNNQDRPSGIPERFSGSPDSRPGTTATLTITSVEAGDEADYYCHIWDSRVPTKWVFGGGTTLTVL,na,na,None,None,4fq1:HL/4jy4:BA/4fqc:HL/7uoj:hl:de:km,2018,2019,HIV-1 gp120,Gilead Sciences,na,na,HIV infections,,,Genetically human,GS-9722;GS9722
Elotuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,SLAMF7/CD319,AbbVie;Australasian Leukaemia & Lymphoma Group;Bristol-Myers Squibb;PDL BioPharma,Multiple myeloma,na,na,,,Humanised,BMS-901608;BMS901608;Empliciti;HuLuc-63;PDL-063;PDL063
Elranatamab,Bispecific mAb,G2;G2,Kappa;Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAIGGSGGSLPYADIVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYQSWPLTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMTWVRQAPGKGLEWVAFIRNRARGYTSDHNPSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRPSYYVLDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLFNVRSRKNYLAWYQQKPGQPPKLLISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYDLFTFGSGTKLEIK,None;None,None;None,None;None,2021,2022,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Pfizer,Multiple myeloma,na,na,,,Genetically human;Humanised,PF-06863135;PF06863135;PF‑3135;PF3135;RN-613;RN613
Eltivutabart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFKSYEMHWVRQAPGQGLEWMGRINPSVGSTWYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGKREGGTEYLRKWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVASSYLAWYQQKPGQAPRLLIYGASNRHTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYHNAITFGGGTKVEIK,na,na,None,None,None,2024,na,ENTPD1/CD39,Adimab;AbbVie;Trishula Therapeutics,na,Adenocarcinoma;Lymphoma;Solid tumours,na,,,Genetically human,TTX-030;TTX 030;TTX030
Eltrekibart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYEFTSYWIHWVRQAPGQGLEWMGNISPNSGSANYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAREGPYSYYPSREYYGSDLWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIYYTSRSVSGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCGQNNEWPEVFGGGTKVEIK,na,na,6wzk:AB:CD/6wzl:AB:CD/6wzj:AB:CD/6wzm:AB:CD,None,None,2023,2024,CXCL1/CXCL2/CXCL3/CXCL5/CXCL6/CXCL7/CXCL8,Eli Lilly,na,Hidradenitis suppurative,Skin disorders,,,Humanised,LY 3041658;LY-3041658;LY3041658
Eluvixtamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGQGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,SIGLEC3/CD33/p67;CD3E,Amgen,na,na,Acute myeloid leukaemia,BiTE Technology,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG-330;AMG330
Emactuzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVIWTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIK,na,na,4liq:HL,None,None,2014,2015,CSF1R/CD115/M-CSFR,Roche;University of Texas M. D. Anderson Cancer Center,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours,Giant cell tumour of tendon sheath;Pigmented villonodular synovitis,,,Humanised,RG-7155;RG7155;RO-5509554;RO5509554
Emapalumab,Whole mAb,G1,Lambda,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDGSSGWYVPHWFDPWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDGSNRWMFGGGTKLTVL,na,na,None,None,None,2016,2017,IFNG,NovImmune SA;Swedish Orphan Biovitrum,Haemophagocytic lymphohistiocytosis,na,na,,,Genetically human,Gamifant;NI-0501;NI0501
Emerfetamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQCLEWMGWINTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWSWSDGYYVYFDYWGQGTSVTVSS,DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPPKLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,SIGLEC3/CD33/p67;CD3E,Amgen,na,na,Acute myeloid leukemia,BiTE Technology,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG 673;AMG-673
Emfizatamab1,Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 1),na;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK,EVQLVQSGAEVKKPGESLKISCKGSGYSFSSSWIGWVRQAPGKGLEWMGIIYPDDSDTRYSPSFQGQVTISADKSIRTAYLQWSSLKASDTAMYYCARHVTMIWGVIIDFWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPFTFGPGTKVDIK,None;None,None;None,None;None,2022,2022,CD3E;CD19,Sichuan Baili Pharmaceutical,na,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,,scFv-IgG1 portion. Joint entry with Emfizatamab2 (tetraspecific),Humanised;Genetically human,GNC-038;GNC038
Emfizatamab2,Tetraspecific (scFv-IgG-scFv-scFv; Bispecific entry 2),na;na,Kappa;Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK,SRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSS,DVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK,None;None,None;None,None;None,2022,2022,PDL1/CD274;TNFRSF9/CD137/4-1BB,Sichuan Baili Pharmaceutical,na,Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,,scFv-scFv portion. Joint entry with Emfizatamab1 (tetraspecific),Genetically human;Humanised,GNC-038;GNC038
Emicizumab,Bispecific mAb,G4;G4,Kappa;Kappa,Approved,NFD,QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,F9;F10,Chugai Pharmaceutical;Roche,Haemophilia A,na,na,,,Humanised;Humanised,ACE 910;ACE910;ACE-910;CH5534262;CH-5534262;Hemlibra;RG 6013;RG6013;RG-6013;RO 5534262;RO5534262;RO-5534262
Emibetuzumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,MET/HGFR,Eli Lilly,na,Gastric cancer;Non-small cell lung cancer;Cancer,na,,,Humanised,LA-480;LA480;LY-2875358;LY 2875358;LY2875358
Emiltatug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLIQPGGSLRLSCAASGFIVSRNYMNWVRQAPGKGLEWVSVIYGSGRTDSADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDADYGLDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLYTFGQGTKLEIK,na,na,None,None,None,2024,2024,VTCN1/B7H4,Mersana Therapeutics,na,Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Triple negative breast cancer,na,,,Genetically human,XMT-1660;XMT1660;XMT 1660
Emirodatamab,Bispecific scFv-scFv-scFc,na;na,Kappa;Lambda,Phase-I,Discontinued,QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWLAHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARIVGYGSGWYGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2022,2022,FLT3/CD135/FLK2;CD3E,Amgen;BeiGene,na,na,Acute myeloid leukaemia,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG-427;AMG427
Empasiprubart,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQATGQGLEWIGDINPNYESTGYNQKFKGRATMTVDKSISTAYMELSSLRSEDTAVYYCAREDDHDAFAYWGQGTLVTVSS,DNVLTQSPDSLAVSLGERATISCRASKSVRTSGYNYMHWYQQKPGQPPKLLIYLASNLKSGVPDRFSGSGSGTDFTLTISSLQAEDAATYYCQHSRELPYTFGQGTKLEIK,na,na,8acf:HL/8aci:HL,None,None,2022,2023,C2,arGEN-X;Broteio,na,Multifocal motor neuropathy;Dermatomyositis;Kidney disorders;Motor neuron disease,COVID-19,,,Humanised,ARGX-117;ARGX117
Emugrobart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGLVQPGGSLRLSCAVSGIDLSHDDISWVRQAPGKGLEWVSIISYAGSTYYASWAKGRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGVPAYSHGGDLWGQGTLTVTVSS,DIVMTQSPATLSLSPGERATLSCTTSQSVYHENWLSWFQQKPGQPPKLLIYWASTLAYGVPSRFSGSGSGTDFTLTISSLQPEDAATYYCAGGYGGGRYAFGQGTKVEIK,na,na,None,None,None,2024,na,ENTPD1/CD39,Chugai Pharmaceutical;Roche,na,Spinal muscular atrophy;Facioscapulohumeral muscular dystrophy;Obesity,Neuromuscular disorders,,,Humanised,GYM-329;GYM 329;GYM329;RG-6237;RG 6237;RG6237;RG-70240​;RG 70240;RG70240;RO-7204239;RO 7204239;RO7204239
Emunkitug,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAELKKPGASVKVSCKASSYSFTDYNMNWVRQAPGQSLEWMGIIFPKYGTTSYAQKLQGRVTLTTDTSTSTAYMELRSLRSDDTAVYYCATDGGTWYFDVWGTGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCRASSSVTYMYWYQQKPGKAPKPWIYLTSNLASGVPSRFSGSGSGTEYTLTISSLQPEDAATYYCQQWSSNPPTFGSGTKLEIK,na,na,None,None,None,2024,na,TNFRSF1B/TNFR2/CD120b/TNFR80/p75,HiFiBiO,na,Solid tumours,na,,Agonist,Humanised,HFB-2003;HFB 2003;HFB2003;HFB-200301;HFB 200301;HFB200301
Enapotamab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSTTSGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIWIAFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPYTFGQGTKLEIK,na,na,None,None,None,2017,2018,AXL/UFO,Genmab,na,na,Solid tumours,,ADC with vedotin,Genetically human,AXL-107;AXL107;AXL-107-MMAE;HuMax-AXL
Enavatuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAEIRLKSDNYATHYAESVKGRFTISRDDSKNSLYLQMNSLRAEDTAVYYCTGYYADAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKLLIKYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWEIPYTFGGGTKVEIK,na,na,None,None,None,2010,2011,TNFRSF12A/CD266/TWEAKR,PDL BioPharma;Abbott Laboratories,na,na,Solid tumours,,,Humanised,PDL-192;PDL192
Encelimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVQSGAEVKKPGATVKISCKASGFSIKDDYIHWVQQAPGKGLEWMGWIDAMNDDSQYSSKFQGRVTITVDTSTNTAYMKLSSLRSEDTAVYYCTYAFGGYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSDSNTYLHWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCGQSTHVPYAFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Anaptys Bio;TESARO,na,Solid tumours,na,,,Humanised,GSK-4074386;GSK4074386;TSR 033;TSR033;TSR-033
Enfortumab,Whole mAb ADC,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYNMNWVRQAPGKGLEWVSYISSSSSTIYYADSVKGRFTISRDNAKNSLSLQMNSLRDEDTAVYYCARAYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISGWLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,PVRL4/Nectin-4,Agensys;Seattle Genetics,Urogenital cancer,Bladder cancer;Prostate cancer;Solid tumours,na,,ADC with vedotin,Genetically human,AGS-22C3;AGS 22C3;AGS-22CE;AGS 22CE;AGS-22M6E;AGS 22M6E;AGS-22ME;AGS 22ME;AGS-M6;AGS M6;ASG-22CE;ASG 22CE;ASG-22M6E;ASG 22M6E;ASG-22ME;ASG 22ME
Englumafusp,Fusion Protein,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYIMHWVRQAPGQGLEWMGYINPYNDGSKYTEKFQGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTYYYGPQLFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLETSTGTTYLNWYLQKPGQSPQLLIYRVSKRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQLLEDPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,CD19,Roche,na,B cell Lymphoma,na,,June '22: Corrected CDRH2 sequence. Aug '22: WHO changed name from ensomafusp to englumafusp in PL127.,na,RG-6076;RG6076;RO-7227166;RO7227166
Enibarcimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSRYWIEWVRQAPGQGLEWIGEILPGSGSTNYNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCTEGYEYDGFDYWGQGTTVTVSS,DVVLTQSPLSLPVTLGQPASISCRSSQSIVYSNGNTYLEWYLQRPGQSPRLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHIPYTFGGGTKLEIK,na,na,None,None,None,2020,2021,ADM,Adrenomed,na,Septic shock;Cardiogenic shock;COVID-19,na,,Genetics: musmus/homosap,Chimeric and/or humanised,HAM 8101;HAM8101;HAM-8101
Enlonstobart,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLTCKASGLTFSSSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNNDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYTASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNWPRTFGQGTKVEIK,na,na,None,None,5ggr:HL:AB/5ggq:HL/5wt9:HL,2023,2023,PDCD1/CD279/PD1,Hangzhou Sumgen Biotech;CSPC ZhongQi Pharmaceutical Technology;Hangzhou Sumgen Biotech,Cervical cancer,Colorectal cancer;Solid tumours,Biliary cancer,,,Genetically human,SG 001;SG-001;SG001;SYSA-1802;SYSA 1802;SYSA1802
Enoblituzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,na,na,None,None,None,2015,2017,B7H3/CD276,MacroGenics;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,na,Prostate cancer;Solid tumours;Head and neck cancer,Malignant melanoma;Non-small cell lung cancer;Squamous cell cancer;Urogenital cancer,,,Humanised,MGA-271;MGA271;TJ-271;TJ271
Enokizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,IL9,Genaera Corporation;Ludwig Institute for Cancer Research;MedImmune,na,na,Asthma,,,Genetically human,7F3com-2H2;MEDI-528;MEDI528
Enoticumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSFLWYDGTNKNYVESVKGRFTISRDNSKNMLYLEMNSLRAEDTAVYYCARDHDFRSGYEGWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHRSNWPPTFGGGTKVEIK,na,na,None,None,None,2012,2013,DLL4,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,VelocImmune Mouse,,Genetically human,REGN-421;REGN421;SAR-153192;SAR153192
Enristomig,Bispecific Single Domains (VH-VH'-G1(h-CH2-CH3) Dimer),G1;G1,na;na,Phase-I,Discontinued,EVQLLESGGGEVQPGGSLRLSCAASGGIFAIKPISWYRQAPGKQREWVSTTTSSGATNYAESVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCNVFEYWGQGTLVTVKP,na,EVQLLESGGGEVQPGGSLRLSCAASGFSFSINAMGWYRQAPGKRREFVAAIESGRNTVYAESVKGRFTISRDNAKNTVYLQMSSLRAEDTAVYYCGLLKGNRVVSPSVAYWGQGTLVTVKP,na,None;None,None;None,None;None,2023,2024,PDL1/CD274;TNFRSF9/CD137/4-1BB,Elpiscience Biopharmaceuticals;Inhibrx,na,na,Hodgkin's disease;Non-Hodgkin's lymphoma;Solid tumours;Non-small cell lung cancer;Oesophageal cancer;Squamous cell cancer,,,Humanised;Humanised,INBRX-105;INBRX105;ES101;ES-101
Ensituximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKESGPDLVAPSQSLSITCTVSGFSLSKFGVNWVRQPPGKGLEWLGVIWGDGSTSYNSGLISRLSISKENSKSQVFLKLNSLQADDTATYYCVKPGGDYWGHGTSVTVSS,QVVLTQSPVIMSASPGEKVTMTCSASSSISYMYWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISNMEAGDAATYYCHQRDSYPWTFGGGTNLEIK,na,na,None,None,None,2010,2011,MUC5AC,Neogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine,na,Colorectal cancer;Pancreatic cancer,na,,,Chimeric,NEO-101;NEO101;NEO-102;NEO102;NPC-1C;NPC1C
Enuzovimab,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVESGGGLIQPGGSLRLSCAASGFIVSSNYMSWVRQAPGKGLEWVSIIYSGGSTFYADSVKGRFTISRDNSKNTLYLQMNSLRVEDTAVYYCARDLQELGSLDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQEANSFPYTFGQGTKLEIK,na,na,7cjf:AB,None,None,2021,2022,SARS-CoV-2 Spike RBD,ABL Bio;HiFiBiO Therapeutics,na,COVID-19,na,,,Genetically human,HFB-3013;HFB3013;HFB30132A;HFB-30132A;P4A1-2A
Envafolimab,Single Domain Variable Fragment;H,G1,na,Approved,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS,na,na,na,None,None,None,2018,2019,PDL1/CD274,Alphamab;3D Medicines;Sun Yat-Sen University,Solid tumours,Biliary cancer;Breast cancer;Gastric cancer;Gastrointestinal cancer;Hepatitis B;Malignant fibrous histiocytoma;Soft tissue sarcoma,na,,Oct '22: Sequence fixed to contain the full DJ/J regions. Genetics: vicpac/homosap,Chimeric and/or humanised,ASC 22;ASC22;ASC-22;ENWEIDA;KN-035;KN035
Enzelkitug,Whole mAb,G1,Kappa,TBC,TBC,EVQLLESGGGLVQPGGSLRLSCAASGIDLSTYAMGWVRQAPGKGLEWVGLIHRSGRTYYATWAKGRFTISKDSSKNTLYLQMNSLRAEDTAVYYCTRSYPDYSATASIWGQGTTVTVSS,DIQVTQSPSSLSASVGDRVTITCQASENIANALAWYQQKPGKPPKFLIYGASNLASGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQAYYGNSFVEGTFGGGTKVEIK,na,na,None,None,None,2025,na,CCR8/CKR-L1/CDw198,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Epacmarstobart,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWITWVKQAPGQGLEWIGDIYPGSGSTNHIEKFKSKATLTVDTSISTAYMELSRLRSDDTAVYYCATGYGSSYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYTAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHQYGPPFTFGQGTKLEIK,na,na,None,None,None,2022,2023,SIRPA,Gilead Sciences,na,na,Non-Hodgkin's lymphoma,,Genetics: musmus/homosap,Chimeric and/or humanised,GS0189;GS-0189;GS189;GS-189;FSI189;FSI-189
Epcoritamab,Bispecific mAb,G1;G1,Lambda;Kappa,Approved,Active,EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL,EVQLVESGGGLVQPDRSLRLSCAASGFTFHDYAMHWVRQAPGKGLEWVSTISWNSGTIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,None;None,None;None,None;3giz:HL/6y92:CD:HL,2019,2020,CD3E;MS4A1/CD20,Genmab,Diffuse large B-cell lymphoma,Haematological malignancies;Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,na,,Chimeric: Mouse/Human,Chimeric;Genetically human,ABBV-GMAB-3013;EPKINLY;GEN-3013;GEN3013;ABBV3013;ABBV-3013;Tepkinly
Epratuzumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK,na,na,None,5vkk:AB:HL/5vl3:EF:AB:HL:CD,None,1999,2000,SIGLEC2/CD22,Charite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB,na,na,Precursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia,,,Humanised,AMG 412;AMG412;AGM-412;Epratucyn;IMMU 103;IMMU103;IMMU-103;IMMU LL2;IMMU-LL2;LymphoCide
Eptinezumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGIDLSGYYMNWVRQAPGKGLEWVGVIGINGATYYASWAKGRFTISRDNSKTTVYLQMNSLRAEDTAVYFCARGDIWGQGTLVTVSS,QVLTQSPSSLSASVGDRVTINCQASQSVYHNTYLAWYQQKPGKVPKQLIYDASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLGSYDCTNGDCFVFGGGTKVEIK,na,na,None,None,None,2016,2017,CALCA and CALCB,Alder Biopharmaceuticals,Migraine,Cluster headache,na,,,Humanised,ALD-403;ALD403;Lu-AG09221;VYEPTI
Etuptamig,Bispecific mAb,G1;G1,Kappa;Lambda,TBC,TBC,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMNWMKQAPGQGLEWIGGIYLNGDSTDYNEKFKGKVTMTVDTSTSTVYMELSSLRSEDTAVYYCTRRGDYFGDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGKYVAWYQQKPGKAPKSLIYSASNRYDGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQYISYPLTFGAGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSA,EAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQEKPGQLPRGLIGGTNKRAPWVPARFSGSLLGGKAALTLSGAQPEDEAEYFCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2025,na,NCR3LG1/B7-H6;CD3E,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Chimeric and/or humanised,TBC
Eramkafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:AB:HL/4kaq:HL/6y90:HL:CD/6vja:HL:IM/8vgn:AB:HL,4kaq:HL/8vgo:AB:HL,None,2020,2021,MS4A1/CD20,Spectrum Pharmaceuticals;ImmunGene,na,na,Non-Hodgkin's lymphoma,,Possibly a Rituximab biosimilar. (June '22): Corrected IMGT VH 128 S->A,Chimeric (Murine/Human),IGN-002;IGN002
Erenumab,Whole mAb,G2,Lambda,Approved,NFD,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS,QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL,na,na,6umg:HL:hl/6umh:HL:hl/6umi:HL/6umj:HL,None,None,2016,2017,CALCRL,Amgen;Novartis,Migraine,na,Hot flushes,Abgenix XenoMouse,,Genetically human,Aimovig;AMG-334;AMG334
Erfonrilimab,Bispecific Single Domains (VH-VH'-CH),G1,na;na,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGKMSSRRCMAWFRQAPGKERERVAKLLTTSGSTYLADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAADSFEDPTCTLVTSSGAFQYWGQGTLVTVSS,na,QVQLVESGGGLVQPGGSLRLSCAASGYIYSAYCMGWFRQAPGKGLEGVAAIYIGGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAADVIPTETCLGGSWSGPFGYWGQGTLVTVSS,na,None;6rqm:B,None;None,None;None,2020,2021,PDL1/CD274;CTLA4/CD152,Alphamab,na,Non-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma,na,,June '22: Corrected FWH1 sequence. Genetics of Fv1: vicpac/homosap,Chimeric (Chimeric and/or humanised);Humanised,KN-046;KN046
Erlizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRFMDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIK,na,na,2fgw:HL,None,None,2000,2001,ITGB2/CD18,Genentech;PDL Biopharma; Roche,na,na,Myocardial infarction;Shock ,,,Humanised,
Ersodetug,Whole mAb,G2,Kappa,Phase-III,Active,EVQLVETGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWYAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHEWGFGMDVWGQGTTVTVSS,DVVMTQSPLSLSVTLGQPASISCRSSLSLVYGDENTYLNWFQQRPGQSPRRLLYKVSDRDSGVPDRFSGSGSGTDFTLKISRVEADDVGVYYCMQGTHWPYTFGQGTKLEIK,na,na,None,None,None,2023,2023,INSR/CD220,XOMA;Rezolute,na,Congenital hyperinsulinism;Hypoglycaemia,na,,,Genetically human,RZ-358;X 358;XOMA 247;XOMA-247;XOMA247;XOMA 358;XOMA-358;XOMA358;XPA.15.247
Erzotabart,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGSSVKVSCKAFGGTFSSYAISWVRQAPGQGLEWMGRIIRFLGIANYAQKFQGRVTLIADKSTNTAYMELSSLRSEDTAVYYCAGEPGERDPDAVDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPLTFGGGTKVEIK,na,na,8byu:HL,None,None,2023,2023,ADPRC1/CD38,Genmab,na,Haematological malignancies,na,,,Genetically human,GEN-3014;GEN3014;GEN 3014
Etakafusp,Fusion Protein,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPGYATANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDAAGIRLFADWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIYGALNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSTYTAPWTFGGGTKVEIK,na,na,None,None,None,2024,2024,CD8,Asher Therapeutics,na,Solid tumours,na,,,Humanised,AB 248;AB-248;AB248
Etalanetug,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLLESGGGLVQPGGSLRLSCAASGYTFTTYWITWVRQAPGKGLEWVSDIYPGSSISNYNEKFKSRFTISVDNSKNTLYLQMNSLRAEDTAVYYCAREDGYDAWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSILHSNGNTYLEWYQQKPGKAPKLLISKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSHVPFTFGQGTKLEIK,na,na,None,None,None,2024,na,MAPT,Eisai Co Ltd;University College London,na,Alzheimer's disease,na,,,Humanised,E-2814;E2814;E 2814
Etaracizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVAKVSSGGGSTYYLDTVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHLHGSFASWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCQASQSISNFLHWYQQRPGQAPRLLIRYRSQSISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSGSWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,ITGAVB3/CD61/VNR,Applied Molecular Evolution;MedImmune,na,na,Colorectal cancer;Malignant melanoma;Prostate cancer;Psoriasis;Rheumatoid arthritis,,,Humanised,LM 609;LM609;LM-609;MEDI-522;MEDI522;Vitaxin
Etentamig,Bispecific mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDSRGYGDYRLGGAYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTVSSYGMSWVRQAPGKGPEWVSGIRGSDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKQGENDGPFDHRGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,None;None,None;None,None;None,2024,2024,CD3E;TNFRSF17/CD269/BCMA/TNFRSF13A,TeneoBio;Abbvie,na,Multiple myeloma;Amyloid light-chain amyloidosis,na,Transgenic rat,,Genetically human;Humanised,ABBV-383;ABBV383;ABBV 383;TNB 383B;TNB383B;TNB
Etesevimab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK,na,na,7c01:CD:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,Eli Lilly and Company;Institute of Microbiology of the Chinese Academy of Sciences;Shanghai Junshi Biosciences,COVID-19,na,na,,,Genetically human,JS 016;JS-016;JS016;JS16;JS-16;JS 16;LY 3832479;LY-3832479;LY3832479;LY-CoV-016
Etevritamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGVVQSGRSLRLSCAASGFTFRNYGMHWVRQAPGKCLEWVAVIWYDGSDKYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGYDILTGNPRDFDYWGQGTLVTVSS,DTVMTQTPLSSHVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYRISRRFSGVPDRFSGSGAGTDFTLEISRVEAEDVGVYYCMQSTHVPRTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,EGFR/ERBB1/HER1;CD3E,Amgen,na,na,Glioblastoma,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG-596;AMG596
Etigilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSITSDYAWNWIRQPPGKGLEWIGYISYSGSTSYNPSLRSRVTISRDTSKNQFFLKLSSVTAADTAVYYCARRQVGLGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYSTPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,TIGIT/WUCAM/VSTM3,OncoMed Pharmaceuticals,na,Solid tumours,na,,,Humanised,MPH-313;MPH313;OMP-313M32
Etokimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLMQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGTIYPRNSNTDYNQKFKARVTMTRDTSTSTVYMELSSLRSEDTAVYYCARPLYYYLTSPPTLFWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQAKTYPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,IL13,AnaptysBio,na,na,Asthma;Atopic dermatitis;Peanut hypersensitivity;Rhinosinusitis,,,Humanised,ANB-020;ANB020
Etrolizumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK,na,na,None,None,None,2010,2011,ITGA4B7 and ITGAEB7,Genentech;Roche,na,na,Crohn's disease;Ulcerative colitis,,,Humanised,PRO 145223;PRO-145223;PRO145223;RG 7413;RG7413;RG-7413;RO 5490261;RO5490261;RO-5490261
Eurestobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYNLKDTFLHWVRQAPGQGLEWMGRIDPAQGNIKYDPKFQGRVTITADTSANTAYMELISLRSEDTAVYYCANSPYYYGSGYRIFDVWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSAFSSVNYMHWYQQKPGQAPRLLIYTTSNLASGIPTRFSGSGSGTSYTLTISSLEPEDFAVYYCQQRSTYPFTFGQGTKLEIK,na,na,None,None,None,2023,2023,ENTPD1/CD39,Enumeral Biomedical Holdings;Elpiscience Biopharmaceuticals,na,Solid tumours,na,,,Humanised,ES 002;ES002;ES-002;ES 002023;ES-002023;ES 002023
Evalstotug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQYVGSSYLAWYLQKPGQSPQLLIYGAFSRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDGSSPWTFGQGTKVEIK,na,na,None,None,None,2023,2024,CTLA4/CD152,BioAtla,na,Solid tumours,na,,,Genetically human,BA3071;BA-3071
Evinacumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGVIQPGGSLRLSCAASGFTFDDYAMNWVRQGPGKGLEWVSAISGDGGSTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAFFYCAKDLRNTIFGVVIPDAFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSYTFGQGTKLEIK,na,na,None,None,None,2014,2015,ANGPTL3,Regeneron Pharmaceuticals;Sanofi,Hyperlipoproteinaemia type II,Hypertriglyceridaemia,na,,,Genetically human,Evkeeza;REGN-1500;REGN1500
Evolocumab,Whole mAb,G2,Lambda,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS,ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL,na,na,None,None,None,2012,2013,PCSK9,Amgen;Amgen Astellas BioPharma;University Hospital Inselspital,Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke,Hyperlipidaemia;Coronary artery disease;Dyslipidaemias,na,Abgenix XenoMouse,,Genetically human,AMG-145;AMG145;Repatha
Evunzekibart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFNFGYSYMSWVRQAPGKGLEWVSSIGSTSSHTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVYSSPGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIGSTLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYTWVPFTFGQGTKLEIK,na,na,8oz3:AB:HL,None,None,2022,2023,TNFRSF9/CD137/4-1BB,Alligator Bioscience,na,Solid tumours,na,,,Genetically human,ATOR-1017;ATOR1017
Exbivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVESGGGVVQPGGSLRLSCAPSGFVFRSYGMHWVRQTPGKGLEWVSLIWHDGSNRFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYFCARERLIAAPAAFDLWGQGTLVTVSS,SYVLTQPPSVSVAPGKTARISCGGNNIGTKNVHWYQQKPGQAPVLVVYADSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSVSYHVVFGGGTTLTVL,na,na,None,None,None,2004,2005,Hepatitis B Surface Antigen,XTL Biopharmaceuticals;Yeda,na,na,Hepatitis B infection,,,Genetically human,19.79.5;XTL-001 (cocktail with Libivirumab);XTL001 (cocktail with Libivirumab)
Exerenibart,Whole mAb,G4,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMTWVRQAPGKGLEWVSAISGSDTSTYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCAKHQDYDFSYYYSAMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVIITCRASQDFNSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTDSFPFTFGPGTKVDIK,na,na,None,None,None,2025,na,TMPRSS6/MT2,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Exidavnemab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIWRGGSTDYSAAFMSRLTISKDTSKNQVSLKLSSVTAADTAVYYCAKLLRSVGGFADWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQTIVHNNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGQGTKLEIK,na,na,None,None,None,2021,2022,SNCA/PARK1/PARK4,AbbVie,na,SNCA/PARK1/PARK4,na,,Genetics: musmus/homosap,Chimeric and/or humanised,PR-1808164;PR1808164;ABBV-0805;ABBV0805;ABBV805;ABBV-805;BAN-0805;BAN0805;BAN805;BAN-805;PD-0805;PD0805;PD-805;PD805
Exlinkibart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFAGFEMHWVRQAPGQGLEWMGAIDPKTGGTDYNQKFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDLGYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRSNLNWYQQKPGGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQSEKLPRTFGGGTKVEIR,na,na,None,None,None,2022,na,TNFRSF9/CD137/4-1BB,MD Anderson Cancer Center;Lyvgen Biopharma,na,Gastric cancer;Soft-tissue carcinoma;Head and neck cancer;Esophageal cancer;Hepatocellular carcinoma;Metastatic cancer,na,,,Humanised,LVGN-6051;LVGN6051
Ezabenlimab,Whole mAb,G4,Kappa,Phase-II,Active,EVMLVESGGGLVQPGGSLRLSCTASGFTFSKSAMSWVRQAPGKGLEWVAYISGGGGDTYYSSSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSNVNYYAMDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATMSCRASENIDVSGISFMNWYQQKPGQAPKLLIYVASNQGSGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCQQSKEVPWTFGQGTKLEIK,na,na,None,None,None,2019,2020,PDCD1/CD279/PD1,Boehringer Ingelheim,na,Solid tumours;Squamous cell cancer;Colorectal caner;Head and neck cancer;Non-small cell lung cancer,na,,June '22: Corrected CDRH3/CDRL3 sequences,Humanised,BI-754091;BI754091
Falbikitug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGGGLVKPGGSLRLSCAASGFTFSHAWMHWVRQAPGKGLEWVGQIKAKSDDYATYYAESVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTCWEWDLDFWGQGTMVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLLDSDGHTYLNWLQQRPGQPPRLLIYSVSNLESGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQATHAPPYTFGQGTKLEIK,na,na,7n0a:BA,None,None,2023,2023,LIF,AstraZeneca,na,Pancreatic cancer;Solid tumours,na,,,Humanised,AZD0171;AZD-0171;MSC-1;MSC1
Fanastomig,Bispecific (L-kappa-H-gamma1_G1(VH-CH1-h)_L-kappa),G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGATVKLSCTASGFNIKDDYMHWVKQRPEQGLDWIGWIVPENANTVYASKFQGKATITADTSTNTAYLELSSLRSEDTAVYYCTVYGDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQEISGYLSWLQQKPGGAIKRLIYAASALDSGVPSRFSGSRSGSDYTLTISSLQPEDFADYYCLQYASYPLTFGQGTKLELK,EVQLVESGGGLVQPGGSLRLSCAASGFTSSDYGMHWVRQAPGKGLEWVSYISSGSYTIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCAKRGGSSHVNVMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYWSPPYTFGGGTKVEIK,None;None,None;None,None;None,2023,2024,LAG3/CD223;PDCD1/CD279/PD1,EpimAb Biotherapeutics,na,Solid tumours,na,,Genetics of both Fvs: musmus/homosap,Chimeric and/or humanised;Chimeric and/or humanised,EMB-02;EMB02;EMB 02
Faricimab,Bispecific mAb,G1;G1,Kappa;Lambda,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL,1cz8:HL:YX;None,None;None,1bj1:HL:KJ/6bft:AB:HL/7v5n:FE:BA;4iml:AB:HL/4imk:AD:BC,2017,2018,VEGFA;ANGPT2,Chugai Pharmaceutical;Roche,Diabetic macular oedema;Wet age-related macular degeneration,Diabetic retinopathy;Retinal oedema,na,Dual-Affinity Re-Targeting Technology,,Humanised;Genetically human,RG 7716;RG7716;RG-7716;RO 6867461;RO6867461;RO-6867461;Vabysmo
Farletuzumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK,na,na,None,None,None,2008,2009,FOLR1,Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd,na,na,Solid tumours;Ovarian cancer;Non-small cell lung cancer,,,Humanised,MORAb-003
Fasinumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS,DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,NGFB,Mitsubishi Tanabe Pharma Corporation;Regeneron Pharmaceuticals;Teva Pharmaceutical Industries;Sanofi,na,na,Back pain;Pain,VelocImmune Mouse,,Genetically human,MT 5547;MT-5547;MT5547;REGN 475;REGN475;REGN-475;SAR 164877;SAR164877;SAR-164877
Favezelimab,Whole mAb,G4,Kappa,Phase-II,Active,QMQLVQSGPEVKKPGTSVKVSCKASGYTFTDYNVDWVRQARGQRLEWIGDINPNDGGTIYAQKFQERVTITVDKSTSTAYMELSSLRSEDTAVYYCARNYRWFGAMDHWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKASQSLDYEGDSDMNWYLQKPGQPPQLLIYGASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSTEDPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Merck,na,Non-small cell lung cancer;Haematological malignancies;Solid tumours,na,,Favezelimab is the new name for Mavezelimab (PL123),Humanised,MK-4280;MK4280
Fazpilodemab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASDFSLTTYGVHWVRQAPGKGLEWLGVIWSGGSTDYNAAFISRLTISKDNSKNTVYLQMNSLRAEDTAVYYCARDYGSTYVDAIDYWGQGTLVTVSS,DIVLTQSPDSLAVSLGERATINCRASESVESYGNRYMTWYQQKPGQPPKLLIYRAANLQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSNYISWVRQAPGKGLEWVGEIDPYDGDTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCATGTDVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTPPTFGQGTKVEIK,None;None,None;None,None;None,2022,2022,KLB;FGFR1/CD331/BFGFR,Genentech,na,Non-alcoholic steatohepatitis,Type 2 diabetes mellitus,,3sob is 94% similar to FGFR1 binding arm. Genetics of Fv1: musmus/homosap,Chimeric and/or humanised;Genetically human,BFKB-8488A;BFKB8488A;RG 7992;RG7992;RG-7992;RO 7040551;RO7040551;RO-7040551
Feladilimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYAMHWVRQAPGQGLEWMGLISIYSDHTNYNQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCGRNNYGNYGWYFDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCFQGSGYPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,ICOS/CD278,GlaxoSmithKline,na,Solid tumours;Multiple myeloma;Non-small cell lung cancer;Head and neck cancer,na,,,Humanised,GSK-3359609;GSK3359609;GSK-609;GSK609
Felmetatug,Whole mAb,G1,Kappa,Phase-I,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK,na,na,None,None,None,2024,na,VTCN1/B7H4,Seagen;Pfizer,na,Solid tumours,na,,ADC with Vedotin,Genetically human,PF-08046048;PF08046048;PF 08046048;SGN-B7H4V;SGN B7H4V
Felzartamab,Whole mAb,G1,Lambda,Preregistration,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVL,na,na,None,None,None,2019,2020,ADPRC1/CD38,MorphoSys,na,Multiple myeloma;Membranous glomerulonephritis;Leukemia;Systemic lupus erythematosus,Non-small cell lung cancer,,,Humanised,MOR 202;MOR202;MOR-202;MOR-03087;MOR 03087;MOR03087;MOR 3087;MOR-3087;MOR3087;TJ-202;TJ202;TJ 202
Fepixnebart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSIVHSTGNTYLEWYQQKPGQPPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCFHGTHVPYTFGGGTKVEIK,na,na,5kn5:AB,None,None,2022,2023,EREG,Eli Lilly and Company,na,Back pain;Neuropathic pain;Pain;Diabetic nephropathies,na,,,Humanised,LY-3016859;LY 3016859;LY3016859
Fezakinumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS,QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL,na,na,None,None,None,2009,2010,IL22,Pfizer;Wyeth,na,na,Psoriasis;Rheumatoid arthritis,,,Genetically human,ILV-094;ILV094;PF-5212367;PF5212367
Fianlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAIIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCASVATSGDFDYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERTTLSCRASQRISTYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTGFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Regeneron Pharmaceuticals,na,Cancer,na,,,Genetically human,REGN-3767;REGN3767
Ficerafusp,Fusion Protein,G1,Kappa,Phase-II/III,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC,5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,2024,2024,EGFR/ERBB1/HER1,Bicara Therapeutics,na,Solid tumours,na,Cetuximab and Ficerafusp have the same Fv sequence.,Chimeric: Mouse/Human,Chimeric,BCA101;BCA-101
Ficlatuzumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS,DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2011,2012,HGF/SF,AVEO Oncology;AVEO Pharmaceuticals;Dana-Farber Cancer Institute;University of Arizona Cancer Center;University of California at San Francisco,na,Head and neck cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Pancreatic cancer,Lymphoma;Multiple myeloma;Solid tumours;Glioblastoma,,,Humanised,AV-299;AV299;SCH-900105;SCH900105
Fidasimtamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,None;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2021,2022,PDCD1/CD279/PD1;ERBB2/CD340/HER2,Hanmi Pharmaceutical;Innovent Biologics,na,na,Solid tumours,,June '22: Corrected FWL4 sequence in LC1,Genetically human;Humanised,BH-2950;BH2950;IBI-315;IBI315
Figitumumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS,DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK,na,na,None,None,None,2008,2009,IGF1R/CD221,Pfizer,na,na,Breast cancer;Colorectal cancer;Gastrointestinal cancer;Gynaecological cancer;Multiple myeloma;Non-small cell lung cancer;Prostate cancer;Rheumatoid arthritis;Sarcoma;Small cell lung cancer;Solid tumours,,,Genetically human,CP-751;CP751;CP-871;CP871;CP751871;CP-751871
Finotonlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKRLEWVATISGGGRDTYYSDSVKGRFTISRDNAKNNLYLQMNSLRAEDTAVYYCSRQYGTVWFFNWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDSYGNSFMHWYQQKPGQPPRLLIYAASNQGSGVPARFSGSGSGTDFTLTISSLEPEDFAMYFCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Sinocelltech,Squamous cell carcinoma,Liver cancer;Colorectal cancer;Lymphoma,na,,Genetics: musmus/homosap,Chimeric and/or humanised,SCT-I10A
Firastotug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIK,na,na,None,None,None,2023,2023,CTLA4/CD152,Adagene,na,Solid tumours,na,,,Humanised,ADG-116;ADG116;ADG 116
Firivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKMPGSSVKVSCKTSGVFFSSHAISWVRQAPGQGLEWMGGISPMFGTTHYAQKFQGRVTITADQSTTTAYMELTSLTSEDTAVYYCARDGAGSYYPLNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENIWNNLAWYQQKPGQAPRLLISGASTGATGVPSRFRGSGSRTEFTLTISSLQSEDFAIYFCQQYNSWPRTFGPGTKVEIK,na,na,None,None,None,2014,2015,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,,,Genetically human,CT-P22;CT-P23
Firsekibart,Whole mAb,G4,Lambda,TBC,TBC,EVQLVESGGGLVKPGRSLRLSCTGSGFTFGDYALNWFRQAPGMGLEWVGFIRGKAYGGTTEYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCNREVEYCRSSENYCYGMDVWGQGTTVTVSS,SYELTQPPSVSVSPGQTASITCSGDKLGDKFACWYQQKPGQSPVLVIYQDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSNTVVFGGGTKLTVL,na,na,None,None,None,2025,na,IL1B,TBC,TBC,TBC,TBC,TBC,https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06072-7,Genetically human,TBC
Fiztasovimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWGWIRQPPGKGLEWIGEINHSGSANSNPSLKSRVTMSVDTSKNQFSLKVSSVTAADTAVYFCARVTRDLEWIPGDYYMDVWGKGTTVTVSS,QSVLTQPPSASGTPGQRVSISCSGSLSNIGTNYVYWYQQLPGTAPKLLIFKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,na,na,None,None,None,2022,2022,Human Herpesvirus Glycoprotein B AD-1,Nobelpharma Co,na,Cytomegalovirus infections,na,,,Genetically human,NPC-21;NPC 21;NPC21
Flanvotumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYTFTSYAMNWVRQAPGQGLESMGWINTNTGNPTYAQGFTGRFVFSMDTSVSTAYLQISSLKAEDTAIYYCAPRYSSSWYLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWLMYTFGQGTKLEIK,na,na,None,None,None,2011,2012,TYRP1,ImClone Systems;Eli Lilly,na,na,Malignant melanoma,,,Genetically human,20D7;20D7S;IMC 20D7S;IMC-20D7S;IMC20D7S
Fletikumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2013,2014,IL20,ZymoGenetics;Novo Nordisk,na,na,Psoriasis;Rheumatoid arthritis,,,Genetically human,NN-8226;NN8226;NNC0109-0012
Flotetuzumab,Bispecific scFv with Crossover,na;na,Kappa;Lambda,Phase-I/II,Discontinued,EVQLVQSGAELKKPGASVKVSCKASGYTFTDYYMKWVRQAPGQGLEWIGDIIPSNGATFYNQKFKGRVTITVDKSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2017,2018,IL3RA/CD123;CD3E,MacroGenics;Servier,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma,Dual-Affinity Re-Targeting Technology,,Humanised;Humanised,MGD 006;MGD-006;MGD006;MGD 6;MGD-6;MGD6;RES-234;RES234;RES 234;S 80880;S-80880;S80880
Fontolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGSSVKVSCKASGYIFTSSWINWVKQAPGQGLEWIGRIDPSDGEVHYNQDFKDKATLTVDKSTNTAYMELSSLRSEDTAVYYCARGFLPWFADWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCKASENVDTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCGQSYNYPFTFGQGTKVEVK,na,na,None,1t3f:BA/1t04:DC:BA,None,2002,2003,IFNG,PDL BioPharma,na,na,Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis,,,Humanised,HuZAF
Foralumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,CD3E,Medarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences,na,Crohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus,Transplant rejection;Type 1 diabetes mellitus,,,Genetically human,NI-0401;NI0401;NI-401;NI401;TZLS-401;TZLS401
Foravirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGAVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVILYDGSDKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVAVAGTHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLNSYPPTFGGGTKVEIK,na,na,None,None,None,2008,2009,Rabies Virus Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,,Genetically human,CL-184;CL184
Forimtamig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Lambda,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDAYINWVRQAPGQGLEWMGWIWPGPVITYYNPKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARREVLSPFAYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSISGINLMNWYQQKPGQQPKLLIYHASILASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTRESPLTFGQGTRLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFQFSSYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHTTFPSSYVSYYGYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2022,2023,GPRC5D;CD3E,Roche,na,na,Multiple myeloma,,,Humanised;Humanised,RG-6234;RG6234;RO-7425781;RO7425781
Fremanezumab,Whole mAb,G2,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWISWVRQAPGKGLEWVAEIRSESDASATHYAEAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCLAYFDYGLAIQNYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCKASKRVTTYVSWYQQKPGQAPRLLIYGASNRYLGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCSQSYNYPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,CALCA and CALCB,Rinat Neuroscience;Teva Pharmaceutical Industries,Migraine,Fibromyalgia;Headache;Interstitial cystitis,Cluster headache,,,Humanised,LBR-101;LBR101;PF-04427429;PF04427429;PF-4427429;PF4427429;RN-307;RN307;TEV-48125;TEV48125
Freneslerbart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFRNYNINWVRQAPGKGLEWVSLISGSSSYIYYADSVKGRFTVSRDNAKNSLYLQMNSLRAEDTAVYYCARRTLSYYVMDVWGQGTTVTVSS,DIQVTQSPSPLSASVGDRVTITCRASQGISNYLAWYQQKPGRVPQLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPYTFGQGTKLEIK,na,na,None,None,None,2022,2023,Fel d 1,Regeneron Pharmaceuticals,na,Cat allergies,na,,Antigen: Felis silvestris catus (domestic cat) allergen 1,Genetically human,REGN-1908;REGN1908;REGN1908-1909 (cocktail with Mevonlerbart)
Fresolimumab,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS,ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK,na,na,None,3eo0:DC:BA/4kxz:JI:HL:NM:QP/4kv5:EE:GG:HH:JJ/3eo1:BA:ED:KJ:HG,None,2009,2010,TGFB,Cambridge Antibody Technology;Baylor College of Medicine;Genzyme Corporation;Sanofi Genzyme,na,na,Fibrosis;Malignant melanoma;Pulmonary fibrosis;Renal cancer;Focal segmental glomerulosclerosis;Osteogenesis imperfecta,CAT Phage Display,,Genetically human,GC-1008;GC1008
Frexalimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQESGPGLVKPSETLSLTCTVSGDSITNGFWIWIRKPPGNKLEYMGYISYSGSTYYNPSLKSRISISRDTSKNQFSLKLSSVTAADTGVYYCAYRSYGRTPYYFDYWGQGTTLTVSS,DIVMTQSPSFLSASVGDRVTITCKASSNLGHAVAWYQQKPGKSPKLLIYSASNRYTGVPDRFSGSGSGTDFTLTISSLQPEDFADYFCQQYDDYPYTFGGGTKLEIK,na,na,None,None,None,2022,2022,CD40LG/CD154,Sanofi,na,Systemic lupus erythematosus;Multiple sclerosis;Sjogren's syndrome,na,,Genetics: musmus/homosap,Chimeric and/or humanised,INX 021;INX021;INX-021;SAR-441344;SAR441344;SAR 441344
Frovocimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFPFSKLGMVWVRQAPGKGLEWVSTISSGGGYTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGISFQGGTYTYVMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHRNGITYSYWYLQKPGQSPQLLIYQLSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQNLELPLTFGQGTKVEIK,na,na,None,None,None,2018,2019,PCSK9,Eli Lilly,na,Hypercholesterolaemia,na,,,Humanised,LY3015014;LY-3015014;LY 3015014
Frunevetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,QVQLVESGAELVQPGESLRLTCAASGFSLTNNNVNWVRQAPGKGLEWMGGVWAGGATDYNSALKSRLTITRDTSKNTVFLQMHSLQSEDTATYYCARDGGYSSSTLYAMDAWGQGTTVTVSA,DIEMTQSPLSLSVTPGESVSISCRASEDIYNALAWYLQKPGRSPRLLIYNTDTLHTGVPDRFSGSGSGTDFTLKISRVQTEDVGVYFCQHYFHYPRTFGQGTKLELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Feline osteoarthritis,na,PETization Technology,,na,NV-02;NV02;SOLENSIA
Fulranumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,4m6o:HL,None,2010,2011,NGFB,Janssen Pharmaceuticals;Janssen Research & Development;Takeda;Amgen,na,na,Pain;Back pain;Cancer pain;Musculoskeletal pain;Neuropathic pain,Abgenix XenoMouse,,Genetically human,AMG-403;AMG403;JNJ-42160443;JNJ42160443
Futermestotug,Whole mAb,G1,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISRGGGYTSYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREDYGSSYVHWFAYWGQGTLVTVSA,DIQMTQSPSFLSASVGDRVTITCRAGENIYSYLAWYQQKPGKAPKLLIYNARTLAEGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQHHYGSPRTFGGGTKLEIK,na,na,None,None,None,2025,na,CTLA4/CD152,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Futuximab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQPGSELVRPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGNIYPGSRSTNYDEKFKSKATLTVDTSSSTAYMQLSSLTSEDSAVYYCTRNGDYYVSSGDAMDYWGQGTSVTVSS,DIQMTQTTSSLSASLGDRVTISCRTSQDIGNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDFSLTINNVEQEDVATYFCQHYNTVPPTFGGGTKLEIK,na,na,None,None,None,2012,2013,EGFR/ERBB1/HER1,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,,,Chimeric,DS-992;DS992;S-95026;S95206;Sym-004 (Combination with Modotuximab);Sym004 (Combination with Modotuximab)
Gacovetug,Dimerised heavy domain (VH-h-CH2-CH3-CHS dimer),A1,na,TBC,Active,QVQLQESGGGLVQPGGSLRLSCTASGSISSINAMGWYRQAPGSKREFVAHITNTGVTEFADSVKGRFTISRDNAKTTVDLQMNSLKPEDTAVYYCAATDWGTLLIKGIDHWGKGTQVTVSS,na,na,na,4wen:B,None,None,2024,na,F4+ ETEC (Veterinary Application),Vrije Universiteit Brussel,na,Veterinary F4+ E coli Infections,na,,anti-[F4+ enterotoxigenic Escherichia coli (ETEC) FaeG (subunit of the major constituent of F4 + fimbriae). Alpaca VHH domain on Sus Scrofa derived heavy chain dimer.,Genetically Alpaca,TBC
Galcanezumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLVQSGAEVKKPGSSVKVSCKASGYTFGNYWMQWVRQAPGQGLEWMGAIYEGTGKTVYIQKFADRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSDYVSGFGYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASKDISKYLNWYQQKPGKAPKLLIYYTSGYHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDALPPTFGGGTKVEIK,na,na,None,None,None,2015,2016,CALCA and CALCB,Eli Lilly,Migraine;Cluster headache,na,Musculoskeletal pain,,,Humanised,Emgality;LY-2951742;LY 2951742;LY2951742
Galegenimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYKFTDSEMHWVRQAPGQGLEWIGGVDPETEGAAYNQKFKGRATITRDTSTSTAYLELSSLRSEDTAVYYCTRGYDYDYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVEFIHWYQQKPGKAPKPLISATSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSAPWTFGQGTKVEIK,na,na,7sjm:HL/7sjn:HL:DE:FG/7sjo:HL:EF:IJ/7sjp:HL,None,None,2021,2022,HTRA1,Roche,na,na,Age-related macular degeneration,,,Humanised, FHTR2163;FHTR-2163;RG-6147;RG6147;RO-7171009;RO7171009
Galiximab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS,ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL,na,na,None,None,None,2003,2004,B7/CD80/CD28LG,Biogen;Biogen Idec,na,na,Autoimmune disorders;Non-Hodgkin's lymphoma;Psoriasis,,,Chimeric,IDEC 114;IDEC114;IDEC-114;IDEC 114-20;IDEC-114-20;IDEC114-20
Galvokimig1,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Bispecific entry,G1;na,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKCLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGCGTKVEIK,8ruu:BC:HL;None,None;5fuo:HL/5fuz:HL,None;None,2023,2024,IL17A and IL17F;ALB,TBC,TBC,TBC,TBC,,G1(VH-CH1-h)-scFv_L-kappa segment. Fv1 identical to Bimekizumab. Fv2 identical to Donzakimig Fv2.,Humanised;Humanised,TBC
Galvokimig2,Trispecific (G1(VH-CH1-h)-scFv_L-kappa-scFv); Monospecific entry,na,Kappa,TBC,Active,EVQLVQSGAEVKKPGSSVKVSCKASGYSFTSYYIHWVRQAPGQCLEWMGRIGPGSGDINYNEKFKGRATFTVDKSTSTAYMELSSLRSEDTAVYYCARFHYDGADWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNINENLDWYQQKPGKAPKLLIYYTDILQTGIPSRFSGSGSGTDYTLTISSLQPEDFATYYCYQYYSGYTFGCGTKLEIK,na,na,None,None,None,2023,2024,IL13,TBC,TBC,TBC,TBC,,Final scFv segment. Fv3 identical to Donzakimig Fv3.,Humanised,TBC
Gancotamab,scFv,na,Lambda,Phase-II,Discontinued,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSYAMSWVRQAPGKGLEWVSAISGRGDNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMTSNAFAFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGNTNRPSGVPDRFSGFKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,None,None,None,2018,2019,ERBB2/CD340/HER2,Merrimack Pharmaceuticals;HERMES BioSciences,na,na,Breast cancer,,,Genetically human,Nano-doxorubicin
Ganitumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK,na,na,None,None,None,2010,2011,IGF1R/CD221,Amgen;Millennium;NantWorks;National Cancer Institute (USA);Novartis;Takeda;Takeda Oncology;UCLAs Jonsson Comprehensive Cancer Center,na,na,Breast cancer;Colorectal cancer;Sarcoma;Small cell lung cancer;Non-small cell lung cancer;Pancreatic cancer;Prostate cancer;Ewing's sarcoma;Solid tumours;Rhabdomyosarcoma,,,Genetically human,AMG-479;AMG479
Gantenerumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,na,na,5csz:HL:AB,None,None,2012,2008,APP,MorphoSys;Chugai Pharmaceutical;Roche,na,na,Alzheimer's disease,,,Genetically human,R-1450;R1450;RG-1450;RG1450;RO-4909832;RO4909832
Garadacimab,Whole mAb,G4,Lambda,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYIMQWVRQAPGKGLEWVSGIDIPTKGTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARALPRSGYLISPHYYYYALDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRNYVYWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLRGVFGGGTKLTVL,na,na,8r8d:HL:EI,None,None,2018,2019,F12,CSL Behring,Hereditary angioedema,na,COVID-19,,,Genetically human,CSL 312;CSL312;CSL-312
Garetatug,Whole mAb ADC,G1,Kappa,TBC,TBC,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQRLEWMGMIHPNSGSTNYNEKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARLKTGNSFDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNAYTYPFTFGQGTKLEIK,na,na,None,None,None,2025,na,CLDN18,TBC,TBC,TBC,TBC,TBC,ADC with rezetecan,Humanised,TBC
Garetosmab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,INHBA,Regeneron Pharmaceuticals,na,Fibrodysplasia ossificans progressiva;Osteroporosis,Musculoskeletal disorders,,,Genetically human,R2477;R-2477;REGN-2477;REGN2477
Garivulimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFSLTSYGVHWVRQAPGKGLEWVAVIWAGGSTNYADSVKGRFTISKDTSKNTVYLQMNSLRAEDTAVYYCAKPYGTSAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIVVAWYQQKPGKAPKLLIYWASIRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPLYTFGQGTKVEIK,na,na,None,None,None,2020,2021,PDL1/CD274,BeiGene,na,Solid tumours,na,,,Humanised,BGB-A333;BGB A333
Gatipotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSMRLSCVASGFPFSNYWMNWVRQAPGKGLEWVGEIRLKSNNYTTHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTRHYYFDYWGQGTLVTVSS,DIVMTQSPLSNPVTPGEPASISCRSSKSLLHSNGITYFFWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLRISRVEAEDVGVYYCAQNLELPPTFGQGTKVEIK,na,na,None,None,None,2016,2017,MUC1/PEM/EMA,NEMOD Biotherapeutics;Glycotope,na,Ovarian cancer;Solid tumours;Fallopian tube cancer,na,GlycoExpress Technology,Gatipotuzumab and PankoMab are the same mAb,Humanised,PankoMab
Gatralimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFPFSNYWMNWVRQAPGKGLEWVGQIRLKSNNYATHYAESVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTPIDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLYSNGKTYLNWVLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCVQGSHFHTFGQGTKLEIK,na,na,6obd:HL:BA,None,None,2019,2020,CD52,Sanofi,na,na,Multiple sclerosis,,,Humanised,GZ-402668;GZ402668
Gedivumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGKSLRLSCAASGLTFSSYAVHWVRQAPGKGLEWVTLISYDGANQYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTAVYYCAVPGPVFGIFPPWSYFDNWGQGILVTVSS,EIVLTQSPATLSVSPGERATLSCRASQVISHNLAWYQQKPGQAPRLLIYGASTRASGIPARFSGSGSGTDYTLTITSLQSEDFAVYYCQHYSNWPPRLTFGGGTKVEIK,na,na,None,None,4kvn:HL,2016,2017,Influenza A HA,Genentech,na,na,Influenza A virus infections,,,Genetically human,MHAA-4549A;MHAA4549A;RG 7745;RG7745;RG-7745;RO 6876802;RO6876802;RO-6876802
Gefurulimab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS,na,EVQLVESGGGLVQPGGSLRLSCAASGRAHSDYAMAWFRQAPGQEREFVAGIGWSGGDTLYADSVRGRFTNSRDNSKNTLYLQMNSLRAEDTAVYYCAARQGQYIYSSMRSDSYDYWGQGTLVTVSS,na,None;8coh:A,None;8coe:B,None;None,2022,2022,C5;ALB,Alexion Pharmaceuticals,na,Myasthenia gravis;Proteinuria,na,,,Humanised;Humanised,ALXN-1720;ALXN1720
Gemtuzumab,Whole mAb ADC,G4,Kappa,Approved,NFD,EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS,DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK,na,na,8w70:BA,None,None,2016,2017,SIGLEC3/CD33/p67,UCB;Celgene Corporation;Pfizer;University of California San Diego,Acute myeloid leukaemia,na,na,,ADC with ozogamicin,Humanised,CDP-771;CDP771 CMA-676;CMA676;Mylotarg
Geptanolimab,Whole mAb,G4,Kappa,Preregistration,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTNFGMNWVRQAPGQGLKWMGWISGYTREPTYAADFKGRFVISLDTSVSTAYLQISSLKAEDTAVYYCARDVFDYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGYSFMNWFQQKPGQPPKLLIYRASNLESGVPARFSGSGSRTDFTLTINPVEADDTANYYCQQSNADPTFGQGTKLEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Genor Biopharma;Appolomics,na,Peripheral T-cell lymphoma;Primary mediastinal B-cell lymphoma;Hepatocellular carcinoma,Lymphoma;Solid tumours,,Genetics: musmus/homosap,Chimeric and/or humanised,APL 501;APL-501;APL501;CBT 501;CBT501;CBT-501;GB 226;GB-226;GB226
Gevokizumab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS,DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK,na,na,4g6k:HL/4g6m:HL,None,None,2010,2011,IL1B,IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA,na,Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma,Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma,,,Humanised,S-78989;S78989;S 78989;VPM 087;VPM087;VPM-087;VPM87;VPM-87;XMA-005.2;XMA-0052;XMA52;XOMA-052;XOMA052;XOMA52;XOMA-52
Giloralimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLQESGPGLVKPSETLSLTCTVSGYSITSNYYWNWIRQPPGKGLEWMGYIRYDGSNNYNPSLKNRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLENTNGNTFLNWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQVTHVPFTFGQGTKLEIK,na,na,None,None,None,2019,2020,TNFRSF5/CD40,AbbVie,na,Solid tumours,na,,Genetics: musmus/homosap,Chimeric and/or humanised,ABBV-927;ABBV927
Gilvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVQSGGDLVKPGGSVRLSCVASGFNIKNTYMHWVRQAPGKGLQWIGRIAPANVDTKYAPKFQGKATISADTAKNTAYMQLNSLRAEDTAVYYCVLIYYDYDGDIDVWGQGTLVTVSS,DIVMTQTPLSLSVSLGEPASISCHASQNINVWLSWYRQKPGQIPQLLIYKASHLHTGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQGQSWPLTFGQGTKVEIK,na,na,None,None,None,2016,2017,PDCD1/CD279/PD1 (Canine),Merck,na,Canine Cancers,na,,,na,AH-PD1
Gimistotug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTSYIIHWVRQAPGQGLEWMGYINPYNEGTRYNQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCARGYYGSSYAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQKPDGAIKLLIYDASTLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSKLPYTFGGGTKVEIK,na,na,None,None,None,2024,2024,TNFRSF4/CD134/OX40,BeiGene,na,Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Urogenital cancer;Solid tumours,na,,,Humanised,BGB-A445;BGB A445
Gimsilumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRHWMHWLRQVPGKGPVWVSRINGAGTSITYADSVRGRFTISRDNANNTLFLQMNSLRADDTALYFCARANSVWFRGLFDYWGQGTPVTVSS,EIVLTQSPVTLSVSPGERVTLSCRASQSVSTNLAWYQQKLGQGPRLLIYGASTRATDIPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYDKWPDTFGQGTKLEIK,na,na,None,None,None,2017,2018,CSF2,Ludwig Institute for Cancer Research;Morphotek,na,na,Cancer;Rheumatoid arthritis,MORPHODOMA Technology,,Genetically human,KIN-1901;KIN1901;MORAb 022;MORAb022;MORAb22;MORAb-22
Ginisortamab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVESGAEVKKPGATVKISCKVSGYTFTDYYMHWVQQAPGKGLEWMGLVDPEDGETIYAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCATDARGSGSYYPNHFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYFCQQYYDTPTFGQGTRLEIK,na,na,8b7h:HL,None,None,2021,2022,GREM1,UCB,na,Solid tumours,na,,,Genetically human,UCB6114;UCB-6114
Girentuximab,Whole mAb Radiolabelled,G1,Kappa,Phase-III,Discontinued,DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS,DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK,na,na,None,None,None,2009,2010,CA9,Centocor Inc;Heidelberg Pharma AG,na,na,Renal cancer,,,Chimeric,Rencarex;WX-G250;WXG250;WX G250
Givastomig,Bispecific (G1-scFv_L-kappa),G1;na,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYPIEWVRQAPGQRLEWMGNFHPYNDDTKYNEKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARRAYGYPYAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNAGNQKNYLTWYQQKPGQPPKLLIYRASSRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYIYPYTFGGGTKLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKCLEWVSWISYSGGSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAQRNSMREFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVTWYQQLPGTAPKLLIYADSHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDYSLSGYVFGCGTKLTVL,None;None,None;None,None;None,2023,2024,CLDN18;TNFRSF9/CD137/4-1BB,I-MAB,na,Solid tumours;Colorectal cancer,na,,Fv2 identical in sequence to Ragistomig Fv2.,Humanised;Humanised,TJ-033721;TJ033721;TJ-CD4B;TJ CLDN4B;ABL111;ABL-111
Glembatumumab,Whole mAb ADC,G2,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK,na,na,None,None,None,2015,2016,GPNMB,CuraGen Corporation;Celldex Therapeutics Inc;National Cancer Institute (USA),na,na,Brain cancer;Breast cancer;Malignant melanoma;Osteosarcoma;Squamous cell cancer;Uveal melanoma,,ADC with vedotin,Genetically human,CDX-011;CDX011;CDX-11;CDX11
Glenzocimab,Fab,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGGIYPGNGDTSYNQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGTVVGDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLENSNGNTYLNWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQLTHVPWTFGQGTKVEIT,na,na,7r58:HL,None,None,2018,2019,GP6,Acticor Biotech,na,Stroke;COVID-19,na,,June '22: Corrected FWL3 sequence,Humanised,ACT-017;ACT017;ACT17;ACT-17
Glofitamab,Bispecific mAb with Domain Crossover,G1;G1,Lambda;Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,None;3pp3:HL/3pp4:HL,None;6y9a:HL,None;6y97:HL,2019,2020,CD3E;MS4A1/CD20,Roche,Diffuse large B cell lymphoma,Follicular lymphoma;Non-Hodgkin's lymphoma,na,,Genetics of Fv1: musmus/homosap,Chimeric and/or humanised;Humanised,Columvi;RG 6026;RG6026;RG-6026;RO 7082859;RO-7082859;RO7082859
Gocatamig1,Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH'); Bispecific entry,na;na,Lambda;na,Phase-I/II,Active,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL,EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSS,na,None;None,None;None,None;8z8v:B,2024,2024,CD3E;ALB,Harpoon Therapeutics,na,Neuroendocrine tumours;Small cell lung cancer,na,,Humanised Fv1: musmus/homosap. Podentamig VH2 and Godatamig VH2 have the same sequence,Humanised;Genetically human,HPN328;HPN 328;HPN-328;MK-6070;MK6070 ;MK 6070
Gocatamig2,Trispecific Mixed scFv and Single Domains (scFvhl-VH-VH'); Monospecific entry,na,na,Phase-I/II,Active,EVQLVESGGGLVQPGGSLTLSCAASSSSVSLLSLAWYRQAPGKKRELVAGISDDGSIVYMDSVKGRFTISRDNAKNSVYLQMNSLRAEDTAVYYCYAYSWITRSPYWGQGTLVTVSS,na,na,na,None,None,None,2024,2024,DLL3,Harpoon Therapeutics,na,Neuroendocrine tumours;Small cell lung cancer,na,,Humanised VH: vicpac/homosap. Podentamig Fv1 and Godatamig Fv1 have the same sequence,Humanised,HPN328;HPN 328;HPN-328;MK-6070;MK6070 ;MK 6070
Golimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,5yoy:RO:IF:QN:GD:HE:PM,None,None,2004,2005,TNF/TNFA,Centocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex,Ankylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,Hearing disorders;Type 1 diabetes mellitus,Asthma;Cardiovascular disorders;Sarcoidosis;Uveitis,Medarex UltiMAb Mouse,Biosimilars available,Genetically human,CNTO-148;CNTO148;CNTO 148;MK-8259;MK8259;MK 8259;SCH 900259;SCH900259;SCH-900259;Shinponi;Simponi;Symposony;Xinpini
Golocdacimab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSMHWVRQAPGKGLEWMGGFDPEDFKYHTHQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCALVWGTQGKGVRGWDYYYGMDVWGQGTTVTVSS,QSVVTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTKLTVL,na,na,7r8u:HL,None,None,2022,2022,OLR1/LOX1,MedImmune,na,na,Atherosclerosis;Coronary disorders,,,Genetically human,MEDI-6570;MEDI 6570;MEDI6570
Gontivimab,Bispecific Single Domains (VH-VH'-VH'),na;na,na;na,Phase-II,Discontinued,DVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,EVQLVESGGGLVQAGGSLSISCAASGGSLSNYVLGWFRQAPGKEREFVAAINWRGDITIGPPNVEGRFTISRDNAKNTGYLQMNSLAPDDTAVYYCGAGTPLNPGAYIYDWSYDYWGRGTQVTVSS,na,None;None,None;None,None;None,2019,2020,Respiratory Syncytial Virus Glycoprotein F;Respiratory Syncytial Virus Glycoprotein F,Ablynx,na,na,Respiratory syncytial virus infections,,,Genetically llama;Genetically llama,ALX-0171;ALX0171;ALX 0171;ALX171;ALX-171;ALX 171;VR 465;VR465;VR-465
Gorivitug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSRYAMYWVRQAPGKGLEYVSAISSDGGSTYDADSVKGRFTISRANSKNTLYLQMSSLRAEDTAVYYCVKGLRELLYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRAGQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYITPFTFGPGTKVDIK,na,na,None,None,None,2022,2023,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,na,COVID-19,na,,,Genetically human,REGN-15160;REGN15160
Gosuranemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVHLVESGGALVKPGGSLRLSCAASGFSFSKYGMSWVRQAPGKGLEWVATISSSGSRTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCSISWDGAMDYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSIVHSNGNTYLEWYLQKPGQSPQLLVYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGTYYCFQGSLVPWAFGGGTKVEIK,na,na,None,None,None,2018,2019,MAPT,Biogen;Bristol-Myers Squibb;iPierian,na,na,Cardiovascular disorders;Metabolic disorders;Alzheimer's disease;Progressive supranuclear palsy;Neurodegenerative disorders,,Genetics: musmus/homosap,Chimeric and/or humanised,BIIB092;BIIB-092;BIIB 092;BIBB92;BIIB-92;BIIB 92;BMS-986168;BMS986168;BMS 986168;IPN-007;IPN007;IPN 007;IPN7;IPN-7;IPN 7
Gotistobart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGLSWIRQPPGKGLEWIGYIWYDGNTNFHSPLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAKTEGHYYGSNYGYYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSNLAWYQQKQGKAPKLLLYAATNLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQHLWGTPYTFGQGTKLEIK,na,na,6xy2:HL,None,None,2023,2023,CTLA4/CD152,OncoImmune;BioNTech,na,Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,,,Genetically human,BNT-316;BNT316;BNT 316;ONC-392;ONC392;ONC 392
Gremubamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK,None;None,None;None,6cyf:FE:ML:UT:DC;None,2019,2020,PcrV type III secretion system;Polysaccharide synthesis locus (Pseudomonas),MedImmune,na,na,Nosocomial pneumonia,,May '22: Added missing Y102 in Fv1 LC.,Humanised,MEDI-3902;MEDI3902;MEDI 3902
Gresonitamab,Bispecific scFv-scFv-scFc,G1;G1,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGWINPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDRITVAGTYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,CLDN18;CD3E,Amgen,na,na,GE Junction Cancer,BiTE Technology,,Genetically human;Humanised,AMG 910;AMG-910;AMG910
Greziprubart,Whole mAb,G1,Kappa,Phase-I/II,Active,EMQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMQWVRQAPGKGPEWVGLIRNKAVGETTQYAASVKGRFTISRDDSKNSVYLQMNSLKTEDTAVYYCVSRAGPPGLSWGQGVLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLASDAYNYIDWYLQKPGQSPQLLIYGGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCLQHRALPPTFGQGTKLEIK,na,na,None,None,None,2024,na,C5,Staidson Beijing BioPharmaceuticals,na,Adult respiratory distress syndrome;SARS-CoV-2 acute respiratory disease;Vasculitis,na,,,Genetically human,STSA-1002;STSA 1002;STSA1002
Grisnilimab,Whole mAb,G2a,Lambda,Phase-I/II,Active,QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSS,QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWCSNHLVFGGGTKLTVL,na,na,None,None,None,2020,2021,CD7,Xenikos,na,Steroid-refractory acute graft-versus-host disease;Graft-versus-host disease,na,,,Murine,WT1
Gruticibart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSITCTVSGFSLTGYGIYWVRQPPGKGLEWLGMIWGDGRTDYNSALKSRVTISKDNSKSQVSLKLSSVTAADTARYYCARDYYGSKDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSTAVAWYQQKPGKAPKLLIYLTSYRNTGVPDRFSGSGSGTDFTFTISSLQPEDIAVYYCQQHYKTPYSFGGGTKVEIK,na,na,None,None,None,2023,2024,F11,Oregon Health & Science University;Aronora,na,Thrombosis,Cardiovascular disorders;Neurological disorders;Sepsis,,Genetics: musmus/homosap,Chimeric and/or humanised,AB-023;AB 023;AB023;AB022;AB 022;AB-022;Xisomab 3G3
Gulgafafusp,Fusion Protein (whole mAb with protein),G2,Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTLSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGGSGSYRYYYYGLDVWGQGTTVTVSS,AIQMTQSPSSVSASIGDRVTITCRASQNINNLLAWYQQKPGKAPKLLIYTASSLQSEVPSRFSGSGSGTDFTLTISSLQPEDFAIYCCQQAHRFPPTFGQGTKVEIR,na,na,None,None,None,2023,na,GLP1R,Gmax Biopharm,na,Type 2 diabetes mellitus,na,,,na,GMA-102 (diabetes indication);GMA102;GMA-105 (obesity indication);GMA105;Glutazumab (not WHO assigned INN)
Gumokimab,Whole mAb,G1,Kappa,Phase-III,Active,DVQLQESGPGLVKPSQTLSLTCTVSSYSFTSDYAWSWIRQPPGKGLEWIGYITYSGVTSYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARADYDSYYTMDYWGQGTSVTVSS,DVVMTQTPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCSQSTHFWTFGGGTKLEIK,na,na,None,None,None,2021,2022,IL17A,Akeso Biopharma,na,Plaque psoriasis;Ankylosing spondylitis,na,,Genetics: musmus/homosap,Chimeric and/or humanised,AK-111;AK111;AK 111
Guselkumab,Whole mAb,G1,Lambda,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL,na,na,4m6m:HL/4m6n:HL,None,None,2013,2014,IL23A,Janssen Biotech;MorphoSys;Taiho Pharmaceutical,Erythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis ,Crohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma,Rheumatoid arthritis,MorphoSys HuCAL Phage Display,,Genetically human,CNTO-1959;CNTO 1959;CNTO1959;TREMFYA
Ianalumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWYNSYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARYDWVPKIGVFDSWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQFISSSYLSWYQQKPGQAPRLLIYGSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQLYSSPMTFGQGTKVEIK,na,na,None,None,None,2017,2018,TNFRSF13C/CD268/BAFFR/BR3,H. Lee Moffitt Cancer Center and Research Institute;MorphoSys;Novartis,na,Autoimmune hepatitis;Idiopathic pulmonary fibrosis;Multiple sclerosis;Pemphigus vulgaris;Rheumatoid arthritis;Sjogren's syndrome;Systemic lupus erythematosus,Chronic lymphocytic leukaemia,POTELLIGENT Technology,Feb '22: Residue 108 changed from Q to D according to amendment in RL83. (June '22) Corrected CDRL1/CDRL3 sequences.,Genetically human,NOV-5;NOV 5;NOV5;NVP-VAY736;NVP VAY736;VAY-736;VAY 736;VAY736
Ibalizumab,Whole mAb,G4,Kappa,Approved,NFD,QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK,na,na,3o2d:HL/7t0r:CB:HL,None,None,2007,2008,CD4,Biogen Idec;TaiMed Biologics;Theratechnologies,HIV-1 infections,na,na,,Biosimilar available,Humanised,Hu1A8;Hu5A8;TMB-355;TMB 355;TMC355;TNX-355;TNX 355;TNX355;Trogarzo
Ibramvibart,Whole mAb,G1,Lambda,TBC,TBC,EVQLVESGGGLVKPGGSLRLSCAASGFEFGSYEMNWVRQAPGKGLEWVSSISEDGYTTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFGGDTNWAGTGFTYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRITISCEGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSVRNYGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSDLGILYTFGTGTKVTVL,na,na,None,None,None,2025,na,SARS-CoV-2 Spike RBD,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Ibentatug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKRLEWVATISIGGTYTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAMYYCARRGYGQYSYYGLDYWGQGTLVTVSS,DIVMTQSALSNPVTLGQSASISCRSSKSLLHSQGITYLYWYLQKPGQSPQLLIYQMSNRASGVPDRFSSSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGQGTKLEIK,na,na,None,None,None,2023,2024,CSP1,ZielBio,na,Cholangiocarcinoma;Ovarian cancer;Pancreatic cancer;Solid tumours ,na,,Genetics: musmus/homosap,Chimeric and/or humanised,ZB-131;ZB131
Ibritumomab,Whole mAb,G1,Kappa,Approved,NFD,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELK,na,na,3bky:HL,None,None,1999,2000,MS4A1/CD20,Biogen;Schering;Spectrum Pharmaceuticals,Non-Hodgkin's lymphoma,na,Diffuse large B cell lymphoma;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Multiple myeloma,,Sequence sourced through DrugBank. ADC with tiuxetan,Murine,BAY86-5128;IDEC-129;IDEC 129;IDEC129;SH-L-749;Zevalin;Zevamab
Icrucumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QAQVVESGGGVVQSGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVRGRFTISRDNSENTLYLQMNSLRAEDTAVYYCARDHYGSGVHHYFYYGLDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2010,2011,FLT1,ImClone Systems,na,na,Colorectal cancer;Urogenital cancer;Breast cancer,,,Genetically human,IMC-18F1;IMC 18F1;IMC18F1;LY 3012212;LY3012212;LY-3012212
Idactamab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEIHHSGGANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGQGKNWHYDYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSIRSWLAWYQQKPGKAPKLLIYKASILKIGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYSYSRTFGQGTKVEIK,na,na,None,None,None,2020,2021,SLC1A5,MedImmune,na,na,Acute myeloid leukemia;Multiple myeloma;Diffuse large B-cell lymphoma,,,Genetically human,INT-001;INT 001;INT001;INT1;INT-1;INT 1;MEDI7247;MEDI-7247;MEDI 7247
Idarucizumab,Fab,G1,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIK,na,na,4jn2:HL:BA/4jn1:HL,None,None,2013,2014,Dabigatran,Boehringer Ingelheim,Blood coagulation disorders,na,na,,,Humanised,BI-655075;BI655075;BI 655075;Praxbind;Prizbind
Ieramilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFTLTNYGMNWVRQARGQRLEWIGWINTDTGEPTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPPYYYGTNNAEAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSSSQDISNYLNWYLQKPGQSPQLLIYYTSTLHLGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYYNLPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,LAG3/CD223,Immutep Limited;Novartis,na,Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours,na,,,Humanised,IMP-701;IMP 701;IMP701;LAG-525;LAG525;LAG 525;NVP-LAG525
Ifabotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK,na,na,None,None,None,2015,2017,EPHA3,Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute,na,Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma,na,POTELLIGENT Technology. Humaneering Technology.,Ifabotuzumab is the new name for Fibatuzumab (PL115),Humanised,KB-004;KB004;KB 004;KB4;KB-4;KB 4
Ifinatamab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYVMHWVRQAPGQGLEWMGYINPYNDDVKYNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARWGYYGSPLYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSRLIYMHWYQQKPGQAPRPLIYATSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWNSNPPTFGQGTKVEIK,na,na,None,None,None,2022,2022,B7H3/CD276,Daiichi Sankyo Company,na,Small cell lung cancer;Solid tumours,na,,ADC with deruxtecan,Humanised,DS-7300;DS7300;DS 7300
Iladatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2017,2019,AGM6/CD79B,Roche,na,na,Non-Hodgkin's lymphoma,,ADC with vedotin,Humanised,MCDS0593A;MCDS-0593A;MCDS593A;MCDS-593A;RO7032005;RO 7032005;RO-7032005
Iluzanebart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDADARYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYFCARRRQGIFGDALDFWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQPEDFAVYYCLQDNNFPPTFGQGTKVDIK,na,na,None,None,None,2023,2023,TREM2,Amgen,na,Leukoencephalopathies;Neurodegenerative disorders,na,,,Genetically human,VGL101;VGL-101
Imalumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYSMNWVRQAPGKGLEWVSSIGSSGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGSQWLYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQRIMTYLNWYQQKPGKAPKLLIFVASHSQSGVPSRFRGSGSETDFTLTISGLQPEDSATYYCQQSFWTPLTFGGGTKVEIK,na,na,6foe:HL:AB,9fqo:AB,None,2014,2015,MIF,Cytokine PharmaSciences;Baxalta;Shire;Takeda,na,na,Solid tumours;Lupus nephritis;Colorectal cancer;Malignant ascites,,,Genetically human,BAX-069;BAX069;BAX 069;BAX-69;BAX69;BAX 69
Imaprelimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVTLKESGPVLVKPTETLTLTCTVSGFSLTSNAVSWVRQPPGKALEWIAAISSGGTTYYNSAFKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARRYGYGWYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQNIYNSLAWYQQKPGKAPKVLIFNANSLQTGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYSGYTFGQGTKLEIK,na,na,None,None,None,2017,2018,MCAM/CD146/MUC18,Neotope Biosciences;Onclave Therapeutics;Prothena;Prothena Corporation,na,na,Cancer;Inflammation;Psoriasis,,,Humanised,PRX-003;PRX003;PRX 003;PRX3;PRX-3;PRX 3
Imeroprubart,Whole mAb,G1,Lambda,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASEFTFGSSVMTWVRQAPGKGLEWVSVISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTPWWLRSPFFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGSNIGSTSVHWYQQKPGQAPVLVVHDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVRDSSSDHVIFGGGTKLTVL,na,na,None,None,None,2024,na,FCGRT/FcRn,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Imgatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK,na,na,None,None,None,2012,2013,EGFR/ERBB1/HER1,GLYCART Biotechnology;Roche,na,na,Colorectal cancer;Head and neck cancer;Non-small cell lung cancer,GlycoMAb Technology,,Humanised,GA-201;GA201;GA 201;R7160;R-7160;RG-7160;RG7160;RG 7160;RO-5083945;RO 5083945;RO5083945
Imneskibart,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSITDDLIHWVRQAPGQGLEWMGWIDPEDGETNYAQKFQGRVTLTADTSTSTAYMELSSLRSEDTAVYYCARSLDSTWIYPFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLRRGNQKNHLAWYQQKPGQPPKLLIYDASTGQSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCLQSYITPPTFGAGTKVEIK,na,na,None,None,None,2024,na,IL2RA/CD25,Biolojic Design;Aulos Bioscience,na,Solid tumours,na,,,Humanised,AU-007;AU007;AU 007;BD-8;BD8;BD 8;BDG8;BD-G8;BD G8
Imsidolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMNWVRQAPRQGLEWMGMFHPTGDVTRLNQKFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARTTSMIIGGFAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHRNAITYFYWYLHKPGQPPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,IL36R,AnaptysBio,na,Generalised pustular psoriasis;Localised pustular psoriasis;Acneiform eruptions;Ichthyosis,Palmoplantas pustulosis;Acne vulgaris;Hidradenitis suppurative,,Genetics: musmus/homosap,Chimeric and/or humanised,ANB 019;ANB019;ANB-019;ANB19;ANB-19;ANB 19
Imvotamab,Pentameric IgM with Fused scFv (Bispecific),M,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHPSYGSGSPNFDYWGQGTLVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLVYSDGNTYLSWLQQRPGQPPRLLIYKISNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCVQATQFPLTFGGGTKVEIK,None;None,None;None,None;None,2022,2022,CD3E;MS4A1/CD20,IGM Biosciences,na,Non-Hodgkin's lymphoma; Diffuse Large B cell lymphoma; Follicular lymphoma;Mantle cell lymphoma;Splenic marginal zone lymphoma;,na,,Geneticsof Fv1: musmus/homosap,Chimeric and/or humanised;Genetically human,IGM 2323;IGM-2323;IGM2323
Imzokitug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDSEMHWVRQATGQGLEWMGAIQPETGGTAYNQKFKARVTMTRDTSISTAYMELSSLRSEDTAVYYCARRRRNFDYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLFHSSGNTYLHWYLQKPGQPPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGQGTKLEIK,na,na,None,None,None,2024,na,CCR8/CKR-L1/CDw198,Bristol Myers Squibb,na,Solid tumours,na,,,Humanised,BMS 986340;BMS-986340;BMS986340
Inclacumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVRPGGSLRLSCAASGFTFSNYDMHWVRQATGKGLEWVSAITAAGDIYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGRYSGSGSYYNDWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK,na,na,None,None,None,2011,2012,SELP/CD62,Genmab;Roche;Global Blood Therapeutics,na,na,Acute coronary syndromes;Myocardial infarction;Peripheral vascular disorders,Medarex UltiMAb Mouse,,Genetically human,R 1512;R1512;R-1512;RG1512;RG-1512;RG 1512;RO 4905417;RO4905417;RO-4905417
Indatuximab,Whole mAb ADC,G4,Kappa,Phase-II,Discontinued,QVQLQQSGSELMMPGASVKISCKATGYTFSNYWIEWVKQRPGHGLEWIGEILPGTGRTIYNEKFKGKATFTADISSNTVQMQLSSLTSEDSAVYYCARRDYYGNFYYAMDYWGQGTSVTVSS,DIQMTQSTSSLSASLGDRVTISCSASQGINNYLNWYQQKPDGTVELLIYYTSTLQSGVPSRFSGSGSGTDYSLTISNLEPEDIGTYYCQQYSKLPRTFGGGTKLEIK,na,na,None,None,None,2011,2012,SDC1/CD138,Biotest AG,na,na,Bladder cancer;Breast cancer;Multiple myeloma,,ADC with ravtansine,Chimeric,BT-062;BT062;BT-62;BT62;BT 62;BT 062
Indematug,Whole mAb,G1,Lambda,TBC,Active,EVQLVESGGGLVKPGDSLTVSCVASGFTFSNYFIHWVRQAPGKGLEWVATISGRTKYMFYSDSLRGRFTVSRDNAQNSVYLHMSSLRGEDTALYYCVRGYDHSDSNSAADLLHWGRGTLVTVSS,NFMLTQPLSVSGYPGKTIVISCVRSSGSVASHYVQWFQQRPGSAPAMVIYEDSHRPSGIPDRFSGSVDASSNSASLTISGLKTEDEADYFCQSYYGNNQVLFGGGTKLTVL,na,na,None,None,None,2024,na,IFNG ,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Indenebart,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSISHLGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGANHGKYYYGMDKWGQGTTVTVSS,QAVLTQPASLSASPGASASLTCTLRSGAPLPKYRIYWYQQKPGSPPQYLLRYKSDADKHQGSGVPSRFSGSKDASANAGILLISGLQSEDEADYYCMVWDHGVWYFGGGTKLTVL,na,na,None,None,None,2024,2024,SNCA/PARK1/PARK4,MedImmune;AstraZeneca;Takeda,na,Multiple system atrophy;Parkinson's disease,na,,,Genetically human,MEDI-1341;MEDI 1341;MEDI1341;TAK 341;TAK-341;TAK341
Indusatumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVFGGSFSGYYWSWIRQPPGKGLEWIGEINHRGNTNDNPSLKSRVTISVDTSKNQFALKLSSVTAADTAVYYCARERGYTYGNFDHWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSRNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIGSLQSEDFAVYYCQQYKTWPRTFGQGTNVEIK,na,na,None,None,None,2014,2015,GUCY2C,Millennium;Takeda Oncology,na,na,Colorectal cancer;Gastrointestinal cancer;Pancreatic cancer,,ADC with vedotin,Genetically human,MLN-0264;MLN0264;MLN264;MLN-264;TAK-264;TAK 264;TAK264
Inebilizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK,na,na,None,None,None,2015,2016,CD19,Cellective Therapeutics;MedImmune,Neuromyelitis optica,Autoimmune disorders;Myasthenia gravis;Renal transplant rejection,B-cell lymphoma;Chronic lymphocytic leukaemia;Diffuse large B-cell lymphoma;Follicular lymphoma;Multiple myeloma;Multiple sclerosis;Systemic scleroderma,POTELLIGENT Technology,,Humanised,16C4-aFuc;MEDI 551;MEDI-551;MEDI551;MT-0551;MT0551;MT 0551;MT551;MT-551;MT 551;Uplizna;VIB-0551;VIB0551;VIB 0551;VIB551;VIB-551;VIB 551
Inezetamab,Bispecific Mixed mAb and scFv,G1;na,Lambda;Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRNAMSWVRQAPGKGLEWVSATGGSGISTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYSNSWWYFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGNYNLVSWYQQHPGKAPKLMIFEVNQRPSGVSNRFSGSKSGTTASLTISGLQAADEADYFCSSYTTSSTYVIFGGGTKLTVL,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKCLEWISYISSSESIIYYVDAVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDVGSHFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISRWLAWYQQKPGKAPKLLISAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQAKSFPRTFGCGTKVEIK,None;None,None;None,None;None,2022,2022,CD40;MSLN,Amgen,na,Solid tumours,na,,,Genetically human;Genetically human,AMG 994;AMG-994;AMG994
Infliximab,Whole mAb,G1,Kappa,Approved,NFD,EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS,DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK,na,na,5vh3:HL:AB/5vh4:HL:AB/4g3y:HL/6ugs:HL:AB/6ugv:HL:AB/6ugt:HL:AB/6ugu:HL:AB,None,None,1997,1998,TNF/TNFA,Centocor;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;National Jewish Medical and Research Center;Xian-Janssen,Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Mucocutaneous lymph node syndrome;Plaque psoriasis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis,na,Berylliosis;Hepatitis C;Pyoderma,,Danvilostomig Fv1;Ipilimumab; Sovipostobart; and Tazlestobart all have the same sequence. Likely biosimilars.,Chimeric,cA2; CenTNF;Remicade;TA-650;TA650;TA 650
Ingitamig,Bispecific Mixed mAb and tandem mAb/scFv,G1;G1,Kappa;Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKCLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGAPMGAAAGWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSFPRTFGCGTKVEIK,None;None,None;None,None;None,2024,na,TNFRSF17/CD269/BCMA/TNFRSF13A;KLRK1/NKG2D/CD314,Dragonfly Therapeutics;Celgene Corporation;Bristol Myers Squibb,na,Multiple myeloma,na,,,Genetically human;Genetically human,BMS-986392;BMS 986392;BMS986392;CC-92328;CC 92328;CC92328;DF3001;DF 3001;DF-3001
Inlecitug,Whole mAb,G1,Kappa,TBC,TBC,QVKLQQSGAELVGSGASVKLSCTTSGFNIKDFYMHWVKQRPEQGLEWIGWIDPENGDSDYAPKFQGKATMTADSSSNTAYLQLSSLTSEDTAVYYCNAYYGDYEGYWGQGTTVTVSS,DIELTQSPAIMSASPGEKVTITCSASSSVSYMHWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPFTFGSGTKLEIK,na,na,None,None,None,2025,na,KDR/CD309/VEGFR2,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric,TBC
Inotuzumab,Whole mAb ADC,G4,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS,DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2004,2005,SIGLEC2/CD22,Alliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group,Precursor cell lymphoblastic leukaemia-lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia,Acute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,,ADC with ozogamicin,Humanised,Besponsa;CMC-544;CMC544;CMC 544;PF-05208773;PF05208773;PF-5208773;PF5208773;WAY-20729;WAY20729;WAY 20729
Intetumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSRRLSCAASGFTFSRYTMHWVRQAPGKGLEWVAVISFDGSNKYYVDSVKGRFTISRDNSENTLYLQVNILRAEDTAVYYCAREARGSYAFDIWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK,na,na,None,None,None,2009,2010,ITGAVB3/CD61/VNR,Centocor Inc;Janssen Biotech;Janssen-Cilag,na,na,Malignant melanoma;Prostate cancer,VelocImmune Mouse,,Genetically human,CNTO 095;CNTO095;CNTO-095;CNTO-95;CNTO95;CNTO 95
Invikafusp,Fusion Protein,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGHDFRLTYIHWVRQAPGQGLEWMGRVSAGSGNVKYNEKFKGRVTITADTSTSTAYMELSSLRSEDTAVYYCAVSYYSYDVLDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCKASQNVADRVVWHQQKPGKAPKALIYSSSHRYKGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCQQFKSYPLTFGQGTKLEIK,na,na,8tfn:HL,None,None,2024,2024,TRBV6&TRBV10,Marengo Therapeutics,na,Solid tumours,na,,,Humanised,STAR 0602;STAR0602;STAR-0602
Iparomlimab,Whole mAb,G4,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWIHWVRQAPGQGLEWMGEIDPYDSYTNYNQKFKGRVTMTVDKSTSTVYMELSSLRSEDTAVYYCARPGFTYGGMDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLFNSGNQKNYLAWYQQKPGKVPKLLIYGASTRDSGVPYRFSGSGSGTDFTLTISSLQPEDVATYYCQNDHYYPYTFGGGTKVEIK,na,na,None,None,None,2021,2022,PDCD1/CD279/PD1,Qilu Puget Sound Biotherapeutics,na,Neoplasms,na,,Chimeric: Mouse/Human,Chimeric and humanised,PSB103;PSB-103;PSB-205 (cocktail with Tuvonralimab);PSB205 (cocktail with Tuvonralimab);QL1706 (cocktail with Tuvonralimab)
Ipilimumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL,None,7su0:HL:IM/7su1:HL,2005,2006,CTLA4/CD152,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Bavarian Nordic;Big Ten Cancer Research Consortium;BioGene Pharmaceutical;Bristol-Myers Squibb;Canadian Cancer Trials Group;Dana-Farber Cancer Institute;European Thoracic Oncology Platform;Grupo Espanol Multidisciplinar de Melanoma;Icahn School of Medicine at Mount Sinai;Intergroupe Francophone de Cancerologie Thoracique;Ludwig Institute for Cancer Research;Massachusetts General Hospital;Medarex;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National University Hospital (Singapore);Northwestern University;Olivia Newton-John Cancer Research Institute;OncoTherapy Science;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University College London;University of California at San Francisco;University of Texas M. D. Anderson Cancer Center,Malignant melanoma;Renal cell carcinoma,Colorectal cancer;Non-small cell lung cancer;Gastric cancer;Glioblastoma;Head and neck cancer;Mesothelioma;Oesophageal cancer;Prostate cancer;Small cell lung cancer;Urogenital cancer;Adrenocortical carcinoma;Breast cancer;CNS cancer;Gastrointestinal cancer;Genitourinary disorders;Gynaecological cancer;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Neuroendocrine tumours;Ovarian cancer;Pancreatic cancer;Penile cancer;Solid tumours;Thyroid cancer;Uveal melanoma;Diffuse large B cell lymphoma;Liver cancer;Lung cancer;Glioma,HIV infections;Lymphoma,Medarex UltiMAb Mouse,Biosimilars available,Genetically human,BMS-734016;BMS734016;MDX-010;MDX010;MDX 010;MDX-10;MDX10;MDX 10;Yervoy
Iratumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSAYYWSWIRQPPGKGLEWIGDINHGGGTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCASLTAYWGQGSLVTVSS,DIQMTQSPTSLSASVGDRVTITCRASQGISSWLTWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPITFGQGTRLEIK,na,na,None,None,None,2005,2006,TNFRSF8/CD30,Medarex,na,na,Hodgkin's disease;Lymphoma;Non-Hodgkin's lymphoma,Medarex UltiMAb Mouse,,Genetically human,5F11;MDX-060;MDX 060; MDX060;MDX60;MDX-60;MDX 60
Isatuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS,DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK,na,na,4cmh:BC,None,None,2014,2015,ADPRC1/CD38,ImmunoGen;Huntsman Cancer Institute;Roche;Sanofi,Multiple myeloma,Acute myeloid leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Colorectal cancer;Diffuse large B cell lymphoma;Hodgkin's disease;Solid tumours;Urogenital cancer,Non-small cell lung cancer;Prostrate cancer;T-cell lymphoma,,,Chimeric,hu38SB19;SAR-650984;SAR650984;Sarclisa
Iscalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2017,2018,TNFRSF5/CD40,Novartis;XOMA,na,Graves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus,Rheumatoid arthritis,,,Genetically human,CFZ-533;CFZ533;CFZ 533;NVP-CFZ533;OM11-62-MF
Isecarosmab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-I,Discontinued,DVQLVESGGGVVQPGGSLRLSCAASGRTVSSYAMGWFRQAPGKEREFVAGISRSAERTYYVDSLKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAADLDPNRIFSREEYAYWGQGTLVTVSS,na,EVQLVESGGGVVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;8z8v:B,2019,2020,ADAMTSL5;ALB,Merck,na,na,Solid tumours,,Humanised: Llama/Human,Humanised;Humanised,M-6495;M 6495;M6495
Ispectamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNISAPGIHWVRQAPGKGLEWVGFINPAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDYIRQYWTYVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,None,None,2022,2022,TNFRSF17/CD269/BCMA/TNFRSF13A,Celgene Corporation,na,Multiple myeloma,na,,,Humanised,BMS-986352;BMS 986352;BMS986352
Istiratumab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-II,Discontinued,EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS,DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK,QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS,SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL,None;None,None;None,None;None,2017,2018,IGF1R/CD221;ERBB3/HER3,Adimab;Merrimack Pharmaceuticals,na,na,Ovarian cancer;Pancreatic cancer;Solid tumours,,,Genetically human;Genetically human,MM-141;MM 141;MM141
Isuventatug,Whole mAb,G1,Kappa,TBC,TBC,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWIRQAPGKGLEWVSYISPGGDYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTTDRRHYGSYAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNLNTYLYWFLQKPGQSPQILIYRMSNLASGVPDRFSGSGSGTAFTLKISRVEAEDVGVYYCMQHLEYPFTFGPGTKLEIK,na,na,None,None,None,2025,na,MICA&MICB,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Itanistomig,Bispecific Mixed Domains (VH-G1CH1-h)-H-gamma1_L-kappa-L-kappa),G1;na,Kappa;Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSTYAISWVRQAPGQGLEWMGGIIPIFGKAHYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYFCARKFHFVSGSPFGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPTFGQGTKVEIK,QVQLVQSGAEVKKPGESLKISCKGSGYTFTNYYIFWVRQMPGKGLEWMGIINPVDGDTNYNPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGYTMDRWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQNTHTPRTFGGGTKVEIK,5ggt:HL;None,None;None,None;None,2024,na,PDL1/CD274;IAP/CD47,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Humanised,TBC
Itepekimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIK,na,na,None,None,None,2019,2020,IL33,Regeneron Pharmaceuticals;Sanofi,na,Chronic obstructive pulmonary disease,Allergic asthma;Inflammation;Asthma;Atopic dermatitis,,,Genetically human,REGN-3500;REGN3500;REGN 3500;SAR-440340;SAR440340;SAR 440340
Itolizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYYPDSVKGRFTISRDNVKNTLYLQMSSLRSEDTAMYYCARRDYDLDYFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDIRSYLTWYQQKPGKAPKTLIYYATSLADGVPSRFSGSGSGQDYSLTISSLESDDTATYYCLQHGESPFTLGSGTKLEIK,na,na,None,None,None,2010,2011,CD6,Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium,Plaque psoriasis,Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis,Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis,,ADC with debotansine or tazide,Humanised,Bmab600;EQ-001;EQ001;EQ 001;EQ-1;EQ1;EQ 1
Ivicentamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYNMGWVRQAPGKGLEWVSVIDASGTTYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARELLYFGSSYYDLWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTITCQASQNIDSNLAWYQQKPGKAPKFLIYYASNLPFGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQSADVGSTYVAAFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFSLSYNAMNWVRQAPGKGLEWVSIIFASGRTDYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSTWGDALDPWGQGTLVTVSS,AYDMTQSPSTLSASVGDRVTITCQASQNIIDYLAWYQQKPGKAPKLLIHKASTLASGVPSRFKGSGSGTEFTLTISSLQPDDFATYYCQQGYSNSNIDNTFGGGTKVEIK,None;None,None;None,None;None,2021,2022,CD37;CD37,Genmab,na,B cell Lymphoma,na,DuoBody,,Humanised;Humanised,GEN3009;GEN 3009;GEN-3009
Ivonescimab,Bispecific (G1-kappa_scFv),G1,Kappa;Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,1bj1:HL:KJ/7v5n:BA:FE;None,None;None,6bft:AB:HL/1cz8:HL:YX;None,2021,2022,VEGFA;PDCD1/CD279/PD1,Akeso Biopharma,Non-small cell lung cancer,Squamous cell cancer;Colorectal cancer;Gynaecological cancer;Liver cancer;Triple negative breast cancer;Adenocarcinoma;Glioblastoma;Ovarian cancer;Solid tumours;Small cell lung cancer ,na,,Bevacizumab and Ivonescimab Fv1 have same sequences. Cugrastomig Fv2; Penpulimab; and Ivonescimab Fv2 have the same sequences. Aug '23: Corrected to be a bispecific. Genetics of Fv2: musmus/homosap.,Genetically human;Chimeric and/or humanised,AK-112;AK 112;AK112;SMT-112;SMT112;SMT 112
Ivuxolimab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSYISSSSSTIDYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARESGWYLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,Pfizer;Dana-Farber Cancer Institute;M. D. Anderson Cancer Center;National Cancer Institute USA;University of Southern California,na,Breast cancer;Renal cell carcinoma;Solid tumours;Acute myeloid leukaemia;Squamous cell cancer;Follicular lymphoma,na,,,Genetically human,B110;PF-04518600;PF04518600;PF4518600;PF-4518600;PF-8600;PF8600
Ixekizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK,na,na,6nov:AB:CD,6nou:AA,None,2011,2012,IL17A,Eli Lilly;Oregon Health & Science University;Torii Pharmaceutical,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Ankylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis,na,,,Humanised,LY-2439821;LY2439821;LY 2439821;Taltz
Ixotatug,Whole mAb ADC,G1,Kappa,TBC,TBC,EVQLLESGGGLVQPGGSMRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAQIRLKSDNYATHYADSVKGRFTISRDDSKNTVYLQMNSLRAEDTGVYYCNDGPPSGSWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRISENIYSYLAWYQQKPGKAPKLLVYNAKILVEGVPSRFSGSGSGTDFTLTISSLQPEDFGTYYCQHHYTVPWTFGQGTKLEIK,na,na,None,None,None,2025,na,CLDN6,TBC,TBC,TBC,TBC,TBC,ADC with vedotin,Chimeric and/or humanised,TBC
Izalontamab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-III,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSS,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,QVQLQESGGGLVKPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSSSTHVIFGGGTKVTVL,5etu:DC:BA/5ff6:DC:BA/5f88:DC:BA/5itf:DC:BA/5ivz:DC:BA/5ir1:DC:BA/5esq:DC:BA/5euk:DC:BA/5hpm:DC:BA/5id1:DC:BA/5icx:DC:BA/5hyq:DC:BA/5icz:DC:BA/5th2:DC:BA/5iop:DC:BA/5i2i:DC:BA/5t1l:DC:BA/5i76:DC:BA/5iv2:DC:BA/5t1k:DC:BA;None,6azk:DC:BA/6azl:BA:DC/6au5:DC:BA/6ayn:BA:DC/6axp:BA:DC/5id0:DC:BA/5t1m:DC:BA/5icy:DC:BA/1yy8:DC:BA/1yy9:DC/4gw5:DC:BA/4kro:DC/4gw1:DC:BA/4krp:DC;None,5gz0:BA:DC/6arp:BA:DC/6aru:CB;None,2022,2022,EGFR/ERBB1/HER1;ERBB3/HER3,Systimmune,na,Colorectal cancers;Non-small cell lung cancers;Head and neck cancers;Esophageal squamous cell carcinoma,na,,Arm 1 is highly identical to cetuximab. Also used as ADC with brengitecan. Chimeric: Mouse/Human,Chimeric;Chimeric,SI-1X6.4;SI1X6;SI 1X6;SI-B001;SI-1;SI 1;SI1;SI B001
Izastobart,Whole mAb,G1,Lambda,Phase-I,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVGRIKSKAQGGTTDYAAHVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCARVSFSTFDVWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCSGSSSNIGSYYVSWYQQLPGTAPKVLIYRNNQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCDSWDHSSMNVFGGGTKLTVL,na,na,None,None,None,2023,2024,C5AR1/CD88,Human Immunology Biosciences; I-MAB Biopharma;MorphoSys,na,Autoimmune disorders;Solid tumours,na,,,Genetically human,HIB210;HIB-210;HIB 210;MOR044254;MOR-044254;MOR 044254;MOR210;MOR-210;MOR 210;TJ 210;TJ-210;TJ210;TJ210001;WBP2191;WBP-2191;WBP 2191
Izeltabart,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYWMHWVRQAPGKGLEWVGEIIPIFGHTNYNEKFKSRFTISLDNSKNTLYLQMGSLRAEDTAVYYCARGGYYYYPRQGFLDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATISCKASQSVDYSGDSYMNWYQQKPGQPPKLLIYAASDLESGIPARFSGSGSGTDFTLTISSLEPEDFATYYCQQSHEDPFTFGQGTKLEIK,na,na,None,None,None,2022,2023,ADAM9,ImmunoGen,na,na,Solid tumours,,ADC with tapatansine,Humanised,IMGC 936;IMGC-936;IMGC936
Izenivetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRSGYDYYFDVWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCRASENIYSFLAWYQQKPGQAPKLLIYNANTLAEGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQHHFGTPFTFGQGTKLEIK,na,na,None,None,None,2022,2022,NGFB (Canine),Zoetis,na,Osteoarthritis,na,,,Caninised,ZTS-00075623;ZTS00075623;ZTS 00075623
Izuralimab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPHSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARTYYYDSSGYYHDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRLLAWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,None;None,2020,2021,ICOS/CD278;PDCD1/CD279/PD1,Xencor,na,na,Sarcoma;Malignant melanoma;Solid tumours,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,XmAb-104;XmAb104;XmAb 104;XmAb-23104;XmAb 23104;XmAb23104
Labetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFDFTTYWMSWVRQAPGKGLEWIGEIHPDSSTINYAPSLKDRFTISRDNAKNTLFLQMDSLRPEDTGVYFCASLYFGFPWFAYWGQGTPVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDVGTSVAWYQQKPGKAPKLLIYWTSTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYSLYRSFGQGTKVEIK,na,na,None,None,None,2015,2016,CEACAM5/CD66e,Immunomedics,na,na,Colorectal cancer;Ovarian cancer;Breast cancer,,,Humanised,MN-14;MN14;MN 14;IMMU-100;IMMU 100;IMMU100;IMMU-14;IMMU14;IMMU 14
Lacnotuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCTVSDYSITSDYAWNWIRQFPGKGLEWMGYISYSGSTSYNPSLKSRITISRDTSKNQFSLQLNSVTAADTAVYYCASFDYAHAMDYWGQGTTVTVSS,DIVLTQSPAFLSVTPGEKVTFTCQASQSIGTSIHWYQQKTDQAPKLLIKYASESISGIPSRFSGSGSGTDFTLTISSVEAEDAADYYCQQINSWPTTFGGGTKLEIK,na,na,None,None,None,2016,2017,CSF1,Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Seoul National University Hospital,na,na,Bone metastases;Prostate cancer;Breast cancer;Gastric cancer;Giant cell tumour of tendon sheath;Pigmented villonodular synovitis;Malignant melanoma;Solid tumours,,,Humanised,MCS-110;MCS 110;MCS110
Lacutamab,Whole mAb,G1,Kappa,Phase-II,Active,QIQLVQSGSELKKPGASVKVSCKASGYTFTTAGMQWVRQAPGQGLEWIGWINSHSGVPKYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYFCARGGDEGVMDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCKASQDVSTAVAWYQQKPGQPPKLLIYWTSTRHTGVPDRFSGSGSGTDYTLTISSLQAEDVAVYYCQQHYSTPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,KIR3DL2/CD158K,University of Genoa;Innate Pharma,na,Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome,na,,Genetics: musmus/homosap,Chimeric and/or humanised,IPH 41;IPH-41;IPH41;IPH4102;IPH-4102;IPH 4102
Ladiratuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGLTIEDYYMHWVRQAPGQGLEWMGWIDPENGDTEYGPKFQGRVTMTRDTSINTAYMELSRLRSDDTAVYYCAVHNAHYGTWFAYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLHSSGNTYLEWYQQRPGQSPRPLIYKISTRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIK,na,na,None,None,None,2017,2018,SLC39A6/ZIP6,Merck & Co;Quantum Leap Healthcare Collaborative;Seattle Genetics,na,Breast cancer,na,,ADC with vedotin,Humanised,MK-6440;MK6440;MK 6440;SGN-LIV1A;SGN LIV1A
Lampalizumab,Fab,G1,Kappa,Phase-III,Discontinued,EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS,DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK,na,na,4d9q:HL:ED/4d9r:HL:ED,None,None,2012,2013,CFD,Tanox;Genentech,na,na,Dry age-related macular degeneration,,Erroneously dropped during Feb '22 update. Readded August '22.,Humanised,FCFD4514S;RG7417;RG-7417;RG 7417;RO 5490249;RO5490249;RO-5490249;TNX-234;TNX 234;TXN234
Lanadelumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYIMMWVRQAPGKGLEWVSGIYSSGGITVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAYRRIGVPRRDEFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYWTFGQGTKVEIK,na,na,4pub:HL/4ogy:HL:MN/4ogx:HL,None,None,2015,2016,KLKB1,Dyax;Shire;Takeda,Hereditary angioedema,na,Diabetic macular oedema,,,Genetically human,DX-2930;DX2390;DX 2930;OHB-401;OHB401;OHB 401;SHP 643;SHP-643;SHP643;TAK-743;TAK743;TAK 743;Takhzyro
Lancastotug,Whole mAb,G1,Kappa,Phase-I,Active,DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQHVSTALAWYQQKPGKSPKLLIYSASSRYSGVPDRFSGSGSGTDFTFTISSLQPEDFATYYCQQHYITPWTFGGGTKLEIK,na,na,None,None,None,2023,2024,TIGIT/WUCAM/VSTM3,Akeso Biopharma,na,Solid tumours,na,,Lucorafusp and Lancastotug have the same Fv sequence,Humanised,AK127;AK-127
Landogrozumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGLTFSRYPMSWVRQAPGKGLVWVSAITSSGGSTYYSDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARLPDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLLIYSTSNLVAGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHHSGYHFTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN/GDF8/GDF-8,Eli Lilly,na,na,Cancer;Cachexia;Muscular atrophy;Pancreatic cancer,,,Humanised,LY-2495655;LY 2495655;LY2495655
Lanerkitug,Whole mAb,G1,Lambda,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVSAINWNGGSTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGHHSGYDGRFFDYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYNVHWYQQLPGTAPKLLIYTNNRRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDASLSGWVFGGGTKLTVL,na,na,None,None,None,2024,2024,CCR8/CKR-L1/CDw198,Bayer,na,Solid tumours,na,,,Genetically human,BAY 3375968;BAY-3375968;BAY3375968
Laprituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVAKPGASVKLSCKASGYTFTSYWMQWVKQRPGQGLECIGTIYPGDGDTTYTQKFQGKATLTADKSSSTAYMQLSSLRSEDSAVYYCARYDAPGYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINNYLAWYQHKPGKGPKLLIHYTSTLHPGIPSRFSGSGSGRDYSFSISSLEPEDIATYYCLQYDNLLYTFGQGTKLEIK,na,na,None,None,None,2015,2016,EGFR/ERBB1/HER1,ImmunoGen,na,na,Solid tumours,,,Chimeric,J2898A;J 2898A;J-2898A
Larcaviximab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPELEMPGASVKISCKASGSSFTGFSMNWVKQSNGKSLEWIGNIDTYYGGTTYNQKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSAYYGSTFAYWGQGTLVTVSA,DIQMTQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQLLVYNAKTLIEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYFCQHHFGTPFTFGSGTELEIK,na,na,None,5ken:CD:GH:NO,None,2016,2017,Zaire Ebolavirus Glycoprotein,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,Ebola virus infections ,na,Zmapp Technology,,Chimeric,c4G7-N
Lasrekibart,Whole mAb,G1,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYYMAWVRQAPGKGLEWVTSISYEGDITYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCASQTLRESFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDIANYLSWYQQKPGKSPKLLIYGTSNLEVGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCLQDKEFPRTFGGGTKVEIK,na,na,None,None,None,2025,na,IL5,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Latikafusp,Whole mAb Fusion,G1,Lambda,Phase-I,Discontinued,EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSGINWNAGRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREFNNFESNWFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISEDAKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFGGGTKLTVL,na,na,None,None,None,2022,2022,PDCD1/CD279/PD1,Amgen,na,na,Solid tumours,,,na,AMG-256;AMG256
Latozinemab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGTIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARQGSIKQGYYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSTGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRAEAEDVGVYYCMQQQEAPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,SORT1/Gp95/NT3,Alector,na,Frontotemporal dementia,na,,,Genetically human,AL-001;AL001;AL 001;AL1;AL-1;AL 1;GSK-4527223;GSK4527223;GSK 4527223
Laventatug,Whole mAb ADC,G1,Kappa,TBC,TBC,EVQLVQSGAEVKKPGATVKISCKASGLNIEDYYMHWVQQAPGKGLEWMGWIDPENGDTEYAEKFQGRVTITADTSTNTAYMELSSLRSEDTAVYYCTVHNAHYGTWFAYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQTLVRSDGNTYLEWYLQKPGQSPQLLIYRVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKLEIK,na,na,None,None,None,2025,na,SLC39A6/ZIP6,TBC,TBC,TBC,TBC,TBC,ADC with tivedotin,Humanised,TBC
Lebrikizumab,Whole mAb,G4,Kappa,Approved,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS,DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK,na,na,4i77:HL,None,None,2009,2010,IL13,Chugai Pharmaceutical;Comprehensive Clinical Research Network;Dermira;Genentech;Roche;Tanox,Atopic dermatitis,Idiopathic pulmonary fibrosis,Asthma;Chronic obstructive pulmonary disease;Hodgkin's disease,,,Humanised,DRM 06;DRM-06;DRM06;DRM 6;DRM-6;DRM6;LY 3650150;LY-3650150;LY3650150;MILR1444A;MILR-1444A;MILR 1444;ARG 3637;ARG-3637;ARG3637;RO 5490255;RO-5490255;RO5490255;TNX 650;TNX-650;TXN650
Lecanemab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCSASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSSTIYYGDTVKGRFTISRDNAKNSLFLQMSSLRAEDTAVYYCAREGGYYYGRSYYTMDYWGQGTTVTVSS,DVVMTQSPLSLPVTPGAPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLRISRVEAEDVGIYYCFQGSHVPPTFGPGTKLEIK,na,na,None,None,None,2019,2020,APP,Biogen;Eisai,Alzheimer's disease,Brain injuries;Down syndrome,na,,June '22: Corrected FWL3 sequence. Genetics: musmus/homosap,Chimeric and/or humanised,BAN-2401;BAN2401;BAN 2401;Leqembi
Lecankitug,Whole mAb,G1,Kappa,TBC,TBC,QFQLVQSGAEVKKPGASVKVSCKASGYTFTDYNLNWVRQAPGKGLEWMGVIHPDYGTTSYNQKFKDRVTMTVDTSTSTVYMELSSLRSEDTAVYYCVRYDYGDAMDYWGQGTLVTVSS,DIVMTQSPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQPPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKLEIK,na,na,None,None,None,2025,na,IL17A&IL17F,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Ledostomig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,TBC,TBC,QVQLVQSGAEVVKPGASVKVSCKASGYSFTGYTMNWVRQAPGQNLEWIGLINPYNAGTSYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARSEYRYGGDYFDYWGQGTTLTVSS,DIVMTQSPSSLAVSVGERVTISCKSSQSLLNSSNQKNYLAWYQQKPGQAPKLLIYFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYDTPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,None;None,None;None,None;None,2025,na,NT5E/CALJA/CD73;PDCD1/CD279/PD1,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised;Chimeric and/or humanised,TBC
Lemalesomab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLQESGPELKKPGETVKISCKASGYTFRNYGMNWVKQAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNVKNEDTATYFCARKGWMDFNGSSLDYWGQGTTVTVSS,DIQLTQTPLSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPNLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPPTFGGGTKLEIK,na,na,None,None,None,2002,2002,NCA90/p95,ND,na,na,Diagnosis of Lesions,,,Murine,78NCA-90;IMMU-MN3
Lemzoparlimab,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGLTFERAWMNWVRQAPGKGLEWVGRIKRKTDGETTDYAAPVKGRFSISRDDSKNTLYLQMNSLKTEDTAVYYCAGSNRAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYAGNNRNYLAWYQQKPGQPPKLLINQASTRASGVPDRFSGSGSGTEFTLIISSLQAEDVAIYYCQQYYTPPLAFGGGTKLEIK,na,na,None,None,None,2020,2021,IAP/CD47,I-Mab Biopharma,na,Lymphoma;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes,na,,,Genetically human,ABBV-IMAB-TJC4;TJ-011133;TJ 011133;TJ011133;TJ-1133;TJ1333;TJ 1333;TJC-4;TJC 4;TJC4
Lenvervimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCSASGFSLTKYKMTWVRQAPGKGLEWVSSISSTSRDIDYADSVKGRFTISRDNAKNSLFLQMSSLRVDDTAVYYCTRDGWLWGWDVRSNYYYNALDVWGQGTTVTVSS,DIVVTQSPSSLSASVGDRVTITCRASQGIYNSIAWYQQKPGKAPKLLLYSTSTLLSGVPSRFSGSGSGTDYTLTITNLQPEDFATYYCQQYFVTPETFGQGTKLEIK,na,na,None,None,None,2017,2018,Hepatitis B Virus,Green Cross;GC Pharma;AbbVie,na,Hepatitis B,na,,,Humanised,GC-1102;GC1102;GC 1102;GC-5103;GC5103;GC 5103;Hepabig
Lenzilumab,Lenzilumab,Lenzilumab,Lenzilumab,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,CSF2,Humanigen;KaloBios Pharmaceuticals,na,COVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease,Asthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours,Humaneering Technology,,Genetically human,KB-003;KB003;KB 003;KB3;KB-3;KB 3;LENZ
Lepunafusp,Whole mAb Fusion,G1,Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFMNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQLSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2021,2022,TfR1/CD71,JCR Pharmaceuticals,na,Mucopolysaccharidosis I,na,,,na,JR-171;JR171;JR 171
Lerdelimumab,Whole mAb,G4,Lambda,Phase-III,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMDSLRAEDTAVYYCGRTLESSLWGQGTLVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSSTHRGVFGGGTKLTVL,na,na,None,None,None,2002,2002,TGFB1,Cambridge Antibody Technology,na,na,Cataracts;Proliferative vitreoretinopathy;Scars,,,Genetically human,6B1;CAT152;CAT-152;CAT 152;Trabio
Leronlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGYTFSNYWIGWVRQAPGKGLEWIGDIYPGGNYIRNNEKFKDKTTLSADTSKNTAYLQMNSLKTEDTAVYYCGSSFGSNYVFAWFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQRLLSSYGHTYLHWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2017,2018,CCR5/CD195,CytoDyn;Progenics Pharmaceuticals;The Scripps Research Institute,Breast cancer,HIV infections;HIV-1 infections;Graft-versus-host disease;Colorectal cancer;Non-alcoholic steatohepatitis;Prostate cancer;COVID-19;Autoimmune disorders;Stroke;Traumatic brain injuries,na,,,Humanised,PA-14;PA14;PA 14;PRO-140;PRO140;PRO 140;Vyrologix
Lesabelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYYWGWIRQAPGKGLEWIGIIYPSGGGTNYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARGGGLGFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSIPSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHYISWPRQFTFGQGTKVEIK,na,na,None,None,None,2022,2022,PDL1/CD274,Dragon Sail Pharmaceutical,na,Cancers,na,,,Genetically human,ADG104;ADG-104;LDP
Lesofavumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKVSGYSFTSQWIGWVRQMPGKGLEWIGMMYPGESETIYSPSFQGQVTISADNSISTAYLQWSSLKASDTAIYYCASGPGYSGYHYGWFDTWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK,na,na,None,None,None,2016,2017,Influenza B Virus,Genentech,na,na,Influenza B virus infections,,,Genetically human,MHAB 5553A;MHAB-5553A;RG6024;RG-6024;RG 6024
Letaplimab,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,na,na,None,None,None,2020,2021,IAP/CD47,Innovent Biologics,na,Acute myeloid leukaemia;Lymphoma;Myelodysplastic syndromes;Solid tumours,na,,,Genetically human,IBI-188;IBI188;IBI 188
Letolizumab,Single Domain Variable Fragment;H,G1,na,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS,na,na,na,None,None,None,2016,2017,CD40LG/CD154,Bristol-Myers Squibb;H. Lee Moffitt Cancer Center and Research Institute,na,Graft-versus-host disease;Idiopathic thrombocytopenic purpura,na,,,Humanised,BMS-986004;BMS 986004;BMS986004;BMS2h-572-633-CT-L2
Levilimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIYSDGTTHYGDSVKGRFTISRDNAKNTVYLQLNSLRAEDTAMYYCAKGAGPTWWYALDAWGQGTLVTVSS,DIQLTQSPSSVSVSVGERVTIDCKSSQSVLSASNTYLNWYQQKPGQAPQLLIYYASTRESGVPDRFSGSGSGTDFTLTISSLQAEDAAVYYCQQAYRAPVTFGQGTKLEIK,na,na,None,None,None,2018,2019,IL6R/CD126,Biocad,COVID-19;Cytokine release syndrome,Rheumatoid arthritis,na,,Genetics: camdrom/homosap,Chimeric and/or humanised,BCD 089;BCD-089;BCD089;BCD89;BCD-89;BCD 89;Ilsira
Lexatumumab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS,SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL,na,na,None,None,4od2:BA,2006,2007,TNFRSF10B/CD262/DR5/TRAILR2,Cambridge Antibody Technology;Human Genome Sciences,na,na,Solid tumours,,,Genetically human,HGS-ETR2
Libevitug,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARGTRWGMDVWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSYYVYWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGVIFGGGTKLTVL,na,na,None,None,5yax:AA,2024,2024,Hepatitis B Virus Surface Antigen,Huahui Health,na,Hepatitis B;Hepatitis D,na,,,Genetically human,HH-003;HH 003;HH003
Libivirumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVRPGRSLRLSCAASGFAFSDYSINWVRQAPGKGLEWVAIISYDGRITYYRDSVKGRFTISRDDSKNTLYLQMNSLRTEDTAVYYCARQYYDFWSGSSVGRNYDGMDVWGLGTTVTVSS,DIVMTQSPLSLSVTPGEPASISCRSSQSLLHRSGNNYLDWYLQKPGHSPQLLIYVGSNRASGVPDRFSGSGSGTEYTLKISRVEAEDVGVYYCMQALQTPRTFGQGTKLEIK,na,na,None,None,None,2004,2005,Hepatitis B Virus Surface Antigen,XTL Biopharmaceuticals;Yeda,na,na,Hepatitis B infection,,,Genetically human,17.1.41;XTL-001 (cocktail with Libivirumab);XTL001 (cocktail with Exbivirumab)
Licaminlimab,scFv,na,Lambda,Phase-II,Active,EVQLVESGGGSVQPGGSLRLSCTASGFTISRSYWICWVRQAPGKGLEWVGCIYGDNDITPLYANWAKGRFTISRDTSKNTVYLQMNSLRAEDTATYYCARLGYADYAYDLWGQGTTVTVSS,EIVMTQSPSTLSASVGDRVIITCQSSQSVYGNIWMAWYQQKPGRAPKLLIYQASKLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQGNFNTGDRYAFGQGTKLTVL,na,na,None,None,None,2020,2021,TNF/TNFA,Oculis,na,Dry eye syndrome,na,,Jan '22: Added missing FWH1 residue. (Jun '22) Corrected CDRH3 sequence,Humanised,ESBA-1622;ESBA 1622;ESBA1622;LME-636;LME636;LME 636;OCS-02;OCS02;OCS 02;OCS2;OCS-2;OCS 2
Lifastuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFAMSWVRQAPGKGLEWVATIGRVAFHTYYPDSMKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHRGFDVGHFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSETLVHSSGNTYLEWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSFNPLTFGQGTKVEIK,na,na,None,None,None,2013,2014,SLC34A2,Genentech,na,na,Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer,,ADC with vedotin,Humanised,DNIB-0600A;DNIB0600A;DNIB600A;DNIB-600A;NaPi3b;RG-7599;RG7599;RG 7599;RO-5541081;RO 5541081;RO5541081
Ligelizumab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVMKPGSSVKVSCKASGYTFSWYWLEWVRQAPGHGLEWMGEIDPGTFTTNYNEKFKARVTFTADTSTSTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIYYASESISGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSWSWPTTFGGGTKVEIK,na,na,6uqr:AA:CC,None,None,2012,2013,IGHE,Novartis;Tanox,na,Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid,Hypersensitivity,,,Humanised,QGE-031;QGE031;QGE 031;QGE31;QGE-31;QGE 31
Ligufalimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMNWVRQRPGQGLEWIGMIDPSDSETHNAQKFQGKATLTVDKSTSTAYMHLSSLRSEDTAVYYCARLYRWYFDVWGAGTTVTVSS,NIVMTQSPATMSMSPGERVTLSCRASEIVGTYVSWFQQKPGQAPRLLIYGASNRYTGVPARFSGSGSGTDFTLTISSVQPEDLADYHCGQSYNFPYTFGGGTKLEIK,na,na,None,None,None,2021,2022,IAP/CD47,Akeso Biopharma,na,Acute myeloid leukaemia;Neoplasms;Myelodysplastic syndromes,na,,Genetics: musmus/homosap,Chimeric and/or humanised,AK-117;AK117;AK 117
Lilotomab,Whole mAb ADC,G1,Kappa,Phase-II,Active,EIQLQQSGPELVKPGASVKVSCKASGYSFTDYNMYWVKQSHGKSLEWIGYIDPYNGDTTYNQKFKGKATLTVDKSSSTAFIHLNSLTSEDSAVYYCARSPYGHYAMDYWGQGTSVTVSS,DIVMTQSHKLLSTSVGDRVSITCKASQDVSTAVDWYQQKPGQSPKLLINWASTRHTGVPDRFTGSGSGTDYTLTISSMQAEDLALYYCRQHYSTPFTFGSGTKLEIK,na,na,None,None,None,2014,2015,CD37,Nordic Nanovector,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma,na,,,Murine,Lymrit 37-02
Linavonkibart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCTASGFTFSSFSMDWVRQAPGKGLEWVSYISPSADTIYYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGVLDYGDMLMPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADNHPPWTFGGGTKVEIK,na,na,None,None,None,2022,2023,TGFB1,Scholar Rock,na,Solid tumours,na,,,Genetically human,SRK-181;SRK 181;SKR181
Linclatamig,Bispecific mAb,G1,Kappa;Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFDFVNNAMIWVREAPGKGLEWVSALSFADNTAYYATWASGRFTISRDSSKTTVYLQMNSLRAEDTAVYYCMRGDLWGPGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQASESITRYLNWYQKKPGKAPKLLIYDASKLPSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQSTSFRGRSYQNTFGGGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGFTFTSYYIHWVRKAPGQGLEWIGWIYPENDNTKYNEKFKDRVTITADTSTSTAYLELSSLRSEDTAVYYCARDGYSRYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQEKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK,None;None,None;None,None;None,2024,2024,LY6G6D/G6D/NG25/LY6-D/MEGT1/C6orf23;CD3E,Genentech,na,na,Metastatic colorectal cancer,,,Humanised;Humanised,BLYG 8824A;BLYG-8824A;BLYG8824A;RG 6286;RG-6286;RG6286
Lintuzumab,Whole mAb Radiolabelled,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK,na,na,None,None,None,1996,1997,SIGLEC3/CD33/p67,PDL BioPharma;Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,,,Humanised,HuM 195;HuM-195;HuM195;SGN-33;SGN33;SGN 33
Linvoseltamab,Bispecific mAb,G4;G4,Kappa;Kappa,Preregistration,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2022,2022,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Regeneron Pharmaceuticals,na,Multiple Myeloma,na,,,Genetically human;Genetically human,REGN-5458;REGN 5458;REGN5458
Lipustobart,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWMGGVNPSNGGTNFNEKFKSRVTITADKSTSTAYMELSSLRSEDTAVYYCARRDYRYDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATISCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQHSRELPLTFGTGTKVEIK,na,na,None,None,None,2022,2023,PDCD1/CD279/PD1,Livzon Pharmaceutical Group,na,na,Solid tumours,,,Humanised,LZM-009;LZM009;LZM 009;LZM-9;LZM9;LZM 9
Lirentelimab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFSLTIYGAHWVRQAPGKGLEWVGVIWAGGSTNYNSALMSRFTISKDNSKNTVYLQMNSLRAEDTAVYYCARDGSSPYYYSMEYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSYPFTFGPGTKLDIK,na,na,None,7quh:HL,None,2020,2021,SIGLEC8/SAF2,Allakos,na,na,Conjunctiviti;Fibrosis;Kertoconjunctivitis;Systemic mastocytosis;Eosinophilic gastroenteritis;Eosinophilic oesophagitis;Urticari;Atopic dermatitis;Chronic obstructive pulmonary disease,,,Humanised,AK 002;AK002;AK-002;AK2;AK-2;AK 2;Antolimab
Lirilumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS,EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK,na,na,8tui:HL,None,None,2012,2013,KIRD2,Novo Nordisk;Bristol-Myers Squibb;Dana-Farber Cancer Institute;Innate Pharma;National Cancer Institute (USA);Ono Pharmaceutical;PrECOG;University of Texas M. D. Anderson Cancer Center,na,na,Acute myeloid leukaemia;Hepatitis C;Haematological malignancies;Multiple myeloma;Lymphoma;Chronic lymphocytic leukaemia;Head and neck cancer;Myelodysplastic syndromes;Solid tumours;Bladder cancer,Medarex UltiMAb Mouse,,Genetically human,BMS-986015;BMS986015;BMS 986015;IPH-21;IPH21;IPH 21;IPH-2101;IPH2101;IPH 2101;IPH-2102;IPH 2102;IPH2102;NN 1975;NN1975;NN-1975;ONO-4483;ONO4483;ONO 4483
Litifilimab,Whole mAb,G1,Kappa,Phase-III,Active,DVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGKGLEWVATISPGDSFGYYYPDSVQGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCTRDIYYNYGAWFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASTLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANEDPRTFGQGTKVEIK,na,na,None,None,None,2022,2022,CLEC4C,Biogen Idec,na,Systemic lupus erythematosus;Cutaneous lupus erythematosus,na,,,Humanised,24F4A;BIIB-059;BIIB059;BIIB 059;BIIB59;BIIB-59;BIIB 59
Livmoniplimab,Whole mAb,G4,Kappa,Phase-II/III,Active,QVQLVQPGAEVRKPGASVKVSCKASGYRFTSYYIDWVRQAPGQGLEWMGRIDPEDAGTKYAQKFQGRVTMTADTSTSTVYVELSSLRSEDTAVYYCARYEWETVVVGDLMYEYEYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQSISSYLAWYQQKPGQAPKILIYGASRLKTGVPSRFSGSGSGTSFTLTISSLEPEDAATYYCQQYASVPVTFGQGTKVEIK,na,na,None,None,None,2021,2022,LRRC32,AbbVie,na,Solid tumours,na,,,Humanised,ABBV-151;ABBV151;ABBV 151;ARGX-115;ARGX115;ARGX 115;MHG-8;MHG 8;MGH8
Lixudebart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYGMNWVRQAPGKGLEWVSSISPSGSYFYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLPGFNPPFDHWGQGTLVTVSS,DIQMTQSPATLSVSPGERATLSCKASQNVGGNVDWYQWKPGQAPRLLIYGASNRYTGIPARFRGSGSGTEFTLTISSLQSEDFAVYYCLQYKNNPWTFGQGTKVEIK,na,na,None,None,None,2023,2023,CLDN1,INSERM;The Mount Sinai Hospital;University of Strasbourg;Alentis Therapeutics,na,Glomerulonephritis;Hepatic fibrosis;Pulmonary fibrosis;Renal fibrosis,na,,,Humanised,ALE-F02;ALE F02;ALE.F02
Lodapolimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Dana-Farber Cancer Institute;Eli Lilly,na,na,Solid tumours,,,Genetically human,LY-3300054;LY 3300054;LY3300054
Lodelcizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTMYMSWVRQAPGQGLEWMGRIDPANEHTNYAQKFQGRVTMTRDTSISTAYMELSRLTSDDTAVYYCARSYYYYNMDYWGQGTLVTVSS,QIVLTQSPATLSVSPGERATLSCRASQSVSYMHWYQQKPGQAPRLLIYGVFRRATGIPDRFSGSGSGTDFTLTIGRLEPEDFAVYYCLQWSSDPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,PCSK9,Novartis,na,na,Hypercholesterolaemia,,,Humanised,LGT209;LGT-209;LGT 209;NVP-LGT209
Lofacimig,Bispecific Tandem VH Domains fused to G1 Constant Domain,G1,na,TBC,Active,QVQLVESGGGSVQAGGSLRLSCAASGHTYSSNYCMAWFRQAPGKEREGVAAIYSDGSTSYADSVKGRFTISKDNSKNTLYLQMNSLRAEDTAVYYCAATAYEGSWTGKQPLCLLYEYTYWGQGTLVTVSS,na,QVQLVESGGSVQAGGSLRLSCTASEFTFDDSDMAWYRQAPGNECELVSTITSDGGTYYADSVKGRFTISQDNSKNTMYLQMNSLRAEDTAVYYCAADQWGSAEGDCTSSYPGGYWGQGTLVTVSS,na,None;None,None;None,None;None,2024,na,F11;F11,TBC,TBC,TBC,TBC,TBC,Fv1 and Fv2: Humanised from Camel. VH1 binds the Apple-2 domain; VH2 binds the Apple-3 domain.,Humanised;Humanised,TBC
Lokivetmab,Canine Whole mAb,G2,Kappa,Approved,NFD,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2014,2015,IL31,Zoetis,Canine atopic dermatitis,na,na,,,na,CAN34D3-65;CAN 34D3-65;PF-06443537;PF06443537
Lomtegovimab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAATGFTFRRYGMHWVRQAPGKGLEWVAGILFDGSNKYYVDSVKGRFTISRDSSRNTLYLQLNSLRREDTAVYYCAKGGDYEWELLESWGQGTLVTVSS,DIQMTQSPSTVSASVGDRVTITCRASQSIDNWLAWYQEKPGKAPKVLIYKASSLESGVPSRFSGRGSGTEFTLTISSLQPGDFATYYCQHYHSFPLTFGGGTKVDIK,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,Boehringer Ingelheim,na,COVID-19,na,,June '22: Corrected VH sequence,Genetically human,BI-00767551;BI00767551;BI 00767551;BI-767551;BI767551;BI 767551;DZIF-10c
Lomvastomig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKTTYMHWVRQAPGKGLEWVGRIDPADDNTKYAPKFQGKATISADTSKNTAYLQMNSLRAEDTAVYYCVRDFGYVAWFAYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRASQSVDNYVAWYLQKPGQSPQLLIYYASNRYIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQHYSSPYTFGQGTKVEIK,None;None,None;None,None;None,2022,2023,PDCD1/CD279/PD1;HAVCR2/TIM3,Roche,na,Non-small cell lung cancers;Small cell lung cancers;Squamous cell carcinoma,na,,Fv1 identical in sequence to Tobemstomig and Eciskafusp.,Humanised;Humanised,RG-7769;RG7769;RG 7769;RO-7121661;RO7121661;RO 7121661
Loncastuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQPGAEVVKPGASVKLSCKTSGYTFTSNWMHWVKQAPGQGLEWIGEIDPSDSYTNYNQNFQGKAKLTVDKSTSTAYMEVSSLRSDDTAVYYCARGSNPYYYAMDYWGQGTSVTVSS,EIVLTQSPAIMSASPGERVTMTCSASSGVNYMHWYQQKPGTSPRRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEPEDAATYYCHQRGSYTFGGGTKLEIK,na,na,None,6ani:HL:IM,None,2017,2018,CD19,ADC Therapeutics,Diffuse large B cell lymphoma,Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma,,ADC with tesirine,Chimeric,ADCT-402;ADCT402;ADCT 402;MT-2111;MT2111;MT 2111;ZYNLONTA
Lonigutamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYIHWVRQAPGQGLEWMGWIWPGDGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYFCASPMITPNYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYYTSRLQSGVPSRFSGRGSGTDYSLTISSLQPEDFATYFCQQGSTLPYTFGGGTKVEIK,na,na,None,None,None,2020,2021,IGF1R/CD221,Pierre Fabre,na,Solid tumours,na,,,Humanised,VB-421;VB421;VB 421
Lorigerlimab,Bispecific Mixed scFv (scFv-CH2-CH3-scFv),G4;G4,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGSNKHYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;5xj3:AB/5tru:HL/6jc2:HL/6rp8:hl/7elx:HL:hl,2021,2022,PDCD1/CD279/PD1;CTLA4/CD152,MacroGenics,na,Solid tumours,na,Dual-Affinity Re-Targeting Technology. Chimeric: Mouse/Human,June '22: Corrected VL sequences,Chimeric;Humanised,AEX1344;AEX-1344;AEX 1344;EXPASY;MGD-019;MGD019;MGD 019;MGD19;MGD-19;MGD 19
Lorukafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,EVQLVQSGAEVEKPGASVKISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSTSTAYMHLKSLRSEDTAVYYCVSGMEYWGQGTSVTVSS,DVVMTQTPLSLPVTPGEPASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK,na,na,None,None,4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL,2018,2019,Ganglioside GD2,Lexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison,na,Malignant melanoma;Neuroblastoma,na,,,na,APN 301;APN301;APN-301;ch14.18-IL2;EMD 273063;EMD-273063;EMD273063
Lorvotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSGSFTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMRKGYAMDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQIIIHSDGNTYLEWFQQRPGQSPRRLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPHTFGQGTKVEIK,na,na,None,None,None,2010,2011,NCAM1/CD56,ImmunoGen,na,na,Multiple myeloma;Solid tumours;Small cell lung cancer;Haematological malignancies,,ADC with mertansine,Humanised,BB-10901;BB10901;BB 10901;IMGN-901;IMGN901;IMGN 901
Losatuxizumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR/ERBB1/HER1,AbbVie,na,na,Solid tumours,,Losatuxizumab and Serclutamab have identical variable domains. ADC with vedotin,Chimeric and humanised,ABBV-221;ABBV221;ABBV 221
Lotivibart,Whole mAb,G1,Kappa,TBC,Active,RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVVSA,YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIK,na,na,None,None,5te4:HL/5te5:HL/5th6:HL,2024,na,HIV-1 gp120,TBC,TBC,TBC,TBC,TBC,Epitope: CD4 binding site,Genetically human,TBC
Lucatumumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS,DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR,na,na,None,None,None,2007,2008,TNFRSF5/CD40,Novartis;XOMA,na,na,Chronic lymphocytic leukaemia;Follicular lymphoma;Lymphoma;Multiple myeloma,,,Genetically human,CHIR-12.12;CHIR 12.12;CHIR12.12;HCD-122;HCD122;HCD 122
Lucorafusp,Whole mAb,G4,Kappa,Phase-I,Active,DVQLQESGPGLVKPSQTLSLTCTVSGHSFTSDYAWSWIRQPPGKGLEWIGYISYSDSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARLDYGNYGGAMDYWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQHVSTALAWYQQKPGKSPKLLIYSASSRYSGVPDRFSGSGSGTDFTFTISSLQPEDFATYYCQQHYITPWTFGGGTKLEIK,na,na,None,None,None,2024,2024,TIGIT/WUCAM/VSTM3,Akeso Biopharma,na,Solid tumours,na,,Lancastotug and Lucorafusp have the same Fv sequence,Humanised,AK-130;AK130;AK 130
Lulizumab,Single Domain Variable Fragment;L,na,Kappa,Phase-II,Active,na,DIQMTQSPSSLSASVGDRVTITCRASRPIWPFLEWYQQKPGKAPKLLIYFTSRLRHGVPSRFSGSGSGTCFTLTISSLQPEDFATYYCLQNVANPATFSQGTKVEIK,na,na,None,None,None,2014,2015,CD28,Bristol-Myers Squibb,na,Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection,na,,,Humanised,BMS-931699;BMS 931699;BMS931699
Lumiliximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK,na,na,None,3fzu:HL:CD,None,2004,2004,FCER2/CD23,Biogen Idec,na,na,Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia,,Lumiliximab and Gomiliximab are the same mAb,Chimeric,IDEC-152;IDEC152; IDEC 152;ST-152;ST152;ST 152
Lumistobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGYYWSWIRQHPGKGLEWIGYISYDGSRYNNPSLKNRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREEYANYFAYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLFYSSNQKNFLAWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPPTFGQGTKLEIK,na,na,None,None,None,2024,2024,SIRPA,Zhejiang Hisun Pharmaceutical,na,Cancer,na,,,Humanised,BR105;BR-105;BR 105
Lumrotatug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGIHWLRQPPGKGLEWIGVIWRGGSTDYNPSLKSRVTISKDTSKSQVSLKLSSVTAADTAVYYCAKGKVTTGFYFDFWGQGTLVTVSS,EIVMTQSPPTLSLSPGERVTLSCRASEDIYNRLVWYQQKPGQAPRLLISGVTSLETSIPARFSGSGSGTDYTLTISSLQPEDFAVYYCQQYWSTPYTFGQGTKVEIK,na,na,None,None,None,2023,2024,ADPRC1/CD38,Institute of Hematology & Blood Diseases Hospital;KeyMed Biosciences,na,Idiopathic thrombocytopenic purpura;Systemic lupus erythematosus;Lymphoma;Multiple myeloma,na,,,Humanised,CM313;CM-313
Lumretuzumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK,na,na,4leo:AB,None,None,2014,2015,ERBB3/HER3,Roche,na,na,Breast cancer;Solid tumours;Non-small cell lung cancer,GlycoMAb Technology,,Humanised,RG-7116;RG7116;RG 7116;RO-5479599;RO5479599;RO 5479599
Lunaxafusp,Fusion Protein,na,Kappa,TBC,Active,QVQLQQSGPELKKPGETVKISCKASGYPFTNYGMNWVKQAPGQGLKWMGWINTSTGESTFADDFKGRFDFSLETSANTAYLQINNLKSEDSATYFCARWEVYHGYVPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVYNAVAWYQQKPGQSPKLLIYSASSRYTGVPSRFTGSGSGPDFTFTISSVQAEDLAVYFCQQHFRTPFTFGSGTKLEIK,na,na,None,None,None,2022,2023,ERBB2/CD340/HER2,TBC,TBC,TBC,TBC,,Murine scFv against a human antigen,na,TBC
Lunlekitug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGRFTNYAILWVRQAPGQGLQWLGGIIPIFDETDHAQDFQDRLTITVDESMTTAYMELSSLRPEDTAIYYCATGSNSYYGLYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSSPPTFGGGTKVEIK,na,na,None,None,None,2024,na,IL1A,XBiotech Inc.,TBC,TBC,TBC,TBC,TBC,Genetically human,XB20-12;XB2012;XB20 12
Lunsekimig1,Trispecific and Pentavalent (sc-5-VH); Bispecific entry,na;na,na;na,Phase-II,Active,DVQLVESGGGVVQPGGSLRLSCAASGRTFSSYRMGWFRQAPGKEREFVAALSGDGYSTYTANSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAAKLQYVSGWSYDYPYWGQGTLVTVSS,na,EVQLVESGGGVVQPGGSLRLSCAASGFTFNNYAMKWVRQAPGKGLEWVSSITTGGGSTDYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCANVPFGYYSEHFSGLSFDYRGQGTLVTVSS,na,None;None,None;None,None;None,2023,2024,IL13;IL13,Sanofi,na,Asthma;Inflammation,na,,Pentavalent; targets two different epitopes on IL13 and TSLP. Fv1 Chimeric: Alpaca/human.,Chimeric;Humanised,SAR443765;SAR-443765
Lunsekimig2,Trispecific and Pentavalent (sc-5-VH); Bispecific entry,na;na,na;na,Phase-II,Active,EVQLVESGGGVVQPGGSLRLSCAASGSGFGVNILYWYRQAAGIERELIASITSGGITNYVDSVKGRFTISRDNSENTMYLQMNSLRAEDTGLYYCASRNIFDGTTEWGQGTLVTVSS,na,EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;8oi2:B,2023,2024,TSLP;ALB,Sanofi,na,Asthma;Inflammation,na,,Pentavalent; targets two different epitopes on IL13 and TSLP. Fv3 Chimeric: Llama/Human,Chimeric;Humanised,SAR443765;SAR-443765
Lunsekimig3,Trispecific and Pentavalent (sc-5-VH); Monospecific entry,na,na,Phase-II,Active,EVQLVESGGGVVQPGGSLRLSCAASGFTFADYDYDIGWFRQAPGKEREGVSCISNRDGSTYYADSVKGRFTISRDNSKNTVYLQMNSLRPEDTALYYCAVEIHCDDYGVENFDFDPWGQGTLVTVSS,na,na,na,None,None,None,2023,2024,TSLP,Sanofi,na,Asthma;Inflammation,na,,Pentavalent; targets two different epitopes on IL13 and TSLP. Fv5 Chimeric: Llama/Human,Chimeric,SAR443765;SAR-443765
Lupartumab,Whole mAb ADC,G1,Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGLWAFDYWGQGTLVTVSS,ESVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYVVHWYQQLPGTAPKLLIYDNNKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDDRLNGPVFGGGTKLTVL,na,na,None,None,None,2016,2017,LYPD3,Bayer HealthCare,na,na,Solid tumours,,ADC with amadotin,Genetically human,BAY 1129980;BAY1129980;BAY-1129980
Lusvertikimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGGLVKPGGSLRLSCAVSGFTLSDYYMAWIRQAPGKGLEWVSTISASGLRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPLSAHYGFNYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSEDIYQGLAWYQQKPGKAPKLLLYSANTLHIGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYYDYPLAFGGGTKVEIK,na,na,None,None,None,2020,2021,IL7R/CD127,OSE Immunotherapeutics,na,Autoimmune diseases,na,,,Humanised,OSE-127;OSE127;OSE 127;OSE-217;OSE 217;OSE217;S-95011;S 95011;S95011
Lutikizumab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQIT,QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK,None;None,None;None,None;None,2016,2017,IL1A;IL1B,Abbott Laboratories;AbbVie,na,na,Osteoarthritis,Dual Variable Domain Immunoglobulin Technology,,Humanised;Humanised,ABT-981;ABT981;ABT 981
Luvagrobart,Whole mAb,G1,Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGFDLSGYDLNWIRQPPGKGLEWIGIVWGDGSSDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCVRGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESISSNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPFTFGQGTKLEIK,na,na,None,None,4edw:HL,2023,2024,NGF,Akeso Biopharma,na,Cancer pain;Pain,na,,,Humanised,AK115;AK-115
Luveltamab,Whole mAb ADC,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIRTQSIHWVRQAPGKGLEWIGDIFPIDGITDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGSWSWPSGMDYYLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,None,None,2022,2022,FOLR1,Sutro Biopharma,na,Ovarian cancers;Fallopian tube cancers;Primary peritoneal cancers;Endometrial cancer;Acute myeloid leukemia;Non-small cell lung cancer,na,,ADC with tazevibulin,Humanised,STRO-002;STRO 002;STRO002;STRO2;STRO-2;STRO 2
Maftivimab,Whole mAb,G1,Kappa,Preregistration,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTSSSYAMNWVRQAPGKGLEWVSTISGMGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKRGYPHSFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSFLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTLTFGQGTRLEIK,na,na,7tn9:QR:MN:OP,None,None,2018,2019,Zaire Ebolavirus Glycoprotein,Regeneron Pharmaceuticals,na,na,Ebola virus infections,,,Genetically human,REGN 3479;REGN-3479;REGN3479;INMAZEB (combination with Atoltivimab and Odesivimab)
Magrolimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYNMHWVRQAPGQRLEWMGTIYPGNDDTSYNQKFKDRVTITADTSASTAYMELSSLRSEDTAVYYCARGGYRAMDYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSIVYSNGNTYLGWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGQGTKLEIK,na,na,None,5iwl:AA:BB,None,2018,2019,IAP/CD47,Forty Seven;Merck KGaA;Stanford University,na,Diffuse large B cell lymphoma;Follicular lymphoma;Non-Hodgkin's lymphoma;Colorectal cancer;Solid tumours;Acute myeloid leukaemia;Myelodysplastic syndromes;Ovarian cancer,Lymphoma,,Genetics: musmus/homosap,Chimeric and/or humanised,5F9;GS-4721;GS4721;GS 4271;ONO 7913;ONO7913;ONO-7913
Manelimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVESGGGVVRPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSDISWSGSNTNYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYHCARAPLLLAMTFGVGSWGQGTLVTVSS,QTVVTQEPSLSVSPGGTVTLTCGLSSGTVTAINYPGWYQQTPGQAPRTLIYNTNTRHSGVPDRFSGSISGNKAALTITGAQAEDEADYYCALYMGNGGHMFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Biocad,na,na,Solid tumours;Cancer,,Same Fv sequence as Amostomig Fv2,Genetically human,BCD-135;BCD135;BCD 135
Manfidokimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVVKPGASVKVSCKTSGYTFTEYTIHWVRQAPGQSLEWIGGINPNNGGTVYNQKFQGKVTLTVDKSTSTAYMELSSLRSEDTAVYYCARVRRGMDYWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVTTAVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSVQPEDLATYYCQQHYSAPWTFGGGTNLEIK,na,na,None,None,None,2021,2022,IL4R/CD124,Akeso Biopharma,na,Atopic dermatitis,na,,,Humanised,AK-120;AK120;AK 120
Margetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGPELVKPGASLKLSCTASGFNIKDTYIHWVKQRPEQGLEWIGRIYPTNGYTRYDPKFQDKATITADTSSNTAYLQVSRLTSEDTAVYYCSRWGGDGFYAMDYWGQGASVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVNTAVAWYQQKPGHSPKLLIYSASFRYTGVPDRFTGSRSGTDFTFTISSVQAEDLAVYYCQQHYTTPPTFGGGTKVEIK,na,na,None,None,None,2013,2014,ERBB2/CD340/HER2,Raven biotechnologies;GC Pharma;Green Cross;MacroGenics;Merck Sharp & Dohme,Breast cancer,Gastric cancer;Oesophageal cancer,Bladder cancer;Non-small cell lung cancer;Ovarian cancer;Haematological malignancies;Solid tumours,,,Chimeric,MARGENZA;MGAH-22;MGAH 22;MGAH22
Maridebart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGEGLEWVAAIWFDASDKYYADAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDQAIFGVVPDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAATRATGIPARVSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,na,na,6dkj:HL:BA,None,None,2023,2023,GIPR,Amgen,na,Obesity,na,,ADC with cafraglutide,Genetically human,AMG-133;AMG133;AMG 133;MariTide
Marlotamig,Bispecific mAb,G4,Kappa;Kappa,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGDSIITFYWSWIRQPPGRGLEWIGYIYYSGITNYNPSLKSRVTISVDTSKNQVSLKLSSVTAADTAVYYCARVSEDSYFHYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGITHYNPSLKSRVTISVDTSKIQFSLKLSSVTAADTAVYYCARWGVRRDYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2024,na,EGFR/ERBB1/HER1;CD28,Regeneron,na,Solid tumours,na,,Feb '25: Name change from Dalmitamig to Marlotamig [PL132]. Nezastomig Fv2 and Marlotamig Fv2 have the same sequence.,Genetically human;Genetically human,REGN7075;REGN-7075
Marstacimab,Whole mAb,G1,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAILGATSLSAFDIWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGSGVFGGGTKLTVL,na,na,None,None,None,2013,2014,ERBB2/CD340/HER2,Pfizer,na,Haemophilia,na,,,Genetically human,PF-06741086;PF06741086;PF-6741086;PF6741086
Masavibart,Whole mAb,G1,Lambda,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL,na,na,6xdg:CA/7zjl:ji:jg:lk/8j26:BA/8j1q:BA,None,None,2020,2021,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,COVID-19,na,na,,Imdevimab is former name for Masavibart,Genetically human,ZRC-3308A7;ZRC3308A7;ZRC 3308A7;ZRC-3308;ZRC3308;ZRC 3308
Matuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK,na,na,3c08:HL/5vr9:HL:AB,5vsi:HL/3c09:HL:CB,None,2003,2003,EGFR/ERBB1/HER1,ImClone Systems;Merck KGaA;Takeda,na,na,Cervical cancer;Colorectal cancer;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer,,,Humanised,EMD 72000;EMD-72000;EMD72000
Mavrilimumab,Whole mAb,G4,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS,QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL,na,na,None,None,None,2009,2010,CSF2RA/CD116,Zenyth Therapeutics Kiniksa Pharmaceuticals;MedImmune,na,Giant cell arteritis;COVID-19;Inflammation,Rheumatoid arthritis,CAT Phage Display,,Genetically human,CAM-3001;CAM3001;CAM 3001;KPL-301;KPL301;KPL 301
Mavrostobart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLVESGGGLVQPGQSLKLSCKASGYAFSSYWMNWVKQRPGKGLEWIGQIYPGDGDTYYSGKFKGRATLSADKSKNTAYLQLNNLRAEDTAVYYCAREAIYYGNYVFTYWGQGTLVTVSS,DIVMTQSPSLLSASLGDRVTISCKSSQSLLNSSNQKNYLAWYQQKPGQSPKLLVYFASTRDSGVPDRFSGSGSGTDFTLTISSLEPEDFATYFCQQHYSTPLTFGAGTKLEIK,na,na,None,None,None,2024,na,NT5E/CALJA/CD73,Phanes Therapeutics,na,Solid tumours,na,,,Chimeric and/or humanised,PT-199;PT 199;PT199
Mazorelvimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLILSCAASGFTFSGFAMSWVRQAPGKGLEWVATISSGGTYTYSPDSVMGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRLRRNYYSMDYWGQGTMVTVSS,DIVMTQSPLSLPVTPGEPASISCKSTKSLLNSDGFTYLDWYLQKPGQSPQLLIYLVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQSNYLPFTFGGGTKVEIK,na,na,None,None,None,2021,2022,Rabies Virus Spike Glycoprotein G,Synermore,na,Rabies post-exposure,na,,Genetics: musmus/homosap,Chimeric and/or humanised,CTB012;CTB-012;CTB 012;CTB12;CTB-12;CTB 12;SYN023;SYN-023;SYN 023;SYN23;SYN-23;SYN 23
Mecbotamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKVSGYSFWGATMNWIRQPPGKGLEWIGLIKPSNGGTSYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGHYESYEAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVVSAVAWYQQKPGQAPRLLIYWQDTRHTGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEHFSPPLTFGQGTKVEIK,na,na,None,None,None,2022,2022,AXL/UFO,BioAtla,na,Non-small cell lung cancer;Ovarian cancer;Soft tissue sarcoma;Solid tumours,na,,ADC with vedotin,Humanised,BA-3011;BA3011;BA 3011;HTBA-3011;HTBA3011;HTBA 3011
Melredableukin,Whole mAb Fusion,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGSGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIK,na,na,None,6ghg:HL:AB,5i1c:HL,2021,2022,Non-Binding,Roche,na,Ulcerative colitis,na,,Fused to IL2. (June '22: Corrected FWL3 sequence),na,RG-7835;RG7835;RG 7835;RO-7049665;RO7049665;RO 7049665
Melrilimab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYDMIWVRQAPGKGLEWVSSIRGEGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPWSTEGSFFVLDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVDDDLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYITAPLTFGQGTKVEIK,na,na,None,None,None,2020,2021,IL1RL1/ST2,GlaxoSmithKline,na,na,Asthma;Atopic dermatitis,,,Genetically human,CNTO 7160;CNTO-7160;CNTO7160;GSK-3772847;GSK3773847;GSK 3772847
Metelimumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKELEWVAVISYDGSIKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTGEYSGYDTDPQYSWGQGTTVTVSS,EIVLTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQKPGKAPILLIYGTSTLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCLQDSNYPLTFGGGTRLEIK,na,na,6amj:HL:BA/6amm:HL,6anp:HL:BA,None,2003,2003,TGFB1,Cambridge Antibody Technology,na,na,Cancer;Fibrosis;Scleroderma,,,Genetically human,CAT-192;CAT192;CAT 192
Mepolizumab,Whole mAb,G1,Kappa,Approved,Active,QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK,na,na,None,None,None,1999,2000,IL5,GlaxoSmithKline;McMaster University;National Institute of Allergy and Infectious Diseases,Asthma;Churg-Strauss syndrome;Hypereosinophilic syndrome,Chronic obstructive pulmonary disease;Hypereosinophilic syndrome;Nasal polyps;Eosinophilic oesophagitis,Atopic dermatitis,,Biosimilars available,Humanised,Bosatria;Nucala;SB-240563;SB240563;SB 240563
Mevonlerbart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGRGYNADYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLEYFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTDFTLTISSLRPEDFATYYCQQYNSYPLTFGGGTKVEIK,na,na,5vyf:HL:BA,None,None,2022,2023,Fel d 1,Regeneron,na,Cat allergies,na,,Antigen: Felis silvestris catus (domestic cat) allergen 1,Genetically human,REGN-1909;REGN1909;REGN1908-1909 (cocktail with Freneslerbart)
Mezagitamab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSDISWNGGKTHYVDSVKGQFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSLFHDSSGFYFGHWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGDNYVSWYQQLPGTAPKLLIYRDSQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSGSVFGGGTKLTVL,na,na,None,None,None,2019,2020,ADPRC1/CD38,Takeda,na,Multiple myeloma;Systemic lupus erythematosus;Idiopathic thrombocytopenic purpura;Myasthenia gravis,Rheumatoid arthritis,,,Humanised,TAK-079;TAK079;TAK 079;TAK-79;TAK79;TAK 79
Mibavademab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVESGGSVVQPGRSLRLSCAASGFTFSTYAMYWVRQTPGKGLEWVAVLYSDGSNKYYIDSVKGRFTISRDTSTNTLYLQMSSLRADDSALYYCARLNWDYWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,na,na,None,None,None,2020,2021,LEPR/CD295/OBR,Regeneron Pharmaceuticals,na,Lipodystrophy,na,,,Genetically human,REGN-4461;REGN4461;REGN 4461
Micvotabart,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,None,7ah1:AA,None,2024,2024,FN extracellular domain B,Pyxis Oncology;Pfizer,na,Solid tumours,na,,,Genetically human,PYX-201;PYX201;PYX 201
Milatuzumab,Whole mAb,G1,Kappa,Phase-I/II,Discontinued,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGVNWIKQAPGQGLQWMGWINPNTGEPTFDDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCSRSRGKNEAWFAYWGQGTLVTVSS,DIQLTQSPLSLPVTLGQPASISCRSSQSLVHRNGNTYLHWFQQRPGQSPRLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSSHVPPTFGAGTRLEIK,na,na,None,None,None,2007,2008,CD74/HLA class II histocompatibility antigen gamma chain,Immunomedics,na,na,Graft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma;Systemic lupus erythematosus,,,Humanised,IMMU-115;IMMU 115;IMMU115
Mipasetamab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHPIYYTYDDTMDYWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCSASSSVSSGNFHWYQQKPGLAPRLLIYRTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSGYPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,AXL/UFO,ADC Therapeutics,na,na,Solid tumours;Advanced or metastatic solid tumours,,ADC with uzoptirine,Humanised,ADCT-601;ADCT601;ADCT 601;BGB 601;BGB-601;BGB601
Mipletamig,Bispecific Mixed scFv (scFv-CH2-CH3-scFv),G1;G1,Kappa;Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEGVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEKLRYFDWLSDAFDIWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTTFGGGTKVEIK,QVQLVQSGPEVKKPGSSVKVSCKASGYTFSRSTMHWVRQAPGQGLEWIGYINPSSAYTNYNQKFKDRVTITADKSTSTAYMELSSLRSEDTAVYYCARPQVHYDYNGFPYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTMTCSASSSVSYMNWYQQKPGKAPKRWIYDSSKLASGVPSRFSGSGSGTDYTLTISSLQPDDFATYYCQQWSRNPPTFGGGTKVEIK,None;None,None;None,None;None,2024,2024,IL3RA/CD123;CD3E,Aptevo Therapeutics,na,Acute myeloid leukaemia;Myelodysplastic syndromes,na,,,Genetically human;Humanised,APVO-436;APVO436;APVO 436
Miptenalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVTLVESGGGVVQPGRSLRLSCAFSGFSLSTSDMGVGWIRQAPGKGLEWVAHIWWDDVKRYNPALKSRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARIEDYGVSYYFDYWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVSITCKASQDVSTAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSIPLTFGQGTKLEIK,na,na,None,None,None,2019,2020,LAG3/CD223,Boehringer Ingelheim,na,Solid tumours;Head and neck cancer;Non-small cell lung cancer,na,,Genetics: musmus/homosap,Chimeric and/or humanised,BI-754111;BI754111;BI 754111
Mirikizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTRYVMHWVRQAPGQGLEWMGYINPYNDGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNWDTGLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHILKFLTWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQMYWSTPFTFGGGTKVEIK,na,na,None,None,None,2017,2018,IL23A,Eli Lilly,Ulcerative colitis,Plaque psoriasis;Crohn's disease,na,,,Humanised,LY 3074828;LY-3074828;LY3074828
Miromavimab,Whole mAb (Mouse),G1,Kappa,Approved,NFD,QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS,DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK,na,na,None,None,None,2019,2020,Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-II,Candila Healthcare,Rabies,na,na,,,Murine,M777-16-3;Zydus Cadila (cocktail with Miromavimab);Rabimabs (cocktail with Miromavimab);Twinrab (cocktail with Miromavimab))
Mirvetuximab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS,DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK,na,na,None,None,None,2015,2016,FOLR1,ImmunoGen;National Comprehensive Cancer Network,Ovarian cancer;Fallopian tube cancer;Peritoneal cancer,Breast cancer;Endometrial cancer,Solid tumours,,,Chimeric,IMGN853;IGMN-853;IMGN 853;M9346A;M-9346A
Mirzotamab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIK,na,na,None,None,None,2019,2020,B7H3/CD276,AbbVie,na,na,Haematological malignancies;Solid tumours,,Chimeric: Mouse/Human. ADC with clezutoclax,Chimeric,ABBV-155;ABBV155;ABBV 155
Misitatug,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTIVYTPSLKDKFIISRDNAKNTLYLQMNSLRAEDTALYYCARRGSHYYGYRTGYFDVWGAGTTVTVSS,DVVMTQSPAFLSVTPGEKVTMTCSASSSVSYMYWHQQKPDQAPKLLIYDTSNLASGVPVRFSGSGSGTDFTFTISRMEAEDAATYYCQQWSSYPPTFGGGTKVEIK,na,na,None,None,None,2024,2024,MSLN,RemeGen Co,na,Solid tumours,na,,Humanised: musmus/homosap,Humanised,RC-88;RC88;RC 88
Mitazalimab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWLSYISGGSSYIFYADSVRGRFTISRDNSENALYLQMNSLRAEDTAVYYCARILRGGSGMDLWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYNVYWYQQLPGTAPKLLIYGNINRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCAAWDKSISGLVFGGGTKLTVL,na,na,None,None,None,2017,2019,TNFRSF5/CD40,Alligator Bioscience;Janssen Biotech,na,Solid tumours,na,,Mitazalimab is the new name for Vanalimab (PL119),Humanised,ADC 1013;ADC-1013;ADC1013;JNJ 7107;JNJ7107;JNJ-7107;JNJ-64457107;JNJ64457107;JNJ 64457107;Vanalimab
Modakafusp,Whole mAb Fusion,G4,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGATVKISCKVSGYTFTDSVMNWVQQAPGKGLEWMGWIDPEYGRTDVAEKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARTKYNSGYGFPYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDSDVDWYQQKPGKAPKLLIYKASNDYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCMQSNTHPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,ADPRC1/CD38,Takeda,na,na,Multiple myeloma,,,na,TAK-573;TAK573;TAK 573;TEV-48573;TEV 48573;TEV48573
Modotuximab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQQPGAELVEPGGSVKLSCKASGYTFTSHWMHWVKQRPGQGLEWIGEINPSSGRNNYNEKFKSKATLTVDKSSSTAYMQFSSLTSEDSAVYYCVRYYGYDEAMDYWGQGTSVTVSS,DIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELPYTFGGGTKLEIK,na,na,None,None,None,2012,2014,EGFR/ERBB1/HER1,Symphogen;Merck,na,Colorectal cancer;Glioma;Non-small cell lung cancer,Head and neck cancer;Oesophageal cancer,,Modotuximab is the new name for Zatuximab (PL110),Chimeric,DS-1024;DS1024;S-95026;S95206;Sym-004 (Combination with Futuximab);Sym004 (Combination with Futuximab)
Moflerafusp,Fusion Protein,G1,Kappa,TBC,TBC,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSNWMHWVRQAPGQGLEWMGMIHPNSGSSNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSYYGSSPYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIINYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGDTLPWTFGQGTKVEIK,na,na,None,None,None,2025,na,SIRPA,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Mogamulizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS,DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CCR4/CD194,Amgen;Bristol-Myers Squibb;Kagoshima University Dental School;Kyowa Hakko;Kyowa Hakko Kirin;Ono Pharmaceutical,Adult T-cell leukaemia-lymphoma;Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Mycosis fungoides;Sezary syndrome;Mycosis fungoides,Spinal cord disorders,Non-small cell lung cancer;Asthma;Hypersensitivity;Solid tumours,POTELLIGENT Technology,,Humanised,AMG 761;AMG-761;AMG761;KW-0761;KW0761;KW 0761;Poteligeo
Monalizumab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMNWVRQAPGQGLEWMGRIDPYDSETHYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGYDFDVGTLYWFFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPRTFGGGTKVEIK,na,na,None,None,None,2015,2016,KLRC1,Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk,na,Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies,Inflammation;Rheumatoid arthritis,,,Humanised,IPH-22;IPH22;IPH 22;IPH-2201;IPH2201;IPH 2201;IPH-22XX;IPH22XX; IPH 22XX;NN-8765;NN8765;NN 8765
Mosunetuzumab,Bispecific mAb,G1,Kappa;Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCTQSFILRTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,None;None,None;None,None;4k7p:YX,2017,2018,CD3E;MS4A1/CD20,Genentech,na,Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma,na,,,Humanised;Humanised,BTCT 4465A;BTCT-4465A;RG7828;RG-7828;RG 7828;RO7030816;RO-7030816;RO 7030816
Motavizumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK,na,na,3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC/6ywd:AB,5k8a:BA:FE:VM:HL/4jlr:AB:HL,None,2006,2007,Respiratory Syncytial Virus Glycoprotein F,MedImmune,na,na,Respiratory syncytial virus infections,Affinity Matured from Palivizumab,Biosimilars available,Humanised,MEDI-524;MEDI 524;MEDI524;Numax;Rezield
Moxetumomab,Fv Fusion,na,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKCLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGTHWGVLFAYWGQGTLVTVSA,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGCGTKLEI,na,na,None,None,None,2009,2010,SIGLEC2/CD22,National Cancer Institute (USA);AstraZeneca;M. D. Anderson Cancer Center;MedImmune;National Cancer Institute (USA),Hairy cell leukaemia,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,CAT Phage Display,ADC with pasudotox,Murine,CAT-8015;CAT8015;CAT 8015;GCR-8015;GCR8015;GCR 8015;HA22;Lumoxiti
Mozistobart,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLLESGGGVVQPGGSLRLSCAASGFAFSIYDMNWVRQAPGKGLEWVSAISSGGGTTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHSGYGTHWGVLFAYWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIHGYLNWYQQKPGKAPKLLIYYTSILHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQGSTLPWTFGQGTKLEIK,na,na,None,None,None,2024,2024,SIGLEC2/CD22,Tallac Therapeutics,na,Solid tumours,na,,,Humanised,TAC001;TAC-001;TAC 001
Murlentamab,Whole mAb,G1,Kappa,Phase-II,Active,QVRLVQSGAEVKKPGASVKVSCKASGYTFTSYHIHWVRQAPGQRLEWMGWIYPGDDSTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRGDRFAYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASSSVRYIAWYQQKPGKAPKLLTYPTSSLKSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCLQWSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,AMHR2,LFB Biotechnologies;GamaMabs Pharma,na,Colorectal cancer;Gynaecological cancer,na,,,Humanised,3C23K;GM-102;GM102;GM 102
Mupadolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVEKPGASVKVSCKASGYTFTSYWITWVRQAPGQGLEWMGDIYPGSGNTNYNEKFKTRVTITADKSTSTAYMELSSLRSEDTAVYYCAKEGGLTTEDYALDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASKNVSTSGYSYMHWYQQKPGQAPRLLIYLASNLESGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQHSRELPFTFGQGTKVEIK,na,na,None,None,None,2021,2022,NT5E/CALJA/CD73,Corvus Pharmaceuticals,na,COVID-19 infections;Oropharyngeal cancer;Cancer,na,,,Humanised,COR-004;COR004;COR 004;COR-4;COR4;COR 4;CPI-006;CPI006;CPI 006;CPI-6;CPI6;CPI 6;CPX-006;CPX006;CPX 006;CPX-6;CPX6;CPX 6
Muromonab,Whole mAb,G2a,Kappa,Approved (withdrawn),Discontinued,QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS,QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN,na,na,1sy6:HL,None,None,1988,1989,CD3E,Cancer Research UK;Ortho-McNeil;XOMA,na,na,Diabetes mellitus;Graft-versus-host disease;Renal transplant rejection;Rheumatoid arthritis,,LC IMGT 127 is N not K as in Jain paper.,Murine,Zolimomab
Muzastotug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIK,na,na,None,None,None,2023,2023,CTLA4/CD152,Adagene;Roche,na,Liver cancer;Solid tumours;Cancer,na,,,Humanised,ADG126;ADG-126
Nadecnemab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVISGSGGSTYYADAVKGRFTISRDNSKHTLYLQMNSLRAEDTAVYYCTKPSSYSSSNFYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTNSFPFPFGPGTKVDIK,na,na,None,None,None,2020,2021,GFRA3,Regeneron Pharmaceuticals,na,Osteoarthritis;Pain chronic,na,,,Genetically human,REGN-5069;REGN5069;REGN 5069
Nadunolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTSSWMNWVRQAPGQGLEWMGRIYPGDGNTHYAQKFQGRVTLTADKSTSTAYMELSSLRSEDTAVYYCGEGYLDPMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQGINNYLNWYQQKPGKAPKLLIHYTSGLHAGVPSRFSGSGSGTDYTLTISSLEPEDVATYYCQQYSILPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,IL1RAP,Lund University;Cantargia,na,Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Triple negative breast cancer,na,,Nadunolimab is the new name for Nidanilimab (PL122),Humanised,CAN-04;CAN04;CAN 04;CAN-4;CAN4;CAN 4
Namilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKAFGYPFTDYLLHWVRQAPGQGLEWVGWLNPYSGDTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCTRTTLISVYFDYWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTIACRASQNIRNILNWYQQRPGKAPQLLIYAASNLQSGVPSRFSGSGSGTDFTLTINSLQPEDFATYYCQQSYSMPRTFGGGTKLEIK,na,na,None,None,None,2010,2011,CSF2,Micromet Inc;Izana Bioscience;Takeda Pharmaceuticals International GmbH,na,Ankylosing spondylitis;COVID-19,Plaque psoriasis;Rheumatoid arthritis,Human Phage Display,,Genetically human,AMG 203;AMG203;AMG-203;IZN 101;IZN101;IZN-101;MT-203;MT203;MT 203;MT03;MT-03;MT 03;MT3;MT-3;MT 3
Naptumomab,Fab Fusion,G1,Kappa,Phase-III,Discontinued,EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSPGKGLEWIGRINPNNGVTLYNQKFKDKATLTVDKSSTTAYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQGTSVTVSS,SIVMTQTPTSLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSPKLLISYTSSRYAGVPDRFSGSGYGTDFTLTISSVQAEDAAVYFCQQDYNSPPTFGGGTKLEIK,na,na,None,None,None,2006,2007,TPBG/WAIF1,Active Biotech,na,na,Non-small cell lung cancer;Pancreatic cancer;Renal cancer,,,Murine,ABR-217620;ABR217620;ABR 217620;NTX 352;NTX-352;NTX352
Naratuximab,Whole mAb ADC,G1,Kappa,Phase-II,Active,QVQVQESGPGLVAPSQTLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIWGDGSTNYHPSLKSRLSIKKDHSKSQVFLKLNSLTAADTATYYCAKGGYSLAHWGQGTLVTVSS,DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVATNLADGVPSRFSGSGSGTDYSLKINSLQPEDFGTYYCQHYWGTTWTFGQGTKLEIK,na,na,None,None,None,2015,2016,CD37,ImmunoGen;Chronic lymphocytic leukaemia,na,Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,Chronic lymphocytic leukaemia,,ADC with emtansine,Chimeric,DEBIO 1562;DEBIO-1562;DEBIO1562;IMGN-529;IMGN529;IMGN 529;K7153A-SMCC-DM1
Narlumosbart,Whole mAb,G4,Kappa,Phase-III,Approved,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK,na,na,None,None,None,2022,2023,TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF,CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology,Giant cell tumour of bone,Hypercalcemia of malignancy;Glucocorticoid-induced osteoporosis;Bone metastases from solid tumours,Malignant hypercalcaemia,,6ghg is technically within 95% ID; but CDRH3 length 7 vs length 15. Same Fv sequence as Denosumab.,Genetically human,JMT103;JMT-103
Narnatumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYLMTWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLNLQMNSLRAEDTAVYYCTRDGYSSGRHYGMDVWGQGTTVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,MST1R/CD136,ImClone Systems;Eli Lilly;ImClone Systems,na,na,Solid tumours,,,Genetically human,IMC-RON-8;RON-8;RON 8;RON8
Narsoplimab,Whole mAb,G4,Lambda,Preregistration,Active,QVTLKESGPVLVKPTETLTLTCTVSGFSLSRGKMGVSWIRQPPGKALEWLAHIFSSDEKSYRTSLKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIRRGGIDYWGQGTLVTVSS,QPVLTQPPSLSVSPGQTASITCSGEKLGDKYAYWYQQKPGQSPVLVMYQDKQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL,na,na,None,None,None,2019,2020,MASP2,Omeros,na,Haemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis,Stroke;Wet age-related macular degeneration,,,Genetically human,OMS 00620646;OMS-00620646;OMS00620646;OMS 620646;OMS620646;OMS-620646;OMS 721;OMS-721;OMS721
Natalizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK,na,na,None,4irz:HL/6fg1:HL/6fg2:HL:IM,None,1998,1999,ITGA4/CD49D,Biogen;Biogen Idec;Elan Corporation;Perrigo,Crohn's disease;Multiple sclerosis,Epilepsy;Graft-versus-host disease;Stroke,Multiple myeloma;Rheumatoid arthritis,,Biosimilars available,Humanised,AN 10022;AN10022;AN-10022;AN 100226;AN-100226;AN100226;Antegren;BG-00002;BG 00002;BG00002;BG-0002;BG0002;BG 0002;BG2;BG-2;BG 2;Tysabri
Navenibart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSSYWMNWVRQAPGQGLEWIGQIYPGDDDTNYNAKFQGRVTITVDKSTTTAYMELSSLRSEDTAVYFCAGSLMVTTGAPFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKAPKFLIYYASHRGWGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCQQYRSYPLTFGQGTKLEIK,na,na,8fgx:BA,None,None,2024,2024,KLKB1,Astria Therapeutics Inc,na,Hereditary angioedema,na,,,Humanised,STAR-0215;STAR0215;STAR 0215
Navivumab,Whole mAb,G1,Kappa,Preclinical,Discontinued,QVQLVQSGAEVKKPGASVKVSCKTSGYSFSTYGVSWVRQAPGQGPEWVGWISAYTGITDYAQKFQGRVTLTTDATTATAFLDLRSLRPDDTATYFCARDKVQGRVEVGSGGRHDYWGQGTLVIVSS,EVVLTQSPGTLALPPGERATLSCRASHRVGSTYIAWYQQKSGQAPRRLIYGASNRATDIPDRFSGSGSGTDFTLTIRRLEPEDSAVYYCQQFSVSPWTFGQGTRVEIK,na,na,4r8w:HL/4ubd:CD:KL:YX:ST:OP:GH,6fg1:HL/6fg2:HL,None,2015,2016,Influenza A HA,Celltrion,na,na,Influenza A virus H1N1 subtype;Influenza A virus H5N1 subtype;Influenza virus infections,,,Genetically human,CT-P23;CT P23
Navicixizumab,Bispecific mAb,G2;G2,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKISCKASGYSFTAYYIHWVKQAPGQGLEWIGYISNYNRATNYNQKFKGRVTFTTDTSTSTAYMELRSLRSDDTAVYYCARDYDYDVGMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGDINPSNGRTSYKEKFKRRVTLSVDKSSSTAYMELSSLRSEDTAVYFCTIHYDDKYYPLMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATISCRASESVDNYGISFMKWFQQKPGQPPKLLIYAASNQGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEVPWTFGGGTKVEIK,None;None,None;None,None;None,2015,2016,DLL4;VEGFA,OncoMed Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer,Colorectal cancer;Solid tumours,,,Chimeric and humanised;Chimeric and humanised,OMP 305B83;OMP305B83;OMP 305B83
Naxitamab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,na,na,None,None,None,2018,2019,Ganglioside GD2,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,Neuroblastoma,Osteosarcoma,Breast cancer;Sarcoma;Small cell lung cancer,,Genetics: musmus/homosap,Chimeric and/or humanised,Danyelza;Hu3F8
Nebokitug,Whole mAb,G1,Kappa,Phase-II,Active,QIQLVQSGPELKKPGASVKVSCRASGYPFTNSGMNWVKQAPGKGLKWMGWINTYNGEPTYTDDFKGRFAFSLETSASTAYLQINNLRNEDTATYFCASHSYGSSYAMDNWGQGTSVTVSS,DIVLTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLKSGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEEPWTFGGGTKVEIK,na,na,None,None,None,2024,na,CCL24/SCYA24/Ckb-6/MPIF-2/eotaxin-2,Chemomab Therapeutics,na,Hepatic fibrosis;Non-alcoholic steatohepatitis;Primary sclerosing cholangitis,na,,,Chimeric and/or humanised,CM-101;CM 101;CM101
Nebratamig1,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1),na;G1,Kappa;Kappa,Phase-I/II,Active,SRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSS,DVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEIK,SQSVEESGGGLVQPGGSLRLSCTASGIDLNTYDMIWVRQAPGKGLEWVGIITYSGSRYYANWAKGRFTISKDNTKNTVYLQMNSLRAEDTAVYYCARDYMSGSHLWGQGTLVTVSS,AYDMTQSPSSVSASVGDRVTIKCQASEDIYSFLAWYQQKPGKAPKLLIHSASSLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYGKNNVDNAFGGGTKVEIK,None;None,None;None,None;None,2023,2023,TNFRSF9/CD137/4-1BB;PDL1/CD274,Sichuan Baili Pharmaceutical;SystImmune,na,Chronic lymphocytic leukaemia;Haematological malignancies;Non-Hodgkin's lymphoma;Gastric cancer;Leukaemia;Lung cancer;Lymphoma;Ovarian cancer;Solid tumours;Triple negative breast cancer,na,,scFv-IgG1 portion. Joint entry with Nebratamig2 (tetraspecific),Humanised;Humanised,GNC-035;GNC035
Nebratamig2,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 2),na;na,Kappa;Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTISRYHMTWVRQAPGKGLEWIGHIYVNNDDTDYASSAKGRFTISRDNSKNTLYLQMNSLRAEDTATYFCARLDVGGGGAYIGDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQSSQSVYNNNDLAWYQQKPGKVPKLLIYYASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCAGGYDTDGLDTFAFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK,None;None,None;None,None;None,2023,2023,ROR1;CD3D and CD3E,Sichuan Baili Pharmaceutical;SystImmune,na,Chronic lymphocytic leukaemia;Haematological malignancies;Non-Hodgkin's lymphoma;Gastric cancer;Leukaemia;Lung cancer;Lymphoma;Ovarian cancer;Solid tumours;Triple negative breast cancer,na,,scFv-scFv portion. Joint entry with Nebratamig2 (tetraspecific),Humanised;Humanised,GNC-035;GNC035
Necitumumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK,na,na,6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL,None,None,2008,2009,EGFR/ERBB1/HER1,ImClone Systems;Eli Lilly,Non-small cell lung cancer,Solid tumours,Colorectal cancer,,,Genetically human,IMC-11F8;IMC 11F8;IMC11F8;LY 3012211;LY3012211;LY-3012211;Portraza;Portrazza
Negalstobart,Whole mAb,G4,Kappa,Phase-II,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSIYSESYYWGWIRQPPGKGLEWIGSIVYSGYTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVRTWDAAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQVLELPPWTFGGGTKVEIK,na,na,None,None,None,2023,2024,LAG3/CD223,Innovent Biologics,na,Squamous cell cancer;Lymphoma;Non-small cell lung cancer;Small cell lung cancer;Solid tumours,na,,,Genetically human,IBI-110;IBI 110;IBI110
Nelmastobart,Whole mAb,G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTHYNMDWVRQAPGQGLEWIGYIYPSNGGTGYNQKFKSRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARGAYHYGSSYAYWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAVKLLISYTSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQSSKLPFTFGQGTELEIK,na,na,None,None,None,2023,2024,BTN1A1,STCube,na,Solid tumours,na,,,Humanised,STT-003;STT003;hSTC810
Nelistotug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFVEYAISWVRQAPGQGLEWMGGIIPAFGTAQYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGAGYYGDKDPMDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQVLHTITFGGGTKVEIK,na,na,None,None,None,2023,2023,TACTILE/CD96,GlaxoSmithKline;23andMe,na,Squamous cell cancer;Solid tumours,na,,,Genetically human,GSK 6097608;GSK-6097608;GSK6097608
Nemolizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYIMNWVRQAPGQGLEWMGLINPYNGGTDYNPQFQDRVTITADKSTSTAYMELSSLRSEDTAVYYCARDGYDDGPYTLETWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASEDIYSFVAWYQQKPGKAPKLLIYNAQTEAQGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYDSPLTFGGGTKVEIK,na,na,None,None,None,2014,2015,IL31RA,Chugai Pharmaceutical;Galderma;Maruho,Atopic dermatitis,Prurigo nodularis;Pruritus;Scleroderma,na,,,Humanised,CD-14152;CD14152;CD 14152;CIM 331;CIM-331;CIM331;M 5250;M5250;M-5250
Nepuvibart,Whole mAb,G1,Kappa,Approved,NFD,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYITYSGSTIYYADSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDRGTTMVPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDITNYLNWYQQKPGKAPKLLIYAASNLETGVPSRFSGSGSGTDFTFTISGLQPEDIATYYCQQYDNLPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,SARS-CoV-2 Spike RBD,Regeneron Pharmaceuticals,COVID-19,na,na,,Casirivimab is the former name for Nepuvibart,Genetically human,ZRC-3308;ZRC3308;ZRC 3308
Nesfrotamig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKCLEWVSWISYSGGSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAQRNSMREFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVTWYQQLPGTAPKLLIYADSHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDYSLSGYVFGCGTKLTVL,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA;None,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL;None,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None,2025,na,ERBB2/CD340/HER2;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,TBC,TBC,Humanised;Genetically human,TBC
Nesvacumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDIHWVRQATGKGLEWVSAIGPAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARGLITFGGLIAPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYDNSQTFGQGTKVEIK,na,na,None,None,None,2012,2013,ANGPT2,Regeneron Pharmaceuticals;Sanofi,na,na,Solid tumours,,,Genetically human,REGN-910;REGN910;SAR-307746;SAR307746
Netakimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGGGLVQAGGSLRLSCAASGGTFATSPMGWLRQAPGKGTEFVAAISPSGGDRIYADSVKGRFTISRDNAGYFIYLQMNSLKPEDTAVYYCAVRRRFDGTSYYTGDYDSWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYSYSPVTFGQGTKVEIK,na,na,None,None,None,2017,2018,IL17A,CJSC Biocad,Plaque psoriasis,Ankylosing spondylitis;Psoriatic Arthritis;Primary biliary cirrhosis,na,,Chimeric: Llama/Human,Chimeric,BCD 085;BCD-085;BCD085;BCD 85;BCD-85;BCD85;Efleira
Nezastomig,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-I/II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFMSYDGSNKFYSDSVKGRFTISRDNSRKMLFLQMNNLRAEDTAVYYCARDQYYDFLTDHGVFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGITHYNPSLKSRVTISVDTSKIQFSLKLSSVTAADTAVYYCARWGVRRDYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2023,2024,FOLH1/GCPII/PSMA;CD28,Regeneron Pharmaceuticals,na,Prostate cancer,na,,,Genetically human;Genetically human,REGN5678;REGN-5678
Nezutatug,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGYSITSGYSWHWIRQHPGKGLEWIGSIRYSGGTDYNPSLKSLVTISADTSKNQFSLKLSSVTAADTAVYYCARMTTAPWYPFDYWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQIVGSNVAWYQQKPGKAPEPLIYSASYLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSHPLTFGQGTKLEIK,na,na,None,None,None,2023,2023,ERBB3/HER3,Hummingbird Bioscience;Cancer Research UK,na,Solid tumours;Non-small cell lung cancer;Colorectal cancer; Prostate cancer; Squamous cell cancer,na,,,Humanised,HMBD001;HMBD-001;HMBD 001
Nimacimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYEFSYYWMNWVRQAPGQGLEWMGQIYPGDGETKYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSHGNYLPYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPPTFGQGTKVEIK,na,na,None,None,None,2018,2019,CNR1/CB1,Bird Rock Bio,na,Diabetic nephropathies;Diabetic gastroparesis;Obesity,Non-alcoholic steatohepatitis;Non-alcoholic fatty liver disease,,,Humanised,JNJ 2463;JNJ-2463;JNJ2463;Namacizumab;RYI-018;RYI018;RYI 018;RYI 18;RYI-18;RYI18
Nimotuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT,na,na,None,3gkw:HL,None,2005,2006,EGFR/ERBB1/HER1,Biocon Biopharmaceuticals;Biotech Pharmaceutical;Center of Molecular Immunology;CIMYM;Daiichi Sankyo Inc;Eurofarma;Gilead Sciences;Innogene Kalbiotech;InnoMab;Kuhnil Pharmaceutical Company;Laboratorios Pisa;Oncoscience,Anaplastic astrocytoma;Brain cancer;Glioblastoma;Glioma;Head and neck cancer;Nasopharyngeal cancer;Oesophageal cancer,Cervical cancer;Non-small cell lung cancer;Pancreatic cancer;Breast cancer;Colorectal cancer,Gastric cancer;Polycystic kidney disease;Prostrate cancer;Brain metastases;Squamous cell cancer,,Feb '22: Conflict between our sequence and IMGT-mAb/DB. We take the seminal paper as source of the sequence: https://cancerres.aacrjournals.org/content/69/14/5851.,Humanised,DE-766;DE766;DE 766;KI-0501;KI0501;KI 0501;KI-501;KI 501;KI501;KI-0502;KI0502;KI 0502;KI-502;KI502;KI 502;OSAG101;OSAG-101;OSAG 101;Taixinsheng;TheraCIM;Theraloc;VECTHIX 
Nipocalimab,Whole mAb,G1,Lambda,Preregistration,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSS,QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMIYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVL,na,na,None,None,5whk:HL/5whj:HL,2019,2020,FCGRT/FcRn,Momenta,na,Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis,na,,,Genetically human,JNJ 80202135;JNJ-80202135;JNJ80202135;M 281;M-281;M281
Nirsevimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVMVSCQASGGLLEDYIINWVRQAPGQGPEWMGGIIPVLGTVHYGPKFQGRVTITADESTDTAYMELSSLRSEDTAMYYCATETALVVSETYLPHYFDNWGQGTLVTVSS,DIQMTQSPSSLSAAVGDRVTITCQASQDIVNYLNWYQQKPGKAPKLLIYVASNLETGVPSRFSGSGSGTDFSLTISSLQPEDVATYYCQQYDNLPLTFGGGTKVEIK,na,na,5udc:HL:BC:EG/5udd:JP:KQ:LR:MS:OU:NT,None,4jha:HL/4jhw:HL/6s3d:AB:CD:EF:HL,2018,2019,Respiratory Syncytial Virus,AIMM Therapeutics;MedImmune,Respiratory syncytial virus infections,na,na,,,Genetically human,MEDI 8897;MEDI-8897;MEDI8897;SP 0232;SP0232;SP-0232;SP-232;SP232;SP 232
Nisevokitug,Whole mAb,G2,Lambda,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGLWEVRALPSVYWGQGTLVTVSS,SYELTQPPSVSVAPGQTARITCGANDIGSKSVHWYQQKAGQAPVLVVSEDIIRPSGIPERISGSNSGNTATLTISRVEAGDEADYYCQVWDRDSDQYVFGTGTKVTVL,na,na,None,None,None,2022,2023,TGFB1/TGFB2,Novartis,na,Pancreatic cancers;Colorectal cancers;Myelodysplastic syndromes;Pancreatic ductal adenocarcinoma;Metastatic cancers,na,,,Genetically human,NIS-793;NIS793
Nivatrotamab,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,Phase-I/II,Active,QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDYWGQGTLVTVSS,EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIK,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKCLEWIGYINPSRGYTNYNQKFKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYSLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGCGTKLQIT,None;None,None;None,None;None,2020,2021,GD2;CD3E,Memorial Sloan-Kettering Cancer Center,na,Neuroblastoma,na,,Genetics of Fv1: musmus/homosap,Chimeric and/or humanised;Genetically human,
Nivisnebart,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTKYYMSWVRQAPGQGLEWMGIINPIGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDPSGIALAGPASRGYQGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQARLGPWTFGGGTKVEIK,na,na,None,None,None,2024,na,SORT1/Gp95/NT3,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Nivolumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK,na,na,5ggq:HL/5wt9:HL/5ggr:HL:AB,None,None,2012,2013,PDCD1/CD279/PD1,Aduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics,Colorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer,Bladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Glioma,Chronic myeloid leukaemia;Hepatitis C;Sepsis,Medarex UltiMAb Mouse,Biosimilars available,Genetically human,BMS-936558;BMS936558;BMS 936558;MDX-1106;MDX1106;MDX 1106;ONO-4538;ONO4538;ONO 4538;OPDIVO;OPDUALAG (combination of Nivolumab and Relatlimab)
Nofazinlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGFTFTTYYISWVRQAPGQGLEYLGYINMGSGGTNYNEKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAIIGYFDYWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLLDSDGGTYLYWFQQRPGQSPRRLIYLVSTLGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQLTHWPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,PDCD1/CD279/PD1,Cstone Pharmaceuticals,na,Solid tumours;Hepatocellular carcinoma,na,,,Humanised,CS-1003;CS1003;CS 1003
Nolavetbart,Whole mAb (Canine),G2,Kappa,Unknown,Active,EVTLQESGPGLVKPSQTLSLTCVASGFSIKSSFIHWLRQRPGRGLEWIGRIDPAFGATEYNPAFQGRFSITADTAKNQASLQLSSMTTEDSAVYYCARYHYAASHFDAWGQGTLVTVSS,RIVMTQSPGSLAGSVGESVSINCKSSQSVTNDLTWYQQKPGEAPKVLITYASQRYTGVPARFSGSGYGTDFTLTINNLQAEDVGDYFCQQDYASPFTFGQGTKLEIK,na,na,None,None,None,2023,2023,IL31RA (Canine),TBC,na,Canine Lupus,na,,,na,VTQ-2101;VTQ2101
Nurulimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,5xj3:AB:DE:GH:JK/5tru:HL:hl/6jc2:HL/6rp8:HL:hl/7elx:HL:hl,None,2019,2020,CTLA4/CD152,Biocad,na,na,Malignant melanoma,,Likely to be an Ipilimumab Biosimilar,Genetically human,BCD-145;BCD145;BCD 145
Nuvustotug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLSSSWYLDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKLEIK,na,na,None,None,None,2024,na,TNFRSF4/CD134/OX40,HiFiBiO,na,Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Squamous cell cancer;Uterine cancer,na,,,Genetically human,HFB301001;HFB-301001;HFB 301001;HFB-301;HFB 301;HFB301
Oberotatug,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTYSNAWMSWVRQAPGKGLEWVGRIKSKTDGGTTDYAAPVQGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTIFGVVSFDYWGQGTLVTVSS,DVQMTQSPSSLSASVGDRVTITCRASQSISDYLSWYQQRPGKAPNLLIYAASNLKTGVPSRFSGSGSGTDFTLTISTLQPEDFATYYCQQSYRSPWTFGQGTKVEIK,na,na,None,None,None,2023,2023,LY75/CD205/DEC205,Agenus;Groupe Oncologie Radiotherapie Tete et Cou;Menarini;Oxford BioTherapeutics,na,Adenoid cystic carcinoma;Solid tumours;Cancer,na,,ADC with ravtansine,Genetically human,MEN1309;OBT076;MEN-1309;OBT-076
Obertamig,Bispecific Mixed mAb and scFv,G1;na,Lambda;Kappa,Phase-I,Discontinued,QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQISLQLNSVTPEDTAVYYCAGDRRYGIVGLPFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLHSSNNKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2023,2023,CD3E;HLA-G,Janssen Research & Development;Zymeworks,na,na,Solid tumours,,,Genetically human;Genetically human,JNJ-78306358;JNJ78306358
Obexelimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,Xencor,na,Autoimmune disorders;Rheumatoid arthritis;Systemic lupus erythematosus,na,XmAb Antibody Engineering Technology,Genetics: musmus/homosap,Chimeric and/or humanised,AMG 729;AMG-729;AMG729;XmAb 5871;XmAb-5871
Obiltoxaximab,Whole mAb,G1,Kappa,Approved,NFD,QVQLQQSGPELKKPGASVKVSCKDSGYAFSSSWMNWVRQAPGQGLEWIGRIYPGDGDTNYNGKFQGRVTITADKSSSTAYMELSSLRSEDTAVYFCARSGLLRYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAVKLLIYYTSRLLPGVPSRFSGSGSGTDYSLTISSQEQEDIGTYFCQQGNTLPWTFGQGTKVEIR,na,na,None,None,None,2015,2016,Anthrax Protective Antigen,Elusys Therapeutics,Anthrax,na,na,,,Chimeric,ETI-204;ETI204;ETI 204
Obinutuzumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK,na,na,3pp3:HL:IK/3pp4:HL,6y9a:HL,6y97:HL,2008,2011,MS4A1/CD20,GLYCART Biotechnology;Biogen Idec;Chugai Pharmaceutical;Dana-Farber Cancer Institute;Genentech;Lymphoma Academic Research Organisation;Nippon Shinyaku;OHSU Knight Cancer Institute;Pharmacyclics;Polish Myeloma Consortium;Roche;Thomas Jefferson University;University of Heidelberg;University of Leeds,Chronic lymphocytic leukaemia;Follicular lymphoma;Non-Hodgkin's lymphoma,Diffuse large B cell lymphoma;CNS cancer;Graft-versus-host disease;Lupus nephritis;Mantle-cell lymphoma;Waldenstrom's macroglobulinaemia,Primary biliary cirrhosis,GlycoMAb Technology,Obinutuzumab is the new name for Afutuzumab (PL101),Humanised,Afutuzumab;GA-101;GA101;GA 101;Gazyva;Gazyvaro;R-7159;R 7159;R7159;RG 7195;RG-7159;RG7159;RO-5072759;RO5072759;RO 5972759
Obrindatamab,Bispecific scFv with Domain Crossover,na;na,Kappa;Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISSDSSAIYYADTVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCGRGRENIYYGSRLDYWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVDTNVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPFTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,B7H3/CD276;CD3E,MacroGenics,na,na,Advanced or Metastatic solid tumours,,Genetics of both Fvs: musmus/homosap,Chimeric and/or humanised;Chimeric and/or humanised,MGD-009;MGD009;MGD 009;MGD-9;MGD9;MGD 9;Orlotamab
Obrixtamig,Bispecific mAb (L-kappa-H-gamma1_L-lambda-H-gamma1),G1;G1,Kappa;Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYVHWVRQAPGQGLEWMVIINPGGGTTSYAQKFLGRVTMTRDTSTNTVYMELKSLRSEDTAVYYCARGEAVTGNYFYYGMDVWGQGTTVTVSS,DIQMTQSPSAMSASVGDRVTITCRASQGISNYLVWFQQKPGKAPKRLIYAVSSLYSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHDSYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSA,EAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQEKPGQLPRGLIGGTNKRAPWVPARFSGSLLGGKAALTLSGAQPEDEAEYFCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2024,2024,DLL3;CD3E,Boehringer Ingelheim,na,Neuroendocrine tumours;Small cell lung cancer;Glioma,na,,,Genetically human;Humanised,BI-764532;BI764532;BI 764532;OBT-620;OBT620;OBT 620
Ocankitug,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGIIDPSDSDTSLNQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARSLDGYYDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYFAKTLTDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPWTFGQGTKVEIK,na,na,None,None,None,2024,2024,TSLP,CSPC Pharmaceutical Group;KeyMed Biosciences,na,Asthma;Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease,na,,,Humanised,CM-326;CM326;CM 326
Ocaratuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGRTFTSYNMHWVRQMPGKGLEWMGAIYPLTGDTSYNQKSKLQVTISADKSISTAYLQWSSLKASDTAMYYCARSTYVGGDWQFDVWGKGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVPYIHWYQQKPGQAPRLLIYATSALASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWLSNPPTFGQGTKLEIK,na,na,None,None,None,2012,2013,MS4A1/CD20,Applied Molecular Evolution;MENTRIK Biotech,na,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Rheumatoid arthritis,,,Humanised,AME-133;AME133;AME 133;LY 2469298;LY-2469298;LY2469298
Ociperlimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAYITKGGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARQTNYDFTMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVGTSVAWYQQKPGQAPRLLIYWASARHTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYSSYPLTFGGGTKVEIK,na,na,8jel:AB:CD:FG:JK/8jen:AB:CD:EF:GH/8jep:AB:CD,None,None,2020,2021,TIGIT/WUCAM/VSTM3,BeiGene,na,Non-small cell lung cancer; Cervical cancer; Small-cell lung cancer; Squamous cell cancer; Solid tumours,na,,June '22: Corrected CDRH1 sequence,Humanised,BGB-A1217;BGB A1217;WCD-118;WCD118;WCD 118
Ocrelizumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK,na,na,None,None,4k7p:YX,2005,2006,MS4A1/CD20,Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche,Multiple sclerosis,na,Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus,,Biosimilars available,Humanised,Ocrevus;PRO 70769;PRO-70769;PRO70769;R 1594;R1594;R-1594;RG 1594;RG-1594;RG1594;RO4964913;RO-4964913;RO 4964913
Odesivimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKGLEWVSAIGTAGDTYYPGSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARTWFGELYFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTEFTLTITSLQAEDVAVYYCQQYYSSPLTFGGGTKVEIK,na,na,7tn9:QR:MN:OP,None,None,2019,2020,Zaire Ebolavirus Glycoprotein,Regeneron Pharmaceuticals,Ebola virus infections ,na,na,,,Genetically human,REGN 3471;REGN3471;REGN-3471;INMAZEB (combination with Atoltivimab and Maftivimab)
Odronextamab,Bispecific mAb,G4;G4,Kappa;Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCVASGFTFNDYAMHWVRQAPGKGLEWVSVISWNSDSIGYADSVKGRFTISRDNAKNSLYLQMHSLRAEDTALYYCAKDNHYGSGSYYYYQYGMDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYTMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDNSGYGHYYYGMDVWGQGTTVTVAS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQHYINWPLTFGGGTKVEIK,None;None,None;None,None;None,2019,2020,MS4A1/CD20;CD3E,Regeneron Pharmaceuticals,Diffuse large B cell lymphoma;Follicular lymphoma,B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,,,Genetically human;Genetically human,REGN-1979;REGN1979;REGN 1979;ZL-1307;ZL1307;ZL 1307
Ofatumumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK,na,na,3giz:HL/6y92:HL:CD,None,None,2005,2006,MS4A1/CD20,Genmab;GlaxoSmithKline;Mundipharma International;National Cancer Centre (Singapore);Novartis;Roswell Park Cancer Institute;University Health Network,Chronic lymphocytic leukaemia,B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Multiple sclerosis;Marginal zone B-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma,Neuromyelitis optica;Pemphigus vulgaris;Rheumatoid arthritis;Waldenstrom's macroglobulinaemia,Medarex HuMAb Mouse,Biosimilars available,Genetically human,Arzerra;GSK-1841157;GSK1841157;;GSK 1841157;Kesimpta;OMB-157;OMB157;OMB 157
Ogalvibart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVIPFDGRNKYYADSVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASSSGYLFHSDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISNWLAWFQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYPWTFGQGTKVEIK,na,na,7k8r:HL/7k8z:HL:MN,None,None,2022,2022,SARS-CoV-2 Spike RBD,National Institute of Allergy and Infectious Diseases;Rockefeller University;Xencor,na,COVID-19,na,,,Genetically human,"C-135-LS;BMS-986414;BMS 986414;BMS986414 	"
Olaratumab,Whole mAb,G1,Kappa,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK,na,na,None,None,None,2010,2011,PDGFRA/CD140A,ImClone Systems;Eli Lilly;Institute for Clinical Oncological Research,Soft tissue sarcoma,Pancreatic cancer;Solid tumours,Gastrointestinal stromal tumours;Glioblastoma;Non-small cell lung cancer;Ovarian cancer;Prostate cancer,Medarex UltiMAb Mouse,,Genetically human,IMC-3G3;IMC 3G3;IMC3G3;Lartruvo;LY 3012207;LY-3012207;LY3012207
Oleclumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVL,na,na,None,None,None,2016,2017,NT5E/CALJA/CD73,MedImmune;AstraZeneca;European Network of Gynaecological Oncological Trial Groups;Jules Bordet Institute,na,Non-small cell lung cancer;Ovarian cancer;Breast cancer;Pancreatic cancer;Bladder cancer;Solid tumours,Prostate cancer,,,Genetically human,MEDI-9447;MEDI 9447;MEDI9447
Olendalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK,na,na,None,None,None,2015,2017,C5,Alexion Pharmaceuticals,na,na,Antiphospholipid syndrome;Graft-versus-host disease;Inflammation,,Olendalizumab is the new name for Lendalizumab (PL116),Humanised,ALXN-1007;ALXN1007;ALXN 1007
Olintatug,Whole mAb,G1,Kappa,TBC,Active,QIQLVQSGAEVKKPGASVKVSCKASGYTFTDDYMSWVKQAPGQGLEWIGDINPYNGDTNYNQKFKGKATLTVDKSTSTAYMELSSLRSEDTAVYYCARDPGAMDYWGQGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGNTYLEWYLQKPGQSPQLLIYTVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK,na,na,None,None,None,2024,2024,KAAG1/RU2AS,TBC,TBC,TBC,TBC,,Chimeric/Humanised: musmus/homosap,Chimeric and humanised,TBC
Olinvacimab,Whole mAb,G1,Lambda,Phase-II,Active,QMQLVQSGAEVKKPGASVKLSCKASGYTFSSYWMHWVRQAPGQRLEWMGEINPGNGHTNYNEKFKSRVTITVDKSASTAYMELSSLRSEDTAVYYCAKIWGPSLTSPFDYWGQGTLVTVSS,NFMLTQPPSVSVSPGKTARITCRGDNLGDVNVHWYQQRPGQAPVLVMYYDADRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDRTSEYVFGTGTKVTVL,na,na,None,None,None,2018,2019,KDR/CD309/VEGFR2,PharmAbcine;3SBio,na,Glioblastoma;Breast cancer,Cancer;Choroidal neovascularisation;Solid tumours,,Olinvacimab is the new name for Tanibirumab,Genetically human,SSS-23;SSS23;SSS 23;TTAC-0001;TTAC0001;TTAC 0001;TTAC-1;TTAC1;TTAC 1
Oloctinebart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYMHWVRQAPGQRLEWMGWIYPGSGNTNYNEKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCSTAPGGFDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSKSLLHSDGITYLYWYLQKPGQSPQLLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQMLEFPLTFGQGTKLEIK,na,na,None,None,None,2023,2023,LGALS3/GAL3,TBC,TBC,TBC,TBC,,,Humanised,TBC
Olokizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK,na,na,4cni:HL:AB,None,None,2010,2011,IL6,R-Pharm;UCB,Rheumatoid arthritis;SARS-CoV-2 acute respiratory disease,Inflammation,na,,,Humanised,Artlegia;CDP-6038;CDP6038;CDP 6038
Omalizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK,na,na,4x7s:HL/2xa8:HL/4x7t:HL:AB/5hys:HL:AB:EF:CD/6tcm:HL/6tcn:HL/6tco:BA/6tcp:HL/7shy:EF:IJ:KL:CD,5g64:IM:HL/6tcq:HL/6tcr:HL/6tcs:AA,7shu:CD:EF/7shz:CD:EF:IJ:KL/7si0:CD:IJ:EF:KL,2000,2001,IGHE,Dana-Farber Cancer Institute;Genentech;John Hopkins University;Novartis,Allergic asthma;Urticaria,Seasonal allergic rhinitis;Nasal polyps;Mastocytosis;Asthma;Nephritis,Hypersensitivity;Peanut hypersensitivity,,Biosimilars available,Humanised,IGE25;IGE-25;IGE 25;Olizumab;XOLAIR
Omburtamab,Whole mAb Radiolabelled,G1,Kappa,Preregistration,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTNYDINWVRQRPEQGLEWIGWIFPGDGSTQYNEKFKGKATLTTDTSSSTAYMQLSRLTSEDSAVYFCARQTTATWFAYWGQGTLVTVSA,DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPLTFGAGTKLELK,na,na,5cma:BA,None,None,2018,2019,B7H3/CD276,Memorial Sloan-Kettering Cancer Center;Y-mAbs Therapeutics,na,Neuroblastoma;Meningeal carcinomatosis;Soft tissue sarcoma;Peritoneal cancer,Solid tumours,,,Murine,OMBLASTYS
Omectatug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVINWVRQATGQGLEWIGEIHPRGGNTYYSEKFRGRVTLTADTSISTAYMELSSLRSEDTAVYYCARLRRGNAMDYWDQGTTVTVSS,DIVMTQSPSSLAVSLGEMATINCKSSQSLLNSGNQRNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNSYNYPYTFGQGTKLERK,na,na,None,None,None,2024,na,CLDN18,AskGene Pharma;Jiangsu Aosaikang Pharmaceutical,na,Gastric cancer;Solid tumours,na,,,Humanised,ASKB 589;ASKB-589;ASKB589
Omoprubart,Whole mAb,G2/G4,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGHIFTDFYMQWVRQAPGQGLEWMGEILPGTGHTEYAQKFQGRVTMTRDTSISTVYMEVRRLRSDDTAVYYCARYFFGSTPNWYFDVWGQGTLVTVSS,EIVMTQSPSSLSASVGDRVTITCGATENIYGALNWYQHEPGKAPKLLIYGASNRYTGVTSRFSGSGSGTDFTLTISTLQPEDFATYYCQQVLNTPVSFGGGTKVDIK,na,na,None,None,None,2023,2024,C5,CANbridge Pharmaceuticals;WuXi Biologics,na,Paroxysmal nocturnal haemoglobinuria,na,,,Genetically human,CAN106;CAN-106
Omodenbamab,Whole mAb,G3,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVSSITGSGRSTFYADSVKGRFTISRDNSTNTLSLQMNSLRAEDTAVYYCARSPADIVTGYYPWWFDLWGQGTLVTVSS,DIQMTQSPSSLSASIGDRVTITCRASQSINTYLNWYQQKPGKAPRLLIAGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGQGTRLEIK,na,na,None,None,None,2020,2021,Staphylococcus aureus Protein A,XBiotech Inc.,na,Staphylococcal infections,na,,,Genetically human,514-G3
Ompekimig1,Trispecific Mixed mAb and scFv; Bispecific entry,G1;na,Kappa;Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISSGDTTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNEGYYFGLTLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASESVDHFGWSLVHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK,EVTLRESGPALVKPTQTLTLTCTFSGFSLSNFGEGLSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVDEEGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNKDPPTFGGGTKVEIK,None;None,None;None,None;None,2025,na,IL13;IL4,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Genetically human,TBC
Ompekimig2,Trispecific Mixed mAb and scFv; Monospecific entry,G1,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQAPGKGLEWVAAITPNAGEDYYPESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGQYYYTKYSLGYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQPIHNHLDWYQQKPGKAPKLLIYFGKNLQEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQYKKGWSFGGGTKVEIK,na,na,None,None,None,2025,na,IL33,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Onartuzumab,Fab + di-Fc,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK,na,na,4k3j:HL,None,None,2010,2011,MET/HGFR,Chugai Pharmaceutical;Genentech,na,na,Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours,,,Humanised,5D5;MetMAb;OA-5D5;PRO-143966;PRO 143966;PRO143996;RG-3638;RG3638;RG 3638;RO-5490258;RO5490258;RO 5490258
Onfekafusp,Whole mAb Fusion,na,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,7ah1:AA,None,None,2010,2011,FN extracellular domain B,Philogen,na,Malignant melanoma;Basal cell cancer;Squamous cell cancer;Solid tumours,na,,Radretumab+Bifikafusp+Onfekafusp have identical V domains,na,L19-TNF-alpha;L19-IL2/L19-TNF; L19IL2/L19TNF; L19(scFv)-IL2/L19(scFv)2-TNF
Ongericimab,Whole mAb,G4,Kappa,Approved,Active,QVQLQESGPGLVKPSQTLSLTCTVSGFSISSYGIHWIRQSPGKGLEWIGVIWRGGITDYNAPFMSRVTISKDNSKNQVSFKLSSVTAADTAVYYCANHRDWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDINKYIDWYQHKPGKAPKLLIHYASTLQPGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGQGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Shanghai Junshi Biosciences,Dyslipidaemias;Hypercholesterolaemia,Hyperlipoproteinaemia type IIa;Hyperlipidaemia,Cancer,,,Humanised,JS-002;JS002;JS 002;JS-2;JS2;JS 2
Ontamalimab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGINWVRQAPGQGLEWMGWISVYSGNTNYAQKVQGRVTMTADTSTSTAYMDLRSLRSDDTAVYYCAREGSSSSGDYYYGMDVWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCKSSQSLLHTDGTTYLYWYLQKPGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNIQLPWTFGQGTKVEIK,na,na,4hcr:MN:HL,None,None,2018,2019,MADCAM1,Pfizer;Takeda,na,na,Crohn's disease;Ulcerative colitis,,,Genetically human,PF-00547659;PF00547659;PF-547659;PF547659;SHP-647;SHP647;SHP 647;TAK-647;TAK647;TAK 647
Ontuxizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVRPSQTLSLTCTASGYTFTDYVIHWVKQPPGRGLEWIGYINPYDDDTTYNQKFKGRVTMLVDTSSNTAYLRLSSVTAEDTAVYYCARRGNSYDGYFDYSMDYWGSGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWLQQTPGKAPKLLIYSASNRYTGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYTNYPMYTFGQGTKVQIK,na,na,None,None,None,2013,2014,CD248/CD164L1,Ludwig Institute for Cancer Research;Morphotek;National Cancer Institute (USA),na,Colorectal cancer;Malignant melanoma;Soft tissue sarcoma,Lymphoma;Solid tumours,,,Chimeric and humanised,MORAb-004;MORAb004;MORAb-4;MORAb4;Ontecizumab
Onvatilimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSSYGWSYEFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIDTRLNWYQQKPGKAPKLLIYSASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSAYNPITFGQGTKVEIK,na,na,None,None,None,2017,2018,VSIR/VISTA/B7H5/PD1H/SISP1,Janssen Research & Development,na,na,Solid tumours,,,Genetically human,CI 8993;CI8993;CI-8993;JNJ 61610588;JNJ-61610588;JNJ61610588
Opamistomig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,TBC,TBC,EVQLQESGPGLVKPSQTLSLTCTVSGDSFSSGYWNWIRQHPGKGLEYIGYVSYTGSTYYIPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCAGYRDWLHGYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVMDNVAWYQQKPGKAPKRLIYSASYRFSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYNGYPLTFGQGTKLEIK,QVQLQESGGGLVQPGGSLRLSCAVSGFTFSSYAMHWVRQAPGKCLEWVAVISYDGSKKWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNQGSGSYLYYYYMDVWGKGTTVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQLPGKAPKVIIYEVSNRPSGVSNRFSGSKSGNTASLTISGVQSEDEADYYCSSYTSSSTFYVFGCGTQLTVL,None;None,None;None,None;None,2025,na,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,TBC,TBC,Humanised;Genetically human,TBC
Opelkibart,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMAIINPRDSDTRYRPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARHGRGYEGYEGAFDIWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQGIRSDLGWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANGFPLTFGGGTKVEIK,na,na,None,None,None,2023,2024,KIT/CD117,Heidelberg Pharma;Harvard University;Dianthus Therapeutics;Magenta Therapeutics,na,na,Acute myeloid leukaemia;Haemoglobinopathies;Lysosomal storage diseases;Myelodysplastic syndromes,,Trial discontinued due to patient death.,Genetically human,MGTA-117;MGTA 117;MGTA117;M-1224;M1224;M 1224
Opicinumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS,DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK,na,na,4oqt:HL,None,None,2015,2016,LINGO1,Biogen Idec;Dyax;Biogen,na,na,Multiple sclerosis;Optic neuritis,Dyax Human Phage Display,,Genetically human,BIIB-033;BIIB033;BIIB 033;BIIB-33;BIIB33;BIIB 33
Oportuzumab,scFv,na,Kappa,Preregistration,Discontinued,EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS,DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK,na,na,None,None,None,2008,2009,EPCAM/CD326,University of Zurich;National Cancer Institute (USA);Sesen Bio;Viventia Biotechnologies,na,na,Bladder cancer;Head and neck cancer;Liver cancer;Ovarian cancer,,ADC with monatox,Humanised,VB-4847;VB4847;VB 4847;VB-845;VB845;VB 845;VB4-845;VB4 845;Vicineum;Vysyneum
Opucolimab,Whole mAb,G1,Lambda,Phase-I,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYTMNWVRQAPGKGLEWVSSISSGSDYLYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNELRWYPQAGAFDRWGQGTMVTVSS,QSVVTQPPSMSAAPGQRVTISCSGSSSYIESSYVGWYQQLPGTAPRLLIYDDDMRPSGIPDRFSGSKSGTSATLAITGLQTGDEADYYCEIWRSGLGGVFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Shanghai Henlius Biotech,na,na,Solid tumours,,,Genetically human,HLX-20;HLX20;HLX 20
Opugotamig,Bispecific Mixed mAb and scFv ((G1_L-kappa)_scFvkh-G1(h-CH2-CH3)),G1;G1,Kappa;Kappa,Phase-I,Active,QVQLVQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFYNQKFQGKATLTVDKSSNTAHMELLSLTSEDFAVYYCTRYDGSRAMDYWGQGTTVTVSS,DIVLTQSPLSLAVSLGQPAIISCKASQSVSFAGTSLMHWYHQKPGQQPRLLIYRASNLEAGVPDRFSGSGSKTDFTLTISPVEAEDAATYYCQQSREYPYTFGGGTKLEIK,EVQLVQSGGGLVQPGGSRRLSCAASGFTFSSFGMHWVRQAPGKCLEWVAYISSGSSTISYADSVKGRFTISRDNSKKTLLLQMTSLRAEDTAMYYCAREAYGSSMEYWGQGTLVTVSS,EIVLTQSPATLSVTPGDRVSLSCRASQNINNNLHWYQQKPGQSPRLLIKYVSQSVSGIPDRFSGSGSGTDFTLSISSVEPEDEGMYFCQQSNSWPHYTFGCGTKLEIK,None;None,None;None,None;None,2024,2024,FOLR1;FOLR1,ImmunoGen,na,Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Non-small cell lung cancer,Breast cancer;Cervical cancer,,Humanised: musmus/homosap,Humanised,IMGN-151;IMGN151;IMGN 151
Ordesekimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKVSGYFFTTYWIGWVRQMPGKGLEYMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGGNWNCFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQRYGSSHTFGQGTKLEIS,na,na,None,None,None,2020,2021,IL15,Genmab;Immunex Corporation;Amgen;Cellimmune,na,Psoriasis;Inflammatory arthritis diseases;Celiac disease,na,,,Genetically human,AMG-714;AMG714;AMG 714;MAb146B7;PRV-015;PRV015;PRV 015;PRV-15;PRV15;PRV 15
Orilanolimab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAELKKPGASVKLSCKASGYTFTSYGISWVKQATGQGLEWIGEIYPRSGNTYYNEKFKGRATLTADKSTSTAYMELRSLRSEDSAVYFCARSTTVRPPGIWGTGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDHINNWLAWYQQKPGQAPRLLISGATSLETGVPSRFSGSGTGKDYTLTISSLQPEDFATYYCQQYWSTPYTFGGGTKVEIK,na,na,6nha:HL,None,None,2018,2019,FCGRT/FcRn,Syntimmune,na,na,Autoimmune haemolytic anaemia;Autoimmune disorders;Pemphigus,,Genetics: musmus/homosap,Chimeric and/or humanised,ALXN 1830;ALXN1830;ALXN-1830;SYNT-001;SYNT001;SYNT 001;SYNT-1;SYNT1;SYNT 1;SYNT1001;SYNT-1001;SYNT 1001
Ormutivimab,Whole mAb,G1,Lambda,Approved,NFD,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,None,8r3w:AA:RR/8r40:AA:RR,None,2021,2022,Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1,North China Pharmaceutical Company,Rabies,na,na,,,Genetically human,NM-57;NM57;NM 57;SO-57;SO57;SO 57;SOJB
Orticumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVSSISVGGHRTYYADSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARIRVGPSGGAFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNTNIGKNYVSWYQQLPGTAPKLLIYANSNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCASWDASLNGWVFGGGTKLTVL,na,na,None,None,None,2012,2013,OxLDL,Abcentra;BioInvent International;Genentech,na,Psoriasis,Atherosclerosis;Aortic valve stenosis,Human Phage Display,,Genetically human,2D03;BI-204;BI204;BI 204;MLDL-1278A;MLDL 1278A;MLDL1278A;RG-7418;RG7418;RG 7418
Osemitamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYNMNWVRQAPGQGLEWMGNIDPYYGGTSYNQKFKGRVTMTIDKSTSTVYMELSSLRSEDTAVYYCARMYHGNAFDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNLKNYLTWYQQKPGQPPKLLIYWASTRKSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPLTFGGGTKVEIK,na,na,None,None,None,2022,2022,CLDN18,Transcenta,na,Solid tumours,na,,,Humanised,TST-001;TST001;TST 001;TST-1;TST1;TST 1
Osocimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYGMDWVRQAPGKGLEWVSGIGPSGGSTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGPYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADSFPVTFGGGTKVEIK,na,na,None,6hhc:HL,None,2018,2019,F11,Bayer HealthCare,na,na,Arterial thrombosis;Venous thrombosis;Venous thromboembolism,,,Genetically human,BAY-121379;BAY121379;BAY 121379
Otelixizumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS,DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL,na,na,None,None,None,2007,2008,CD3E,BTG;GlaxoSmithKline;Tolerx,na,Type 1 diabetes mellitus,Graves ophthalmopathy;Multiple sclerosis;Myasthenia gravis;Psoriasis;Psoriatic arthritis;Rheumatoid arthritis,,,Chimeric and humanised,ChAglyCD3;GSK-2136525;GSK2136525;GSK 2136525;TRX4;TRX-4;TRX 4
Otilimab,Whole mAb,G1,Lambda,Phase-III,Discontinued,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVL,na,na,None,5c7x:MN:HL/5d7s:HL,5d72:MN:HL/5d71:HL,2018,2019,CSF2,GlaxoSmithKline;MorphoSys,na,na,Inflammation;Multiple sclerosis;Osteoarthritis;Rheumatoid arthritis,MorphoSys HuCAL Phage Display,,Genetically human,GSK-3196165;GSK3196165;GSK 3196165;GSK165;GSK-165;GSK 165;MOR-103;MOR 103;MOR103
Otlertuzumab,di-scFv+Fc,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK,na,na,None,None,None,2013,2014,CD37,Trubion Pharmaceuticals;Aptevo Therapeutics,na,na,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma,ADAPTIR Monospecific Platform,,Humanised,TRU-016;TRU016;TRU 016
Oturkibart,Whole mAb,G4,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGIDLRTNSMSWVRQAPGKGLEWVGIIGSSGYMDYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARHGDSSSFALWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVYKNNRLSWYQQKPGKAPKLLIYEASKVASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCAGAYRGNIYPFGQGTKVEIK,na,na,None,None,None,2025,na,IL4R/CD124,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Oxelumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2010,2011,TNFSF4/CD134/CD252/OX40L,Genentech;Genmab;Roche,na,na,Allergic asthma;Allergic rhinitis,,,Genetically human,RG 4930;RG4930;RG-4930;RO4989991;RO-4989991;RO 4989991
Ozanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS,DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK,na,na,None,None,None,2012,2013,RTN4/Nogo,GlaxoSmithKline,na,na,Amyotrophic lateral sclerosis;Multiple sclerosis,,,Humanised,GSK1223249;GSK 1223249;GSK-1223249
Ozekibart,VH-IgG,G1,na,Phase-I,Discontinued,EVQLLESGGGEVQPGGSLRLSCAASGLTFPNYGMGWFRQAPGKEREFVSAIYWSGGTVYYAESVKGRFTISRDNAKNTLYLQMSSLRAEDTAVYYCAVTIRGAATQTWKYDYWGQGTLVTVKPG,na,na,na,None,None,None,2023,2023,TNFRSF10B/CD262/DR5/TRAILR2,AstraZeneca,na,na,Solid tumours,,,Humanised,AZD 8853;AZD-8853;AZD8853
Ozoralizumab,Bispecific Single Domains (VH-VH'-VH),na;na,na;na,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,8z8m:B:D:F:H:J;8z8v:B,None;None,5m2j:D;None,2011,2012,TNF/TNFA;ALB,Ablynx;Eddingpharm;Pfizer;Taisho Pharmaceutical,Rheumatoid arthritis,na,Ankylosing spondylitis;Crohn's disease;Psoriatic arthritis,Nanobody Technology,,Humanised;Humanised,ATN-103;ATN103;ATN 103;PF-5230896;PF5230896;PF 5230896;TS-152;TS152;TS 152
Ozureprubart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWVRQAPGKGLEWVSVITYAGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGTHYFGHWHFAVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASQSVGDEADSYMNWYQQKPGKAPKLLIYAASYLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKLEIK,na,na,None,None,None,2024,2024,IGHE,Jemincare,na,Allergic asthma;Chronic urticaria;Asthma,na,,,Humanised,JYB-1904;JYB 1904;JYB1904;RPT-904;RPT 904;RPT904
Ozuriftamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTEYTMHWVRQAPGQGLEWMGGINTNNGGTGYNQKFKGRVTISADKSISTAYLQWSSLKASDTAMYYCAHGSLYSYGNSYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCSATSSVSYMHWYLQKPGQSPQLLIYGTSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQRSSYPFTFGQGTKVEIK,na,na,None,None,None,2022,2022,ROR2,BioAtla,na,Malignant Melanoma;Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,,Genetics: musmus/homosap,Chimeric and/or humanised,BA-3021;BA3021;BA 3021;BA302;BA302;BA 302HTBA-3021;HTBA3021;HTBA 3021
Pabinafusp,Whole mAb Fusion,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQWSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,TFRC/CD71,JCR Pharmaceuticals,Mucopolysaccharidosis II,na,na,,,na,IZCARGO;JR 141;JR141;JR-141;TAK-141;TAK141;TAK 141
Pacanalotamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQGLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Amgen,na,na,Multiple myeloma,BiTE Technology,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG-420;AMG420;AMG 420;BI 836909;BI-836909;BI 836909
Pacibekitug,Whole mAb,G2,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAIYGGSFREYYWSWIRQPPGKGLEWIGEIFHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREELDDFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYKSYPRTFGQGTKVEIK,na,na,None,None,None,2024,2024,IL6,Pfizer;Tourmaline Bio,na,Cardiovascular disorders;Graves ophthalmopathy;Kidney disorders,Crohn's disease;Rheumatoid arthritis;Systemic lupus erythematosus,,,Genetically human,PF-04236921;PF-4236921;PF 04236921;PF 4236921;PF04236921;PF4236921;TOUR-006;TOUR006;TOUR 006
Pacmilimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSSIWRNGIVTVYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKWSAAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDNGYPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDL1/CD274,CytomX Therapeutics,na,Solid tumours;Lymphoma,na,,,Genetically human,CX-072;CX072;CX 072
Palivizumab,Whole mAb,G1,Kappa,Approved,NFD,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK,na,na,None,2hwz:HL,None,1998,1999,Respiratory Syncytial Virus Glycoprotein F,MedImmune,Respiratory syncytial virus infections,na,na,GS Gene Expression System,Biosimilars available,Humanised,MEDI-493;MEDI493;MEDI 493;Synagis
Palverafusp,Fusion Protein,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK,na,na,5x8l:FK:HM:GL:JO:SN,5xxy:HL,None,2024,2024,VEGF,ImmuneOnco Biopharma,na,Solid tumours,na,,,Genetically human,IMM-2510;IMM2510;IMM 2510
Pamlectabart,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWISWVRQAPGKGLVWVGEINPSSSTINYAPSLKDKFTISRDNAKNTLYLQMNSLRAEDTAVYYCASLYYDYGDAYDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQSVESNVAWYQQKPGQAPRALIYSASLRFSGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNYPLTFGAGTKLELK,na,na,8qyb:HL,None,8qya:HL/8qy9:HL,2024,na,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Heidelberg Pharma AG,na,Multiple myeloma,na,,ADC with Tismanitin,Humanised,J22.9;HDP-101;HDP 101;HDP101;HDM-2027;HDM 2027;HDM2027
Pamrevlumab,Whole mAb,G1,Kappa,Phase-III,Active,EGQLVQSGGGLVHPGGSLRLSCAGSGFTFSSYGMHWVRQAPGKGLEWVSGIGTGGGTYSTDSVKGRFTISRDNAKNSLYLQMNSLRAEDMAVYYCARGDYYGSGSFFDCWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPPTFGQGTKLEIK,na,na,None,None,None,2015,2016,CTGF/CCN2,FibroGen,na,Duchenne muscular dystrophy;Idiopathic pulmonary fibrosis;Pancreatic cancer,Diabetic cardiomyopathy;Diabetic nephropathies;Diabetic neuropathies;Glioblastoma;Glomerulonephritis;Hepatic fibrosis,,,Genetically human,FG-3019;FG3019;FG 3019
Pamvatamig,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Discontinued,QVQLVQSGSELKKPGASVKVSCKASGYTFTTYSMNWVRQAPGQGLEWMGWINTYTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARETYFYDRGGYPFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNANTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAKDRHWHWWLDAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2023,2024,MET/HGFR;EGFR/ERBB1/HER1,Merus;Betta Pharmaceuticals Co Ltd,na,na,Non-small cell lung cancer; Solid tumours,,,Genetically human;Genetically human,MCLA 129;MCLA-129;MCLA129
Panitumumab,Whole mAb,G2,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK,na,na,5sx5:HL:JK/5sx4:HL:JI,None,None,2004,2005,EGFR/ERBB1/HER1,Amgen;Grupo Espanol Multidisciplinario del Cancer Digestivo;Netherlands Cancer Institute;Novartis;Takeda;University of Texas M. D. Anderson Cancer Center;Wissenschaftlicher Service Pharma,Colorectal cancer,Anal cancer;Bladder cancer;Breast cancer;Gastric cancer;Neuroendocrine tumours;Oesophageal cancer;Rectal cancer,Head and neck cancer;Malignant melanoma;Prostate cancer;Renal cell carcinoma;Solid tumours,Abgenix XenoMouse,,Genetically human,ABX-EGF;E7.6.3;Panitumab;Vectibix
Panobacumab,Whole mAb,M,Kappa,Phase-II,Active,EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK,na,na,None,None,None,2008,2009,Serotype IATS O11,Berna Biotech;Aridis Pharmaceuticals,na,Nosocomial pneumonia,na,,,Genetically human,KBPA-101;KBPA 101;KBPA101;AERUMAB 11;AR 101;AR-101;AR101
Paridiprubart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSDTLSLTCAVSGYSITGGYSWHWIRQPPGKGLEWMGYIHYSGYTDFNPSLKTRITISRDTSKNQFSLKLSSVTAVDTAVYYCARKDPSDAFPYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQSISDHLHWYQQKPDQSPKLLIKYASHAISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQGHSFPLTFGGGTKVEIK,na,na,4r7d:AB:CD:EF:GH:IJ:MN:OP,None,4r7n:AB:CD:EF:GH:IJ:MN:OP:QR:ST,2022,2022,TLR4/CD284,Edesa Biotech,na,COVID-19,na,,,Humanised,EB 05;EB05;EB-05;EB 5;EB-5;EB5;EB-07;EB07;EB-07;EB-7;EB7;EB 7;NI-0101;NI 0101;NI0101;NI-101;NI101;NI 101
Parsatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,EGFL7,Chugai Pharmaceutical;Genentech,na,na,Colorectal cancer;Non-small cell lung cancer;Solid tumours,,,Humanised,M-444A;M 444A;M444A;M0444A;MEGF-0444A;MEGF 0444A; MEGF0444A;RG-7414;RG7414;RG 7414;RO-5490248;RO5490248;RO 5490248
Pasotuxizumab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYRYSDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2014,2015,FOLH1/GCPII/PSMA;CD3E,Amgen;Bayer HealthCare Pharmaceuticals;Micromet Inc,na,na,Prostate cancer,,,Chimeric and humanised;Chimeric and humanised,AMG-212;AMG212;AMG 212;BAY-2010112;BAY2010112;BAY 2010112;MT-112;MT112;MT 112
Pasritamig,Bispecific Mixed Domains ((H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3)),G1;G1,Kappa;Kappa,Phase-I,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGTTIFGVVTPNFYYGMDVWGQGTTVTVSS,DIQMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKFLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPLTFGGGTKVEIK,EVQLVESGGGLVKPGGSLRLSCAASGFTFSRYNMNWVRQAPGKGLEWVSSISTSSNYIYYADSVKGRFTFSRDNAKNSLDLQMSGLRAEDTAIYYCTRGWGPFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRARQSIGTAIHWYQQKPGKAPKLLIKYASESISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSGSWPYTFGQGTKLEIK,None;None,None;None,None;None,2024,na,KLK2/KLK2A2/hGK-1/hK2;CD3E,Janssen Research & Development;Zymeworks,na,Prostate cancer,na,,,Genetically human;Humanised,JNJ-78278343;JNJ 78278343;JNJ78278343
Patecibart,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVTLKESGPTLVKPTQTLTLTCTFSGFSLTTSGLGVAWIRQPPGKALEWLAHIWSDGDTRYYPALKNRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHMKDDSLYFDNWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQNIGTSIHWYQQKPDQYPKLLIKYASKSISGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQHSYSFPWTFGQGTKVEIK,na,na,None,None,None,2023,2023,EDNRA,Gmax Biopharm,na,na,Pulmonary arterial hypertension,,,Humanised,GMA-301;GMA301;GMA 301;Getagozumab
Pateclizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYVIHWVRQAPGKGLEWVGYNNPYNAGTNYNEKFKGRFTISSDKSKNTAYLQMNSLRAEDTAVYYCSRPTMLPWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQAVSSAVAWYQQKPGKAPKLLIYSASHRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQESYSTPWTFGQGTKVEIK,na,na,4mxv:HL:YX:FE/4mxw:HL:WV,None,None,2011,2012,LTA,Genentech,na,na,Rheumatoid arthritis,,,Humanised,MLTA3698A;MLTA-3698A;MLTA 3698A;PRO283698;PRO-283698;PRO 283698;RG7416;RG-7416;RG 7416
Patritumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS,DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,ERBB3/HER3,Amgen;U3 Pharma;Daiichi Sankyo Company,na,na,Breast cancer;Solid tumours;Non-small cell lung cancer;Head and neck cancer,,,Genetically human,AMG-888;AMG888;AMG 888;U3-1287;U3 1287
Pavurutamab,Bispecific scFv,na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGYINPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDGYYRDTDVLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSGSGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Amgen,na,na,Multiple myeloma,BiTE Technology,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG 701;AMG-701;AMG701
Pegrizeprument,Fab (VH-G1CH1h_L-kappa),G1,Kappa,TBC,Active,QVQLQQSGAELKKPGASVKVSCKASGYTFTEYIIHWIKLRSGQGLEWIGWFYPGSNDIQYNAQFKGKATLTADKSSSTVYMELTGLTPEDSAVYFCARRDDFSGYDALPYWGQGTLVTVSA,DIQMTQSPSSLSASVGDRVTITCKTNENIYSNLAWYQQKDGKSPQLLIYAATHLVEGVPSRFSGSGSGTQYSLTISSLQPEDFGNYYCQHFWGTPCTFGGGTKLEIK,na,na,None,None,None,2024,2024,CD28,TBC,TBC,TBC,TBC,,Humanised: musmus/homosap,Humanised,TBC
Pelgifatamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFAFSRYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTQYLQMNSLRAEDTAVYYCARGGDFLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKTGKVPKFLIYEASTLQSGVPSRFSGGGSGTDFTLTISSLQPEDVATYYCQNYNSAPFTFGPGTKVDIK,na,na,None,None,None,2020,2021,FOLH1/GCPII/PSMA,Bayer,na,na,Prostate cancer;Metastatic cancers,,ADC with corixetan,Genetically human,BAY-2315497;BAY2315497;BAY 2315497
Peluntamig,Bispecific Whole mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNIDPSDSETHYAQKFQGRVTLTVDKSTSTVYMELSSLRSEDTAVYYCAGTDLAYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCHASQNINVWLSWYQQKPGQAPRLLIYKASNLHTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGQSYPFTFGQGTKVEIK,EVRLSQSGGQMKKPGESMRLSCRASGYTFTSYVMHWVRQAPGRRPEWIGYINPYNDATKYARKFQGRATLTSDKYSDTAFLELRSLTSDDTAVYYCARGGYDYDGDYWGRGAPVTVSS,EIVLTQSPGTLSLSPGERATLSCHASQNINVWLSWYQQKPGQAPRLLIYKASNLHTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGQSYPFTFGQGTKVEIK,None;None,None;None,None;None,2024,na,IAP/CD47;DLL3,Phanes Therapeutics,na,Neuroendocrine carcinoma;Small cell lung cancer,na,,,Genetically human;Humanised,PT-217;PT 217;PT217
Pembrolizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK,na,na,5dk3:GF:BA/5ggs:CD:AB/5b8c:BA:HG:KJ:ED/5jxe:GF:DC/8sjk:BA,None,None,2013,2014,PDCD1/CD279/PD1,Aduro BioTech;AIO Studien gGmbH;Amgen;Augusta University;Bayer;BerGenBio;Big Ten Cancer Research Consortium;BioLineRx;Canadian Cancer Trials Group;Celgene Corporation;Columbia University;Dana-Farber Cancer Institute;DNAtrix;Duke University;Eisai Co Ltd;Eli Lilly;Emory University;Fox Chase Cancer Center;Genexine;Gilead Sciences;H. Lee Moffitt Cancer Center and Research Institute;Hoosier Cancer Research Network;Icahn School of Medicine at Mount Sinai;ImmunoGen;Incyte Corporation;Institut fuer Frauengesundheit;Institute of Cancer Research;M. D. Anderson Cancer Center;Massachusetts General Hospital;Mayo Clinic;Memorial Sloan-Kettering Cancer Center;Merck & Co;Merck Sharp & Dohme;National Cancer Center Hospital East;National Cancer Institute (France);National Cancer Institute (USA);Netherlands Cancer Institute;Northwestern University;NYU Langone Medical Center;Oslo University Hospital;Plexxikon;Providence Health & Services;Royal Marsden NHS Foundation Trust;Sarcoma Alliance for Research through Collaboration;Sellas Life Sciences Group;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Spanish Breast Cancer Research Group;Syndax Pharmaceuticals;TG Therapeutics Inc;University Health Network;University of Alabama;University of Birmingham;University of California at Los Angeles;University of California at San Francisco;University of California San Diego;University of Colorado at Denver;University of Miami;University of Pittsburgh;University of Utah;University of Washington;Verastem Oncology;Wakayama Medical University;Washington University School of Medicine;Yale University;The Leukemia & Lymphoma Society,Cervical cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Hodgkin's disease;Liver cancer;Malignant melanoma;Non-small cell lung cancer;Pancreatic cancer;Solid tumours;Urogenital cancer;Cancer;Merkel cell carcinoma;Renal cell carcinoma,Small cell lung cancer;Bladder cancer;Breast cancer;Endometrial cancer;Fallopian tube cancer;Gastrointestinal cancer;Mesothelioma;Multiple myeloma;Nasopharyngeal cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Squamous cell cancer;Acute myeloid leukaemia;Adenoid cystic carcinoma;Bone cancer;Brain metastases;Cholangiocarcinoma;Follicular lymphoma;Germ cell and embryonal neoplasms;Glioblastoma;Glioma;Inflammatory breast cancer;Liver metastases;Lymphoma;Meningioma;Myelodysplastic syndromes;Neuroendocrine tumours;Non-Hodgkin's lymphoma;Osteosarcoma;Penile cancer;Rectal cancer;Recurrent respiratory papillomatosis;Sarcoma;Soft tissue sarcoma;Thymoma;Thyroid cancer;Uveal melanoma;Chronic lymphocytic leukaemia;Haematological malignancies;Leiomyosarcoma;Mantle-cell lymphoma;Precursor cell lymphoblastic leukaemia-lymphoma;T-cell lymphoma;Gliosarcoma;Human papillomavirus infections,na,,Pembrolizumab is the new name for Lambrolizumab (PL110),Humanised,MK-3475;MK3475;MK 3475;Keytruda;Lambrolizumab;SCH-900475;SCH900475;SCH 900475
Pemivibart,Whole mAb,G1,Lambda,Approved,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFGSYEMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFGGDTAWAGTGFTYWGQGTLVTVSS,QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNYGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSDLSGLYTFGTGTKVTVL,na,na,None,None,7u2d:HL,2023,2024,SARS-CoV-2 Spike RBD,Invivyd,COVID-19,na,na,,Aug '24: Entry modified as per PL131,Genetically human,VYD222;VYD-222;VYD 222
Penpulimab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSS,DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Akeso Biopharma;Chia Tai Tianqing Pharmaceutical,Hodgkin's disease,Non-small cell lung cancer;Cholangiocarcinoma;Colorectal cancer;Gastric cancer;Head and neck cancer;Liver cancer;Nasopharyngeal cancer;Neuroendocrine tumours;Urogenital cancer;Solid tumours,,,Genetics: musmus/homosap. Cugrastomig Fv2; Ivonescimab Fv2 and Penpulimab have the same sequences.,Chimeric and/or humanised,AK 105;AK105;AK 105
Pepinemab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYSFSDYYMHWVRQAPGQGLEWMGQINPTTGGASYNQKFKGKATITVDKSTSTAYMELSSLRSEDTAVYYCARYYYGRHFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPYTFGQGTKLEIK,na,na,None,None,None,2018,2019,SEMA4D/CD100,Bristol-Myers Squibb;Children's Oncology Group;Emory University;Merck KGaA;National Cancer Institute (USA);Teva Pharmaceutical Industries;UCLAs Jonsson Comprehensive Cancer Center;Vaccinex,na,Huntington's disease;Non-small cell lung cancer;Osteosarcoma;Solid tumours;Colorectal cancer;Head and neck cancer;Malignant melanoma;Pancreatic cancer,Multiple sclerosis,,Genetics: musmus/homosap,Chimeric and/or humanised,VX15/2503;VX 15;VX-15;VX 15;VX 15/2503;VX-15/2503
Perakizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYTMLWVRQAPGKGLEWVAIIKSGGSYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDGDYGSSYGAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKSLIVRANRLVDGVPSRFSGSGSGQDYSLTISSLQPEDFATYYCLQYDAFPPYTFGQGTKLEIK,na,na,None,None,None,2012,2013,IL17A,Roche,na,na,Psoriatic arthritis,,,Humanised,RG 4934;RG4934;RG 4934;RO 5310074;RO5310074;RO-5310074
Perenostobart,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSEGISWVRQAPGQGLEWMGSILPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAGYYRYRYFDLWGRGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQHALWPLTFGGGTKVEIK,na,na,None,None,None,2022,2023,ENTPD1/CD39,Surface Oncology;Arcus Biosciences,na,na,Prostate cancers,,,Genetically human,SRF 617;SRF617;SRF-617
Peresolimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKVSGYSLSKYDMSWVRQAPGKGLEWMGIIYTSGYTDYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGNPYYTNGFNSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQSPNNLLAWYQQKPGKAPKLLIYGASDLPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNNYYVGPVSYAFGGGTKVEIK,na,na,None,None,None,2022,2022,PDCD1/CD279/PD1,Eli Lilly,na,Rheumatoid arthritis;Plaque Psoriasis,na,,June '22: Corrected CDRH3 sequence,Humanised,LY-3462817;LY3462817;LY 3462817
Pertuzumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,na,na,1l7i:HL/4llu:AB:CD/1s78:FE:DC/6oge:CB/8q6j:DC/8pwh:DC,4llw:CD:AB/9l1s:CB,5vsh:CD:EF:AB:HL/4lly:AB:CD,2003,2004,ERBB2/CD340/HER2,Chugai Pharmaceutical;Dana-Farber Cancer Institute;FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO;Genentech;International Breast Cancer Study Group;Japan Breast Cancer Research Group;Medica Scientia Innovation Research;Roche;West German Study Group,Breast cancer,Ovarian cancer;Brain metastases;Colorectal cancer,Gastric cancer;Non-small cell lung cancer;Prostate cancer,,Biosimilars available,Humanised,R-1273;R1273;R 1273;RG-1273;RG 1273;RG1273;RO-4368451;RO4368451;RO 4368451
Petosemtamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLVQSGSELKKPGASVKISCKASGYDFTNYAMNWVRQAPGHGLEWMGWINANTGDPTYAQGFTGRFVFSLDTSVSTAYLQISSLKAEDSAVYYCTRERFLEWLHFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,EVQLVQSGSKLKKPGASVKVSCKASGYTFTSYTMNWVRQAPGQGLEWMGWINTDTGDPTYAQGFTGRFVFSLDTSVSTAFLQINSLKAEDTAVYYCARGDCDSTSCYRYSYGYEDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2019,2020,EGFR/ERBB1/HER1;LGR5,Merus,na,na,Colorectal cancer;Solid tumours,,,Genetically human;Genetically human,MCLA 158;MCLA-158;MCLA158
Pexelizumab,scFv,na,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQRKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2002,2002,C5,Stanford University,na,na,Myocardial infarction;Reperfusion injury,,Same VH as eculizumab,Humanised,5G1.1
Picankibart,Whole mAb,G1,Kappa,Preregistration,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYLMHWVRQAPGQGLEWMGYINPYNEGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARNWDLPYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISDYLHWYQQKPGKAPKLLIKYASQSMSGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQGHSFPFTFGQGTKLEIK,na,na,None,None,None,2023,2023,IL23A,Innovent Biologics,na,Plaque psoriasis;Ulcerative colitis;Autoimmune disorders;Gastrointestinal disorders,na,,,Humanised,IBI-112;IBI112;IBI 112
Pidilizumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKISCKASGYTFTNYGMNWVRQAPGQGLQWMGWINTDSGESTYAEEFKGRFVFSLDTSVNTAYLQITSLTAEDTGMYFCVRVGYDALDYWGQGTLVTVSS,EIVLTQSPSSLSASVGDRVTITCSARSSVSYMHWFQQKPGKAPKLWIYRTSNLASGVPSRFSGSGSGTSYCLTINSLQPEDFATYYCQQRSSFPLTFGGGTKLEIK,na,na,None,None,None,2012,2013,PDCD1/CD279/PD1,American Cancer Society;Beth Israel Deaconess Medical Center;CureTech;Georgia Regents University;Hadassah Medical Organization;Northwestern University;The Ohio State University Comprehensive Cancer Center;University of Texas M. D. Anderson Cancer Center,na,Acute myeloid leukaemia;Colorectal cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Malignant melanoma;Multiple myeloma;Pancreatic cancer;Prostate cancer;Renal cell carcinoma;Glioma;Hepatitis C;Liver cancer,na,,,Humanised,CT-011;CT011;CT 011;CT-11;CT11;CT 11;MDV 9300;MDV-9300;MDV9300
Pimivalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFPSYYMHWVRQAPGQGLEWMGIINPEGGSTAYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGTYYDYTYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYEASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSFPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Jounce Therapeutics,na,Solid tumours;Non-small cell lung cancer,na,,,Genetically human,JTX-4014;JTX4014;JTX4014
Pimurutamab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFSLTNYGVHWVRQAPGKGLEWLGVIWSGGNTDYGNEFTSRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARALDYYDYEFAYWGQGTMVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQNNNWPTSFGGGTKVEIK,na,na,None,None,None,2019,2020,EGFR/ERBB1/HER1,Shanghai Henlius Biotech,na,Solid tumours,na,,June '22: Corrected FWH2 sequence. Biobetter available,Humanised,HLX 07;HLX-07;HLX07;HLX-7;HLX7;HLX 7
Pinatuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYEFSRSWMNWVRQAPGKGLEWVGRIYPGDGDTNYSGKFKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDGSSWDWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSIVHSVGNTFLEWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCFQGSQFPYTFGQGTKVEIK,na,na,None,6and:HL,None,2012,2013,SIGLEC2/CD22,Genentech,na,na,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma,,ADC with vedotin,Humanised,DCDT-2980S;DCDT29080S;DCDT 29080S;FCU-2703;FCU2703;FCU 2703;RG-7593;RG7593;RG 7593;RO-5541072;RO5541073;RO 5541073
Pivekimab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYNDGTKYNEKFKGRATLTSDRSTSTAYMELSSLRSEDTAVYYCAREGGNDYYDTMDYWGQGTLVTVSS,EIQMTQSPSSLSASVGDRVTITCRASQDINSYLSWFQQKPGKAPKTLIYRVNRLVDGVPSRFSGSGSGNDYTLTISSLQPEDFATYYCLQYDAFPYTFGQGTKVEIK,na,na,None,None,None,2021,2022,IL3RA/CD123,ImmunoGen,na,Acute myeloid leukaemia;Blastic plasmacytoid dendritic cell neoplasm,na,,ADC with sunirine. Genetics: musmus/homosap,Chimeric and/or humanised,IMGN-632;IMGN632;IMGN 632
Placulumab,Single Domain Variable Fragment (VL) + Fc,G1,Kappa,Phase-II,Discontinued,na,DIQMTQSPSSLSASVGDRVTITCRASQAIDSYLHWYQQKPGKAPKLLIYSASNLETGVPSRFSGSGSGTDFTLTISSLLPEDFATYYCQQVVWRPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,TNF/TNFA,Domantis;Peptech;Arana Therapeutics;Teva Pharmaceutical Industries,na,na,Inflammation;Psoriasis;Rheumatoid arthritis;Sciatica,,,Genetically human,ART-621;ART621;ART 621;CEP-37247;CEP37247;CEP 37247;PN-0621;PN0621;PN 0621;PN-621;PN 621;PN621
Plamotamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGAIYPGNGDTSYNQKFQGRVTITADKSISTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGAGTLVTVSS,QIVLTQSPSSLSASVGDRVTITCRASSSVSYIHWFQQKPGKSPKPLIYATSNLASGVPVRFSGSGSGTDYTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,MS4A1/CD20;CD3E,Xencor,na,B-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma,na,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,XmAb 13676;XmAb-13676;XmAb13676
Plonmarlimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSHYLHWVRQAPGQGLEWMGWIFPGDDKTKYNEKFKGRVTMTSDTSISTAYMELSRLRSDDTAVYYCARGTKYLNWNFDVWGQGTTVTVSS,DIQLTQSPSFLSASVGDRVTITCKANQNVGTTLAWYQQKPGKSPKALIYSASYRYSGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCHQYTTYPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,CSF2,I-Mab Biopharma,na,Rheumatoid arthritis;COVID-19;Osteoarthritis,na,,June '22: Corrected FWL4 sequence,Humanised,TJ 003234;TJ-003234;TJ003234;TJ3234;TJ-3234;TJ 3234;TJM-2;TJM2;TJM 2
Plozalizumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSAYAMNWVRQAPGKGLEWVGRIRTKNNNYATYYADSVKDRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTFYGNGVWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLDSDGKTFLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPYTFGQGTRLEIK,na,na,None,None,None,2015,2016,CCR2/CD192,Millennium;Millennium Pharmaceuticals;Takeda;Takeda Oncology,na,Atherosclerosis;Diabetic nephropathies;Malignant melanoma,Multiple sclerosis;Rheumatoid arthritis;Scleroderma;Solid tumours,,ADC with plevistinag,Humanised by CDR Grafting,MLN-1202;MLN1202;MLN 1202;TAK-202;TAK202;TAK 202
Podentamig1,Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl); Bispecific entry,na;na,na;na,Phase-I,Active,EVQLVESGGGLVQPGRSLTLSCAASTNIFSISPYGWYRQAPGKQRELVAAIHGTSTLYADSVKGRFTISRDNAKNSIYLQMNSLRPEDTALYYCNKVPWGDYHPGNVYWGQGTQVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSKFGMSWVRQAPGKGLEWVSSISGSGRDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSVSSQGTLVTVSS,na,None;None,None;None,None;8z8v:B,2024,2024,TNFRSF17/BCM/BCMA/CD269/TNFRSF13A;ALB,Harpoon Therapeutics,na,Multiple myeloma,na,,Humanised VH1: vicpac/homosap. Godatamig VH2 and Podentamig VH2 have the same sequence,Humanised;Genetically human,HPN-217;HPN 217;HPN217
Podentamig2,Trispecific Mixed scFv and Single Domains (VH-VH'-scFvhl); Monospecific entry,na,Lambda,Phase-I,Active,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAINWVRQAPGKGLEWVARIRSKYNNYATYYADQVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHANFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCASSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLVPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCTLWYSNRWVFGGGTKLTVL,na,na,None,None,None,2024,2024,CD3E,Harpoon Therapeutics,na,Multiple myeloma,na,,Humanised VH: vicpac/homosap. Godatamig Fv1 and Podentamig Fv1 have the same sequence,Humanised,HPN-217;HPN 217;HPN217
Polatuzumab,Whole mAb ADC,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIK,na,na,None,None,None,2012,2013,AGM6/CD79B,Chugai Pharmaceutical;Genentech;Roche,Diffuse large B cell lymphoma,Non-Hodgkin's lymphoma;Follicular lymphoma,Chronic lymphocytic leukaemia,,ADC with vedotin,Humanised,DCDS-4501A;DCDS4501A;DCDS 4501A;FCU-2711;FCU2711;FCU 2711;Polivy;RG-7596;RG7596;RG 7596;RO-5541077;RO5541077;RO 5541077
Polzastobart,Whole mAb,G4,Kappa,Phase-I/II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLNTYAMGVSWIRQPPGKALEWLASIWWNGNKYNNPSLKSRLTVTKDTSKNQVVLTMTNMDPVDTATYYCAHSRIIRFTDYVMDAWGQGTLVTVSS,DIQMTQSPSSLSTSVGDRVTITCRASEDIYNDLAWYQQKPGKAPKLLIYNANSLHTGVASRFSGSGSGTDFTFTISSLQPEDVATYFCQQYYDYPLTFGQGTKLEIK,na,na,None,None,None,2022,2023,LILRB2,Jounce Therapeutics,na,Cancers,na,,,Humanised,JTX-8064;JTX8064;JTX 8064
Ponezumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYYTEAYYIHWVRQAPGQGLEWMGRIDPATGNTKYAPRLQDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCASLYSLPVYWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYSDAKTYLNWFQQRPGQSPRRLIYQISRLDPGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHYPVLFGQGTRLEIK,na,na,3u0t:BA:DC,None,None,2010,2011,APP,Rinat Neuroscience;Pfizer,na,na,Alzheimer's disease;Cerebral amyloid angiopathy,,,Humanised,PF-04360365;PF04360365;PF-4360365;PF4360365;RN 1219;RN-1219;RN1219
Ponsegromab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYNIDWVRQAPGQGLEWMGGINPIFGTAFYNQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCAREAITTVGAMDHWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRTSQSVHNYLAWYQQKPGQAPRLLIYDASTRADGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQFWSWPWTFGQGTKVEIK,na,na,None,None,None,2020,2021,GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB,Pfizer,na,na,Cachexia,,,Genetically human,PF 06946860;PF-06946860;PF06946860;PF 6946860;PF-6946860;PF6946860
Porustobart,VH-CH2-CH3,G1,na,Phase-II,Active,EVQLVESGGGLIQPGGSLRLSCAVSGFTVSKNYMSWVRQAPGKGLEWVSVVYSGGSKTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAVPHSPSSFDIWGQGTMVTVSS,na,na,na,7dv4:H:B:D:F,None,None,2022,2023,CTLA4/CD152,Harbour Biomed,na,Solid tumours,na,,,Genetically human,HBM-4003;HBM4033;HBM 4033;HCAb-4003-2
Posnafusp,Fab Fusion Protein,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFMNYWLGWVRQMPGKGLEWMGDIYPGGDYPTYSEKFKVQVTISADKSISTAYLQLSSLKASDTAMYYCARSGNYDEVAYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,None,None,2024,na,TFRC/CD71,JCR Pharmaceuticals,na,Mucopolysaccharidosis III,na,,,Humanised,JR-441; JR 441; JR441
Posdinemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISKGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGWGDYGWFAYWGQVTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDINRYLNWFQQKPGKAPKSLIYRANRLLDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQYDEFPLTFGQGTKLEIK,na,na,None,None,None,2022,2022,MAPT,Janssen Research & Development,na,Alzheimer's disease;Dementia,na,,,Humanised,JNJ-63733657;JNJ 63733657;JNJ63733657;JNJ-3657;JNJ3657;JNJ 3657
Potravitug,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLQQWGAGLLKPSETLSLTCAVYRGSFSAYYWTWFRQPPGKGLEWIGEINHRGYTNYNPSLRGRVSISVDTSKKQFSLKLRSVNAADTAVYYCATLRSTSGWHDYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQTPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFVVYFCLQYGSSPLTFGPGTKVDIK,na,na,None,None,None,2025,na,BK polyomavirus VP1,Memo Therapeutics,na,Polyomavirus infections,na,,,Genetically human,MTX-005;MTX 005;MTX005
Pozelimab,Whole mAb,G4,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGDSVSSSYWTWIRQPPGKGLEWIGYIYYSGSSNYNPSLKSRATISVDTSKNQFSLKLSSVTAADTAVYYCAREGNVDTTMIFDYWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFAGRGSGTDFTLTISSLQPEDFATYYCLQDFNYPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,C5,Alnylam Pharmaceuticals;Regeneron Pharmaceuticals,Protein-losing enteropathy,Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria;Gastrointestinal disorders,na,,,Genetically human,REGN 3918;REGN3918;REGN 3918
Plutavimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSIIYPGGSTEYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCARELGYYGMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISTWLVWYQQKPGKAPNLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANAYPYTFGQGTKLEIK,na,na,None,None,None,2022,2022,SARS-CoV-2 Spike RBD,Sorrento Therapeutics,na,COVID-19,na,,,Genetically human,COVI-AMG;STI-2020;STI2020;STI 2020
Porgaviximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS,DIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK,na,na,None,5kel:HL:PT:QU,None,2016,2017,Zaire Ebolavirus Glycoprotein,Mapp Biopharmaceutical;Public Health Agency of Canada;National Institute of Allergy and Infectious Diseases,na,na,Ebola virus infections ,Zmapp Technology,,Chimeric,c2G4-N;Zmapp
Pradusinstobart,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGTCVSWIRQPPGKALEWLATICWEDSKGYNPSLKSRLTISKDTSKNQAVLTMTNMDPVDTATYYCARREDSGYFWFPYWGQGTLVTVSS,NIQMTQSPSSLSASVGDRVTITCKAGQNVNNYLAWYQQKPGKAPKVLIFNANSLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSWTTFGGGTKVEIK,na,na,None,None,None,2022,2023,PDCD1/CD279/PD1,MD Anderson Cancer Center;Lyvgen Biopharma,na,na,Gastric cancers;Head and neck cancers;Esophageal cancers;Hepatocellular cancers;Metastatic cancers,,,Humanised,LVGN-3616;LVGN3616;LVGN 3616
Prafnosbart,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGSTFSNYGMKWIRQAPGKGLEWVSSISRSSTYIYYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAAAISTPFYWYFDFWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCLASSSVSYMTWYQQKPGQSPRLWIYGTSNLASGVPDRFSGSGSGTDFLTLTIRLEPEDFAVYYCLHLTSYPPYTFGQGTKVEIK,na,na,None,None,None,2022,2023,ACVR1,Daiichi Sankyo,na,na,Fibrodysplasia ossificans prograssiva,,,Humanised,DS-6016A;DS6016A;DS 6016A
Praluzatamab,Whole mAb,G1,Kappa,Phase-II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTYGMGVGWIRQPPGKALEWLANIWWSEDKHYSPSLKSRLTITKDTSKNQVVLTITNVDPVDTATYYCVQIDYGNDYAFTYWGQGTLVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,ALCAM/CD166,CytomX Therapeutics;Immunogen,na,Solid tumours,na,,ADC with ravtansine,Humanised,CX-2009;CX2009;CX 2009
Prasinezumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASISSGGGSTYYPDNVKGRFTISRDDAKNSLYLQMNSLRAEDTAVYYCARGGAGIDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSIQTLLYSSNQKNYLAWFQQKPGKAPKLLIYWASIRKSGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQYYSYPLTFGGGTKLEIK,na,na,None,None,None,2017,2018,SNCA/PARK1/PARK4,Neotope Biosciences;Chugai Pharmaceutical;Prothena;Roche,na,Parkinson's disease,na,,,Humanised,NEOD-002;NEOD002;NEOD 002;NEOD-2;NEOD2;NEOD 2;PRX-002;PRX002;PRX 002;PRX-2;PRX2;PRX 2;RG 7935;RG7935;RG-7935;RO 7046015;RO-7046015;RO7046015
Precemtabart,Whole mAb,G1,Kappa,Phase-I,Active,EVQLQESGPGLVKPSQTLSLTCTVSDGSVSRGGYYLTWIRQHPGKGLEWIGYIYYSGSTYFNPSLRSRVTMSVDTSKNQFSLKLSSVTAADTAVYYCARGIAVAPFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRTSQSVRSNLAWYQQKPGQAPRLLIYAASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYTNWPFTFGPGTKVDIK,na,na,None,None,None,2024,2024,CEACAM5/CD66e,Merck KGaA;EMD Serono Research & Development Institute,na,Colorectal cancer,na,,,Genetically human,M9140;M-9140;M 9140
Prezalumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,6x4t:BE:DF,None,None,2015,2016,ICOSLG,Amgen;MedImmune,na,na,Cutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus,,May have had a former name of Prezalizumab,Genetically human,AMG-557;AMG557;AMG 557;B7RP-1;MEDI-5872;MEDI 5872;MEDI5872
Pritoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGAELVRSGASVRMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGGTNYIQKFKGKAILTADTSSSTAYMQISSLTSEDSAVYFCTRSPSHYSSDPYFDYWGQGTTLTVSS,DIVMSQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQNPGQSPKFLIYWASTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYPLTFGAGTSLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 1,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,,,Chimeric,caStx1;Shigamabs (Combination with Setoxaximab)
Pritumumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGDLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAITPSGGSTNYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVYICGRVPYRSTWYPLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYAASSLHSKVPTQFSGSGSGTDFTLTISSLQPEDFATYYCLQYSTYPITFGGGTKVEIK,na,na,None,None,None,2003,2004,VIM,UCSD;Nascent Biotech,na,Glioma;Breast cancer;COVID-19,Pancreatic cancer,,,Genetically human,ACA 11;ACA-11;ACA11;CLNH 11;CLNH11;CLNH-11
Produvofusp,Nanobody Fusion Protein,na,na,TBC,Active,QVQLVESGGGLVKPGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVSAISGSGGSTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAADLGDGSWVDYVNAEPYEYDYWGQGTLVTVSS,na,na,na,None,None,None,2024,na,TBC,TBC,TBC,TBC,TBC,TBC,Humanised from Llama (CDRs entirely Llama). Specificity of nanobody not clear from INN entry.,Chimeric and humanised,TBC
Prolgolimab,Whole mAb,G1,Lambda,Approved,Active,QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQVPGKGLEWVSAIDTGGGRTYYADSVKGRFAISRVNAKNTMYLQMNSLRAEDTAVYYCARDEGGGTGWGVLKDWPYGLDAWGQGTLVTVSS,QPVLTQPLSVSVALGQTARITCGGNNIGSKNVHWYQQKPGQAPVLVIYRDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQVWDSSTAVFGTGTKLTVL,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,Biocad,Malignant melanoma,Cervical cancer;Non-small cell lung cancer;Hodgkin's disease,Solid tumours,,Genetics: vicpac/homosap,Chimeric and/or humanised,BCD-100
Pucotenlimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVQSGGGLVQPGGSLKLSCAASGFTFSSYGMSWVRQAPGKGLDWVATISGGGRDTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCARQKGEAWFAYWGQGTLVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNKGTGVPARFSGSGSGTDFTLNINPMEENDTAMYFCQQSKEVPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Taizhou Hanzhong Pharmaceuticals,Solid tumours,Gastrointestinal cancer;Malignant Melanoma;Non-small cell lung cancer;Bladder cancer;Breast cancer;Liver cancer,na,,Genetics: musmus/homosap,Chimeric and/or humanised,HX-008;HX008;HX 008;HX-8;HX8;HX 8;Puyouheng
Pulocimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGLDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,None,3s34:HL/3s37:HL/3s36:HL,None,2021,2022,KDR/CD309/VEGFR2,Akeso Biopharma,na,Solid tumours,na,,,Genetically human,AK-109; AK109;AK 109
Pumitamig1,Bispec Mixed Domains (Fv entry),G1,Kappa,TBC,TBC,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1bj1:HL:KJ/7v5n:BA:FE,None,6bft:AB:HL/1cz8:HL:YX,2025,na,VEGFA,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Pumitamig2,Bispec Mixed Domains (Single domain entry;H),na,na,TBC,TBC,EVQLQESGGGLVQPGGSLRLSCAASGFTFSSYWMYWLRQAPGKGLEWVSSINSDSSSTYYRDSVKGRFTISRDNAKNTLYLQMNSLKSEDTAVYYCAKDPGGYAKGQGTQVTVSS,na,na,na,7czd:A:C,None,None,2025,na,PDL1/CD274,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Puxitatug,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLQQWGAGLLKPSETLSLACTVYGGSFSGYYWNWIRQPPGKGLEWIGEINHSGSTSYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVLYNWNVDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIRNDVGWYQQKPGKAPKRLIYAASRLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTKVEIK,na,na,None,None,None,2023,2023,VTCN1/B7H4,AstraZeneca,na,Solid tumours,na,,ADC with samrotecan,Genetically human,AZD-8205; AZD 8205; AZD8205
Quavonlimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDNWMNWVRQAPGKGLEWLAQIRNKPYNYETYYSASVKGRFTISRDDSKNSVYLQMNSLKTEDTGVYYCTAQFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYGGLNWYQRKPGKSPKLLIYGATNLASGVSSRFSGSGSGTDYTLTISSLQPEDVATYYCQNVLRSPFTFGSGTKLEIK,na,na,None,None,None,2019,2020,CTLA4/CD152,Merck,na,Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Solid tumours,na,,,Humanised,AK-107;MK-1308;AK107;MK1308;AK 107;MK 1308
Quetmolimab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVKQAPGQGLEWIGWIYPGDGSPKFNERFKGRTTLTADKSTNTAYMLLSSLRSEDTAVYFCATGPTDGDYFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASGNIHNFLAWYQQKPGKAPKLLIYNEKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQFWSTPYTFGGGTKVEIK,na,na,None,None,None,2018,2019,CX3CL1,KAN Research Institute;EA Pharma;Eisai Co Ltd,na,na,Primary biliary cirrhosis;Crohn's disease;Rheumatoid arthritis,,Genetics: musmus/homosap,Chimeric and/or humanised,E-6011;E 6011;E6011;KANAb 001;KANAb001;KANAb-001
Quilizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGIAWVRQAPGKGLEWVAFISDLAYTIYYADTVTGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNWDAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHNNANTYLHWYQQKPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQNTLVPWTFGQGTKVEIK,na,na,3hr5:HL:JQ:BA:IP,None,None,2011,2012,IGHE,Genentech,na,na,Allergic asthma;Allergic rhinitis;Urticaria,,,Humanised,MEMP-1972A;MEMP1972A;MEMP 1972A;RG-7449;RG7449;RG 7449
Quisovalimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYNWHWIRQPPGKGLEWIGEITHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCVREIAVAGTGYYGMDVWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQGINSAFAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2021,2022,TNFSF14/CD258,Avalo Therapeutics,na,Crohn's disease;COVID-19,na,,,Genetically human,AEVI-002;AEVI002;AEVI 002;AEVI-2;AEVI2;AEVI 2;AVTX-002;AVTX002;AVTX 002;AVTX-2;AVTX2;AVTX 2;CERC 002;CERC-002;CERC002;CERC 2;CERC-2;CERC2;MDGN-002;MDGN002;MDGN 002;MDGN 2;MDGN-2;MDGN2;SAR 252067;SAR252067;SAR-252067
Racotumomab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQSGAELVKPGASVKLSCKASGYTFTSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCAREDYYDNSYYFDYWGQGTTLTVSS,DIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2008,2009,Idiotope of anti-NeuGc-ganliosides,Center of Molecular Immunology;Elea;Innogene Kalbiotech;Recombio,Non-small cell lung cancer,Neuroblastoma,Breast cancer;Colorectal cancer;Malignant melanoma;Small cell lung cancer;Solid tumours,,,Murine,1E10;Vaxira
Rademikibart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRNAMFWVRQAPGKGLEWVSGIGTGGATSYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGRYYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDHSAGWTFGQGTKVEIK,na,na,None,None,None,2023,2023,IL4R/CD124,Suzhou Connect Biopharmaceuticals,na,Asthma;Atopic dermatitis;Rhinosinusitis,Nasal polyps,,,Genetically human,CBP 201;CBP-201; CBP201
Radretumab,di-scFv + CH4,E,Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK,na,na,7ah1:AA,None,None,2010,2011,FN extracellular domain B,Philogen,na,na,Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease,,Radretumab+Bifikafusp+Onfekafusp have identical V domains,Genetically human,L19-SIP
Rafivirumab,Whole mAb,G1,Lambda,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFNRYTVNWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,na,na,8r3w:AA:RR/8r40:AA:RR,None,None,2008,2009,Rabies Virus Antigenic Site III,Crucell;Sanofi Pasteur,na,na,Rabies,Human Phage Display,,Genetically human,CR57;CR-57;CD 57
Ragifilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMYWVRQAPGQGLEWIGVIRTYSGDVTYNQKFKDRATMTVDKSISTAYMELSRLRSDDTAVYYCAKSGTVRGFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYHCQNDYSYPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,TNFRSF18/CD357/GITR,Incyte,na,Non-small cell lung cancer;Hepatocellular carcinoma;Cutaneous squamous cell cancers,Glioblastoma;Solid tumours,,,Humanised,AGEN-1876;AGEN1876;AGEN 1876;CM-701;CM701;CM 701;INCAGN-01876;INCAGN 01876;INCAGN01876;INCAGN-1876;INCAGN1876;INCAGN 1876
Ragistomig,Bispecific (G1-scFv_L-kappa),G1;na,Kappa;Lambda,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKSLEWVATISDAGGYIYYRDSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYICARELPWRYALDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVTPAVAWYQQKPGKAPKLLIYSTSSRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHYTTPLTFGQGTKLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKCLEWVSWISYSGGSIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDAQRNSMREFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVTWYQQLPGTAPKLLIYADSHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDYSLSGYVFGCGTKLTVL,None;None,None;None,None;None,2023,2024,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,,Fv2 identical in sequence to Givastomig Fv2.,Humanised;Humanised,TBC
Ralpancizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEIHPSGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYHASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK,na,na,None,None,3sqo:HL,2013,2014,PCSK9,Pfizer,na,na,Hypercholesterolaemia,,,Humanised,PF-05335810;PF05335810;PF-5335810;PF5335810;RN 317;RN-317;RN317
Raludotatug,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIK,na,na,None,None,None,2022,2023,CDH6,Daiichi Sankyo,na,Ovarian cancers;Renal cell carcinoma,na,,ADC with deruxtecan,Humanised,DS-6000;DS6000;DS 6000
Ralzapastotug,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLQESGPGLVKPSGTLSLTCAVSGYSITSGYSWHWVRQPPGKGLEWIGYVHYSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARMDYGNYGGAMDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQDVRTAVAWYQQKPGQAPRLLIYSASYRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYYSTQWTFGGGTKVEIK,na,na,None,None,None,2022,2023,TIGIT/WUCAM/VSTM3,Arcus Biosciences,na,na,Multiple myeloma;non-Hodgkin's lymphoma;Non-small cell lung cancer;Melanoma;Solid tumours,,,Humanised,AB-308;AB308;AB 308
Ramantamig1,Trispecific Mixed mAb and scFv; Bispecific entry,G1;na,Lambda;Kappa,TBC,TBC,QVQLQQSGPRLVRPSQTLSLTCAISGDSVFNNNAAWSWIRQSPSRGLEWLGRTYYRSKWLYDYAVSVKSRITVNPDTSRNQFTLQLNSVTPEDTALYYCARGYSSSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSNIGTYKFVSWYQQHPDKAPKVLLYEVSKRPSGVSSRFSGSKSGNTASLTISGLQAEDQADYHCVSYAGSGTLLFGGGTKLTVL,QVTLKESGPVLVKPTETLTLTCTVSGFSLTNIRMSVSWIRQPPGKALEWLAHIFSNDEKSYSTSLKSRLTISRDTSKSQVVLTLTNVDPVDTATYYCARMRLPYGMDVWGQGTTVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLVHSDGNTYLSWLQQRPGQPPRLLIYKISNRFFGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCMQATQFPHTFGQGTKLEIK,None;None,None;None,None;None,2025,na,CD3E;GPRC5D,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Genetically human,TBC
Ramantamig2,Trispecific Mixed mAb and scFv; Monospecific entry,na,Kappa,TBC,TBC,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDEGYSSGHYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSISSSFLTWYQQKPGQAPRLLIYGASSRATGIPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQHYGSSPMYTFGQGTKLEIK,na,na,None,None,None,2025,na,TNFRSF17/CD269/BCMA/TNFRSF13A,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Ramucirumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK,na,na,3s34:HL/3s37:HL/3s36:HL,None,None,2008,2009,KDR/CD309/VEGFR2,Dyax;AstraZeneca;Dana-Farber Cancer Institute;Eli Lilly;Merck Sharp & Dohme;University of Texas M. D. Anderson Cancer Center;Washington University School of Medicine,Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Liver cancer,Oesophageal cancer;Urogenital cancer;Biliary cancer;Carcinoid tumour;Solid tumours;Pancreatic cancer,Breast cancer;Malignant melanoma;Ovarian cancer;Prostate cancer;Renal cell carcinoma,Dyax Human Phage Display,,Genetically human,Cyramza;IMC-1121;IMC1121;IMC 1121;IMC-1C11;IMC1C11;IMC 1C11;LY-3009806;LY 3009806;LY3009806;Ramcilumab;Ramsilmab;Ramsilomab;Ramsylmab;Ramsylumab;Sairamza;Silamza
Ranevetmab,Canine Whole mAb,G1,Kappa,Unknown,Active,EVQLVESGGGLVQPGGSLRLSCVASGFSLTNNNVNWVRQAPGKGLEWVGGVWAGGATDYNSALKSRFTISRDNAKNTVFLQMHSLRSEDTAVYYCARDGGYSSSTLYAMDAWGQGTSVTVSS,DIVMTQSPASLSLSQGETVTITCRASEDIYNALAWYQQKPGQAPKLLIYNTDTLHTGVPSRFSGSGSGTDFSLTISSLEPEDVAVYYCQHYFHYPRTFGQGTKVELK,na,na,None,None,None,2016,2017,NGFB,Nexvet,na,Osterarthritis,na,PETization Technology,,Caninised,NV-01;NV01;NV 01;NV-1;NV1;NV 1
Ranibizumab,Fab,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB/7v5n:BA:FE,2004,2004,VEGFA,Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn,Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy,Retinopathy of prematurity;Polypoidal choroidal vasculopathy,Retinal telangiectasis,,Biosimilars available,Humanised,ACCENTRIX;RG-3645;RG3645;RG 3645;RG-6321;RG6321;RG 6321;Susvimo
Rapaprutug,Whole mAb,G1,Kappa,TBC,TBC,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSAISPYSGRIYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMALDFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGSNYVTWYQQLPGTAPKLLIYDNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSSFSDELGAYVFGGGTKLTVL,na,na,None,None,None,2025,na,KARS1,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Ravagalimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYGMNWVRQAPGKGLEWIAYISSGRGNIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSWGYFDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRGNQKNYLTWFQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYTYPLTFGQGTKLEIK,na,na,6pe7:HL/6pe8:HL:AB,None,6pe9:AB:CD:EF:HL:KM,2017,2018,TNFRSF5/CD40,AbbVie,na,Ulcerative colitis;Sjogren's syndrome,Crohn's disease,,,Humanised,ABBV 323;ABBV-323;ABBV 323;PR 1629977;PR-1629977;PR1629977
Ravulizumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGHIFSNYWIQWVRQAPGQGLEWMGEILPGSGHTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK,na,na,None,5i5k:HL:XY,None,2017,2018,C5,Alexion Pharmaceuticals,Paroxysmal nocturnal haemoglobinuria,Haemolytic uraemic syndrome;Myasthenia gravis;IgA nephropathy,na,,,Humanised,ALXN 1210;ALXN-1210;ALXN1210;ALXN 1810;ALXN-1810;ALXN1810;Ultomiris
Recaticimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGYINPSSGFTKYHQNFKDRVTMTRDTSISTAYMELSRLRSDDTAVYYCARQYDYDEDWYFDVWGQGTTVTVSS,DIVMSQSPSSLSASVGDRVTITCKSSQSLLNSRTRKNFLAWYQQKPGKSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCKQSFNLFTFGQGTKLEIK,na,na,None,None,None,2020,2021,PCSK9,Shanghai Hengrui Pharmaceuticals,Hypercholesterolaemia;Hyperlipidaemia,Hyperlipoproteinaemia type Iia,na,,Genetics: musmus/homosap,Chimeric and/or humanised,SHR-1209;SHR1209;SHR 1209
Recibokibart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSWMHWAKQAPGQGLEWIGEIHPNSAKTNYNQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARVDYGKPWFAYWGQGTLVTVSS,QIVLTQSPGTLSLSPGERATLSCRASSSVSSSYLHWYQQKPGQAPRLWIYSTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFATYYCQQFQSSPLTFGQGTKLEIK,na,na,None,None,None,2024,na,IL1RL2/IL1Rrp2/IL1RRP2/IL-36R/IL36R,TBC,na,na,Pustular psoriasis;Systemic lupus erythematosus;Ulcerative colitis,,,Humanised,HB0034;HB-0034;HB 0034
Refanezumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFTGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCARNPINYYGINYEGYVMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSHSVLYSSNQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHQYLSSLTFGQGTKLEIK,na,na,None,None,None,2015,2016,SIGLEC4/MAG,GlaxoSmithKline,na,na,CNS trauma;Stroke,,,Humanised,GSK-249320;GSK249320;GSK 249320
Reflocibart,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGFWIHWVRQAPGQGLEWMGHINPGNGGTNYNEKFKRRVTMTRDKSISTAYMELSRLRSDDTAVYYCARSYSNYVRAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGKTLPPTFGGGTKVEIK,na,na,None,None,None,2023,2024,VEGFB,CSL;Zenyth Therapeutics,na,na,Type 2 diabetes mellitus;Cancer;Rheumatoid arthritis;Diabetic nephropathies,,,Humanised,CSL-346;CSL346;CSL 346;2H10
Regdanvimab,Whole mAb,G1,Lambda,Approved,NFD,QITLKESGPTLVKPTQTLTLTCSFSGFSLSTSGVGVGWIRQPPGKALEWLALIDWDDNKYHTTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIPGFLRYRNRYYYYGMDVWGQGTTVTVSS,ELVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTELTVL,na,na,7cm4:HL,None,None,2020,2021,SARS-CoV-2 Spike RBD,Celltrion,COVID-19,na,na,,,Genetically human,CT P59;CT-P59;IN-006;IN006;IN 006;IN-6;IN6;IN 6;Regkirona;T-P59
Relatlimab,Whole mAb,G4,Kappa,Approved,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK,na,na,None,7um3:HL:IM,None,2018,2019,LAG3/CD223,Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Malignant melanoma,Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,,,Genetically human,BMS 986016;ONO-4482;BMS986016;BMS 986016;ONO 4482;ONO4482
Relfovetmab,Feline Whole mAb,G1,Kappa,Unknown,Active,DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRSGYDYYFDVWGQGTLVTVSS,EIQMTQSPSSLSASPGDRVTITCRASENIYSFLAWYQQKPGKVPKLLIYNANTLAEGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQHHFGTPFTFGSGTKLEIK,na,na,None,None,None,2018,2019,NGFB,TBC,TBC,TBC,TBC,,,Felinised,ZTS-00084768;ZTS00084768;ZTS 00084768;ZTS-84768;ZTS84768;ZTS 84768
Remternetug,Whole mAb,G1,Kappa,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGGSGSYYNGFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSLGNWLAWYQQKPGKAPKLLIYQASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYKGSFWTFGQGTKVEIK,na,na,None,None,None,2023,2023,APP,Eli Lilly,na,Alzheimer's disease,na,,Jul '23: Corrected antigen label,Genetically human,LY-3372993;LY 3372993;LY3372993;N3pG 4;N3pG4;N3PG-IV
Remtolumab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK,EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS,EIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIK,4nyl:EF:AB:HL:CD/6cr1:HL;None,3wd5:HL/8xj0:AB:CD:EF:GH;None,None;None,2016,2017,IL17A;TNF/TNFA,Abbott Laboratories;Abbvie,na,na,Psoriatic arthritis;Rheumatoid arthritis,Dual Variable Domain Immunoglobulin Technology,,Genetically human;Genetically human,ABT-122;ABT122;ABT 122
Remzistotug,Whole mAb,G1,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSAAISWVRQAPGQGLEWMGNIIPIVGIANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTGRGYTRHFWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDILYTFGGGTKVEIK,na,na,None,None,None,2024,na,PVRIG/NECTIN2 receptor/CD112R,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Renvistobart,Whole mAb,G1,Kappa,Phase-II,Active,QVHLQESGPGLVKPSETLSLTCTVSGGSVSSGIYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYYVSGNYYNVDYYFFGVDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLFTFGPGTKVDIK,na,na,8szy:HL:IM,None,None,2023,2023,TIGIT/WUCAM/VSTM3,Bristol-Myers Squibb;Compugen;Multiple Myeloma Research Consortium;Ono Pharmaceutical,na,Non-small cell lung cancer;Solid tumours;Multiple myeloma,na,,,Genetically human,BMS-986207;BMS 986207;BMS986207
Reozalimab,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-I/II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPSFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL,None;None,None;None,None;None,2022,2022,PDCD1/CD279/PD1;PDL1/CD274,Innovent Biologics,na,na,Solid tumours,,,Genetically human;Genetically human,LY-3434172;LY3434172;LY 343172
Reslizumab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK,na,na,None,None,None,2001,2002,IL5,Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries,Asthma,Sinusitis;Churg-Strauss syndrome,Oesophagitis,,,Humanised,CDP-835;CDP835;CDP 835;CEP-38072;CEP38072;CEP 38072;CINQAERO;CINQAIR;Cinquil;CTx-55700;CTx55700;Ctx 55700;DCP-835;DCP835;DCP 835;SCH 55700;SCH55600;SCH-55700;TRFK-5;TRFK 5;TRFK5
Resugosbart,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNLDWLRQAPGEGLEWIGDIDPNDGDILYNQKFRDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRWAYYFDYWGQGTTVTVSS,DIVMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKSPKLLIYYTSNRFTGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCQQDYSSPVTFGGGTKVEIK,na,na,None,None,None,2022,2023,SOST,Jiangsu Hengrui Medicine,na,Osteoporosis;Postmenopausal women,na,,Genetics: musmus/homosap,Chimeric and/or humanised,SHR-1222;SHR1222;SHR 1222
Retavibart,Whole mAb,G1,Kappa,TBC,TBC,QVQLVQSGAEVKKPGESLKISCQGSGYSFNNYYIGWVRQMPGKGLEWMVIIYPGDSDTKYSPSFQGQVTVSADRSINTAYLQWSSLRASDTAVYYCVRMDTVTTGAGVGFNWFFDLWGRGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQSVTSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSETEFTLTISSLQSEDFAVYYCQQYNDWPAITFGQGTRLENK,na,na,None,None,None,2025,na,RSV gpF,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Retifanlimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,na,na,None,None,None,2019,2020,PDCD1/CD279/PD1,MacroGenics;Incyte Corporation;ZAI Lab,Merkel cell carcinoma,Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Solid tumours;Colorectal cancer;Acute myeloid leukaemia;Squamous cell cancer;Non-small cell lung cancer;Glioblastoma;Head and neck cancer;Liposarcoma;Pancreatic cancer;Penile cancer;Soft tissue sarcoma,Haematological malignancies,,Chimeric: Mouse/Human,Chimeric and humanised,AEX-1188;AEX1188;AEX 1188;INCMGA-0012;INCMGA 0012;INCMGA0012;INCMGA12;INCMGA-12;INCMGA 12;MGA-012;MGA012;MGA 012;MGA-12;MGA12;MGA 12;Zynyz 
Retlirafusp,Whole mAb Fusion,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS,DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK,na,na,None,None,None,2020,2021,PDL1/CD274,Jiangsu Hengrui Medicine,na,Pancreatic cancer;Solid tumours;Head and neck squamous cell carcinoma,na,,,na,SHR 1701;SHR1701;SHR-1701
Revdofilimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,AbbVie,na,na,Solid tumours,,Genetics: musmus/homosap,Chimeric and/or humanised,ABBV-368;ABBV368;ABBV 368;PR-1628103;PR1628103;PR 1628103
Rezetamig,Bispecific (half G4-kappa_G4(VH-h-CH2-CH3)),G4;G4,Kappa;Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGRSLRLSCAASGFTFHNYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDSRGYGDYSLGGAYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,QLQLQESGPGLVKPSETLSLTCTVSGDSISSGDYYWGWIRQPPGKGLEWIGHIYYSGATYYNPSLENRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRDDSSNWRSRGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,None;None,None;None,None;None,2023,2024,CD3;SIGLEC2/CD22,TeneoBio;Janssen Biotech,na,na,Non-Hodgkin's lymphoma;Chronic lymphocytic leukaemia,,,Genetically human;Genetically human,JNJ-75348780;JNJ75348780
Rezorstobart,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSPYAMSWVRQAPGKGLEWVSAISASGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPLDSSFWADFDLWGRGTLVTVSS,DIQLTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHSVLPITFGGGTKVEIK,na,na,None,None,None,2023,2024,KLRB1,Immunitas Therapeutics,na,Lymphoma;Solid tumours;Glioma,na,,,Genetically human,IMT009;IMT-009;IMT 009
Riliprubart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKLSCTASGFNIKDDYIHWVKQAPGQGLEWIGRIDPADGHTKYAPKFQVKVTITADTSTSTAYLELSSLRSEDTAVYYCARYGYGREVFDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCKASQSVDYDGDSYMNWYQQKPGQPPKILIYDASNLESGIPARFSGSGSGTDFTLTISSLEPEDFAIYYCQQSNEDPWTFGGGTKVEIK,na,na,None,None,None,2023,2023,C1S,True North Therapeutics;Bioverativ; Sanofi;Sanofi-Aventis Recherche & Developpement,na,Autoimmune haemolytic anaemia;Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Renal transplant rejection,na,,Genetics: musmus/homosap,Chimeric and/or humanised,BIVV-020;BIVV020;BIVV 020;SAR-445088;SAR445088;SAR 445088;TNT-020;TNT020;TNT 020
Rilogrotug,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFSDYNMDWVRQAPGQGLEWMGQINPNNGLIFFNQKFKGRVTLTADKSTSTAYMELSSLRSEDTAVYYCAREAITTVGAMDYWGQGTVLTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENLHNYLAWYQQKPGKAPKLLIYDAKTLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFWSSPYTFGQGTKLEIK,na,na,None,None,None,2024,na,GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB,AVEO Therapeutics;St Vincents Hospital Sydney,na,Cachexia,na,,,Humanised,AV-380;AV 380;AV380
Rilotumumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK,na,na,None,None,None,2009,2010,HGF/SF,Amgen;Astellas Pharma,na,na,Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours,Abgenix XenoMouse,,Genetically human,AMG-102;AMG102;AMG 102
Riltovetbart,Whole mAb,G2,Kappa,Unknown,Active,EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS,EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK,na,na,None,None,None,2022,2023,IL31 (Canine),TBC,na,Canine Lupus,na,,,na,ZTS-00008183;ZTS00008183;ZTS 00008183;ZTS-8183;ZTS8183;ZTS 8183
Rilvegostomig,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYAGEVKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSSSNIGRRPVNWYQQLPGTAPKLLIYSQNQRPSGVPDRFSGSQSGTSASLAISGLQSEDEADYFCAVWDDIGRVLQLGGGTQLTVL,None;None,None;None,None;None,2022,2023,PDCD1/CD279/PD1;TIGIT/WUCAM/VSTM3,AstraZeneca,na,Non-small cell lung cancers,na,,,Humanised;Genetically human,AZD-2936;AZD2936;AZD 2936
Rimteravimab,Mixed Nanobody (VHH-CH2-CH3 dimer),G1,na,Phase-I/II,Active,DVQLVESGGGLVQPGGSLRLSCAASGRTFSEYAMGWFRQAPGKEREFVATISWSGGATYYTDSVKGRFTISRDNAKNTVYLQMNSLRPEDTAVYYCAAAGLGTVVSEWDYDYDYWGQGTLVTVSS,na,na,na,None,None,None,2021,2022,SARS-CoV-2 Spike RBD,ExeVir,na,COVID-19,na,,Also complementary vs. SARS-CoV Spike RBD and WIV-CoV Spike RBD. Genetics: vicpac/homosap,Chimeric and/or humanised,XVR011;XVR-011;XVR 011;VHH-72
Rinatabart,Whole mAb,G1,Kappa,Phase-III,Active,EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRANSKNTLYLQMNSLRAEDTAVYYCARPRAYYGAYGSSFDYWGQGTQVTVSS,EIVMTQSPSSVSASVGDRVAITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIK,na,na,None,None,None,2024,2024,FOLR1,ProfoundBio,na,Solid tumours,na,,,Genetically human,PRO-1184;PRO1184;PRO 1184
Rinucumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS,EIVLTQSPDTISLSPGERATLSCRASQSISSIYLAWYQQKPGQAPRLLIYGASSRVTGIPDRFSVSGSGTDFTLTISRLEPEDFAVYYCQHYGISPFTFGPGTKVDIR,na,na,None,None,None,2015,2016,PDGFRB/CD140B,Regeneron Pharmaceuticals,na,na,Wet age-related macular degeneration,,,Genetically human,REGN 2176;REGN2176;REGN-2176;
Ripertamab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB/6y90:HL:CD/6vja:HL:IM/8vgn:AB:HL,4kaq:HL,None,2019,2020,MS4A1/CD20,Sinocelltech,Diffuse Large B cell Lymphoma,Non-Hodgkin's lymphoma,na,,Likely to be a Rituximab biosimilar,Chimeric,SCT-400;SCT400;SCT 400
Risankizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK,na,na,None,None,None,2015,2016,IL23A,AbbVie;Boehringer Ingelheim,Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Crohn's disease;Ulcerative colitis;Atopic dermatitis,Psoriasis;Ankylosing spondylitis;Asthma,,,Humanised,ABBV 066;ABBV066;ABBV 066;ABBV 66;ABBV-66;ABBV66;BI-655066;BI655066;BI 655066;SKYRIZ
Rituximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK,na,na,2osl:HL:AB/6y90:HL:CD/6vja:HL:IM/8vgn:AB:HL,4kaq:HL,8vgo:AB:HL,1997,1998,MS4A1/CD20,Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Idiopathic thrombocytopenic purpura;Lymphoproliferative disorders;Microscopic polyangiitis;Nephrotic syndrome;Non-Hodgkin's lymphoma;Pemphigus vulgaris;Rheumatoid arthritis;Wegener's granulomatosis,Mantle-cell lymphoma;Transplant rejection;Neuromyelitis optica;B-cell lymphoma;Chronic inflammatory demyelinating polyradiculoneuropathy;Glomerulonephritis;Precursor cell lymphoblastic leukaemia-lymphoma;Renal transplant rejection,Multiple sclerosis;Ocular inflammation;Primary biliary cirrhosis;Scleritis;Sjogren's syndrome;Ulcerative colitis;Dermatomyositis;Graft-versus-host disease;Lupus nephritis;Systemic lupus erythematosus,,Biosimilars available,Chimeric,IDEC-102;IDEC102;IDEC 102;IDEC-C2B8;IDEC C2B8;RG 105;RG-105;RG105;Ristova;Rituxan;RO-452294;RO 452294;RO452294
Rivabazumab,Fab,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS,DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,PcrV type III secretion system,KaloBios Pharmaceuticals Inc,na,na,Infectiology;Inflammation;Inherited diseases,Humaneering Technology,,Humanised,BA1126;BA-1126;BA 1126
Robatumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK,na,na,None,None,None,2008,2009,IGF1R/CD221,Merck & Co;Schering-Plough,na,na,Colorectal cancer;Osteosarcoma;Sarcoma;Solid tumours,,,Genetically human,19D12;SCH 717454;SCH717454;SCH-717454
Rocatinlimab,Whole mAb,G1,Kappa,Phase-III,Active,QITLKESGPTLVKPKQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAVIYWDDHQLYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRRGAFQHWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSLTFGGGTKVEIK,na,na,None,None,None,2021,2022,TNFRSF4/CD134/OX40,Kyowa Hakko Kirin,na,Ulcerative colitis;Atopic dermatitis,na,,,Genetically human,AMG-451;AMG451;AMG 451;KHK-4083;KHK4083;KHK 4083
Roconkibart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFTNYGMNWMRQAPGQGLEWMGWINDHTGEPTYADKFQGRVTFTLDTSISTAYMELSRLRSDDTAVYYCANYGFGYFDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNSYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKLEIK,na,na,None,None,None,2023,2024,IL17A,Shanghai Junshi Biosciences,na,Plaque psoriasis;Ankylosing spondylitis;Axial spondyloarthritis;Psoriatic arthritis;Psoriasis,na,,Genetics: musmus/homosap,Chimeric and/or humanised,JS005;JS-005
Roledumab,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS,AIRMTQSPSSFSASTGDRVTITCRASQDIRNYVAWYQQKSGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTINSLQSEDFATYYCQQYYNSPPTFGQGTRVEIT,na,na,None,None,None,2010,2011,RhD/CD240D/RhPI,LFB Biotechnologies,na,Haemolytic disease of newborn,na,EMABling Platform,,Genetically human,Dmatria;LFB-R593;LFB R593
Rolinsatamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPSRFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,PRLR,AbbVie,na,na,Solid tumours,,ADC with talirine. Genetics: musmus/homosap,Chimeric and/or humanised,PR-1594804;PR1594804;ABBV-176;ABBV176;DC-1630993;DC1630993;DC 1630993
Rolistobart,Whole mAb,G4,Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGQSFMHWYQQKPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNNEDPYTFGQGTKLEIK,na,na,None,None,None,2023,2023,LILRB4/CD85K,TBC,TBC,TBC,TBC,,,Humanised,TBC
Romilkimab,Bispecific Dual Variable Domain IG,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSS,DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIK,QVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSS,DIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIK,None;None,None;None,None;None,2017,2018,IL13;IL4,Sanofi,na,na,Idiopathic pulmonary fibrosis;Systemic scleroderma,,Chimeric: Mouse/Human,Chimeric and humanised;Chimeric and humanised,SAR156597;SAR-156597;SAR 156597
Romlusevimab,Whole mAb,G1,Lambda,Phase-II/III,Active,QVQLVQSGSELKKPGASVKVSCKASGYTFTTYVMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTASLQISSLKAEDTAVYYCSSEITTLGGMDVWGQGTTVTVSS,SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSISDHRVFGGGTKLTVL,na,na,None,8gx9:PM:ON,None,2021,2022,SARS-CoV-2 Spike RBD,Brii Biosciences,na,COVID-19,na,,,Genetically human,BRII-198;BRII198;BRII 198
Romosozumab,Whole mAb,G2,Kappa,Approved,NFD,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,SOST,ChiroscienceGroup plc;Amgen;UCB,Male osteoporosis;Postmenopausal osteoporosis,na,Fracture,,,Humanised,785A070802;AMG 785;AMG-785;AMG 785;CDP-7851;CDP7851;CDP 7851
Rontalizumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK,na,na,4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY,None,None,2009,2010,IFNA1,Chugai Pharmaceutical;Genentech,na,na,Systemic lupus erythematosus,,,Humanised,RhuMAB IFNalpha
Rosmantuzumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK,na,na,None,None,None,2016,2017,RSPO3,OncoMed Pharmaceuticals,na,na,Colorectal cancer;Solid tumours,,,Humanised,OMP-131R10;OMP131R10;OMP 131R10;Rosmantuzumab
Rosnilimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGSELKKPGASVKVSCKASNYTFTDYSMHWVRQAPGQGLEWMGWINIETYYPTYADQFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARDYYGRFYYAMDYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVSSSYFHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPLTFGGGTKVEIK,na,na,None,None,None,2022,2022,PDCD1/CD279/PD1,AnaptysBio,na,Alopecia areata;Autoimmune disorders,na,,,Humanised,ANB-030;ANB030;ANB 030;ANB-30;ANB30;ANB 30
Rosopatamab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS,DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK,na,na,None,None,None,2019,2020,FOLH1/GCPII/PSMA,Weill Cornell Medical,na,Prostate cancer;Cancers,na,,Genetics: musmus/homosap,Chimeric and/or humanised,J591;J 591;J-591
Rovalpituzumab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK,na,na,None,None,None,2015,2016,DLL3,Bristol-Myers Squibb;Stemcentrx,na,na,Small cell lung cancer;Solid tumours,,ADC with tesirine,Humanised,SC16LD6.5
Rovelizumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNNWMQWVRQAPGQGLEWMGAIFPGDDETRYTQKFRGKATITADTSTSTAYMELSSLRSEDTAVYYCGRGGKLRPFALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESVESYGNNFMYWYQQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDNEDPPTFGQGTKLEIK,na,na,None,None,None,1999,2000,ITGAL/CD11A/LFA1A and ITGB2/CD18,ICOS Corporation,na,na,Adult respiratory distress syndrome;Cerebral vasospasm;CNS trauma;Multiple sclerosis;Myocardial infarction;Peripheral arterial occlusive disorders;Shock;Stroke;Vascular restenosis ,,,Humanised,23F2G;LeukArrest
Rozanolixizumab,Whole mAb,G4,Kappa,Approved,Active,EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK,na,na,6fgb:HL,None,None,2016,2017,FCGRT/FcRn,UCB,Myasthenia gravis,Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;CNS disorders;Encephalitis;Fibromyalgia,Immunological disorders,,,Chimeric and humanised,RYSTIGGO;UCB-7665;UCB7665;UCB 7665
Rozibafusp,Whole mAb Fusion,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK,na,na,6x4t:BE:DF,None,None,2018,2019,ICOS/CD278,Amgen,na,Systemic lupus erythematosus,Rheumatoid arthritis,,,na,AMG 570;AMG-570;AMG570;MEDI0700;MEDI-0700;MEDI 0700;MEDI700;MEDI-700;MEDI 700
Rulonilimab,Whole mAb,G1,Kappa,Phase-II/III,Discontinued,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQTPEKRLEWVATISGGGRDTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARQKDTSWFVHWGQGTLVTVSS,EIVLTQSPATLAVSPGERATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYVASNQGSGVPARFSGSGSGTDFTLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIK,na,na,None,None,None,2021,2022,PDCD1/CD279/PD1,Shandong New Time Pharmaceutical,na,na,Lymphoma;Solid tumours;Liver cancer,,Genetics: musmus/homosap,Chimeric and/or humanised,F-520;F 520;F520
Runimotamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA;None,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL;None,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None,2020,2021,ERBB2/CD340/HER2;CD3E,Genentech,na,Solid tumours,na,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,BTRC-4017A;BTRC4017A;BTRC 4017A;RG-6194;RG6194;RG 6194;RO-7227780;RO7227780;RO 7227780
Ruplizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,na,na,1i9r:HL:KM:XY/6w4w:HL,None,None,2000,2001,CD40LG/CD154,Biogen,na,na,Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus,,,Humanised,BG 9588;BG-9588;BG9588
Ruxoprubart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVAKPGASVKMSCKASGYTFTNYWIHWVKQRPGQGLEWIGYINPNTGYNDYNQKFKDKATLTADKSSSTVYMQLSSLTSEDTAVYYCARGGQLGLRRAMDYWGQGTLVTVSS,DVQITQSPSYLSASPGDTITITCRASKSISKYLAWYQDKPGKTNKLLIYSGSTLQSGIPSRFSGSGSGTEFTLTISSLQPDDFAMYYCQQHDEYPWTFGQGTKLEIK,na,na,None,None,None,2024,na,CFB/BFD,NovelMed Therapeutics,na,Paroxysmal nocturnal haemoglobinuria;Atypical Haemolytic Uraemic Syndrome;Membranoproliferative glomerulonephritis,na,na,Activated (Bb) form,Chimeric and/or humanised,NM-8074;NM 8074;NM8074
Ruzaltatug,Whole mAb ADC,G1,Kappa,TBC,TBC,QVQLVQSGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKEGLPGLDYWGQGTLVTVSS,DIQMTQSPSSLSASIGDRATITCRASQHVGTYLNWYQQKPGKTPKLLISGAANLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYNTPPFSFGQGTKVEIK,na,na,None,None,None,2025,na,ERBB3/HER3,TBC,TBC,TBC,TBC,TBC,ADC with rezetecan,Genetically human,TBC
Sabatolimab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIK,na,na,None,None,None,2019,2020,HAVCR2/TIM3,Novartis,na,na,Chronic myelomonocytic leukaemia;Myelodysplastic syndromes;Acute myeloid leukaemia;Myelofibrosis;Solid tumours;Glioblastoma,,,Humanised,MBG-453;MBG453;MBG 453;NVP-MBG453
Sabestomig,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSYGTYYGNYFEYWGQGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGDNIGGKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVLDRRSDHFLFGGGTKLTVL,None;None,None;8tft:HL:IM,None;None,2023,2023,PDCD1/CD279/PD1;HAVCR2/TIM3,AstraZeneca,na,Adenocarcinoma;Hodgkin's disease;Solid tumours,na,,,Humanised;Genetically human,AZD7789;AZD-7789
Sabirnetug,Whole mAb,G2,Kappa,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAYISRGSSTIYYADTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGITTALDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKASNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSRLGPSFGQGTKLEIK,na,na,None,None,None,2023,2023,APP,Northwestern University;Acumen Pharmaceuticals,na,Alzheimer's disease,na,,,Humanised,ACU193;ACU-193
Sacituzumab,Whole mAb ADC,G1,Kappa,Approved,Active,QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK,na,na,None,None,None,2016,2017,TACSTD2/TROP2/EGP1,IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University,Breast cancer,Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma,na,,ADC with tirumotecan,Humanised,IMMU-132;IMMU132;IMMU 132;SN-38;SN 38;SN38;Hrs7
Safimestomig,Bispecific Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGASVKVSCKASGYKFTNYVMSWVRQAPGQRLEWMGYINPYNDAIKYNEKFTGRVTITRDTSASTAYMELSSLRSEDTAVYYCAREGDFYANYGRLGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLLYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGAGFPYTFGGGTKVEIK,EVQLVQSGAEVKKPGATVKISCKVSGFNIKDIYMHWVQQAPGKGLEWMGRIDPANANTKYDPKFQDRVTITADTSTNTAYMELSSLRSEDTAVYYCASGQLGPLGFDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLLYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGAGFPYTFGGGTKVEIK,7xjf:HL;None,None;None,None;None,2024,na,IAP/CD47;PDL1/CD274,Mabwell (Shanghai) Bioscience,na,Solid tumours,na,,,Humanised;Humanised,6MW3211;6MW 3211;6MW-3211
Samalizumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLQQSGSELKKPGASVKISCKASGYSFTDYIILWVRQNPGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYMELSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSS,DIQMTQSPSSLSASIGDRVTITCKASQDINSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQPEDFAVYYCLQYDEFPYTFGGGTKLEIK,na,na,None,None,None,2010,2011,MOX2/CD200,Alexion Pharmaceuticals;The Leukemia & Lymphoma Society,na,na,Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours,,,Humanised,ALXN 6000;ALXN-6000;ALXN6000
Samatatug,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFDVYGISWVRQAPGQGLEWMGWIAPYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDAGTYSPFGYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQSINNWLAWYQQKPGKAPKLLIYKAYNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLFQSLPPFTFGGGTKVEIK,na,na,None,None,None,2024,2024,F3/CD142,Iconic Therapeutics;Exelixis,na,na,Solid tumours,,,Genetically human,XB002;XB-002;XB 002
Samrotamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYKFSSYWIEWVKQAPGQGLEWIGEILPGSDTTNYNEKFKDRATFTSDTSINTAYMELSRLRSDDTAVYYCARDRGNYRAWFGYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKFLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGEALPWTFGGGTKVEIK,na,na,None,None,None,2017,2018,LRRC15,AbbVie,na,na,Solid tumours,,Chimeric: Mouse/Human,Chimeric and humanised,PR-1498487;PR1498487;PR 1498487;ABBV-085;ABBV085;ABBV 085;ABBV-85;ABBV85;ABBV 85
Sarilumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK,na,na,8iow:HL,None,None,2011,2012,IL6R/CD126,Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi,Rheumatoid arthritis,Juvenile rheumatoid arthritis,Ankylosing spondylitis;COVID-19;Giant cell arteritis;Polymyalgia rheumatica;Uveitis,VelocImmune Mouse,,Genetically human,Kevzara;REGN-88;REGN88;REGN 88;SAR-153191;SAR153191;SAR 153191
Sasanlimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIK,na,na,6xkr:HL,None,None,2019,2020,PDCD1/CD279/PD1,Pfizer,na,Bladder cancer;Non-small cell lung cancer;Solid tumours,na,,,Humanised,PF-06801591;PF06801591;PF-6801591;PF6801591;RN-888;RN888;RN 888
Satralizumab,Whole mAb,G2,Kappa,Approved,NFD,QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS,DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE,na,na,None,None,None,2015,2017,IL6R/CD126,Chugai Pharmaceutical;Roche,Neuromyelitis optica,na,Rheumatoid arthritis,,Satralizumab is the new name for Sapelizumab (PL116),Humanised,ENSPRYNG;RG-6168;RG6168;RG 6168;SA-237;SA237;SA 237
Satumomab,Whole mAb Radiolabelled,G1,Kappa,Approved,NFD,QVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSS,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIK,na,na,None,1bbj:HL:BA,None,1999,2000,TAG72,Cytogen Corporation,Radionuclide imaging enhancers,na,na,,,Murine,CYT 103;CYT-103;CYT103;CR103;CR-103;CR 103;OV103;OV-103;OV 103
Secukinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK,na,na,6wio:AB/6wir:AB,None,None,2009,2010,IL17A,Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon,Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis,Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries,Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis,Abgenix XenoMouse,Biosimilars available,Genetically human,AIN-457;AIN457;AIN 547;Cosentyx;KB-03303A;KB03303A;KB 03303A;KB3303A;KB-3303A;KB 3303A;Kosentikusu;NVP-AIN-457;Scapho
Selicrelumab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,TNFRSF5/CD40,Abramson Cancer Center of the University of Pennsylvania;Roche,na,na,Pancreatic cancer;Solid tumours;Non-Hodgkin's Lymphoma,,,Genetically human,RG-7876;RG7876;RG 7876;RO-7009789;RO7009789;RO 7009789
Semorinemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGLIFRSYGMSWVRQAPGKGLEWVATINSGGTYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANSYSGAMDYWGQGTLVTVSS,DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,MAPT,AC Immune;Genentech,na,na,Alzheimer's disease,,Genetics: musmus/homosap,Chimeric and/or humanised,MTAU-9937A;MTAU9937A;RG6100;RG-6100;RG 6100;RO 7105705;RO7105705;RO-7105705
Semzuvolimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGPELKKPGASVKVSCKASGYTFTDYVIHWVKQATGQGLEWIGEIYPGSGSAYSNAKFKDRVTMTADKSSNTAYMELSSLTSDDTAVYFCARRGNGTGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATITCKAGQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLESGIPARFSGSGSGTDFTLNIHPVEENDAATYYCQQSYKDPLTFGQGTKLEIK,na,na,None,None,None,2022,2022,CD4,United Biopharma;Kaohsiung Medical University Chung-Ho Memorial Hospital;Kaohsiung Veterans General Hospital;United Biomedical,na,HIV1 infections,na,,Genetics: musmus/homosap,Chimeric and/or humanised,UB-421;UB421;UB 421
Seniprutug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGSELKKPGESVKVSCKASGYTFTDYLVHWVRQAPGQGLEWMGWINTYTGTPTYADDFEGRFVFSLDTSVSTANLQISSLKAEDTAVYFCARSWRRGLRGIGFDYWGQGTLVTVSS,DIQMTQSPYSLSASVGDRVTITCKASKSINKYLAWFQQKPGKPNKLLIYDGSTLQSGVPSRFSGSGSGTDFTLTISSLEPEDFATYYCQQHNEYPPTFGQGTKLEIK,na,na,None,None,None,2023,2024,TRBV9,Biocad CJSC,na,Spondylarthritis,na,,,Humanised,BCD-180;BCD180;BCD 180
Serclutamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS,DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK,na,na,None,None,None,2016,2017,EGFR/ERBB1/HER1,AbbVie,na,na,Solid tumours,,Losatuxizumab and Serclutamab have identical variable domains. Genetics: musmus/homosap,Chimeric and/or humanised,ABBV-321;ABBV321;ABBV 321
Seribantumab,Whole mAb,G2,Lambda,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL,na,na,None,None,None,2012,2013,ERBB3/HER3,Merrimack Pharmaceuticals;Sanofi,na,na,Breast cancer;Gynaecological cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,Dyax Human Phage Display,,Genetically human,MM-121;MM121;MM 121;SAR-256212;SAR256212;SAR 256212
Serplulimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWIRQAPGKGLEWVSTISGGGSNIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSYYYGIDFWGQGTSVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTIPWTFGGGTKLEIK,na,na,7e9b:HL,None,None,2019,2020,PDCD1/CD279/PD1,Henlix Biotech;Shanghai Henlius Biotech,Solid tumours,Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B;Gastric cancer;Cervical cancer;Hepatitis B;Liver cancer,na,,,Humanised,HLX-10;HLX10;HLX 10
Setoxaximab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA,DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK,na,na,None,None,None,2012,2013,Shiga Toxin Type 2,Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc,na,na,Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections,,,Chimeric,caStx2;Shigamabs (Combination with Pritoxaximab)
Setrusumab,Whole mAb,G2,Lambda,Phase-III,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS,DIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL,na,na,None,None,None,2017,2018,SOST,MorphoSys;Novartis;Mereo BioPharma,na,Osteogenesis imperfecta,Hypophosphatasia;Postmenopausal osteoporosis,MorphoSys HuCAL Phage Display,,Genetically human,BPS-804;BPS804;BPS 804;MOR-05813;MOR05813;MOR 05813;MOR-5813;MOR5813;MOR 5813
Sibeprenlimab,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYTIHWVRQATGQGLEWMGWIYPLRGSINYAQKFQGRVTMTADKSISTVYMELSSLRSEDTAVYFCARHGAYYSNAFDYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASESVDNDGIRFLHWYQQKPGQAPRLLIYRASTRATGIPARFSGSGSRTEFTLTISSLQSEDFAVYYCQQSNKDPYTFGGGTKVEIK,na,na,None,None,None,2020,2021,TNFSF13/CD256/APRIL,Visterra,na,IgA Nephropathy,na,,,Humanised,VIS-649;VIS649;VIS 649
Sifalimumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK,na,na,4ypg:HL:BA,None,None,2009,2010,IFNA1,Medarex;MedImmune,na,na,Myositis;Psoriasis;Systemic lupus erythematosus,,,Genetically human,MDX-1103;MDX1103;MDX 1103;MEDI-545;MEDI545;MEDI 545
Sigvotatug,Whole mAb,G1,Kappa,Phase-III,Active,QFQLVQSGAEVKKPGASVKVSCKASGYSFTDYNVNWVRQAPGQGLEWIGVINPKYGTTRYNQKFKGRATLTVDKSTSTAYMELSSLRSEDTAVYYCTRGLNAWDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLEDGVPSRFSGSGSGRDYTFTISSLQPEDIATYYCQNVLTTPYTFGQGTKLEIK,na,na,None,None,None,2023,2024,ITGB6,Seattle Genetics;Seagen,na,Non-small cell lung cancer;Solid tumours,na,,Also found as an ADC with vedotin,Humanised,SGN-B6A
Silevimig,Bispecific ((G1_L-kappa)_scFv-G1(h-CH2-CH3)),G1;G1,Kappa;Lambda,Preregistration,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFGSYGMHWVRQAPGKGLEWVATISYDGSIKDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGDRTGNLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNIRNALNWYQQKPGKAPKLLIYDASTRQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNSEFPPTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGGTYSGYTINWVRQAPGQGLEWMGGIIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLDNSGTYYYFSGWFDPWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDLGGYDFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVL,None;None,None;None,None;None,2023,2024,Rabies Lyssavirus Glycoprotein G epitope III;Rabies Lyssavirus Glycoprotein G epitope I,Genrix (Shanghai) Biopharmaceuticals,na,Rabies,na,,,Genetically human,GR1801;GR-1801
Siltartoxatug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGAGLVKPSETLSLTCGVAGGPFTGSYLSWIRQPPGKGLEWIGEVSQSGSTSYNPSLKSRVTISVDTSKSQFSLKLSSVTAADTAVYYCARLTKHYINSAYWGQGTLVTVSS,DIQMTQSPSILSASVGDRVTITCRASQIIGSWLAWYQQKPGKAPTLVIYKASRLDSGVPSRFSGTESGTEFTLTISSLQPDDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2024,2024,Clostridium tetani tetanus toxin (TeNT),Trinomab Biotech Co,na,Tetanus,na,,,Genetically human,TNM002;TNM-002;TNM 002
Siltuximab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK,na,na,None,None,None,2008,2009,IL6,Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center,Giant lymph node hyperplasia,Multiple myeloma,Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma,,,Chimeric,Cclb8;CNTO-328;CNTO328;CNTO 328;Sylvant
Simaravibart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILDRVMYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAIDSDTYVEQSHFDYWGQGTLVTVSS,EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPSLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQPLTFGGGTKVEIK,na,na,7s6j:HL:CD:FG/7s6k:HL:CD:FG/7s6l:HL/7sbu:HL,None,None,2022,2023,SARS-CoV-2 Spike RBD,Toscana Life Sciences,na,COVID-19,na,,,Genetically human,MAD-0004J08;MAD0004J08;MAD 0004J08;MAD-4J08;MAD4J084;MAD 4J08
Simlukafusp,Whole mAb Fusion,G1,Kappa,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,FAP,Roche,na,na,Malignant melanoma;Renal cell carcinoma;Solid tumours,,,na,RG 7461;RG-7461;RG7461;RO 6874281;RO-6874281;RO6874281
Simridarlimab,Bispecific Mixed mAb/VH-VH-CH2-CH3,G1;G1,Kappa;na,Phase-II,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSIEHYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK,QVQLQESGGGLVQPGGSLRLSCAASAYTISRNSMGWFRQAPGKGLEGVAAIESDGSTSYSDSVKGRFTISLDNSKNTLYLEMNSLRAEDTAVYYCAAPKVGLGPRTALGHLAFMTLPALNYWGQGTLVTVSS,na,None;None,None;None,None;None,2021,2022,IAP/CD47;PDL1/CD274,Innovent Biologics,na,Solid tumours,na,,,Genetically human;Humanised,IBI322;IBI-322;IBI 322
Simtuzumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK,na,na,None,None,None,2012,2013,LOXL2,Arresto Biosciences;Gilead Sciences,na,na,Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis,,,Humanised,AB-0024;AB0024;AB-24;AB24;AB 0024;AB 24;GS-6624;GS6624;GS 6624
Sintilimab,Whole mAb,G4,Kappa,Approved,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK,na,na,None,None,None,2018,2019,PDCD1/CD279/PD1,Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University,Hodgkin's disease,Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours,na,,,Genetically human,IBI 308;;IBI-308;IBI308;LY-3342901;LY3342901;LY 3342901;Tyvyt;Xindili Dankang
Sipavibart,Whole mAb,G1,Lambda,Preregistration,Active,EVQLVESGGGLVQPGRSLRLSCAASGFPFDDYAIHWVRLAPGKGLEWVSSISWDSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKGAFPGYSSGWYYGLEVWGQGTTVTVSS,QSVVTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIFEVSKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYAGNKGVFGGGTKLTVL,na,na,8suo:HL,None,7zff:HL/7zr7:DE:FG:HL/8cbf:HL,2023,2024,SARS-CoV-2 Spike RBD,AstraZeneca;RQ Bio,na,COVID 2019 infections,na,,,Genetically human,AZD3152;AZD-3152
Sirexatamab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGGGFGTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPGYNNYYFDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSIQGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSESWPLHFGGGTKVEIK,na,na,None,None,None,2021,2022,DKK1,Leap Therapeutics,na,DKK1,na,,June '22: Corrected VH/VL sequences,Humanised,DKN-01;DKN01;DKN 01;DKN-1;DKN1;DKN 1;LY-2812176;LY 2812176;LY2812176
Sirtratumab,Whole mAb ADC,G2,Kappa,Phase-I,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,SLITRK6,Astellas/Agensys;Seattle Genetics,na,Bladder Cancer,na,,ADC with vedotin,Genetically human,AGS15C;AGS-15C;AGS 15C;Ha15-10ac12
Sirukumab,Whole mAb,G1,Kappa,Preregistration (w),Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK,na,na,None,None,None,2011,2012,IL6,Centocor Inc;GlaxoSmithKline;Janssen Biotech,na,COVID-19,Rheumatoid arthritis;Atherosclerosis;Giant cell arteritis;Asthma;Lupus nephritis;Major depressive disorder,,,Genetically human,CNTO-136;CNTO136;CNTO 136;PLIVENSIA;Shirukumabu
Socazolimab,Whole mAb,G1,Lambda,Approved,Active,EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAPYYYYYMDVWGQGTTVTVSS,QSALTQPASVSGSLGQSVTISCTGSSSDVGSYNLVSWYQQHPGKAPNLMIYDVSKRSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTGISTVVFGGGTKLTVL,na,na,None,None,None,2021,2022,PDL1/CD274,Sorrento Therapeutics;China Oncology Focus Ltd;Lee's Pharmaceutical,Cervical cancer,Small cell lung cancer;Oesophageal cancer;Osteosarcoma;Urogenital cancer;Malignant melanoma,Cancer,,,Genetically human,STI-1014;STI1014;STI 1014;STI-A1014;STI A1014;ZKAB-001;ZKAB001;ZKAB 001;ZKAB-1;ZKAB1;ZKAB 1
Sofituzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK,na,na,None,None,None,2013,2014,MUC16/CA125,Genentech,na,na,Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer,,ADC with vedotin,Humanised,DMUC-5754A;DMUC5754A;DMUC 5754A;RG-7458;RG7458;RG 7458
Solabafusp,Antibody Fusion Protein,G4,Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSETLSITCTVSGFSLSNYDISWIRQPPGKGLEWLGVIWTGGATNYNPALKSRLTISRDNSKNQVSLKMSSVTAADTAVYYCVRDSNYRYDEPFTYWGQGTLVTVSS,EIVLTQSPDTLSVTPKEKVTLTCRASQSIGTNIHWFQQKPGQSPKLLIKYASESISGVPSRFSGSGSGTDFTLTINSVEAEDAATYYCQQSNSWPYTFGQGTKLEIK,na,na,None,None,None,2024,na,PDL1/CD274,Pieris Pharmaceuticals;Servier,na,Solid tumours,na,,,Genetically human,PRS-344;PRS 344;PRS344;ONC0055;ONC 0055;ONC-0055;S095012;S 095012;S-095012;PRS-344S095012;PRS 344S095012;PRS344S095012;S-95012;S 95012;S95012
Solanezumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK,na,na,None,4xxd:ED:BA,None,2008,2009,APP,Eli Lilly,na,Alzheimer's disease,na,,,Humanised,LY-2062430;LY 2062430;LY206430
Solitomab,Bispecific scFv,na;na,Kappa;Kappa,Phase-I,Discontinued,EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS,ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK,DVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWIGYINPSRGYTNYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYYDDHYCLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSYMNWYQQKPGKAPKRWIYDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQWSSNPLTFGGGTKVEIK,None;None,None;None,None;None,2011,2012,EPCAM/CD326;CD3E,Micromet Inc;Amgen,na,na,Solid tumours,,,Murine;Murine,AMG-110;AMG110;AMG 110;MT110;MT-110;MT 110;Solitumomab 
Solnerstotug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYSMNWVRQAPGKGLEWVSYISSDADTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREAGGVLGRVDFQHWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASKLGTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQADFVPPWTFGGGTKVEIK,na,na,None,8tbq:HL:AB,None,2024,na,VSIR/VISTA/B7H5/PD1H/SISP1,Sensei Biotherapeutics,na,Solid tumours,na,,,Humanised,SNS-101;SNS 101;SNS101
Solrikitug,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFTDYAMHWVRQAPGQGLEWMGTFIPLLDTSDYAQKFQGRVTMTADTSTSTAYMELRSLRSDDTAVYYCARMGVTHSYVMDAWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQPISISVHWYQQKPGQAPRLLIYFASQSISGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTFSLPYTFGQGTKVEIK,na,na,None,None,None,2023,2024,TSLP,Merck & Co,na,na,Atopic dermatitis,,,Humanised,MK-8226;MK8226;MK 8226
Sonavibart,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSYNAVWNWIRQSPSRGLEWLGRTYYRSGWYNDYAESVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARSGHITVFGVNVDAFDMWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSQSLSSYTHWYQQKPGKAPKLLIYAASSRGSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSRTFGQGTKVEIK,na,na,5jw3:HL/5jw4:MN:OP:QR:ST:UV:WX/5jw5:HL:AB,None,None,2024,na,Influenza A HA,Humabs BioMed;AstraZeneca,na,na,Influenza A virus infections,,,Genetically human,MEDI8852;MEDI-8852;MEDI 8852
Sonelokimab1,Trispecific Single Domains (VH-VH'-VH''); Bispecific Entry,na;na,na;na,Phase-III,Active,DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYVVGWFRQAPGKEREFIGAISGSGESIYYAVSEKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTADQEFGYLRFGRSEYWGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,None;None,None;None,None;8z8v:B,2019,2020,IL17A;ALB,Ablynx;Avillion; MoonLake Immunotherapeutics;Merck Serono,na,Hidradenitis suppurativa;Psoriasis;Psoriatic arthritis;Ankylosing spondylitis,na,,VH-VH' portion. Joint entry with Sonelokimab2 (trispecific). Humanised: Llama/Human,Humanised;Humanised,ALX 0761;ALX-0761;ALX0761;ALX-761;ALX761;ALX 761;M 1095;M1095;M-1095;MSB-0010841;MSB 0010841;MSB0010841;MSB10841;MSB-10841;MSB 10841;Sonelokinab
Sonelokimab2,Trispecific Single Domains (VH-VH'-VH''); Monospecific Entry,na,na,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGRTYDAMGWLRQAPGKEREFVAAISGSGDDTYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCATRRGLYYVWDANDYENWGQGTLVTVSS,na,na,na,None,None,None,2019,2020,IL17F,Ablynx;Avillion; MoonLake Immunotherapeutics;Merck Serono,na,Hidradenitis suppurativa;Psoriasis;Psoriatic arthritis;Ankylosing spondylitis,na,,VH'' portion. Joint entry with Sonelokimab1 (trispecific). Humanised: Llama/Human,Humanised,ALX 0761;ALX-0761;ALX0761;ALX-761;ALX761;ALX 761;M 1095;M1095;M-1095;MSB-0010841;MSB 0010841;MSB0010841;MSB10841;MSB-10841;MSB 10841;Sonelokinab
Sonesitatug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSNYAWNWIRQPPGKGLEWIGYIYYSGNTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCATSYYGNSFIYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNAYSFPWTFGQGTKVEIK,na,na,None,None,None,2024,na,CLDN18,KeyMed Biosciences;Miracogen;AstraZeneca,na,Adenocarcinoma,na,,ADC with vedotin,Humanised,AZD-0901;AZD 0901;AZD0901;CMG-901;CMG 901;CMG901
Sotiburafusp,Fusion Protein (whole mAb with protein),G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYAFTGYTIHWVRQAPGQRLEWMGWFYPGSGTLKYSEKFQGRVTITRDKSLSTAYMELSSLRSEDTAVYYCARHGTGTLMAMDYWGQGTLVTVSS,DVVMTQTPLSLSVTPGQPASISCKSSQSLANSYGNTYLSWYLHKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPPTFGQGTKLEIK,na,na,None,None,None,2023,2023,VEGFR-1,Huabo Biopharm,na,Renal cell carcinoma;Solid tumours,na,,,na,HB-0025;HB 0025;HB0025
Sotigalimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKGRFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSS,DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIK,na,na,None,None,None,2020,2021,TNFRSF5/CD40,Apexigen,na,Pancreatic cancer;Metastatic cancer;Non-small cell lung cancer;Renal cell carcinoma;Gastric adenocarcinoma;Soft-tissue sarcoma;Esophageal carcinoma;Rectal cancer;Malignant melanoma,Brain cancer;Glioma;Solid tumours,,,Humanised,APX 005;APX005;APX 005;APX5;APX-5;APX 5;EPI-0050;EPI0050;EPI 0050;EPI 50;EPI-50;EPI50
Sotevtamab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGATVKISCKVSGFNIKDIYMHWVQQAPGKGLEWMGRIDPAYGNTKYDPKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARRYDTAMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLWTFGQGTKLEQL,na,na,None,None,None,2021,2022,CLU,Alethia Biotherapeutics,na,Solid tumours,na,,,Humanised,16B5;AB-16B5;AB16B5;AB 16B5
Sotrovimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK,na,na,None,7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB/7tm0:JK:LM:NO/7tn0:BA:CD/7xck:AB/7x1m:AB/7xsw:AB:HL/7yad:AB:CD/7yr0:CB/7yqy:HF:IG:JE/7yqx:HF:IG/7yxz:IG:JH/8df5:AB:CD/8dw2:DC/8dw3:DC/8fxb:HL/8fxc:HL/8hws:IJ/8s9g:HL/8vye:AD:IJ:RS/8vyg:AB/8wpw:AB/8wpy:BA/8wyj:ST:EG:IK/8y6a:CD/9au1:MN,None,2020,2021,SARS-CoV-2 Spike RBD,GlaxoSmithKline;Vir Biotechnology,COVID-19,na,na,,,Genetically human,GSK-4182136;GSK 4182136;GSK 4182136;VIR-7831;VIR 7831;VIR7831;WBP 2275;WBP-2275;WBP2275
Sovipostobart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:GH:JK/6jc2:HL/6rp8:HL:hl/7elx:HL:hl,None,None,2023,2023,CTLA4/CD152,CytomX Therapeutics;Bristol-Myers Squibb,na,Malignant melanoma;Solid tumours,na,,Danvilostomig Fv1;Ipilimumab; Sovipostobart; and Tazlestobart all have the same sequence. Cleavable prodomain.,Genetically human,BMS-986249;BMS 986249;BMS986249
Spartalizumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK,na,na,None,None,None,2017,2018,PDCD1/CD279/PD1,Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital,na,Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer,Neuroendocrine tumours,,,Humanised,PDR 001;PDR-001;PDR001
Spesolimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSS,QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIK,na,na,6u6u:HL,None,None,2018,2019,IL36RN,Boehringer Ingelheim,Pustular psoriasis,Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis,na,,,Humanised,BI 655130;BI655130;BI-655130;SPEVIGO
Spevatamig,Bispecific Whole mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVREAPGQGLEWIGNIDPSDSETHYAQKFQGRVTLTVDKSTSTVYMELSSLRSEDTAVYYCAGTDLAYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCHASQNINVWLSWYQKKPGQAPRLLIYKASNLHTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGQSYPFTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFIFSSFGMHWVRKAPGKGLEWVAYISSGRSTMYYADSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARGGFYGNSLDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSLSLLNSGNQKNYLTWYQEKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYSCQNAYSYPLTFGQGTKVEIK,None;None,None;None,None;None,2024,na,IAP/CD47;CLDN18,Phanes Therapeutics,na,Adenocarcinoma;Cancer;Pancreatic cancer,na,,,Genetically human;Humanised,PT-886;PT 886;PT886
Stamulumab,Whole mAb,G1,Lambda,Phase-I/II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDENWGFDPWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGHALGDKFVSWYQQKPGQSPVLVIYDDTQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSFVFGGGTKVTVL,na,na,None,None,None,2006,2006,MSTN/GDF8/GDF-8/GDF8,Cambridge Antibody Technology;Wyeth,na,na,Muscular dystrophies;Sarcopenia,,,Genetically human,MYO 29; MYO-029;MYO029;MYO-29;MYO 0029;MYO29
Stapokibart,Whole mAb,G4,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVSTISSGGSYTNYADSVKGRFTISRDNVKNTLYLQMNSLRAEDTAVYYCARATARATEFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGNTLPLTFGGGTKVEIK,na,na,None,None,None,2023,2023,IL4R/CD124,KeyMed Biosciences;CSPC Pharmaceutical Group,Allergic rhinitis;Atopic dermatitis;Rhinosinusitis,Prurigo nodularis;Asthma;Chronic obstructive pulmonary disease,na,,,Humanised,CM-310;CM 310;CM310
Suciraslimab,Whole mAb,G1,Kappa,Preregistration,Active,QVQLQESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGSSYGVLFAYWGQGTLVTVSS,DIQLTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGGGTKLEIK,na,na,None,None,None,2021,2022,SIGLEC2/CD22,Lonn Ryonn Pharma; SinoMab Bioscience Ltd,na,Rheumatoid arthritis;Non-Hodgkin's lymphoma;Systemic lupus erythematosus;Sjogren's syndrome,na,,,Chimeric,SM-03;SM03;SM 03;SM-3;SM3;SM 3;SM-06;SM06;SM 06;SM-6;SM6;SM 6
Sudubrilimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSETWLHWVRQAPGKGLEWVAWVSPFGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFLYHPATFGQGTKVEIK,na,na,None,None,5x8l:GL:FK:SN:HM:JO/5xxy:HL,2020,2021,PDL1/CD274,Zhejiang Hisun Pharmaceutical,na,Hematologic Neoplasms;Solid tumours,Cancer;Triple-Negative Breast Carcinoma;Primary mediastinal large B-cell lymphoma recurrent,,,Genetically human,HS636;HS-636;HS 636
Sugemalimab,Whole mAb,G4,Lambda,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPPRGYNYGPFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2019,2020,PDL1/CD274,Cstone Pharmaceuticals,Non-small cell lung cancer,Cancers;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma;Gastric cancer,na,,,Genetically human,Cejemly;CS-1001;CS1001;CS 1001;Sugelimab;WBP-3155;WBP3155;WBP 3155;Zegema;Zegemet;Zegemex;ZEJIEMEI
Suptavumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSS,EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,Respiratory Syncytial Virus Glycoprotein F,Regeneron Pharmaceuticals,na,na,Respiratory syncytial virus infections,VelocImmune Mouse. VelociGene,,Genetically human,REGN-2222;SAR-438584;REGN222;SAR438584;REGN 2222;SAR 438584
Surovatamig,Bispecific Mixed Domains ((H-gamma4_L-kappa)_VH-G4(h-CH2-CH3)),G4;G4,Kappa;na,Phase-III,Active,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDSRGYGDYRLGGAYWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPWTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFSFSDFWMSWVRQAPGKGLEWVATISQAGSEKDYVDSVKGRFTISRDNAKKSLYLQMNSLRAEDTAVYYCASGVYSFDYRGQGTLVTVSS,na,None;None,None;None,None;None,2024,na,CD3D&CD3E;CD19,AstraZeneca;TeneoBio;TeneoTwo,na,Follicular lymphoma;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma,na,,VH2 likely humanised from camelid. Feb '25: MedNet file updated [PL132],Genetically human;Humanised, AZD-0486;AZD 0486;AZD0486;TNB-486;TNB 486;TNB486
Surzebiclimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVAAISSGGSLYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGREADGGYFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASESVEYYGTSLMQWYQQKPGQAPRLLIYAASNVESGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSLKVPLTFGGGTKVEIK,na,na,None,None,None,2020,2021,HAVCR2/TIM3,BeiGene,na,Solid tumours,na,,,Genetically human,BGB-A425;BGB A425
Sutacimig,Bispecific Whole mAb,G4;G4,Kappa;Kappa,Phase-I/II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGYSISSDSAWSWIRQPPGKGLEWIGYIQYSGSTNYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARSVNYYGNSFAVGYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQGISDYLHWYQQKPGEAPRLLIKYTSQPATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQNGHSFPLTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMTWVRQAPGKGLVWVGEINPDSSTINYAPSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGVFTSWGQGTLVTVSS,DIVMTQTPLSSPVTLGQPASISCRSSQSLVHRQGNTYFHWLQQRPGQPPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLKISRVEAEDVGVYYCSQSTHVPYTFGQGTKLEIK,8cn9:BA:GF:LK:QP;8che:HL:AB,None;None,None;None,2024,na,F7a/F7A/FVIIa/FVIIA;TREML1/GLTL1825/PRO3438/TLT-1/TLT1,Hemab,na,Thrombasthenia;Factor VII deficiency,na,,,Humanised;Humanised,HMB001;HMB-001;HMB 001
Sutimlimab,Whole mAb,G4,Kappa,Approved,NFD,EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSS,QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK,na,na,None,None,None,2017,2018,C1S,Bioverativ;True North Therapeutics,Autoimmune haemolytic anaemia,na,Idiopathic thrombocytopenic purpura;Bullous pemphigoid;Renal transplant rejection,,Chimeric: Mouse/Human,Chimeric and humanised,BIVV 009;BIVV009;BIVV-009;BIVV 9;BIVV9;BIVV-9;Enjaymo;Sutimlimab-jome;TNT 009;TNT009;TNT-009;TNT 9;TNT9;TNT-9
Suvemcitug,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFSFSNNDVMCWVRQAPGKGLEWIGCIMTTDVVTEYANWAKSRFTVSRDSAKNSVYLQMNSLRAEDTAVYFCARDSVGSPLMSFDLWGPGTLVTVSS,DIQMTQSPSSLSASVGDRVTINCQASQSIYNNNELSWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCGGYKSYSNDGNGFGGGTKVEIK,na,na,None,None,None,2023,2023,VEGFA,Epitomics;Jiangsu T-mab BioPharma;Simcere Pharmaceutical Group,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Colorectal cancer;Solid tumours,Wet age-related macular degeneration,,,Humanised,APX003;APX-003;BD0801;BD-0801;TK001;TK-001;Sevacizumab (not WHO assigned INN)
Suvizumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS,DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK,na,na,3ntc:HL,None,None,2009,2010,HIV-1 gp120,Kaketsuken;Kumamoto University;University of Missouri-Columbia,na,na,HIV-1 infections,,,Humanised,KD-247;KD247;KD 247
Suvonstobart,Whole mAb,G1,Kappa,TBC,TBC,DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYSWHWIRQFPGNKLEWMGYIHYSGSTKYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCARGADYALDYWGQRTSVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYSSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNFIYPLTFGGGTKVELK,na,na,None,None,None,2025,na,CD24,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Suvratoxumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK,na,na,4u6v:HL:KM,None,None,2016,2017,Staphylococcus aureus Toxin A,Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune,na,na,Nosocomial pneumonia,,,Genetically human,AR-320;AR320;AR 320;MEDI-4893;MEDI4893;MEDI 4893
Tabalumab,Whole mAb,G4,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,na,na,None,None,None,2011,2012,TNFSF13B/CD257/BAFF,Eli Lilly,na,na,Multiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus,,,Genetically human,LY 2127399;LY-2127399;LY2127399
Tabirafusp,Antibody Fusion Protein,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMHWVRQAPGKGLEWVAKISPGGSWTYYSDTVTDRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARQAWGYYALDIWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASISVSYLYWYQQKPGKAPKLLIYDDSSLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSGYPYTFGQGTKVEIK,na,na,None,None,None,2024,na,IL6,Kodiak Sciences,na,Wet age-related macular degeneration;Diabetic macular oedema;Dry age-related macular degeneration,Uveitis,,ADC with Tedromer,Genetically human,KSI-501;KSI 501;KSI501;KSI-501ABC;KSI 501ABC;KSI501ABC
Tabituximab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA,DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK,na,na,None,None,None,2018,2019,FZD10/CD350,OncoTherapy Science;Centre Leon Berard,na,na,Synovial sarcoma,,,Chimeric,OTSA101;OTSA-101;OTSA 101;ONC-005;ONC005;ONC 005;ONC-5;ONC5;ONC 5
Tacatuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLQQSGAEVKKPGSSVKVSCKASGYAFTSYVIHWVRQAPGQGLYWIGYIHPYNGGTKYNEKFKGKATITADESTNTAYMELSSLRSEDTAFYFCARSGGGDPFAYWGQGSLVTVSS,DIQLTQSPSSLSASVGDRVTITCKASQDINKYIGWYQQKPGKAPKLLMHYTSALLPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGGGTKLQIK,na,na,None,None,None,2005,2006,Alpha Ferroprotein,Immunomedics,na,na,Liver cancer,,,Humanised,IMMU-105;IMMU105;IMMU 105
Tadocizumab,Fab,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS,DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQGTKVEVK,na,na,None,None,None,2005,2006,ITGA2B and ITGB3,PDL BioPharma;Yamanouchi,na,na,Coronary artery restenosis;Stroke;Thrombosis,,,Humanised,C4G1;YM-337;YM337;YM 337
Tafasitamab,Whole mAb,G1,Kappa,Approved,Active,EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS,DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK,na,na,None,None,None,2018,2019,CD19,MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor,Diffuse large B cell lymphoma,Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Follicular lymphoma;Marginal zone B-cell lymphoma,na,MorphoSys HuCAL Phage Display. XmAb Engineering Technology.,Genetics: musmus/homosap,Chimeric and/or humanised,ICP-B04;ICP B04;MOR 208;MOR208;MOR-208;XENP-5574;XENP5574;XENP 5574;XmAb-5574;XmAb5574;XmAb 5574
Tafolecimab,Whole mAb,G2,Kappa,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSASYYWSWIRQPPGKGLEWIGSINYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARENSGVVPAAGPNWFGPWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,PCSK9,Innovent Biologics,Hypercholesterolaemia,na,na,,,Genetically human,IBI 306;IBI-306;IBI306
Tagitanlimab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSITCTVSGFSLSNYDISWIRQPPGKGLEWLGVIWTGGATNYNPALKSRLTISRDNSKNQVSLKMSSVTAADTAVYYCVRDSNYRYDEPFTYWGQGTLVTVSS,EIVLTQSPDTLSVTPKEKVTLTCRASQSIGTNIHWFQQKPGQSPKLLIKYASESISGVPSRFSGSGSGTDFTLTINSVEAEDAATYYCQQSNSWPYTFGQGTKLEIK,na,na,None,None,None,2021,2022,PDL1/CD274,Sichuan Kelun-Biotech Biopharmaceutical,Nasopharyngeal cancer,Breast cancer;Hodgkin's disease;Non-small cell lung cancer,na,,June '22: Corrected FWL4 sequence,Humanised,A-167;A 167;A167;HBM-9167;HBM9167;HBM 9167;KL-A167;KL A167
Talacotuzumab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS,DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK,na,na,4jzj:HL:AB,None,None,2017,2018,IL3RA/CD123,CSL;Janssen Biotech,na,Myelodysplastic syndromes,Acute myeloid leukaemia;Systemic lupus erythematosus,,,Humanised,CSL-362;CSL362;CSL 362;JNJ 473;JNJ473;JNJ473;JNJ 56022473;JNJ56022473;JNJ-56022473
Talizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFSMYWLEWVRQAPGHGLEWVGEISPGTFTTNYNEKFKARATFTADTSTNTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS,DILLTQSPGTLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPSRFSGSGSGTDFTLTISRLEPEDFAMYYCQQSDSWPTTFGQGTKVEIK,na,na,None,None,None,2002,2004,IgE,Tanox,na,na,Peanut hypersensitivity,,,Humanised,HU 901;HU901;HU-901;TNX 901;TNX-901;TNX901
Talquetamab,Bispecific mAb,G4;G4,Kappa;Lambda,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,9ima:CD;None,None;None,None;None,2019,2020,GPRC5D;CD3E,Genmab;Janssen Research & Development,Multiple myeloma,na,na,,Chimeric: Mouse/Human,Humanised;Chimeric,JNJ 64407564;JNJ64407564;JNJ-64407564;JNJ-7564;JNJ7564;JNJ 7564;TALVEY
Tamgiblimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTEYYMHWVRQAPGQGLEWMGIISPSAGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDHDIRLAGRLADYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAVILPITFGGGTKVEIK,na,na,None,None,None,2021,2022,TIGIT/WUCAM/VSTM3,Innovent Biologics,na,Cancer,na,,,Genetically human,IBI-939;IBI939;IBI 939
Tamrintamab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK,na,na,6vgr:HL:CD,None,None,2018,2019,DPEP3,Stemcentrx,na,na,Ovarian cancer;Solid tumours,,ADC with pamozirine,Humanised,SC-003;SC003;SC 003;SC-3;SC3;SC 3;SC34.28ss1
Tamtuvetmab,Canine Whole mAb,G2,Kappa,Unknown,Active,EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS,DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL,na,na,None,None,1bfo:HG:FE:BA:DC,2015,2016,CD52,Aratana Pharmaceuticals,na,Canine T-cell lymphoma,na,,Chimeric: Rat/Dog,Chimeric,AT005;AT-005;AT 005;AT5;AT-5;AT 5
Tanezumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK,na,na,4edw:HL,None,None,2008,2009,NGFB,Rinat Neuroscience;Pfizer,na,na,Diabetic neuropathies;Postherpetic neuralgia;Cancer pain;Back pain;Musculoskeletal pain,,,Humanised,PF-04383119;PF04383119;PF-4383119;PF4383119;RI-624;RI624;RI 624;RN-624;RN624;RN 624
Tanruprubart,Whole mAb,G4,Kappa,TBC,TBC,QVQLVQSGAELKKPGASVKVSCKSSGYHFTSYWMHWVKQAPGQGLEWIGVIHPNSGSINYNEKFESRVTITVDKSTSTAYMELSSLRSEDTAVYYCAGERDSTEVLPMDYWGQGTTVTVSS,DVQITQSPSSLSASLGERATINCRASKSINKYLAWYQQKPGKAPKLLIYSGSTLQSGIPARFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFGQGTKLEIK,na,na,None,None,None,2025,na,C1q,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised,TBC
Tarcocimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,na,na,1cz8:HL:YX,None,1bj1:HL:KJ/6bft:HL:AB/7v5n:BA:FE,2021,2022,VEGFA,Kodiak Biosciences,na,Age-related macular degeneration;Retinal diseases;Diabetic macular edema,na,,Name corrected from tarcolimab in previous version. ADC with tedromer,Humanised,KSI-301;KSI301;KSI 301
Tarextumab,Whole mAb,G2,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK,na,na,None,None,None,2013,2014,NOTCH2 and NOTCH3,OncoMed Pharmaceuticals,na,Pancreatic cancer;Small cell lung cancer,Solid tumours,MorphoSys HuCAL Phage Display. XmAb Engineering Technology,,Genetically human,OMP-59R5;OMP59R5;OMP 59R5
Tarlatamab,Bispecific scFv,na;na,Kappa;Lambda,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2020,2021,DLL3;CD3E,Amgen,Small cell lung cancer,Prostate cancer,Malignant melanoma,BiTE Technology,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG-757;AMG757;AMG 757
Tarperprumig,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-II,Discontinued,QVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS,na,EVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS,na,None;8q6r:A:B,None;None,None;None,2022,2023,ALB;CFP,Alexion Pharmaceuticals,na,na,Sickle cell disease,,Feb '25: Specificity ordering corrected from PL127 based on solved crystal structures. 8q78:A:B:C:D:E also 100% match but not currently in SAbDab.,Humanised;Humanised,ALXN-1820;ALXN1820;ALXN 1820
Tavolimab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQESGPGLVKPSQTLSLTCAVYGGSFSSGYWNWIRKHPGKGLEYIGYISYNGITYHNPSLKSRITINRDTSKNQYSLQLNSVTPEDTAVYYCARYKYDYDGGHAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGSALPWTFGQGTKVEIK,na,na,None,None,None,2016,2018,TNFSF4/CD134/CD252/OX40L,European Network of Gynaecological Oncological Trial Groups;MedImmune,na,na,Ovarian cancer;Solid tumours,,Tavolimab is the new name for Tavolixizumab (PL118),Chimeric and humanised,MEDI-0562;MEDI0562;MEDI 0562;MEDI-562;MEDI562;MEDI 562;Tavolixizumab
Tazlestobart,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL,None,7su0:HL:IM/7su1:HL,2024,2024,CTLA4/CD152,TBC,TBC,TBC,TBC,,Danvilostomig Fv1;Ipilimumab; Sovipostobart; and Tazlestobart all have the same sequence,Humanised,TBC
Tebentafusp,scFv Fusion,na,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVSS,AIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIK,na,na,None,None,None,2017,2018,CD3E,Immunocore;MedImmune,Uveal melanoma,Malignant melanoma,na,,T-Beta section specific for PMEL peptide 280-288 presented by MH1. 6kr0:DD has an identical heavy chain. Identical sequence to Brenetafusp.,na,IMC-gp100
Tebotelimab,Bispecific scFv with Crossover,G4;G4,Kappa;Kappa,Phase-II/III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQAPGQGLEWMGDINPDNGVTIYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREADYFYFDYWGQGTTLTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVSSVVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYSTPWTFGGGTKLEIK,None;None,None;None,None;None,2019,2020,PDCD1/CD279/PD1;LAG3/CD223,MacroGenics,na,na,Biliary cancer;Cholangiocarcinoma;Endometrial cancer;Gastric cancer;Haematological malignancies;Head and neck cancer;Liver cancer;Malignant melanoma;Oesophageal cancer;Solid tumours;Triple negative breast cancer,,,Humanised;Humanised,MGD-013;MGD013;MGD 013;MGD-13;MGD13;MGD 13
Tecaginlimab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I/II,Active,EVQLVQSGAEVKKPGASVKVSCKTSGYTFTEYIMHWVRQAPGQGLEWMGGIIPNNGGTSYNQKFQGRVTMTVDKSTSTGYMELSSLRSEDTAVYYCTRREVYGRNYYALDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQGINNYLNWYQQKPGKAVKLLIYYTSSLHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQYSNLPYTFGGGTKVEIK,EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS,DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK,None;None,None;None,None;None,2021,2022,CD40;TNFRSF9/CD137/4-1BB,Genmab,na,Solid tumours,na,,,Humanised;Humanised,BNT-312;BNT312;BNT 312;GEN-1042;GEN1042;GEN 1042
Teclistamab,Bispecific mAb,G4;G4,Lambda;Lambda,Approved,Active,QLQLQESGPGLVKPSETLSLTCTVSGGSISSGSYFWGWIRQPPGKGLEWIGSIYYSGITYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHDGAVAGLFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQPPGQAPVVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEAVYYCQVWDSSSDHVVFGGGTKLTVL,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2018,2019,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Genmab;Janssen Research & Development,Multiple myeloma,na,na,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,JNJ 7957;JNJ7957;JNJ-7957;JNJ-64007957;JNJ64007957;JNJ 64007957;TECVAYLI
Tecotabart,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTFGMHWVRQAPGKGLEWVSYITSGESPIYFTDTVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSSYYGNSMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRSSQSLLNAGNRKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNAYSYPFTFGGGTKLEIK,na,na,None,None,None,2024,2024,CLDN18,LaNova Medicines,na,Solid tumours,na,,,Humanised,LM-102;LM 102;LM102
Tegoprubart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,na,na,1i9r:HL:KM:XY/6w4w:HL,None,None,2023,2023,CD40LG/CD154,ALS Therapy Development Institute;Eledon Pharmaceuticals,na,Allotransplant rejection;Amyotrophic lateral sclerosis;IgA nephropathy;Renal transplant rejection;Autoimmune disorders,na,,Same Fv sequence as Ruplizumab,Chimeric,AT-1501;AT1501;AT 1501
Telazorlimab,Whole mAb,G1,Kappa,Phase-II,Active,QVTLKESGPALVKPTQTLTLTCSFSGFSLSTSGMGVGWIRQPPGKALEWIAHIWWDDDKYYNTALKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIDWDGFAYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGQAPRPWIYATSNRATGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQWSSNPWTFGQGTKVEIK,na,na,None,None,None,2019,2020,TNFRSF4/CD134/OX40,Glenmark Pharmaceuticals,na,Atopic dermatitis;Systemic lupus erythematosus;Ulcerative colitis;Rheumatoid arthritis,na,,,Humanised,GBR-830;GBR830;GRB 830;ISB-830;ISB830;ISB 830
Telikibart,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAVSGFTFSSYAMSWVRQAPGKGLEWVSSITGGGGGIYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDRISITIRPRYFGLDFWGQGTTVTVSS,DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQSFKAPYTFGQGTKLEIK,na,na,None,None,None,2024,na,IL4R/CD124,Genrix (Shanghai) Biopharmaceuticals,na,Atopic dermatitis;Rhinosinusitis;Allergic rhinitis;Asthma;Chronic urticaria,na,,,Genetically human,GR-1802;GR 1802;GR1802
Telisotuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYIFTAYTMHWVRQAPGQGLEWMGWIKPNNGLANYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSEITTEFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVDSYANSFLHWYQQKPGQPPKLLIYRASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSKEDPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,MET/HGFR,Pierre Fabre;AbbVie,na,na,Solid tumours,,,Humanised,ABT-700;ABT700;ABT 700;h224G11
Temelimab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEMHWVRQAPGQGLEWIGAVAPETGGTAYNQKFKGRATITADKSTSTAYMELSSLRSEDTAVYYCTSTVVPFAYWGQGTLVTVSS,QIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKAWIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYQSLPLTFGGGTKVEIK,na,na,None,None,None,2018,2019,MS-associated Retrovirus Envelope Protein,GeNeuro,na,Multiple sclerosis;Type 1 diabetes mellitus;Chronic inflammatory demyelinating polyradiculoneuropathy,na,,,Humanised,GNN001;GNN-001;GNN 001;GNN1;GNN-1;GNN 1
Temtokibart,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMNWVRQAPGKGLEWVSSIYNDASNTAYSDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGFSGTYYSESWGQGTLVTVSS,SQELTQPSSVSVALGQTARITCQGGYYAHWYQQKPGQAPVLVIYGQNNRPSGIPERFSGSGAGNTATLTISRAQAEDEADYYCQSGSSSSNAVFGGGTKLTVL,na,na,None,None,None,2023,2023,IL22RA1,argenx;LEO Pharma,na,Atopic dermatitis,na,,,Humanised,LEO 138559;LEO-138559;LEO138559;ARGX112;ARGX-112;LP0145;LP-0145
Tenatumomab,Whole mAb Radiolabelled,G2b,Kappa,Phase-I,Discontinued,EIQLQQSGPELVKPGASVKVSCKASGYAFTSYNMYWVKQSHGKSLEWIGYIDPYNGVTSYNQKFKGKATLTVDKSSSTAYMHLNSLTSEDSAVYYCARGGGSIYYAMDYWGQGTSVTVSS,DIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYLYWFLQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPLTFGAGTKLELK,na,na,None,None,None,2007,2008,TNC,sigma-tau SpA,na,na,Cancer,,,Murine,ST2146;ST-2146;ST 2146
Teneliximab,Whole mAb,G1,Kappa,Phase-II,ND,QIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQWVQEMPGKGLKWIGWINTHSGVPKYVEDFKGRFAFSLETSANTAYLQISNLKNEDTATYFCVRSGNGNYDLAYFAYWGQGTLVTVSA,DIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGGGTKLEIK,na,na,5dmi:HL,None,None,2002,2003,TNFRSF5/CD40,Bristol-Myers Squibb,na,Cancer,na,,,Chimeric,Chi220
Teplizumab,Whole mAb,G1,Kappa,Approved,NFD,QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSNPFTFGQGTKLQIT,na,na,None,None,None,2007,2008,CD3E,Immune Tolerance Network;MacroGenics;National Institute of Diabetes and Digestive and Kidney Diseases;National Institutes of Health (USA);Provention Bio;Tolerance Therapeutics,Type 1 diabetes mellitus,na,Multiple sclerosis;Psoriasis;Psoriatic arthritis,,,Humanised,MGA-031;MGA031;MGA 031;MGA31;MGA-31;MGA 31;PRV 031;PRV-031;PRV031;PRV 31;PRV-31;PRV31;PVR031;PVR-031;PVR 031;PVR 31;PVR-31;PVR31;TZIELD
Tepoditamab,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKGTTGDWFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGGGVVQPGRSLRLSCVASGFTFSSYGMHWVRQAPGKGLEWVAAIWYNARKQDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGTGYNWFDPWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,None;None,None;None,None;None,2017,2018,CLEC12A;CD3E,Genmab;Janssen Research & Development,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,,,Genetically human;Genetically human,MCLA-117;MCLA117;MCLA 117
Teprotumumab,Whole mAb,G1,Kappa,Approved,Active,QVELVESGGGVVQPGRSQRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWFDGSSTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARELGRRYFDLWGRGTLVSVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASKRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSKWPPWTFGQGTKVESK,na,na,None,None,None,2009,2010,IGF1R/CD221,Genmab;Roche;Horizon Therapeutics plc,Graves ophthalmopathy,Diffuse scleroderma,Diabetic macular oedema;Advanced breast cancer;Hodgkin's disease;Non-Hodgkin's lymphoma;Non-small cell lung cancer;Sarcoma;Solid tumours,Medarex UltiMAb Mouse,,Genetically human,HZN 001;HZN-001;HZN001;HZN-1;HZN1;HZN 1;R 1507;R1507;R-1507;RG 1507;RG-1507;RG1507;RO-4858696;RO 4858696;RO4858696;Tepezza
Teropavimab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDVWGSGTQVTVSS,DIQMTQSPSSLSASVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGVPSRFSGRRWGQEYNLTINNLQPEDIATYFCQVYEFVVPGTRLDLK,na,na,8c8t:RT:SU,4lsv:HL/4jpv:HL/5v8l:HL:GK:IM:GN/5v8m:HL:RT:SU/7ly9:HL:AM:EI:BC/7mxd:CD:JK:SU/7n28:CD:JK:SU/7pc2:GH:IJ:KL/8gje:HL:GJ:IK/9bew:CD:FI:OP,None,2021,2022,HIV-1 gp120 CD4bs,Gilead,na,HIV-1,na,,,Genetically human,3BNC 117;3BNC-117;GS-5423;GS 5423;GS5423;Lafuvitug
Tesidolumab,Whole mAb,G1,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS,SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL,na,na,None,None,None,2014,2015,C5,MorphoSys;Novartis,na,Paroxysmal nocturnal haemoglobinuria,Choroiditis;Dry age-related macular degeneration;Panuveitis;Thrombotic microangiopathy;Wet age-related macular degeneration,MorphoSys HuCAL Phage Display. XmAb Engineering Technology,,Genetically human,LFG-316;LFG316;LFG 316;NOV-4;NOV 4;NOV4
Tesnatilimab,Whole mAb,G4,Kappa,Phase-II,Active,QVHLQESGPGLVKPSETLSLTCTVSDDSISSYYWSWIRQPPGKGLEWIGHISYSGSANYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCANWDDAFNIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2019,2020,KLRK1/NKG2D/CD314,Janssen Research & Development,na,Crohn's disease,na,,,Genetically human,IPH-2301;IPH2301;IPH 2301;JNJ 4500;JNJ4500;JNJ-4500;JNJ-64304500;JNJ 64304500;JNJ64304500;NN-8555;NN8555;NN 8555
Tezepelumab,Whole mAb,G2,Lambda,Approved,Active,QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL,na,na,5j13:CB,None,None,2015,2016,TSLP,Amgen;AstraZeneca;Bispebjerg Hospital;Lund University;MedImmune;University of Copenhagen;University of Newcastle in Australia,Asthma,Atopic dermatitis;Rhinosinusitis;Chronic obstructive pulmonary disease,na,,,Genetically human,AMG 157;AMG-157;AMG157;MEDI-9929;MEDI9929;MEDI 9929;Tezspire 
Tibulizumab,Bispecific Mixed mAb and scFv,G4;G4,Kappa;Kappa,Phase-I,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGYKFTDYHIHWVRQAPGQCLEWMGVINPTYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGETYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGCGTKLEIK,None;None,None;None,None;6nou:AA/6nov:AB,2017,2018,TNFSF13B/CD257/BAFF;IL17A,Eli Lilly,na,na,Rheumatoid arthritis;Sjogren's syndrome,,,Humanised;Humanised,LY-3090106;LY3090106;LY 3090106;ZB-106;ZB106;ZB 106
Tidutamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMAWFRQAPGKGLEWVSFISNLGYSIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAPYDYDSFDPMDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRNRKNYLAWYQQKPDQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYYLWTFGGGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,None;None,None;None,None;None,2018,2019,SSTR2;CD3E,ICON;Xencor,na,na,Gastrointestinal stromal tumours;Neuroendocrine tumours,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,XmAb-18087;XmAb18087;XmAb 18087
Tifcemalimab,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKLSCKASGYNFKHTYAHWVRQAPGQGLEWIGRIDPANGNTKYDPKFQGRATMTADTASNTAYLELSSLRSEDTAVYYCVADHYGSSLLDYWGQGTLVTVSS,DVVMTQTPLSLSVTPGQPASISCKSSQSLLDSDGKTYLNWFQQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTYFPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,BTLA/CD272,Shanghai Junshi Biosciences,na,Solid tumours,na,,Chimeric. Tifcemalimab is the new name for Icatolimab (PL124). Genetics: musmus/homosap,Chimeric and/or humanised,Icatolimab;JS-004;JS004;JS 004;JS-4;JS4;JS 4;TAB-004;TAB004;TAB 004;TAB-4;TAB4;TAB 4
Tigatuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDSMITTDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVGTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSSYRTFGQGTKVEIK,na,na,None,None,None,2007,2008,TNFRSF10B/CD262/DR5/TRAILR2,Daiichi Sankyo Company;University of Alabama at Birmingham,na,na,Breast cancer;Colorectal cancer;Liver cancer;Lymphoma;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer,,IgG version of Aplitabart (same Fv sequence),Humanised,CS-1008;CS1008;CS 1008;TRA-8;TRA8;TRA 8
Tilatamig,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYIHWVRQATGQGLEWMGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCARGQGYTHSWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASEGIYHWLAWYQQKPGKAPKLLIYKASSLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSNYPPTFGGGTKLEIK,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSDNDFSWVRQAPGQGLEWMGAIVAVFRTETYAQKFQDRVKITADISTRTTYMELSSLRSEDTAVYYCARRLMSAISGPGAPLLMWGQGTLVTVSS,QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSDTLEIFGGGTKLTVL,None;None,None;None,None;None,2024,2024,MET/HGFR;EGFR/ERBB1/HER1,AstraZeneca,na,Solid tumours,na,,,Genetically human;Genetically human,AZD9592;AZD-9592;AZD 9592
Tilavonemab,Whole mAb,G4,Kappa,Phase-II,Active,EVKVVESGGGLVQPGGSMKLSCVVSGFTFSNYWVNWVRQAPGKGLEWVAQIRLKSDNYATHYEESVKGRFTISRDDSKSSVYLQMNNLRAEDSGIYYCTNWEDYWGQGTTVTVSS,DIVLTQSPDSLAVSLGERATISCRASQSVSTSRYSYIHWYQQKPGQPPKLLIKYASNLESGVPSRFSGSGSGTDFTLNIHPLEPEDFATYYCHHSWEIPLTFGQGTKLEIK,na,na,None,None,None,2018,2019,MAPT,AbbVie;C2N Diagnostics,na,Alzheimer's disease;Progressive supranuclear palsy,na,,Fixed missing FWL3 residue from Jan '22 release onwards. Genetics: musmus/homosap,Chimeric and/or humanised,ABBV-8E12;ABBV8E12;ABBV 8E12
Tildrakizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADYNEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIK,na,na,None,None,None,2012,2013,IL23A,Almirall S.A.;Merck & Co;Schering-Plough;Sun Pharmaceutical Industries,Plaque psoriasis,Ankylosing spondylitis;Intervertebral disc degeneration;Non-radiographic axial spondyloarthritis;Psoriatic arthritis,Autoimmune disorders,,,Humanised,Ilumetri;ILUMYA;MK-3222;MK3222;MK 3222;SCH-900222;SCH 900222;SCH900222;SUNPG 1622;SUNPG1622;SUNPG-1622;SUNPG 1623;SUNPG-1623;SUNPG1623
Tilogotamab,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTHMHWVRQAPGQRLEWIGRIDPANGNTEYDQKFQGRVTITVDTSASTAYMELSSLRSEDTAVYYCARWGTNVYFAYWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVTITCSASSSVSYMYWYQQKPGKAPKPWIYRTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYHSYPPTFGGGTKVEIK,na,na,None,6t3j:CD:HI,None,2019,2020,TNFRSF10B/CD262/DR5/TRAILR2,Genmab,na,Solid tumours,na,,June '22: Corrected FWL4 sequence,Humanised,GEN-1029;GEN1029;GEN 1029
Tilvestamab,Whole mAb,G1,Kappa,Phase-I,Active,EVQLVESGGGLVQPGGSLRLSCAASGYSFTDFYINWVRQAPGKGLEWVARIFPGGDNTYYNEKFKGRFTLSADTSKSTAYLQMNSLRAEDTAVYYCARRGLYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGIPYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQGTHVPPTFGQGTKVEIK,na,na,None,None,None,2019,2020,AXL/UFO,BerGenBio,na,Cancer,na,,Feb '22: Removed erroneous W insertion from CDRH1.,Humanised,BGB 149;BGB-149;BGB149
Tilrekimig1,Trispecific Mixed mAbs; Bispecific entry,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVASISSGDTTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARNEGYYFGLTLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASESVDHFGWSLVHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK,EVTLRESGPALVKPTQTLTLTCTFSGFSLSNFGEGLSWIRQPPGKGLEWLAHIYWDDDKRYNPSLKSRLTISKDTSRNQVVLTMTNMDPVDTATYYCARRETVFYWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVDEEGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNKDPPTFGGGTKVEIK,None;None,None;None,None;None,2025,na,IL13;IL4,Pfizer,na,Atopic dermatitis,na,,,Genetically human;Genetically human,PF-07275315;PF 07275315;PF07275315
Tilrekimig2,Trispecific Mixed mAbs; Monospecific entry,G1,Lambda,Phase-II,Active,QMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVAVIWYDGSNKHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAPQWYLVHEAFDIWGQGTMVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYDDKDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSKSDHVVFGGGTKLTVL,na,na,None,None,5j13:CB,2025,na,TSLP,Pfizer,na,Atopic dermatitis,na,,,Genetically human,PF-07275315;PF 07275315;PF07275315
Timigutuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2/CD340/HER2,Roche,Breast cancer,na,na,,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains.,Humanised,GEXMab73;GEXMab-73;GEXMab 73
Timolumab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFFSYAMHWVRQTPGKGLEWVAVIWFDGSNENYVDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDAWSYFDYWGQGTLVTVSS,VIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKGPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,AOC3/VAP1,Acorda Therapeutics;Biotie Therapies Corp.;Seikagaku Corporation,na,na,Inflammation;Plaque psoriasis;Rheumatoid arthritis;Primary sclerosing cholangitis,,,Genetically human,BTT-1023;BTT1023;BTT 1023;SI-3106;SI3106;SI 3106
Timcevibart,Whole mAb,G1,Kappa,TBC,Active,QVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVADAFDIWGQGTMVTVSS,DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPFTFGPGTKVDIK,na,na,7b3o:HL,None,None,2023,2024,SARS-CoV-2 Spike RBD,TBC,TBC,TBC,TBC,,8elo:HL is 94.6% identical,Genetically human,TBC
Tinurilimab,Whole mAb,G2,Kappa,Phase-I,Discontinued,QVTLRESGPALVKPTQTLTLTCTFSGFSLSTYGIGVGWIRQPPGKALEWLAHIWWNDNKYYSTSLKTRLTISKDTSKNQVVLTMTNMDPVDTATYYCARISLPYFDYWGQGTTLTVSS,DIQLTQSPSFLSASVGDRVTITCKASQNVGTAVAWYQQKPGKAPKLLIYSASNRYTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQYSSYPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,CEACAM6/CD66c,Bayer;German Cancer Research Center,na,na,Solid tumours,,,Humanised,BAY-1834942;BAY1834942;BAY 1834942
Tiragolumab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEIK,na,na,8jeo:BC:EF/8jeq:AB,None,None,2017,2018,TIGIT/WUCAM/VSTM3,Genentech,na,Non-small cell lung cancer;Solid tumours;Oesophageal cancer;Small cell lung cancer;Squamous cell cancer;Cervical cancer;Liver cancer;B-cell lymphoma;Breast cancer;Multiple myeloma,na,,,Genetically human,MTIG-7192A;MTIG7192A;MTIG 7192A;RG-6058;RG6058;RG 6058;RO 7092284;RO-7092284;RO7092284
Tirnovetmab,Whole mAb (Canine),G2,Kappa,Unknown,Active,EVQLVESGPSLVKPGGSLRLTCSVTGDSITSGYWNWIRKFPGNKLEYMGYISYSGITDYNPSLKSRITISRDTSKNQYYLQLNSVTTEDTATYYCARYGNYGYAMDYWGQGTSVTVSS,DIVMTQSPASLSVSLGQRATISCRASESVDTYGNSFMHWYQQKPGQSPKLLIYRASNLESGIPARFGGSGSGTDFTLTIDPVQADDVATYYCQQSYEDPWTFGGGTKLEIK,na,na,None,None,None,2020,2021,IL31 (Canine),Kindred Biosciences,na,Canine atopic dermatitis,na,,,Caninised,KIND-016;KIND016;KIND 016;KIND-16;KIND16;KIND 16
Tislelizumab,Whole mAb,G4,Kappa,Approved,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK,na,na,7bxa:BC:HL/7cgw:HL:AB,None,None,2017,2018,PDCD1/CD279/PD1,BeiGene;Celgene Corporation,Hodgkin's disease;Urogenital cancer,Gastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Solid tumours;Ovarian cancer;Renal cancer,na,,,Humanised,BGB-A317;BGB A317;TEVIMBRA;Tilelizumab;VDT-482;VDT 482;VDT482
Tisotumab,Whole mAb,G1,Kappa,Approved,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSSISGSGDYTYYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSPWGYYLDSWGQGTLVTVSS,DIQMTQSPPSLSASAGDRVTITCRASQGISSRLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK,na,na,None,None,None,2015,2016,F3/CD142,Genmab;Seattle Genetics,Cervical cancer,Bladder cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours,na,,ADC with vedotin,Genetically human,TF-011;TF011;TF 011;TF-11;TF11;TF 11
Tixagevimab,Whole mAb,G1,Kappa,Approved,NFD,QMQLVQSGPEVKKPGTSVKVSCKASGFTFMSSAVQWVRQARGQRLEWIGWIVIGSGNTNYAQKFQERVTITRDMSTSTAYMELSSLRSEDTAVYYCAAPYCSSISCNDGFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSRGWTFGQGTKVEIK,na,na,7l7d:HL/8d8r:HL/8d8q:CB,7l7e:AB:HL:IJ:TU,7b0b:HL/7e3k:DE:HL:FG/7mm0:HL/7mlz:HL/7tbf:HL/7tb8:HL/7tcc:FG:JK:OP/7u0d:OP,2020,2021,SARS-CoV-2 Spike RBD,AstraZeneca,COVID-19,na,na,,,Genetically human,COV2-2196;COV2 2196;AZD-8895;AZD8895;AZD 8895;AZD7442 (combination of cilgavimab and tixagevimab);AZD-7442 (combination of cilgavimab and tixagevimab);EVUSHELD (combination of cilgavimab and tixagevimab)
Tixentamig,Bispecific Mixed Domains  (H-gamma1_L-kappa)_scFvhh-G1(h-CH2-CH3),G1;na,Lambda;na,TBC,TBC,EVQLVESGGGLVQPGGSLKLSCAASGFTFSTYAMNWVRQASGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRHGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGDKAALTLLGAQPEDEAEYFCALWYSNLWVFGGGTKLTVL,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMHWVRQVPGKGLVWVSRISSDASRTIYADSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGEDHDILTGYPIRGQGTTVTVSS,na,None;None,None;None,None;None,2025,na,CD3E;CLDN18,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised;Chimeric and/or humanised,TBC
Tixestobart,Whole mAb,G1,Lambda,TBC,TBC,QVQLMQSGSELKKPGASVKVSCRASGYTFTTYAMNWVRQAPGQGPEWMGWINTNTGNPTYAQGFTGRFVFSLDTTVTTTYLQISSLKAEDTAVYFCAREAGSFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVYYYNYVSWYQQHPGRAPKLVIYDVSNRPSGVSNRFSGSKSGNTASLTISGLRAEDEADYYCSSYTVNRVWVFGGGTKLTVL,na,na,None,None,None,2025,na,TNFRSF7/CD27,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Tizetatug,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTQDFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARGGFGSSYWYFDVWGQGTLVTVSS,DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK,na,na,None,None,None,2024,na,TACSTD2/TROP2/EGP1,Atridia;Suzhou Suncadia Biopharmaceuticals,na,Ovarian cancer;Salivary gland cancer;Solid tumours,na,,ADC with Rezetecan,Humanised,SHR-1921;SHR 1921;SHR1921
Tobemstomig,Bispecific mAb with Domain Crossover,G1;G1,Kappa;Kappa,Phase-II,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSYTMSWVRQAPGKGLEWVATISGGGRDIYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLLTGRVYFALDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKASESVDTSDNSFIHWYQQKPGQSPKLLIYRSSTLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNYDVPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFIFDDYTMNWVRQAPGKGLEWVAVISWDGGGTYYTDSVKGRFTISRDDFKNTLYLQMNSLRAEDTAVYYCAKGLTDTTLYGSDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSSPLTFGGGTKVEIK,None;None,None;None,None;None,2022,2023,PDCD1/CD279/PD1;LAG3/CD223,Roche,na,na,Melanoma;Liver cancers;Esophageal squamous cell carcinoma,,Fv1 identical in sequence to Eciskafusp and Lomvastomig Fv1.,Humanised;Humanised,RO7247669;RO-7247669;RO 7247669;RG-6139;RG 6139;RG6139
Tobevibart,Whole mAb,G1,Lambda,Phase-II,Active,ELQLVESGGGWVQPGGSQRLSCAASGRIFRSFYMSWVRQAPGKGLEWVATINQDGSEKLYVDSVKGRFTISRDNAKNSLFLQMNNLRVEDTAVYYCAAWSGNSGGMDVWGQGTTVSVSS,SYELTQPPSVSVSPGQTVSIPCSGDKLGNKNVAWFQHKPGQSPVLVIYEVKYRPSGIPERFSGSNSGNTATLTISGTQAMDEAAYFCQTFDSTTVVFGGGTRLTVL,na,na,None,None,None,2022,2023,Human Papillomavirus Envelope Protein,Vir Biotechnology,na,Hepatitis B;Hepatitis D,na,,,Genetically human,VIR-3434;VIR3434;BRII-877;BRII877
Tocilizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIK,na,na,8j6f:HL,None,None,2004,2004,IL6R/CD126,Assistance Publique Hopitaux de Paris;Charite - Universitatsmedizin Berlin;Chugai Pharmaceutical;Hospital for Special Surgery;JW Pharmaceutical;Roche;University Hospital Inselspital;University Hospital;Osaka University Tubingen;University of Bern;University of Pittsburgh,Drug hypersensitivity;Giant cell arteritis;Giant lymph node hyperplasia;Juvenile rheumatoid arthritis;Rheumatoid arthritis;Vasculitis,Adult-onset Still's disease;Osteoarthritis;Systemic scleroderma;Amyotrophic lateral sclerosis;Dermatomyositis;Familial Mediterranean fever;Polymyalgia rheumatica;Polymyositis;Pulmonary arterial hypertension;Schnitzler syndrome;Urogenital cancer,Chronic lymphocytic leukaemia;Ankylosing spondylitis;Crohn's disease;Multiple myeloma;Pancreatic cancer;Systemic lupus erythematosus,,Biosimilars available,Humanised,Atlizumab;R-1569;R1569;R 1569;RG-1569;RG1569;RG 1569;RO4877533;RO-4877533;RO 4877533;RoActemra
Tomaralimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVQSGSELKKPGASVKLSCKASGFTFTTYGINWVRQAPGQGLEWIGWIYPRDGSTNFNENFKDRATITVDTSASTAYMELSSLRSEDTAVYFCARLTGGTFLDYWGQGTTVTVSS,DIVLTQSPATLSLSPGERATLSCRASESVEYYGTSLMQWYQQKPGQPPKLLIFGASNVESGVPDRFSGSGSGTDFTLKISRVEAEDVGMYFCQQSRKLPWTFGGGTKVEIK,na,na,None,None,None,2018,2019,TLR2/CD282,Opsona Therapeutics,na,Delayed graft function;Myelodysplastic syndromes;Cancer,Autoimmune disorders;Inflammation,,Genetics: musmus/homosap,Chimeric and/or humanised,NM-101;NM101;NM 101;NM-102;NM102;NM 102;NM-103;NM103;NM 103;OPN 305;OPN305;OPN-305
Tomuzotuximab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVST,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK,na,na,None,6au5:DC:BA/6axp:BA:DC/6ayn:BA:DC/6azk:DC:BA/6azl:BA:DC/5i76:DC:BA/1yy8:DC:BA/5th2:DC:BA/5f88:DC:BA/5hyq:DC:BA/5ir1:DC:BA/5ivz:DC:BA/5iv2:DC:BA/5t1k:DC:BA/5t1l:DC:BA/5id0:DC:BA/5id1:DC:BA/5euk:DC:BA/5ff6:DC:BA/5iop:DC:BA/5icy:DC:BA/5itf:DC:BA/5etu:DC:BA/5t1m:DC:BA/5esq:DC:BA/5icz:DC:BA/5i2i:DC:BA/5icx:DC:BA/5hpm:DC:BA/4gw5:DC:BA/4gw1:DC:BA/1yy9:DC/4krp:DC/4kro:DC,5gz0:BA:DC/6arp:BA:DC/6aru:CB,2016,2017,EGFR/ERBB1/HER1,Glycotope,na,Head and neck cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer;Renal cancer;Solid tumours,na,GlycoExpress Technology,Cetuximab biobetter,Chimeric,GT-MAB 5.2-GEX
Toripalimab,Whole mAb,G4,Kappa,Approved,Active,QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK,na,na,6jbt:HL,None,None,2018,2019,PDCD1/CD279/PD1,Fudan University;Peking University;Shanghai Junshi Biosciences;Sun Yat-Sen University,Malignant melanoma,Nasopharyngeal cancer;Oesophageal cancer;Biliary cancer;Gastric cancer;Non-small cell lung cancer;Solid tumours;Urogenital cancer;Head and neck cancer;Alveolar soft part sarcoma;Breast cancer;Cancer;Liver cancer;Lymphoma;Neuroendocrine tumours;Renal cancer,na,,Genetics: musmus/homosap,Chimeric and/or humanised,CHS-007;CHS007;CHS 007;CHS-7;CHS7;CHS 7;JS 001;JS001;JS-001;JS1;JS-1;JS 1;SO-001;SO 001;SO001;SO1;SO-1;SO 1;TAB-001;TAB001;TAB 001;TAB1;TAB-1;TAB 1;Tripleitriumab;Triprizumab;Tuoyi
Torudokimab,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVETGGGLIQPGGSLRLSCAASGFTFSFYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTIHGIRAAYDAFIIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVGINLSWYQQKPGQAPRLLIYGASHRLTGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYSQPPPFTFGGGTKVEIK,na,na,None,None,None,2020,2021,IL33,Eli Lilly,na,Atopic dermatitis,na,,,Genetically human,LY-3375880;LY3375880;LY 3375880;ZB-880;ZB880;ZB 880
Torvutatug,Whole mAb ADC,G1,Kappa,Phase-I/II,Active,LVQLQQSGPGLVKPSQTLSLTCAISGDSVSSDSATWNWIRQSPSRGLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARGVGSFDYWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASGLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSQLTFGGGTKVEIK,na,na,None,None,None,2025,na,FOLR1,AstraZeneca,na,Solid tumours,na,,ADC with samrotecan,Genetically human,AZD-5335;AZD 5335;AZD5335
Tosatoxumab,Whole mAb,G1,Lambda,Phase-III,Active,EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS,QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL,na,na,None,None,None,2013,2014,Staphylococcus aureus Toxin A,Aridis Pharmaceuticals;Kenta Biotech,na,Nosocomial pneumonia,Sepsis,,,Genetically human,AR 301;AR301;AR-301;KBSA-301;KBSA301;KBSA 301;Salvecin
Tovecimig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-II/III,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMSWVRQAPGKCLEWVSWIYSGSGNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARADWPFDYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCTGSSSNIGSNDVTWYQQLPGTAPKLLIYADSKRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCGTWDYSLSAYVFGCGTKLTVL,1bj1:HL:KJ/7v5n:BA:FE;None,None;None,6bft:AB:HL/1cz8:HL:YX;None,2024,na,VEGFA,ABL Bio;Compass Therapeutics;Elpiscience Biopharmaceuticals;National OncoVenture;University of Texas M. D. Anderson Cancer Center;TRIGR Therapeutics,na,Biliary cancer;Colorectal cancer,Solid tumours,,,Humanised,ABL-001;ABL 001;ABL001;CTX-009;CTX 009;CTX009;ES 104;ES-104;ES104;HD-B001A;NOV1501;NOV-1501;NOV 1501;TR-009;TR 009;TR009
Tovetumab,Whole mAb,G2,Kappa,Phase-II,Discontinued,QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK,na,na,None,None,None,2013,2014,PDGFRA/CD140A,Cambridge Antibody Technology;MedImmune,na,na,Glioblastoma;Non-small cell lung cancer;Solid tumours,,,Genetically human,MEDI-575;MEDI575;MEDI 575
Tozorakimab,Whole mAb,G1,Lambda,Phase-III,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISAIDQSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQKFMQLWGGGLRYPFGYWGQGTMVTVSS,SYVLTQPPSVSVSPGQTASITCSGEGMGDKYAAWYQQKPGQSPVLVIYRDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCGVIQDNTGVFGGGTKLTVL,na,na,None,None,None,2020,2021,IL33,AstraZeneca,na,Chronic Obstructive Pulmonary Disease;Diabetic nephropathy,na,,,Genetically human,MEDI-3506;MEDI3506;MEDI 3506
Trabikibart,Whole mAb,G4,Kappa,Phase-I,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFPWYRVHWVRQAPGKGLEWVSSIRSSGGFPYYNYKVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARFYDSFFDIWGQGTMVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK,na,na,5dwu:HL,None,None,2023,2023,CSF2RB/CD131/IL3RB/IL5RB,CSL,na,Asthma,na,,,Genetically human,CSL311;CSL-311
Tralokinumab,Whole mAb,G4,Lambda,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS,SYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL,na,na,5l6y:HL/8blq:EC,None,None,2009,2010,IL13,Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune,Atopic dermatitis,Alopecia areata,Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis,,,Genetically human,CAT-354;CAT354;CAT 354;Adbry;Adtralza;LP 016;LP016;LP-016;LP-16;LP16;LP 16
Trastuzumab,Whole mAb,G1,Kappa,Approved,NFD,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB/8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,1997,1998,ERBB2/CD340/HER2,Roche,Breast cancer,na,na,,Timigutuzumab is a biosimilar of Trastuzumab and Coprelotamab with an identical Variable region. Cinrebafusp and Anvatabart have identical V domains. Also found as an ADC with brengitacan.,Humanised,Herceptin;4D5-8
Traxivitug,Whole mAb,G1,Lambda,Phase-II,Active,QVQLVESGGTLVQPGGSLRLSCAASGFTFNNYWMTWVRQAPGKGLEWVANIKKDGSEKYYVDSVRGRFTISRDNAKNSLFLQMNSLRPEDTAVYFCATVRSGRYFALDDWGQGTLVTVSS,QSVLTQPPSVSVAPGKTARITCGGDNIGSRPVHWYQQKPGQAPILVVYDDSNRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWSSSTDHPFGGGTKVTVL,na,na,8u5l:FF:HH:JJ:KK:NN,None,None,2023,2024,BK Polyomavirus Major Capsid Protein VP1,Novartis Pharmaceuticals;Amplyx Pharmaceuticals,na,Human polyomavirus infections,na,,,Genetically human,MAU-868;MAU868;MAU 868
Tregalizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EEQLVESGGGLVKPGGSLRLSCAASGFSFSDCRMYWLRQAPGKGLEWIGVISVKSENYGANYAESVRGRFTISRDDSKNTVYLQMNSLKTEDTAVYYCSASYYRYDVGAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSYIYWYQQKPGQPPKLLIYLASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSRELPWTFGQGTKVEIK,na,na,None,None,None,2010,2011,CD4,Biotest AG,na,na,Multiple sclerosis;Plaque psoriasis;Rheumatoid arthritis,,,Humanised,BT-061;BT061;BT 061;BT-61;BT61;BT 61
Tremelimumab,Whole mAb,G2,Kappa,Approved,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,na,na,5ggu:HL:AB/5ggv:HL,None,None,2005,2008,CTLA4/CD152,AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine,Non-small cell lung cancer;Liver cancer,Head and neck cancer;Mesothelioma;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer,Diffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes,Abgenix XenoMouse,Tremelimumab is the new name for Ticilimumab (PL97),Genetically human,CP-675;CP675;CP 675;CP-675206;CP 675206;CP675206;IMJUDO;Ticilimumab
Trevogrumab,Whole mAb,G4,Kappa,Phase-II,Active,EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSS,DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,MSTN/GDF8/GDF-8,Regeneron Pharmaceuticals;Sanofi,na,Muscular atrophy;Osteoporosis,na,VelocImmune Mouse,,Genetically human,REGN-1033;REGN1033;REGN 1033;SAR-391786;SAR 391786;SAR391786
Trevotamig,Bispecific Mixed Domains (H-gamma1_L-kappa-scFvhl),G1;na,Kappa;Lambda,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWMHWIRQSPSRGLEWLGYIRPSTGYTEYNQKFKDRFTISRDDSKNTAYLQMNSLKTEDTAVYYCGRGDNWVGFKNWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSISYMHWYQQKPGQAPRLLIYSTSNLASGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCHQWSTYHTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHSNFGNSKVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCRSSAGAVTTSNYDNWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2024,na,EPCAM/CD326;CD3E,TBC,TBC,TBC,TBC,TBC,TBC,Humanised;Chimeric,TBC
Trinbelimab,Whole mAb,G1,Lambda,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGIFRTYAISWVRQAPGQGLEWMGGIIPMFGTVNYAQKFQGRVTISADKSTSTAYMELSRLRSEDTAVYYCARPPSGGCGGDCSRRGYYYAMDVWGQGTTITVSS,QSALTQPASVSGSPGQSITISCSGSSSDVGGYKYVSWYQQHPGKAPQLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGGGTKLTVL,na,na,None,None,None,2021,2022,RhD/CD240D/RhPI,Bharat Serums and Vaccines,TBC,TBC,TBC,,June '22: Corrected CDRH3 sequence,Genetically human,r-anti-D
Trontinemab,Bispecific Mixed Format with Domain Crossover,G1;G1,Kappa;Kappa,Phase-II,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS,DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK,QSMQESGPGLVKPSQTLSLTCTVSGFSLSSYAMSWIRQHPGKGLEWIGYIWSGGSTDYASWAKSRVTISKTSTTVSLKLSSVTAADTAVYYCARRYGTSYPDYGDASGFDPWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQNYASSNVDNTFGGGTKVEIK,5csz:AB:HL;None,None;None,None;None,2022,2022,APP Abeta 1-40/42;TFRC/CD71,Roche,na,Dementia,na,,Arm 1 has same Fv as Gantenerumab,Humanised;Humanised,RG-6102;RG6102;RG 6102;RO 7126209;RO7126209;RO-7126209
Trosunilimab,Whole mAb,G1,Kappa,TBC,Active,EVQLVQSGAEVKKPGSSVKVSCKASGFNIKNTYMHWVRQAPGQGLEWIGRIDPAKGHTEYAPKFLGRVTITADESTNTAYMELSSLRSEDTAVYYCYYVDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCHASQDISDNIGWLQQKPGKSFKLLIYHGTNLEDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKVEIK,na,na,None,None,None,2024,2024,ITGA4B7,TBC,TBC,TBC,TBC,,Humanised: musmus/homosap,Humanised,PR-1794842;PR 1794842;PR1794842
Trovostobart,Whole mAb,G1,Kappa,TBC,TBC,QVQLVESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKSQFSLKLSSVTAADTAVYYCARDIPAFAFDIWGQGTMVIVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSYYLAWYQQKPGQAPRLLIYDAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRINWPLTFGGGTKVEIK,na,na,None,None,None,2025,na,VSIR/VISTA/B7H5/PD1H/SISP1,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human,TBC
Tucotuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,EIQLVQSGAEVKKPGETVKISCKASGYTFTNYGMNWVKQTPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLETSTSTAFLQINNLRSEDTATYFCVRFISKGDYWGQGTSVTVSS,EIVLTQSPATLSLSPGERVTLTCSASSSVSYMLWYQQKPGSSPKPWIFDTSNLASGFPARFSGSGSGTSYSLIISSMEAEDAATYYCHQRSGYPYTFGGGTKLEIK,na,na,None,None,None,2005,2006,EPCAM/CD326,EMD Lexigen;Merck KGaA,na,na,Ovarian cancer;Small cell lung cancer,,ADC with celmoleukin,Humanised,EMD-273066;EMD273066;EMD 273066
Tulisokibart,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGFDIQDTYMHWVKQRPGQGLEWMGRIDPASGHTKYDPKFQVRVTITRDTSTSTVYLELSSLRSEDTAVYYCARSGGLPDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASSSVSYMYWYQQKPGQAPRPLIYATSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWEGNPRTFGGGTKLEIK,na,na,None,None,None,2022,2023,TNFSF15/TL1A/VEGI,Prometheus Biosciences,na,Crohn's disease;Ulcerative colitis;Diffuse cutaneous systemic sclerosis;Interstitial lung disease,na,,,Humanised,PRA-023;PRA 023;PRA023;PRA-23;PRA23;PRA 23
Tuparstobart,Whole mAb,G1,Kappa,Phase-II,Active,QVQMVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQGLEWMGEIDPANDNTKYDPKFQGRVTITADTSTSTVYMELSSLRSEDTAVYYCATYYYKYDVGGFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCSVSSSISSSNLHWYQQKPGQAPRLLIYGTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWSSYPFTFGQGTKVEIK,na,na,None,None,None,2022,2023,LAG3/CD223,Incyte Biosciences,na,Head and neck cancers;Melanoma;Endometrial cancers;Urothelial cancers,na,,,Humanised,Incagn-02385;Incagn02385;Incagn 02385
Turenkibart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVQSGAEVKKPGATVKISCKASGYTFTDYEMHWVQQAPGHGLEWMGVIHPGGGGTAYNQKFKGRVTITADTSTDTAYMELSSLRSEDTAVYYCTRGDHDGRTDYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNRSNQKNYLAWYQQKPGQPPKLLVDFASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYFCQQHYTTPFTFGPGTKVDIK,na,na,None,None,None,2024,na,IL17A,Sinocelltech,na,Axial spondyloarthritis;Autoimmune disorders,na,,,Humanised;Chimeric,SCT650C;SCT 650C;SCT-650C
Tusamitamab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYAPSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS,DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK,na,na,8bw0:HL,None,None,2020,2021,CEACAM5/CD66e,Sanofi-Aventis,na,na,Non-small cell lung cancer;Breast cancer;Pancreatic cancer;Solid tumours,,ADC with ravtansine. Genetics: musmus/homosap,Chimeric and/or humanised,IBI-126;IBI126;IBI 126;SAR 701;SAR701;SAR-701;SAR-408701;SAR 408701;SAR408701
Tuvonralimab,Whole mAb,G1,Kappa,Approved,Active,QVQLVESGGGVVEPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYKPSEKDYADSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGGLLGYFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSINSYLAWYQQKPGQAPRPLIYGVSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRYPFTFGPGTKVDIK,na,na,None,None,None,2021,2022,CTLA4/CD152,Qilu Puget Sound Biotherapeutics,Cervical cancer,Nasopharyngeal cancer;Non-small cell lung cancer;Liver cancer;Colorectal cancer;Small cell lung cancer;Squamous cell cancer;Triple negative breast cancer;Solid tumours ,na,,,Genetically human,PSB105;PSB-105;PSB-205 (cocktail with Tuvonralimab);PSB205 (cocktail with Tuvonralimab);QL1706 (cocktail with Tuvonralimab)
Ubamatamab,Bispecific mAb,G4;G4,Kappa;Kappa,Phase-II,Active,QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYYMSWVRQAPGKGLEWISYISGRGSTIFYADSVKGRITISRDNAKNSLFLQMNSLRAEDTAVYFCVKDRGGYSPYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2021,2022,MUC16/CA125;CD3E,Regeneron Pharmaceuticals,na,Fallopian tube cancer;Ovarian cancer;Peritoneal cancer,na,,,Genetically human;Genetically human,REGN4018;REGN-4018;REGN 4018
Ubletamig,Bispecific mAb,G1;G1,Kappa;Kappa,TBC,TBC,EVQLVESGGGLEQPGRSLRLSCTASGFAFGDHTMSWVRQAPGKGLEWVGFIRSRAYGGTTEYAASVKGRFTISRDDSKSIAYLQMDSLKTEDTAVYYCTSGGYDSSLHYYYYYHGMDVWGRGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYYSGITHYNPSLKSRVTISVDTSKIQFSLKLSSVTAADTAVYYCARWGVRRDYYYYGMDVWGQGTTVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,None;None,None;None,None;None,2025,na,MUC16/CA125;CD28,TBC,TBC,TBC,TBC,TBC,TBC,Genetically human;Genetically human,TBC
Ublituximab,Whole mAb,G1,Kappa,Approved,Active,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGGIYPGNGDTSYNQKFKGKATLTVGKSSSTAYMQLSSLTSEDSAVYFCARYDYNYAMDYWGQGTSVTVSS,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSFTISRVEAEDAATYYCQQWTFNPPTFGGGTRLEIK,na,na,None,None,None,2010,2011,MS4A1/CD20,LFB Biotechnologies;rEVO Biologics;Johns Hopkins University;TG Therapeutics Inc,Multiple sclerosis,Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma,Neuromyelitis optica,EMABling Platform,Rituximab biobetter,Chimeric,BRIUMV;EMAB-6;EMAB6;EMAB 6;EMAB-603;EMAB603;EMAB 603;LFB-R603;LFB R603;TG-1101;TG1101;RG 1101;TG-20;TG20;TG 20;TGTX-1101;TGTX1101;TGTX 1101
Ucenprubart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFSFSSGYYMAWVRQAPGQGLEWMGLIGVGSGSLWYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARHFALSDPFNLWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCQASESIDSYLLWYQQKPDQSPKLLIKQASTLASGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQNYYDISSNDFGGGTKVEIK,na,na,None,None,None,2023,2024,MOX2R/CD200R1,Eli Lilly and Company,na,Atopic dermatitis;Chronic urticaria;Immunological disorders,na,,,Humanised,LY3454738;LY-3454738;LY 3454738
Ulenistamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDYYMHWVRQAPGQGLEWMGWIDPENGNTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARRAITTATAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLYTFGQGTKVEIK,na,na,None,None,None,2021,2022,PAUF,Prestige Biopharma,na,Pancreatic cancer;Ovarian cancer,na,,,Humanised,PBP-1510;PBP1510;PBP 1510
Uliledlimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLQESGPGLVKPSETLSLTCAVSGYSITSGYYWNWIRQPPGKKLEWMGYINYGGSNGYNPSLKSRITISRDTSKNQFSLKLSSVTAADTAVYYCARDYDAYYEALDDWGQGTTVTVSS,EIVLSQSPATLSLSPGERATLSCRASSRVNYMHWYQQKPGQSPRPWISATSNLASGVPARFSGSGSGTSYTLTISSLEPEDFAVYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,NT5E/CALJA/CD73,TRACON Pharmaceuticals;I-Mab Biopharma,na,Breast cancer;Gastrointestinal cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours,na,,Genetics: musmus/homosap,Chimeric and/or humanised,TJ 004309;TJ004309;TJ-004309;TJ 4309;TJ4309;TJ-4309;TJD 5;TJD-5;TJD5
Ulocuplumab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAAAGFTFSSYSMNWVRQAPGKGLEWVSYISSRSRTIYYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARDYGGQPPYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQYNSYPRTFGQGTKVEIK,na,na,None,None,None,2013,2014,CXCR4/CD184,Bristol-Myers Squibb;Medarex;University of Bari,na,Acute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours,B-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma,,,Genetically human,BMS-936564;BMS936564;BMS 936564;MDX-1338;MDX 1338;MDX1338
Ulviprubart,Whole mAb,G1,Kappa,Phase-II/III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTDHNMHWVKQATGQGLEWFGFINPNTGVTRYNQKFQGRVTLTINKAISTAYLELSSLRSEDTAVYYCARDYYGSAWFAYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQTLLYSSDQKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNYPTFGGGTKVEIK,na,na,None,None,None,2022,2023,KLRG1,Abcuro,na,T-cell large granular lymphocytic leukemia;Inclusion body myositis,na,,,Humanised,ABC-008;ABC008;ABC 008
Umesolerbart,Whole mAb,G4,Kappa,Phase-III,Active,EVQLVESGGDLVQPGGSLRLSCAASGFTFSSYEMNWVRQAPGKGLEWVSFISDSSSNIYYADSVKGRFTISRDNAKKSLYLQMTSLRAEDTAVYYCAREAIGSTSFDNWGQGTLVTVSS,EIVMTQSPATLSVSPGERATLSCRASQSVSSSLAWYQQKPGQAPRRLIYSASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAIYYCHQYNNWPLTFGGGTKVEIK,na,na,7mxl:HL,None,None,2022,2023,Bet v 1,Regeneron,na,Allergic rhinitis;Birch pollen allergy,na,,Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5714.,Genetically human,REGN5713-5714-5715 (combination of Atisnolerbart; Bremzalerbart; and Umesolerbart)
Umikibart,Whole mAb,G4,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYYMSWVRQAPGKGLEWVAYIGTSSGTTYYADSVKGRFTISRDGSKNTLYLQMNSLRAEDTAVYYCARGLGRINLWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISNILAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQSGYYSRGATFGQGTKVEIK,na,na,None,None,None,2024,2024,HGF,Yooyoung Pharm Co;National OncoVenture;Cell Lab Med,na,Colorectal cancer,Solid tumours,,,Humanised,YYB101;YYB-101;YYB 101;CLM-101;CLM 101;CLM101;NOV 1105;NOV-1105;NOV1105
Umizortamig1,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 1),na;G1,Kappa;Kappa,TBC,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS,DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIK,DVQLQESGPSLVKPSQSLSLTCTVTGYSITSDFAWNWIRQFPGNKLEWMGYISYSGNTRYNPSLKSRISITRDTSKNQFFLQLNSVTIEDTATYYCVTAGRGFPYWGQGTLVTVSA,DILMTQSPSSMSVSLGDTVSITCHSSQDINSNIGWLQQRPGKSFKGLIYHGTNLDDEVPSRFSGSGSGADYSLTISSLESEDFADYYCVQYAQFPWTFGGGTKLEIK,None;None,None;3g5x:DC:BA,None;3g5v:BA/3g5z:BA,2022,2023,EGFRvIII;CD3E,TBC,TBC,TBC,TBC,,scFv-IgG1 portion. Joint entry with Umizortamig2 (tetraspecific),na,TBC
Umizortamig2,Tetraspecific scFv-IgG-scFv-scFv (Bispecific entry 2),na;na,Kappa;Kappa,TBC,Active,EVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK,SQSLVESGGGLVQPGGSLRLSCAASGFSFSSNYWICWVRQAPGKGLEWIACIYVGSSGDTYYASSAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSSSYYMFNLWGQGTLVTVSS,ALVMTQSPSTLSASVGDRVTINCQASEDIDTYLAWYQQKPGKAPKLLIFYASDLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQGGYYTSSADTRGAFGGGTKVEIK,None;None,None;None,None;None,2022,2023,PDL1/CD274;TNFRSF9/CD137/4-1BB,TBC,TBC,TBC,TBC,,scFv-scFv portion. Joint entry with Umizortamig2 (tetraspecific),na,TBC
Unasnemab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGRSLRLSCTASGFTFSDAWMDWVRQAPGKGLEWVAEIRSKANNHATYYAESVKGRFTISRDDSKSIVYLQMNSLRTEDTALYYCTRRDGAYWGKGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFASYFCQQLNTLPWTFGGGTKVEME,na,na,None,None,None,2020,2021,RGMA,Mitsubishi Tanabe Pharma Corporation,na,Acute spinal cord injury,na,,Genetics: musmus/homosap,Chimeric and/or humanised,MT-3921;MT3921;MT 3921
Upanovimab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVKLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWVRQAPGKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARFRYDGGGGTVDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVDNYGISFMNWFQQKPGQAPRLLIYAASNQGSGVPARFSGSGSGTDFSLTISSLEPEDFAVYFCQQSKEVPRTFGQGTKVEIK,na,na,None,None,7cyh:ED/7cyp:GF:IH:ED/7cwt:IJ:GF:ED/7e5s:RO,2021,2022,SARS-CoV-2 Spike RBD,Sinocelltech,na,COVID-19,na,,Genetics: musmus/homosap,Chimeric and/or humanised,SCTA-01;SCTA01;SCTA 01;SCTA-1;SCTA1;SCTA 1
Uprevstobart,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYTFTSYGLSWVRQMPGKGLEWMGEIYPGSGNTYYNEKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDYLGSSYGFDYWGAGTTVTVSS,DIVMTQSPDSLAVSLGERATINCKASQDVSTAVAWYQQKPGQPPKLLIYSASYRYSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYNTPYTFGGGTKLEIK,na,na,None,None,None,2023,2024,NT5E/CALJA/CD73,Incyte Corporation,na,na,Gastrointestinal cancer;Solid tumours;Squamous cell cancer,,,Humanised,INCA-00186;INCA00186;INCA 00186
Upinitatug,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVVKPGASVKMSCKASGYTFTGYNIHWVKQAPGQGLEWIGAIYPGNGDTSYKQKFRGRATLTADTSTSTVYMELSSLRSEDSAVYYCARGETARATFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDIGNFLNWYQQKPGKTVKVLIYYTSSLYSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQYSKLPLTFGQGTKLELK,na,na,None,None,None,2019,2020,SLC34A2,Mersana Therapeutics,na,na,Non-small cell lung cancer;Ovarian cancer,,Upinitatug is the new name for Upifitamab (PL128). Genetics: musmus/homosap,Chimeric and/or humanised,XMT-1536;XMT1536;XMT 1536
Urabrelimab,Whole mAb,G4,Kappa,Phase-I,Discontinued,QVQLQESGPGLVKPSGTLSLTCAVSGVSIRSINWWNWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLNSVTAADTAVYYCARDGGIAVTDYYYYGLDVWGQGTTVTVSS,EIVLTQSPATLSLSPGERATLSCRASESVSSNLAWYQQKPGQAPRLLIYGAFNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSDWFTFGGGTKVEIK,na,na,None,None,None,2019,2020,IAP/CD47,Surface Oncology,na,na,Haematological malignancies;Solid tumours,,,Genetically human,SRF-231;SRF231;SRF 231
Urelumab,Whole mAb,G4,Kappa,Phase-II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK,na,na,6mhr:AB:DE,None,None,2010,2011,TNFRSF9/CD137/4-1BB,Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex,na,Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma,Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer,Medarex UltiMAb Mouse,"Jain paper: ""VL sequence modified at one position to match patent document (US7659384) and JK germline""",Genetically human,BMS-663513;BMS663513;BMS 663513;BMS-66513;BMS66513;BMS 66513;ONO-4481;ONO4481;ONO 4481
Urtoxazumab,scFv,na,Kappa,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATISTGGSYTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGDAWGNLDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASQTISNNLHWYQQKPGQAPRLLIKSASQSISGIPARFSGSGSGTDFTLTISSLESEDFAVYYCQQSYSWPLTFGQGTKVEIK,na,na,None,None,None,2004,2005,Shiga-like Toxin II,Teijin Pharma,na,na,Haemolytic uraemic syndrome,,Anti-e coli mAb,Humanised,TMA-15;TMA15;TMA 15
Usilnetug,Whole mAb,G1,Kappa,TBC,Active,EVQLQESGPGLVKPSQTLSLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPYMKRRLTISKDTSKNQVSLKISSVTAADTAVYYCARRADDYDVGFAYWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCLASQTIGTWLAWYQQKPGKSPKLLIYAATSLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQLYSSPFTFGQGTKLEIK,na,na,None,None,None,2023,2024,APP Abeta N3pGlu,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap,Chimeric and/or humanised,PR-1905069;PR 1905069;PR1905069
Ustekinumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIK,na,na,3hmw:HL/3hmx:HL,None,None,2008,2009,IL12B/CLMFp40,Centocor Inc;Janssen Biotech;Medarex,Crohn's disease;Plaque psoriasis;Psoriatic arthritis,Ulcerative colitis;Spondylarthritis;Systemic lupus erythematosus;Atopic dermatitis,Multiple sclerosis;Palmoplantar pustulosis;Primary biliary cirrhosis;Rheumatoid arthritis;Sarcoidosis,Medarex UltiMAb Mouse,Biosimilars available,Genetically human,CNTO 1275;CNTO-1275;CNTO1275;TT-20;TT20;TT 20
Utomilumab,Whole mAb,G2,Lambda,Phase-II,Active,EVQLVQSGAEVKKPGESLRISCKGSGYSFSTYWISWVRQMPGKGLEWMGKIYPGDSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGYGIFDYWGQGTLVTVSS,SYELTQPPSVSVSPGQTASITCSGDNIGDQYAHWYQQKPGQSPVLVIYQDKNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCATYTGFGSLAVFGGGTKLTVL,na,na,6a3w:GH:DE:AB:JK/6mi2:DE:AB,None,None,2016,2017,TNFRSF9/CD137/4-1BB,Dana-Farber Cancer Institute;Immatics US;Kite Pharma;Kyowa Hakko Kirin;M. D. Anderson Cancer Center;Pfizer,na,Breast cancer;Oropharyngeal cancer;Solid tumours;B-cell lymphoma;Diffuse large B cell lymphoma;Follicular lymphoma;Ovarian cancer,Non-Hodgkin's lymphoma;Colorectal cancer,MorphoSys HuCAL Phage Display,,Genetically human,PF-05082566;PF05082566;PF-5082566;PF5082566;PF-2566;PF2566
Vadastuximab,Whole mAb ADC,G1,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKYNEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK,na,na,None,None,None,2015,2016,SIGLEC3/CD33/p67,Seattle Genetics,na,na,Acute myeloid leukaemia;Myelodysplastic syndromes,,ADC with talirine,Chimeric,SGN CD33A;SGN-CD33A
Valanafusp,Whole mAb Fusion,G1,Kappa,Phase-II,Active,QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK,na,na,None,5kqv:PQ:CD/4zxb:CD,3loh:CD/2dtg:CD/3w14:CD:PQ,2017,2018,INSR/CD220,ArmaGen Technologies,na,Mucopolysaccharidosis I,na,,,na,AGT-181;AGT181;AGT 181
Vamikibart,Whole mAb,G2,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYVLPNYLIEWVRQAPGQGLEWMGVTTPGGGTINYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSRWDPLYYYALEYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASESVDNYGIPFMNWYQQKPGQPPKLLIYAASNRGSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSEEVPLTFGQGTKLEIK,na,na,None,None,None,2023,2023,IL6,Roche,na,Retinal oedema;Diabetic macular oedema,na,,,Humanised;Chimeric,RG-6179;RG6179;RG 6179;RO-7200220;RO 7200220;RO7200220
Vandortuzumab,Whole mAb ADC,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSDYAWNWVRQAPGKGLEWVGYISNSGSTSYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARERNYDYDDYYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKSSQSLLYRSNQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYNYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,STEAP1,Roche;Genentech,na,na,Cancers;Prostate Cancer,,ADC with vedotin,Humanised,DSTP-3086S;DSTP 3086S;DSTP3086S;RG-7450;RG7450;RG 7450
Vantictumab,Whole mAb,G2,Lambda,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSHYTLSWVRQAPGKGLEWVSVISGDGSYTYYADSVKGRFTISSDNSKNTLYLQMNSLRAEDTAVYYCARNFIKYVFANWGQGTLVTVSS,DIELTQPPSVSVAPGQTARISCSGDNIGSFYVHWYQQKPGQAPVLVIYDKSNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYANTLSLVFGGGTKLTVL,na,na,None,None,None,2013,2014,FZD,Bayer HealthCare Pharmaceuticals;OncoMed Pharmaceuticals,na,na,Breast cancer;Non-small cell lung cancer;Pancreatic cancer,MorphoSys HuCAL Phage Display,Targets the FZD Family,Genetically human,OMP-18R5;OMP18R5;OMP 18R5
Vanucizumab,Bispecific mAb,G1;G1,Lambda;Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSPNPYYYDSSGYYYPGAFDIWGQGTMVTVSS,QPGLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK,4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ/7v5n:BA:FE,None;None,None;6bft:AB:HL/1cz8:HL:YX,2014,2015,ANGPT2;VEGFA,Roche,na,na,Solid tumours;Colorectal cancer,,,Humanised;Humanised,RG-7221;RG7221;RG 7221;RO-5520985;RO5520985;RO 5520985
Varisacumab,Whole mAb,G1,Kappa,Phase-II/III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGRSMVRGVIIPFNGMDVWGQGTTVTVSS,DIRMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK,na,na,None,None,None,2016,2017,VEGFA,Peregrine Pharmaceuticals;University of Texas Southwestern Medical Center;Affitech Research AS,na,na,Breast cancer;Colorectal cancer;Eye disorders;Glioblastoma;Non-small cell lung cancer,,,Genetically human,AT-001;AT001;AT 001;GNR-011;GNR011;GNR 011;GNR-11;GNR11;GNR 11;R-84;R 84;R84
Varlilumab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK,na,na,None,None,None,2014,2015,TNFRSF7/CD27,Celldex Therapeutics Inc;Oncothyreon;University of California at San Francisco;University of Virginia,na,Malignant melanoma;Solid tumours;Non-Hodgkin's lymphoma;Renal cell carcinoma;Glioblastoma,Haematological malignancies;Prostate cancer;Breast cancer;Ovarian cancer;Glioma,,,Genetically human,CDX-1127;CDX1127;CDX 1127
Varokibart,Whole mAb,G4,Lambda,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGGSISNGGYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASLGNWFDYWGQGTLVTVSS,SYVLTQPPSVSVAPGQTARITCGGNNIGSKNVYWYQQKPGQAPVLVVHDDSDRPSGIPERFSGSNSGNTATLTISRVEVGDEADYSCQVWDSSSDHVVFGGGTKLTVL,na,na,None,None,None,2022,2023,IL5,Teva Pharmaceutical,na,Asthma,na,,,Genetically human,TEV-53275;TEV53275;TEV 53275
Vatelizumab,Whole mAb,G4,Kappa,Phase-II/III,Discontinued,QVQLQESGPGLVKPSETLSLTCTVSGFSLTNYGIHWIRQPPGKGLEWLGVIWARGFTNYNSALMSRLTISKDNSKNQVSLKLSSVTAADTAVYYCARANDGVYYAMDYWGQGTLVTVSS,DFVMTQSPAFLSVTPGEKVTITCSAQSSVNYIHWYQQKPDQAPKKLIYDTSKLASGVPSRFSGSGSGTDYTFTISSLEAEDAATYYCQQWTTNPLTFGQGTKVEIK,na,na,None,None,None,2011,2012,ITGA2/CD49B,Chromos Molecular Systems;Glenmark Pharmaceuticals S.A.;Sanofi,na,na,Cancer;Chronic obstructive pulmonary disease;Multiple sclerosis;Retinal disorders;Rheumatoid arthritis;Ulcerative colitis,,,Humanised,CHR-1103;CHR1103;CHR 1103;GBR 500;GBR-500;GBR500;SAR 339658;SAR339658;SAR-339658;TMC-2003;TMC 2003;TMC2003
Vebanvibart,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFRSHVISWVRQAPGQGLEWMGGFIPLFGTTIYAQAFQGRVMISADESTSTAYMELSSLRSEDTAVYFCARLFPNGDPNSPEDGFDIWGQGTLVTVSA,DIQMTQSPSSLSASVGDRVTITCQASQDIGNYLNWYQQKPGKAPKLLIYDASHLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQRYDDLPSYTFGQGTKVEIK,na,na,7y0w:AB,None,8wyj:QR:DF:HJ,2024,2024,SARS-CoV-2 Spike RBD,Sinovac Biotech,na,COVID-19,na,,,Genetically human,SA-55;SA 55;SA55;BD55-5514
Vecantoxatug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWIYWVRQAPGQGLEWIGEINPTNAFANYNEKFKTKATITVDKSTSTAYMELSSLRSEDTAVYYCAIHFRFPYWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDIGSSLTWLQQKPGKAPKRLIYATSSLDSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQYASSPYTFGQGTKLEIK,na,na,None,None,None,2025,na,Clostridium tetani tetanus toxin (TeNT),Genrix (Shanghai) Biopharmaceuticals,na,Tetanus,na,,,Humanised,GR-2001;GR 2001;GR2001
Vedolizumab,Whole mAb,G1,Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSS,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIK,na,na,None,None,None,2008,2009,ITGA4B7,Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology,Crohn's disease;Ulcerative colitis,Graft-versus-host disease;Coeliac disease,Malignant melanoma,,,Humanised,Entyvio;Kynteles;LDP-02;LDP02;LDP 02;LDP-2;LDP2;LDP 2;MLN-0002;MLN 0002;MLN0002;MLN-002;MLN002;MLN 002;MLN02;MLN 02;MLN-02;MLN-2;MLN2;MLN 2
Velaprumig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Kappa,TBC,TBC,QVQLVQSGGGPVKPGGSLRLSCAASGFMFRAYSMNWVRQAPGKGLEWVSSISSSGRYIHYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARETVMAGKALDYWGQGTLVTVSS,DIVLTQSPGTLSLSPGETATLSCRASQSVGSNLAWYQQKPGQAPRLLIYGASTGATGVPARFSGSRSGTDFTLTITSLQPEDFATYYCQQYYSFLAKTFGQGTQLEIK,QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS,DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK,None;1i9r:KM:HL:XY/6w4w:HL,None;None,None;None,2025,na,ALB;CD40LG/CD154,TBC,TBC,TBC,TBC,TBC,TBC,Chimeric and/or humanised;Chimeric and/or humanised,TBC
Veligrotug,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPSNGRTNYNQKFQGKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGRPDYYGSSKWYFDVWGQGTTVTVSS,DVVMTQTPLSLPVSLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGSHVPPTFGGGTKLEIK,na,na,None,None,None,2023,2023,IGF1R/CD221,ImmunoGen;sanofi-aventis;Viridian Therapeutics;Zenas BioPharma,na,Graves ophthalmopathy,Breast cancer;Multiple myeloma;Solid tumours,,,Chimeric,AVE-1642;AVE1642;AVE 1642;VRDN-001;VRDN001;VRDN 001;ZB 001;ZB-001;ZB001
Velinotamig,Bispecific Whole mAb,G1;G1,Kappa;Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWFDGSRKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFGLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLTWYQQKPGKAPKLLIYEASSRPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSRLPVTFGQGTKVEIK,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCTRGAVYAGYDVLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISNYLTWYQQKPGKAPKLLIYEASSRPSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSRLPVTFGQGTKVEIK,None;None,None;None,None;None,2024,na,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Genrix (Shanghai) Biopharmaceuticals,na,Multiple myeloma,na,,,Genetically human;Genetically human,GR-1803;GR 1803;GR1803
Veltuzumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVKQAPGQGLEWIGAIYPGMGDTSYNQKFKGKATLTADESTNTAYMELSSLRSEDTAFYYCARSTYYGGDWYFDVWGQGTTVTVSS,DIQLTQSPSSLSASVGDRVTMTCRASSSVSYIHWFQQKPGKAPKPWIYATSNLASGVPVRFSGSGSGTDYTFTISSLQPEDIATYYCQQWTSNPPTFGGGTKLEIK,na,na,None,None,None,2007,2008,MS4A1/CD20,Immunomedics;Weill Cornell Medical College,na,na,Chronic lymphocytic leukaemia;Rheumatoid arthritis;Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma,,,Humanised,IMMU-106;IMMU106;IMMU 106
Venanprubart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGFSLSSYGVSWVRQAPGQGLEWMGAISYDGITYYASWAKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGDYYDDYVYVYALDIWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCQASQSISTALAWYQQKPGQAPRLLIYAASTLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGYSSSNLDNVFGGGTKVEIK,na,na,8f6o:AB,None,None,2023,2024,BTLA/CD272,Eli Lilly,na,Systemic lupus erythematosus,na,,,Humanised,LY-3361237;LY3361237;LY 3361237
Vensobafusp,Fusion Protein (whole mAb with protein),G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTITDYHFDWVRQAPGQGLEWMGDISMNYGYHIYNQKFKDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRDIRYSGNSYKWYFDEWGQGTMVTVSS,DIQLTQSPSFLSASVGDRVTITCRTSKSISKHLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQHNEYPYTFGQGTKLEIK,na,na,None,None,None,2023,2023,C5,Kira Pharmaceuticals,na,Paroxysmal nocturnal haemoglobinuria,na,,,na,KP104;KP-104;P014;P-014
Vepsitamab,Bispecific (scFv-scFv-scFc),na;na,Lambda;Lambda,Phase-I,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKCLEWIGDIDASGSTKYNPSLKSRVTISLDTSKNQFSLKLNSVTAADTAVYFCARKKYSTVWSYFDNWGQGTLVTVSS,SYELTQPSSVSVPPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGVPERFSGSNSGNTATLTISGTQAMDEADYYCQAWGSSTAVFGCGTKLTVL,EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,MUC17;CD3E,Amgen,na,na,GE Junction Cancer;Gastric Adenocarcinoma,BiTE Technology,Fv3 has the same sequence as Fv1. Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMG199;AMG-199;AMG 199
Vesencumab,Whole mAb,G1,Kappa,Phase-I,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSQISPAGGYTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARGELPYYRMSKVMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQYFSSYLAWYQQKPGKAPKLLIYGASSRASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLGSPPTFGQGTKVEIK,na,na,2qqn:HL,None,None,2010,2011,NRP1,Genentech;Roche,na,na,Solid tumours,,,Genetically human,M 1685A;M1685A;M-1685A;MNRP 1685A;MNRP-1685A;MNRP1685A;R 7347;R7347;R-7347;RG7347;RG-7347;RG 7347
Verekitug,Whole mAb,G1,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFRSSAMHWVRQAPGKGLKWVSSVSGSGAGTYYADSVKGRFTISRDNPKNTLYLQMNSLRAEDTAVYYCVKEGGSRGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYTASSLQSGVPSKFSGSGSGTDFTLTISSLQPEDFATYYCQQYNLYPPTFGQGTKVEIK,na,na,None,None,None,2023,2024,CRLF2,Astellas Pharma;Upstream Biosciences,na,Asthma;Rhinosinusitis,na,,,Genetically human,UPB-101;UPB101;ASP7266;ASP-7266
Verenafusp,Fab Fusion Protein,G1,Kappa,Phase-II/III,Active,QVQLQQSGPELVKPGALVKISCKASGYTFTNYDIHWVKQRPGQGLEWIGWIYPGDGSTKYNEKFKGKATLTADKSSSTAYMHLSSLTSEKSAVYFCAREWAYWGQGTLVTVSA,DIQMTQSPSSLSASLGERVSLTCRASQDIGGNLYWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYSSSPWTFGGGTKMEIK,na,na,None,5kqv:PQ:CD/4zxb:CD,3loh:CD/2dtg:CD/3w14:CD:PQ,2024,na,INSR/CD220,GENERIUM Pharmaceuticals,na,Mucopolysaccharidosis II,na,,,Chimeric,GNR-055;GNR055;GNR 055
Verzistobart,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFRQNAWSWVRRAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGGDYGGNYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPASFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIK,na,na,None,None,None,2023,2023,HAVCR2/TIM3,Agenus;Ludwig Institute for Cancer Research;Incyte Corporation;University of Washington,na,Endometrial cancer;Squamous cell cancer;Malignant melanoma;Solid tumours;Cancer;Merkel cell carcinoma,na,,,Genetically human,INCAGN2390;INCAGN02390;INCAGN-2390;INCAGN-02390
Vibecotamab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-I,Discontinued,QVQLQQSGAEVKKPGASVKVSCKASGYTFTDYYMKWVKQSHGKSLEWMGDIIPSNGATFYNQKFKGKATLTVDRSTSTAYMELSSLRSEDTAVYYCARSHLLRASWFAYWGQGTLVTVSS,DFVMTQSPDSLAVSLGERATINCKSSQSLLNTGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGGGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVLEPK,None;None,None;None,None;None,2018,2019,IL3RA/CD123;CD3E,Xencor,na,na,Haematological malignancies,,Genetics of both Fvs: musmus/homosap,Chimeric and/or humanised;Chimeric and/or humanised,SQZ 622;SQZ622;SQZ-622;XmAb 14045;XmAb-14045;XmAb14045
Vibostolimab,Whole mAb,G1,Kappa,Phase-III,Discontinued,EVQLVQSGAEVKKPGSSVKVSCKASGYTFSSYVMHWVRQAPGQGLEWIGYIDPYNDGAKYAQKFQGRVTLTSDKSTSTAYMELSSLRSEDTAVYYCARGGPYGWYFDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASEHIYSYLSWYQQKPGKVPKLLIYNAKTLAEGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQHHFGSPLTFGQGTRLEIK,na,na,None,None,None,2019,2020,TIGIT/WUCAM/VSTM3,Merck,na,na,Solid tumours;Non-small cell lung cancer;Malignant melanoma,,,Humanised,MK-7684;MK7684;MK 7684
Vilamakitug,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGRFTNYAILWVRQAPGQGLQWLGGIIPIFDETDHAQDFQDRLTITVDESMTTAYMELSSLRPEDTAIYYCATGSNSYYGLYWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPSTFGQGTKVEIK,na,na,None,None,None,2022,2023,IL1A,XBiotech USA; Inc,na,Pancreatic cancer;Arthritis;Colorectal cancer,na,,,Genetically human,Natrunix;XB-2001;XB2001;XB 2001
Vilastobart,Whole mAb,G1,Kappa,Phase-I/II,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTNYFMNWVRQAPGQGLEWMGRVDPEQGRADYAEKFKKRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAMDNYGFAYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCSANSALSYMYWYQQKPDQSPKLWVHGTSNLASGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCHHWSNTQWTFGGGTKVEIK,na,na,8g8n:AB:DE:GI:HL:KM,None,8g2m:HL,2023,2024,CTLA4/CD152,Xilio Therapeutics,na,Solid Tumours,na,,Prodomain Kappa,Humanised,XTX-101;XTX 101;XTX101
Vilobelimab,Whole mAb,G4,Kappa,Approved,Active,QVQLQQSGPQLVRPGTSVKISCKASGYSFTTFWMDWVKQRPGQGLEWIGRIDPSDSESRLDQRFKDRATLTVDKSSSTVYMQLSSPTSEDSAVYYCARGNDGYYGFAYWGQGTLVTVSS,DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMKWYQQKPGQPPKLLIYAASNLQSGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPYTFGGGTKLEIK,na,na,None,None,None,2019,2020,C5,InflaRX,COVID-19 pneumonia,Hidradenitis suppurativa;Inflammation;Microscopic polyangiitis;Pyoderma gangrenosum;Sepsis;Systemic inflammatory response syndrome;Squamous cell cancer,Inflammation,,,Chimeric,CaC-P29;Gohibic;IFX-1;IFX 1;IFX1
Vipalanebart,Whole mAb,G4,Kappa,Phase-II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSAISLSGGSTYYAASHKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVREVGASTHNYYGMDVWGQGTMVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSIWRWLAWYQQKPGKAPKLLIHDASQLFEGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQFDLLPLTFGGGTKVEIK,na,na,None,None,None,2023,2024,ADCYAP1/PACAP,Eli Lilly and Company,na,Migraine,na,,,Genetically human,LY3451838;LY-3451838;LY 3451838
Visilizumab,Whole mAb,G2,Kappa,Phase-III,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQAPGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYMELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPGKAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSSNPPTFGGGTKVEIK,na,na,None,None,None,2000,2001,CD3E,PDL BioPharma,na,na,Crohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis,,,Humanised,HuM-291;HuM291;HuM 291
Vislarafusp,Fusion Protein,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTIYHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,na,na,None,6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB//8pwh:BA/8q6j:BA,1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL/5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2024,2024,SIRPA,ImmuneOnco Biopharma,na,Solid tumours,na,,,Genetically human,IMM2902;IMM-2902;IMM 2902
Visugromab,Whole mAb,G4,Kappa,Phase-II,Active,QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGMGVSWIRQPPGKGLEWLAHIYWDDDKRYNPTLKSRLTITKDPSKNQVVLTMTNMDPVDTATYYCARSSYGAMDYWGQGTLVTVSS,DIVLTQSPSFLSASVGDRVTITCKASQNVGTNVAWFQQKPGKSPKALIYSASYRYSGVPDRFTGSGSGTEFTLTISSLQPEDFAAYFCQQYNNFPYTFGGGTKLEIK,na,na,None,None,None,2022,2022,GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB,CatalYm,na,Solid tumours,na,,Genetics: musmus/homosap,Chimeric and/or humanised,CTL-002;CTL002;CTL 002
Vixarelimab,Whole mAb,G4-G1,Lambda,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEWMGWMNPNSGYTGYAQKFQGRVTMTRDTSISTAYMEMSSLRSEDTAVYYCARDIVAANTDYYFYYGMDVWGQGTTVTVSS,QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKLLIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDDSLDGVVFGGGTKLTVL,na,na,None,None,None,2020,2021,OSMR,Kiniksa Pharmaceuticals,na,Prurigo nodularis;Pruritus;Atopic dermatitis,na,,,Genetically human,KPL-716;KPL716;KPL 716;RG-6536;RG6536;RG 6536;RO-7622888;RO7622888;RO 7622888
Vixticibart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGASVTVSCKASGYTFTDYYMHWVRQAPGQGLEWMGWIKPNSGGTNSAQRFQGRITMTWDTSISTAYMELSRLRSDDTAVYYCSRGGPVMNYYYYYGMDVWGQGTTVTVSS,NIQMTQSPSSLSASVGDRVTITCRASQSIDSYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGKDFTLTISSLQPEDFATYYCQQSYSIPTFGQGTRLEIK,na,na,8tga:EF:HL/8tg9:HL:EF,None,None,2024,2024,NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA,TBC,TBC,TBC,TBC,,Agonist,Genetically human,TBC
Vixtimotamab,Bispecific Homodimer (VK-VH-VL'-VH'; Tandem diabody),na;na,Kappa;Lambda,Phase-I,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWMGWMNPNSGNTGFAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDRANTDYSLGMDVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYANWVQQKPGKAPKALIGGTNKRAPGVPSRFSGSLIGDKATLTISSLQPEDFATYYCALWYSNLWVFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSYFAYWGQGTLVTVSS,QSVLTQPPSASGTPGQRVTISCSGSRSNIGSNTVNWYQQLPGTAPKLLIYGNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLIGWVFGGGTKVTVL,None;None,None;None,None;None,2020,2021,CD3E;SIGLEC3/CD33/p67,Amphivena Therapeutics,na,na,Acute myeloid leukemia;Myelodysplastic syndromes;Solid tumours,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,AMV-564;AMV564;AMV 564;T-564;T564;T 564;T-652;T652;T 652
Vobarilizumab,Bispecific Single Domains (VH-VH'),na;na,na;na,Phase-II,Discontinued,EVQLVESGGGLVQPGGSLRLSCAASGSVFKINVMAWYRQAPGKGRELVAGIISGGSTSYADSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCAFITTESDYDLGRRYWGQGTLVTVSS,na,EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS,na,7xl0:B:A;None,None;None,None;None,2015,2016,IL6R/CD126;ALB,Ablynx,na,na,Rheumatoid arthritis;Systemic lupus erythematosus,Nanobody Technology,,Humanised;Humanised,ALX 0061;ALX0061;ALX-0061;ALX61;ALX-61;ALX 61
Vobramitamab,Whole mAb,G1,Kappa,Phase-II/III,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATINSGGSNTYYPDSLKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARHDGGAMDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASESIYSYLAWYQQKPGKAPKLLVYNTKTLPEGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGTPPWTFGQGTRLEIK,na,na,None,None,None,2022,2022,B7H3/CD276,MacroGenics,na,Prostate cancer;Small cell lung cancer;Solid tumours;Neuroblastoma,na,,ADC with Duocarmazine,Humanised,MGA017;MGA-017;MGA17;MGA-17;MGA 017;MGA 17;MGA018;MGA-018;MGA18;MGA-18;MGA 018;MGA 18;AEX4089;AEX-4089;AEX 4089
Vofatamab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFTSTGISWVRQAPGKGLEWVGRIYPTSGSTNYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARTYGIYDLYVDYTEYVMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVDTSLAWYKQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGHPQTFGQGTKVEIK,na,na,None,None,4wv1:BA:ED/3grw:HL,2018,2019,FGFR3/CD333,BioClin Therapeutics;Rainier Therapeutics,na,Urogenital cancer,Multiple myeloma;Solid tumours;Achondroplasia,,,Genetically human,B701;B 701;B-701;MFGR 1877A;MFGR-1877A;MFGR1877A
Volagidemab,Whole mAb,G2,Kappa,Phase-II,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVMWYDGSNKDYVDSVKGRFTISRDNSKNTLYLQMNRLRAEDTAVYYCAREKDHYDILTGYNYYYGLDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSVQPEDFVTYYCLQHNSNPLTFGGGTKVEIK,na,na,None,4lf3:ED:BA/5xf1:HL:CD/5xez:CD:HL/4ers:HL,None,2018,2019,GCCR/NR3C1,Amgen;REMD Biotherapeutics,na,Type 1 diabetes mellitus;Type 2 diabetes mellitus;Metabolic disorders;Glucose intolerance,na,,,Genetically human,AMG-477;AMG477;AMB 477;REMD-477;REMD477;REMD 477
Volociximab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLKESGPGLVAPSQSLSITCTISGFSLTDYGVHWVRQPPGKGLEWLVVIWSDGSSTYNSALKSRMTIRKDNSKSQVFLIMNSLQTDDSAMYYCARHGTYYGMTTTGDALDYWGQGTSVTVSS,QIVLTQSPAIMSASLGERVTMTCTASSSVSSNYLHWYQQKPGSAPNLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQYLRSPPTFGGGTKLEIK,na,na,None,None,None,2005,2006,ITGA5B1,Abbott Biotherapeutics Corp;Biogen Idec;IVERIC bio;National Cancer Institute (USA);PDL BioPharma,na,na,Age-related macular degeneration;Intestinal cancer;Non-small cell lung cancer;Peritoneal cancer;Malignant melanoma;Pancreatic cancer;Renal cell carcinoma,,,Chimeric,Eos 200-4;Eos200-4;M 200;M-200;M200
Volrustomig,Bispecific mAb,G1,Kappa;Kappa,Phase-III,Active,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS,QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK,5ggu:HL:AB/5ggv:HL;None,None;None,None;None,2022,2023,CTLA4/CD152;PDCD1/CD279/PD1,AstraZeneca,na,Solid tumours;Renal cell carcinoma,na,,,Genetically human;Humanised,MEDI-5752;MEDI5752;MEDI 5752
Vonlerolizumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGDMYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAPRWYFSVWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPPTFGQGTKVEIK,na,na,6okn:AB:CD/6ogx:CD/7yk4:HL:IM,None,None,2015,2017,TNFRSF4/CD134/OX40,Genentech,na,na,Solid tumours;Urogenital cancer,,Vonlerolizumab is the new name for Pogalizumab (PL116),Humanised,MOXR-0916;MOXR0916;MOXR 0916;MOXR-916;MOXR916;MOXR 916;Pogalizumab;RG 7888;RG7888;RG-7888
Vonsetamig,Bispecific mAb,G4,Kappa;Kappa,Phase-I/II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMTWVRQAPGKGLEWVANMNQDGSEKYYVDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCARDREYCISTSCYDDFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIK,None;None,None;None,None;None,2023,2023,TNFRSF17/CD269/BCMA/TNFRSF13A;CD3E,Regeneron Pharmaceuticals,na,Regeneron Pharmaceuticals,na,,,Genetically human;Genetically human,REGN-5459;REGN 5459;REGN5459
Vopikitug,Whole mAb,G1,Kappa,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSLAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARGGSVSGTLVDFDIWGQGTMVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNIYPITFGGGTKVEIK,na,na,6yio:HL,None,None,2023,2023,IL2RA/CD25,Roche,na,Acute myeloid leukaemia,Solid tumours,,,Genetically human,RG 6292;RG-6292;RG6962;RO 7296682;RO-7296682;RO7296682
Vopratelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMDWVRQAPGKGLVWVSNIDEDGSITEYSPFVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRWGRFGFDSWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLSGSFNYLTWYQQKPGQPPKLLIFYASTRHTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCHHHYNAPPTFGPGTKVDIK,na,na,None,None,None,2017,2018,ICOS/CD278,Jounce Therapeutics,na,Solid tumours;Urogenital cancer;Non-small cell lung cancer,na,,,Humanised,JTX-2011;JTX2011;JTX 2011
Vorsetuzumab,Whole mAb ADC,G1,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS,DIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK,na,na,None,None,None,2012,2013,TNFSF7/CD70/CD27LG,Seattle Genetics,na,na,Autoimmune disorders;Cancer;Inflammation;Plaque psoriasis,,,Humanised,h1f6;SGN-70;SGN70;SNG 70
Voxalatamab,Bispecific mAb,G4;G4,Kappa;Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFKSDAMHWVRQAPGKGLEWVSEISGSGGYTNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSYDSSLYVGDYFDYWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS,QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2021,2022,FOLH1/GCPII/PSMA;CD3E,Janssen Research & Development,na,na,Solid tumours,,Fv2 Chimeric: Mouse/Human,Genetically human;Chimeric and humanised,JNJ-63898081;JNJ63898081;JNJ 63898081;JNJ-8081;JNJ8081;JNJ 8081
Vudalimab,Bispecific Mixed mAb and scFv,G1;G1,Kappa;Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNNKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARTGWLGPFDYWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,EVQLVESGGGLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLEWVAEIRLYSNNYATHYAESVKGRFTISRDDSKSTLYLQMNNLKTEDTGVYYCTRYYGNYGGYFDVWGRGTLVTVSS,EIVLTQSPATLSASPGERVTLTCRASQSVGNDVAWYQQKPGQAPRLLINYASHRYTGVPDRFTGSGYGTEFTLTISSVQSEDFGVYYCQQDFSSPRTFGGGTKVEIK,None;None,None;None,5tru:HL:hl/5xj3:AB:DE:GH:JK/6jc2:HL/6rp8:HL:hl/7elx:HL:hl;None,2020,2021,CTLA4/CD152;PDCD1/CD279/PD1,Xencor,na,Solid tumours,na,,Genetics of Fv2: musmus/homosap,Genetically human;Chimeric and/or humanised,XmAb 717;XmAb717;XmAb-717;XmAb-20717;XmAb 20717;XmAb20717
Vulinacimab,Whole mAb,G1,Kappa,Phase-I,Discontinued,QVQLVQSGGGLVQPGGSLRLSCAASGFSFSTYAMSWVRQAPGKGLEWVSGISGSGGTTHYADSVKGRFTISRDNSKNTVNLQMNSLRAEDTAVYYCAKGLWFGEGLWGQGTLVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLYYRSGYTFLDWYVQKPGQSPQLLIYQSSKRDSGVPDRISGSGSGTDFTLRISRVEAEDVGVYYCFQGTHWPYTFGQGTKLEIK,na,na,None,None,None,2019,2020,KDR/CD309/VEGFR2,Henlix,na,na,Solid tumours,,,Genetically human,HLX-06;HLX06;HLX 06
Vunakizumab,Whole mAb,G1,Kappa,Approved,Active,EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEVHWVRQAPGQGLEWMGVIDPGTGGVAYNQKFEGRVTMTADTSTSTAYMELRSLRSDDTAVYYCTRYSLFYGSSPYAMDYWGQGTLVTVSS,EIVLTQSPDFQSVTPKEKVTITCSASSSVNYMHWFQQKPDQSPKLWIYRTSNLASGVPSRFSGSGSGTDYTLTINSLEAEDAATYYCQQRSSYPWTFGQGTKLEIK,na,na,None,None,None,2016,2017,IL17A,Atridia;Jiangsu Hengrui Medicine Co.,Plaque psoriasis,Ankylosing spondylitis;Psoriatic arthritis;Graves ophthalmopathy,,,,Humanised,SHR 1314;SHR-1314;SHR1314
Xaluritamig,Bispecific Mixed mAb and scFv,G1;na,Kappa;Lambda,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEWMGEILPGSGQTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLVTVSS,EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIK,EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGDSYVSWFAYWGQGTLVTVSS,QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQQKPGKSPRGLIGGTNKRAPGVPARFSGSLLGGKAALTISGAQPEDEADYYCALWYSNHWVFGGGTKLTVL,8ucd:HL;None,None;None,None;None,2022,2023,STEAP1;CD3,Amgen;Xencor;BeiGene,na,Prostate cancer;Ewing's sarcoma,na,,,Genetically human;Genetically human,AMG-509;AMG509;AMG 509
Xeligekimab,Whole mAb,G4,Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGMSMSDYWMNWVRQAPGKGLEWVAAINQDGDEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDLISDYYIHYWYFDLWGRGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQNVHNRLTWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNGSPTTFGQGTKVEIK,na,na,None,None,None,2021,2022,IL17A,Genrix Biopharmaceutical,Plaque Psoriasis,Axial spondyloarthritis;Lupus nephritis,Rheumatoid arthritis,,,Genetically human,GR-1501;GR1501;GR 1501
Xentuzumab,Whole mAb,G1,Lambda,Phase-II,Active,QVELVESGGGLVQPGGSLRLSCAASGFTFTSYWMSWVRQAPGKGLELVSSITSYGSFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNMYTHFDSWGQGTLVTVSS,DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYDNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQSRDTYGYYWVFGGGTKLTVL,na,na,None,None,None,2015,2016,IGF1 and IGF2,Boehringer Ingelheim;Eli Lilly,na,Breast cancer;Prostate cancer,Non-small cell lung cancer;Solid tumours,MorphoSys HuCAL Phage Display,,Humanised,BI-836845;BI836845;BI 836845
Xirestomig,Bispecific (G1-scFv_L2 dimer),G1;na,Lambda;Lambda,Phase-I,Active,QVQLVQSGAEVKKPGSSVKVSCKASRGPFSTYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARTMEGYGFGNFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTVSEVGGYNEVSWYQQHPGKAPKLMIYGNSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYDSSLSGTVFGGGTKLTVL,QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTNWGPSDAFDIWGQGTMVTVSS,QSVLTQPPSASGTPGQRVTISCSGSTSDIGSYSVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGYVFGTGTKVTVL,None;None,None;None,None;None,2023,2024,PDL1/CD274;TNFRSF9/CD137/4-1BB,OriCell Therapeutics;Antengene Corporation,na,Non-Hodgkin's lymphoma;Solid tumours,na,,,Genetically human;Genetically human,ATG-101;ATG101
Zadoprubart,Whole mAb,G4,Kappa,TBC,Active,QVQLVQSGAEVKKPGSSVKVSCKASGYVFSTSWMNWVRQAPGQGLEWMGRIYPGDADTNYVGKFKGRVTITADKSTTTAYMELSSLRSEDTAVYFCAKSGTFNFGNYRWYFDVWGKGTTVTVSS,AIQLTQSPSSLSASVGDRVTITCRVSENIYSHLAWYQQKPGKAPKLLIYAATNLALGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQLFWGPPLTFGGGTKVEIK,na,na,None,None,None,2024,na,BTLA/CD272,TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Zagotenemab,Whole mAb,G4,Kappa,Phase-II,Discontinued,EVQLVQSGAEVKKPGESLKISCKGSGYTFSNYWIEWVRQMPGKGLEWMGEILPGSDSIKYEKNFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARRGNYVDDWGQGTLVTVSS,EIVLTQSPGTLSLSPGERATLSCRSSQSLVHSNQNTYLHWYQQKPGQAPRLLIYKVDNRFSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCSQSTLVPLTFGGGTKVEIK,na,na,None,None,None,2019,2020,MAPT,Eli Lilly,na,na,Alzheimer's disease,,,Humanised,LY 3303560;LY-3303560;LY3303560
Zalifrelimab,Whole mAb,G1,Kappa,Phase-II,Active,EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLMGPFDIWGQGTMVTVSS,EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK,na,na,None,None,None,2018,2019,CTLA4/CD152,4-Antibody;Ludwig Institute for Cancer Research;Agenus;Recepta biopharma,na,Non-small cell lung cancer;Cervical cancer;Cancer;Haemangiosarcoma;Soft tissue sarcoma;Sold tumours,na,,,Genetically human,AGEN-1884;AGEN1884;AGEN 1884;RebmAb-600;RebmAb 600;RebmAb600;UGN-301;UGN301;UGB 301
Zaltenibart,Whole mAb,G4,Kappa,Phase-II,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGKWIEWVRQAPGQGLEWIGEILPGTGSTNYNEKFKGRATFTADSSTSTAYMELSSLRSEDTAVYYCLRSEDVWGQGTLVTVSS,DIVMTQSPDSLAVSLGERATINCKSSQSLLASRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNIPTFGQGTKVEIK,na,na,None,None,None,2024,2024,MASP3,Helion Biotech;Medical Research Council;University of Leicester;Omeros Corporation,na,Glomerulonephritis;Paroxysmal nocturnal haemoglobinuria,Arthritis,,Humanised: musmus/homosap,Humanised, OMS-906;OMS 906;OMS906
Zalutumumab,Whole mAb,G1,Kappa,Phase-II,Discontinued,QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS,AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK,na,na,None,None,None,2005,2006,EGFR/ERBB1/HER1,Danish Head and Neck Cancer Group;Genmab,na,na,Head and neck cancer;Colorectal cancer;Non-small cell lung cancer,,,Genetically human,HuMax-EGFr
Zamerovimab,Whole mAb,G1,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYIMLWVRQAPGQRLEWIGDIYPYYGSTSYNLKFKGKATLTVDTSASTAYMELSSLRSEDTAVYYCARQGGDGNYVLFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQNVGTTVAWYQQKPGKAPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNSYPFTFGQGTKLEIK,na,na,None,None,None,2021,2022,Rabies Virus Spike Glycoprotein G,Synermore,na,Rabies Exposure,na,,,Humanised,SYN023;SYN-023;SYN 023;SYN23;SYN023;SYN 23;CTB011;CTB-011;CTB 011;CTB11;CTB-11;CTB 11
Zampilimab,Whole mAb,G4,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTLSTHAMSWVRQAPGKGLEWVATISSGGRSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCARLISTYWGQGTLVTVSS,DITMTQSPSSLSASVGDRVTITCKASQDINSYLTWFQQKPGKAPKILIYLVNRLVDGVPSRFSGSGSGQDYALTISSLQPEDFATYYCLQYDDFPYTFGQGTKVEIK,na,na,None,None,None,2018,2019,TGM2,UCB,na,Autoimmune disorders,na,,Chimeric: Mouse/Human,Chimeric and humanised,UCB 7858;UCB-7858;UCB7858
Zamubafusp,Antibody Fusion Protein,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSETLSLTCTVSGFSLSSYGVSWIRQPPGKGLEWLGVIWGEGSTNYHPNLMSRVTISVDTSKSQVLFKLSSVTAADTAVYYCATLDYWGQGTSVTVSS,DVVMTQSPLSLPVTLGQPASISCRSSQSLVHRSGNTYLHWFQQRPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCFQTTYVPNTFGGGTKLEIK,na,na,None,None,None,2024,na,Human variable immunoglobulin light chain (N-terminal cryptic neo-epitope),TBC,TBC,TBC,TBC,TBC,TBC,Humanised,TBC
Zanidatamab,Bispecific mAb,G1;G1,Kappa;Kappa,Approved,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGLEWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPATFGQGTKVEIK,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,None;6bi0:HL:IM/4hkz:BA/6mh2:BA:DC/5xhg:DC:BA/1n8z:BA/6bi2:HL:IM/1fvc:BA:DC/6bhz:HL:IM/6oge:ED/7mn8:DC/7t97:HL:AB:CD:EF/7t99:HL:AB:CD:EF/4ub0:HL/5xhf:BA:DC/8ti4:HL/8tjf:HL:AB,None;1fve:BA:DC/4x4x:AB:CD/5tdn:BA:DC/6bgt:BA/7kbp:CC/7t98:AB:HL,1s78:FE:DC/4llu:AB:CD/1l7i:HL/4llw:CD:AB/5vsh:CD:EF:AB:HL/4lly:AB:CD/8q6j:DC/8pwh:DC/9l1s:CB;5tdn:BA:DC/1fvd:BA:DC/5tdp:BA:DC/4x4y:CD:AB/5tdo:BA:DC/6dn0:CD:AB/3be1:HL/3bdy:HL/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL,2019,2020,ERBB2/CD340/HER2;ERBB2/CD340/HER2,Zymeworks,Biliary cancer,Colorectal cancer;Gastric cancer;HER2 positive breast cancer;Oesophageal cancer;Endometrial cancer;Solid tumours,Ovarian cancer,,Biparatopic Bispecific. Humanised,Humanised;Humanised,ZW 25;ZW-25;ZW25
Zanolimumab,Whole mAb,G1,Kappa,Phase-III,Discontinued,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK,na,na,None,None,None,2004,2004,CD4,Emergent BioSolutions;Genmab,na,na,Cutaneous T-cell lymphoma;Peripheral T-cell lymphoma;Psoriasis;Rheumatoid arthritis,Medarex HuMAb Mouse,,Genetically human,MDX-016;MDX016;MDX 016;MDX-16;MDX16;MDX 16
Zansecimab,Whole mAb,G4,Kappa,Phase-II,Discontinued,QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARTRDRYDVWYFDVWGQGTLVTVSS,DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIK,na,na,None,None,None,2020,2021,ANGPT2,Eli Lilly,na,na,Solid tumours;COVID-19,,,Humanised,LY 3127804;LY-3127804;LY3127804
Zeleciment,Fab,G1,Kappa,TBC,Active,QVQLQESGPGLVKPSQTLSLTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGQPVKLLIYYTSRLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGHTLPYTFGQGTKLEIK,na,na,None,None,None,2023,2024,TFRC/CD71,TBC,TBC,TBC,TBC,,Genetics: musmus/homosap,Chimeric and/or humanised,TBC
Zelminemab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLVESGAEVVKPGASVKVSCKASGFTFSRFAMHWVRQAPGQGLEWMGVISYDGGNKYYAESVKGRVTMTRDTSTSTLYMELSSLRSEDTAVYYCARGYDVLTGYPDYWGQGTLVTVSS,DIQLTQSPSFLSASVGDRVTITCRASQSIGRSLHWYQQKPGKAPKLLIKYASQSLSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCHQSSRLPFTFGPGTKVDIK,na,na,None,None,None,2019,2020,ADCYAP1R1/PAC1,Amgen,na,Migraine,na,,,Humanised,AMG-301;AMG301;AMG 301
Zeluvalimab,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSLISGGGSQTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPSGHYFYAMDVWGQGTTVTVSS,DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGGGTKVEIK,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Amgen,na,Solid tumours,na,,June '22: Corrected CDRH1 sequence,Genetically human,20C1.009;AMG-404;AMG404;AMG 404
Zemocimig,Bispecific mAb,G4;G4,Kappa;Lambda,TBC,TBC,QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREEGGWIFDYWGQGTLVTVSS,EIVLTQSPATLSVSPGERATLSCRASRSVRRELAWYQQKPGQAPELLIYGASTRETGIPARFSGSGSGTDFTLTINSLEAEDAATYYCQQYRDPPGTFGGGTKVEIK,QVQLVQSGSELKKPGASVKVSCKASGYTFTQNNMDWVRQAPGQGLEWMGDINTRSGGVIYNEEFQDRLIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDVWGEGTLVTVSS,SYVLTQPVSVSVALGQTATITCEGEQIGSKEVHWYHQRPGQAPILVMFRDARRPSGIPERLSGSNSGNTASLTISGAEAGDEGDYYCQVWDSSSYTVFGGGTKVTVV,8gv0:AB:CD:EF:GH/8guz:AB:CD;8gv1:AB/8gv2:AB,None;None,None;None,2025,na,F9a;F10,TBC,TBC,TBC,TBC,TBC,TBC,Humanised;Humanised,TBC
Zenocutuzumab,Bispecific mAb,G1;G1,Kappa;Kappa,Approved,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK,5o4o:BA/5o7p:BA;5o4g:BA,None;None,None;None,2017,2018,ERBB3/HER3;ERBB2/CD340/HER2,Merus,Adenocarcinoma;Non-small cell lung cancer,HER2 positive breast cancer;Prostate cancer;Solid tumours;Cancer,,GlymaxX Technology,,Humanised;Humanised,MCLA-128;MCLA128;MCLA 128
Zeripatamig,Bispecific mAb,G1;G1,Kappa;Lambda,Phase-I,Discontinued,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQMHPRAPKTFGQKTKVEIK,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSYGAFDYWGQGTLVTVSS,NFMLTQPHSVSESPGKTVTISCTRSSGSIEDKYVQWYQQRPGSSPTIVIYYDNERPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQTYDQSLYGWVFGGGTKVTVL,8rp8:AB:HL;None,None;None,None;None,2022,2023,IAP/CD47;CD19,TG Therapeutics,na,na,B-cell lymphoma;Chronic lymphocytic leukaemia,,,Genetically human;Genetically human,TG-1801;TG1801;TG 1801
Zifibancimig,Bispecific mAb,G1;G1,Kappa;Kappa,Phase-I,Active,SEHLVESGGGLVKPGGSLRLSCATADFFEYDDMSWVRQAPGKGLEWVGSISPKGDHKYLNTKFIGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVGFFDWWGQGTLVTVSS,AIYMHQEPSSLSASVGDRVTITCHGSYWLNSEVAWYQQKPGKAPKLLIFDGDFKVYEVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGHGTKVEIK,SEHLVESGGGLVKPGGSLRLSCATADFFEYDDMSWVRQAPGKGLEWVGSISPKGDHKYLNTKFIGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVGFFDWWGQGTLVTVSS,AIYMHQEPSSLSASVGDRVTITCHGSYWLNSEVAWYQQKPGKAPKLLIFDGDFKVYEVPSRFSGSGSHEDYTLTISSLQPEDFATYYCQQYRYHPYTFGHGTKVEIK,None;None,None;None,None;None,2022,2023,ANPT2;VEGFA,Roche,na,Age-related macular degeneration,na,,Biparatopic Bispecific with same V region,Genetically human;Genetically human,RO7250284;RO-7250284;RO 7250284
Zigakibart,Whole mAb,G4,Kappa,Phase-III,Active,QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVMHWVRQAPGQGLEWMGYINPYNDAPKYNEKFKGKATMTSDTSASTAYMELSSLRSDDTAVYYCARGLGYALYYAMDYWGQGTTVTVSS,DIVMTQSPSTLSASVGDRVTITCKASQNVGNNVAWYQQKPGKAPKLLISSASNRDSGVPSRFSGSGSGTEFTLTISSLQPDDFATYFCQQYNIYPFTFGQGTKLEIK,na,na,None,None,None,2022,2023,TNFSF13/CD256/APRIL,Chinook Therapeutics,na,IgA Nephropathy,Multiple myeloma,,,Humanised,BION-1301;BION1301;BION 1301
Ziltivekimab,Whole mAb,G1,Kappa,Phase-III,Active,EVQLVESGGGLVQPGGSLRLSCAASGFTISSNYMIWVRQAPGKGLEWVSDLYYYAGDTYYADSVKGRFTMSRDISKNTVYLQMNSLRAEDTAVYYCARWADDHPPWIDLWGRGTLVTVSS,DIQMTQSPSTLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKVLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQSWLGGSFGQGTKLEIK,na,na,None,None,None,2019,2020,IL6,AstraZeneca;Corvidia,na,Cardiovascular disorders,na,,,Humanised,COR 001;COR001;COR-001;NN 6018;NN-6018;NN6018
Zilovertamab,Whole mAb,G1,Kappa,Phase-II,Active,QVQLQESGPGLVKPSQTLSLTCTVSGYAFTAYNIHWVRQAPGQGLEWMGSFDPYDGGSSYNQKFKDRLTISKDTSKNQVVLTMTNMDPVDTATYYCARGWYYFDYWGHGTLVTVSS,DIVMTQTPLSLPVTPGEPASISCRASKSISKYLAWYQQKPGQAPRLLIYSGSTLQSGIPPRFSGSGYGTDFTLTINNIESEDAAYYFCQQHDESPYTFGEGTKVEIK,na,na,None,None,None,2020,2021,ROR1,University of California;Oncternal Therapeutics;Merck,na,Chronia lymphocytic leukemia;Mantle-cell Lymphoma;Prostate cancer;Endometrial cancer;Ovarian cancer,HER2 negative breast cancer,,June '22: Corrected FWL2 sequence,Humanised,UC-961;UC961;UC 961
Zimberelimab,Whole mAb,G4,Lambda,Approved,Active,QLQLQESGPGLVKPSETLTLTCTVSADSISSTTYYWVWIRQPPGKGLEWIGSISYSGSTYYNPSLKSRVTVSVDTSKNQFSLKLNSVAATDTALYYCARHLGYNGRYLPFDYWGQGTLVTVSS,QSALTQPASVSGSPGQSITISCTGTSSDVGFYNYVSWYQQHPGKAPELMIYDVSNRPSGVSDRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSISTWVFGGGTKLTVL,na,na,None,None,None,2020,2021,PDCD1/CD279/PD1,Harbin Gloria Pharmaceuticals;WuXi Biologics;Arcus Biosciences;Beijing Cancer Hospital;Guangzhou Gloria Biosciences;Strata Oncology,Hodgkin's disease,Cervical cancer;Non-small cell lung cancer;Breast cancer;Cancer;Ovarian cancer;Pancreatic cancer;Solid tumours,na,,,Genetically human,AB 122;AB-122;AB122;GLS 010;GLS010;GLS010;GLS10;GLS-10;GSL 10;GS-0122;GS0122;GS 0122;GS-122;GS122;GS 122;WBP 3055;WBP3055;WBP-3055;YUTUO
Zinlirvimab,Whole mAb,G1,Lambda,Phase-II,Active,QVQLQESGPGLVKPSETLSVTCSVSGDSMNNYYWTWIRQSPGKGLEWIGYISDRESATYNPSLNSRVVISRDTSKNQLSLKLNSVTPADTAVYYCATARRGQRIYGVVSFGEFFYYYSMDVWGKGTTVTVSS,SYVRPLSVALGETARISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVL,na,na,6orn:AB:FI:OP/6udk:AB:FI:OP/6udj:AR:KL:QB/6v8z:DE:PQ:JK/6ccb:DE:HL/6okp:KL/7ucf:HL/7ucg:HL:JK:QR/7ugn:MP:NQ:OR/7ugo:MP:NQ:OR/7ugp:MP:NQ:OR/7ugq:MP:NQ:OR/8czz:MN:OP:QR/8dok:MN:OP:QR/8g6u:MN:OP:QR/8ttw:MN:OP:QR/9bew:HL:JK:QR,5t3x:HL/5t3z:HL,4fq2:HL,2022,2022,HIV-1 gp120 V3,Gilead,na,HIV-1 infections;AIDS,na,,VL sequence truncation prevents 3D modelling with ABodyBuilder2,Genetically human,10-1074;10 1074;GS-2872;GS2872;GS 2872
Zolbetuximab,Whole mAb,G1,Kappa,Approved,Active,QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS,DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK,na,na,None,None,None,2017,2018,CLDN18,Ganymed Pharmaceuticals,Gastric cancer,Oesophageal cancer;Pancreatic cancer,Solid tumours,,Zolbetuximab and Claudiximab are the same mAb,Chimeric,Claudiximab;IMAB 362;IMAB-362;IMAB362
Zovostotug,Whole mAb,G1,Kappa,Phase-I/II,Active,EVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARENVRPYYDFWSGYYSEYYYYGMDVWGQGTTVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPRGTFGQGTKVEIK,na,na,None,None,None,2023,2023,CD163,OncoResponse,na,Solid tumours,na,,,Genetically human,OR-2805;OR 2805;OR2805
Zuberitamab,Whole mAb,G1,Kappa,Phase-II,Discontinued,EVQLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSS,DIELSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLEIK,na,na,None,None,3bky:HL,2019,2020,MS4A1/CD20,Zhejiang Hisun Pharmaceutical,na,na,Diffuse large B-cell lymphoma,,Rituximab biosimilar,Chimeric,HS-006;HS006;HS 006;RHCACD20MA
Zubotamig,Bispecific mAb ((H-gamma1_L-kappa)_(H-gamma1_Llambda2)),G1;G1,Kappa;Lambda,Phase-I/II,Active,QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEISHSGSTNYNPSLKSRVTISIDTSKNQFSLKLTSVTAADTAVFYCARGLFNWNFDSWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYGASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPRTFGQGTTVEIK,EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRGGNFGNSYVSWFAYWGQGTLVTVSS,QAVVTQEPSFSVSPGGTVTLTCRSSTGAVTTSNYANWVQQTPGQAFRGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQADDESIYFCALWYSNLWVFGGGTKLTVL,None;None,None;None,None;None,2024,2024,VTCN1/B7H4;CD3E,Genmab,na,Solid tumours,na,,Humanised Fv2: musmus/homosap,Genetically human;Humanised,GEN-1047;GEN 1047;GEN1047
